nevirapine has been researched along with HIV Coinfection in 1992 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We hypothesize that Nevirapine is a cheaper alternative that possesses equal efficacy as Efavirenz in HIV-Tuberculosis (TB) co-infected patients." | 9.24 | Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. ( Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S, 2017) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 9.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| " However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART." | 9.19 | Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014) |
| "In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs." | 9.17 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013) |
| "HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 9.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
| "To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women." | 9.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
| "To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment." | 9.17 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013) |
| "Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)." | 9.17 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013) |
| "Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available." | 9.17 | Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013) |
| "Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 9.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
| "Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 9.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
| "eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400)." | 9.15 | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ( Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011) |
| "Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB)." | 9.15 | Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. ( Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011) |
| "Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available." | 9.15 | HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. ( Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K, 2011) |
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 9.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "The aim was to develop a model to describe the population pharmacokinetics of nevirapine in South African human immunodeficiency virus (HIV)-infected patients who were taking nevirapine-based antiretroviral therapy concomitantly or in the absence of rifampicin-based tuberculosis therapy." | 9.14 | Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. ( Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009) |
| "Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 9.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
| "The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 9.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
| "We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin." | 9.13 | Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ( Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H, 2008) |
| "Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer." | 9.12 | Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007) |
| "To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy." | 9.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
| "To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study." | 9.09 | Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. ( Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001) |
| " We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens." | 8.91 | Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015) |
| " Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)." | 8.90 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 8.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| "Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria." | 8.31 | Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023) |
| "Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)." | 7.91 | Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019) |
| "Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)." | 7.88 | A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( Borgiani, P; Ciccacci, C; Ciccacci, F; Lucaroni, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Politi, C, 2018) |
| " No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0." | 7.88 | Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. ( Bangsberg, DR; Boum, Y; Bwana, M; Chang, JL; Haberer, JE; Hunt, PW; Martin, JN; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC, 2018) |
| "Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed." | 7.88 | Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018) |
| " Patients were allocated to 2groups according to exposure to nevirapine during pregnancy." | 7.83 | [Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016) |
| "We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations." | 7.83 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016) |
| "We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial." | 7.81 | Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ( Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM, 2015) |
| "HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)." | 7.81 | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015) |
| "The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 7.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
| "An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006." | 7.81 | A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| "We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen." | 7.80 | Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014) |
| "To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses." | 7.80 | Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014) |
| "Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 7.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
| "We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 7.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
| "We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation." | 7.78 | Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ( Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N, 2012) |
| " We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester." | 7.77 | Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 7.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| "Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment." | 7.76 | Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010) |
| "The concurrent use of nevirapine-based antiretroviral therapy (ART) and rifampin-containing anti-tuberculosis regimens for the treatment of HIV and tuberculosis (TB) is common in resource-limited countries." | 7.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
| "This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 7.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
| "Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 7.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
| "Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment." | 7.75 | Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ( Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P, 2009) |
| "To determine the relationship between nutritional status and nevirapine exposure by comparing the pharmacokinetics of nevirapine in HIV-infected children of different ages with and without malnutrition receiving divided tablets of Triomune 30 (stavudine + lamivudine + nevirapine) in accordance with Malawi National Guidelines." | 7.75 | Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. ( Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S, 2009) |
| "Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding." | 7.74 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008) |
| "Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 7.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
| "Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study." | 7.74 | Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. ( Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S, 2007) |
| "We prospectively followed 27 HIV-infected adult Malawians after starting Triomune (a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of tuberculosis treatment." | 7.74 | Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. ( Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE, 2007) |
| "Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children." | 7.74 | Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007) |
| "Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 7.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
| "To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population." | 7.74 | Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008) |
| "To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL." | 7.74 | Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Mankatitham, W; Manosuthi, W; Moolasart, V; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S, 2008) |
| "There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin." | 7.74 | Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. ( Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S, 2008) |
| "Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated." | 7.73 | Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005) |
| "The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy." | 7.73 | Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005) |
| "In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively." | 7.73 | Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. ( Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW, 2005) |
| "To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity." | 7.73 | Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006) |
| "The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 7.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
| " We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation." | 7.73 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006) |
| "Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy." | 7.72 | Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003) |
| " We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation." | 7.72 | Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003) |
| "At the defined period, 306 patients started a nevirapine-containing regimen, of whom eight developed an acute hepatitis (2." | 7.72 | Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. ( Beijnen, JH; de Maat, MM; Mairuhu, AT; Mulder, JW; ter Heine, R; van Gorp, EC, 2003) |
| "HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C." | 7.72 | Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. ( Castellano, V; García-García, JA; Gómez-Mateos, JM; Lozano, F; Macías, J; Merchante, N; Mira, JA; Palacios, RB; Pineda, JA; Sáez, C, 2004) |
| "To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN." | 7.71 | Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. ( Bouwes-Bavinck, JN; Fagot, JP; Mockenhaupt, M; Naldi, L; Roujeau, JC; Viboud, C, 2001) |
| "To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis." | 7.71 | Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ( Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001) |
| "Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available." | 6.79 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014) |
| "Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling." | 6.77 | Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012) |
| " The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL." | 6.71 | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004) |
| "The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)." | 6.69 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000) |
| "Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate." | 6.43 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005) |
| "The clinical significance of the reduced in vitro susceptibility of HIV to antiretroviral agents has been difficult to elucidate for nucleoside analogs such as zidovudine." | 6.17 | Resistance, drug failure, and disease progression. ( Richman, DD, 1994) |
| "Nevirapine has been used as antiretroviral agent since early '90." | 5.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
| " Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0." | 5.42 | The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. ( Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL, 2015) |
| "To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database." | 5.39 | Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013) |
| "Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards." | 5.35 | Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ( Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G, 2008) |
| "Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations." | 5.35 | Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008) |
| " The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques." | 5.33 | A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006) |
| "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis." | 5.32 | Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. ( Krivoy, N; Pollack, S; Shahar, E; Weltfriend, S, 2004) |
| "Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection." | 5.31 | Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. ( Farmer, KL; Hebert, AA; Lahart, CJ; Metry, DW, 2001) |
| "Nevirapine is a nonnucleoside reverse transcription inhibitor that is used as part of highly active antiretroviral therapeutic combinations." | 5.31 | Jaundice and hepatocellular damage associated with nevirapine therapy. ( Bonacini, M; Poreddy, V; Prakash, M; Tiyyagura, L, 2001) |
| "In this study the influence of first-line antimalarial drug artemether-lumefantrine on the pharmacokinetics of the antiretroviral drug nevirapine was investigated in the context of selected single nucleotide polymorphisms (SNPs) in a cohort of adult HIV-infected Nigerian patients." | 5.30 | Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction? ( Abdullahi, ST; Bakare-Odunola, MT; Bolarinwa, RA; Khoo, S; Olagunju, A; Olarewaju, OJ; Owen, A; Soyinka, JO, 2019) |
| " We hypothesize that Nevirapine is a cheaper alternative that possesses equal efficacy as Efavirenz in HIV-Tuberculosis (TB) co-infected patients." | 5.24 | Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study. ( Dhooria, S; Gupta, K; Pandey, RM; Ranjan, S; Sinha, S; Tripathy, S, 2017) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 5.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "In the CHAPAS-3 trial, HIV-infected children (ART-naive or on d4T for ≥2 years without clinical lipodystrophy) were randomized to d4T, abacavir or zidovudine with lamivudine (3TC) plus a non-nucleoside reverse transcriptase inhibitor." | 5.19 | Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial. ( Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D, 2014) |
| " However, there was a high risk of recurrent parasitemia following AL treatment, which was significantly lower in children taking LPV/r-based ART compared with nevirapine-based ART." | 5.19 | Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. ( Achan, J; Arinaitwe, E; Charlebois, E; Clark, TD; Dorsey, G; Havlir, D; Ikilezi, G; Kakuru, A; Kamya, MR; Muhindo, MK; Mwangwa, F; Rosenthal, PJ; Ruel, T; Tappero, JW, 2014) |
| "In countries with a high incidence of HIV and tuberculosis co-infection, nevirapine and efavirenz are widely used as antiretroviral therapy but both interact with antituberculosis drugs." | 5.17 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial. ( Bastos, R; Baudin, E; Bhatt, N; Bonnet, M; Calmy, A; Ciaffi, L; Jani, I; Michon, C; Nunes, E; Rouzioux, C; Silva, C; Sobry, A; Taburet, AM, 2013) |
| "HIV-infected, Zambian children were randomized to initiate antiretroviral therapy (ART) with full-dose twice-daily nevirapine versus 2-week nevirapine dose-escalation." | 5.17 | Is nevirapine dose-escalation appropriate in young, African, HIV-infected children? ( Burger, DM; Chintu, C; Cook, A; Fillekes, Q; Gibb, DM; Kabamba, D; Kankasa, C; Mulenga, V; Thomason, MJ; Walker, AS, 2013) |
| "To confirm whether 7 days of phenytoin, an enzyme inducer, would decrease the elimination half-life of single-dose nevirapine and to investigate its effect on the development of nevirapine resistance in pregnant, HIV-infected women." | 5.17 | Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial. ( Aitken, S; Burger, DM; Chunda, C; Fillekes, Q; Gibb, DM; Kankasa, C; Kisanga, ER; Muro, EP; Thomason, MJ; Walker, AS, 2013) |
| "ART use did not affect risk of ovulation or pregnancy in women taking COCs, suggesting that nevirapine-containing ART does not interfere with COC contraceptive effectiveness." | 5.17 | Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness. ( Delany-Moretlwe, S; Dubé, K; Edward, VA; Kwok, C; Lendvay, A; Mirembe, FM; Molife, L; Mpairwe, B; Nakubulwa, S; Nanda, K, 2013) |
| "To describe the longitudinal changes in hepatic function among HIV-infected tuberculosis (TB) patients receiving once-daily nevirapine (NVP)- or efavirenz (EFV)-based antiretroviral treatment (ART) along with rifampin-containing anti-TB treatment." | 5.17 | Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy. ( Bhavani, PK; Chandrasekar, C; Hannah, E; Kumar, H; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Ramesh, C; Swaminathan, S; Tang, A; Wanke, C, 2013) |
| "Administration of rifampicin along with nevirapine reduces the plasma concentration of nevirapine in human immunodeficiency virus positive individuals with concomitant tuberculosis (HIV-TB patients)." | 5.17 | Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. ( Ahmad, H; Chandrashekhar, R; Dhooria, S; Ekka, M; Khan, NH; Kumar, S; Pandey, RM; Raghunandan, P; Ranjan, S; Rewari, BB; Samantaray, JC; Sharma, SK; Sinha, S; Velpandian, T; Venkatesh, S, 2013) |
| "Although substantiated by little evidence, concerns about zidovudine-related anaemia in pregnancy have influenced antiretroviral (ARV) regimen choice for preventing mother-to-child transmission of HIV-1, especially in settings where anaemia is common." | 5.17 | Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries. ( Chersich, MF; Farley, TM; Luchters, S; Meda, N; Mwaura, M; Newell, ML; Sartorius, BK; Temmerman, M, 2013) |
| "Pharmacokinetic data for lopinavir in late pregnancy and in breastfeeding are limited, and no data for abacavir in breast milk are available." | 5.17 | Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana. ( Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL, 2013) |
| "030 mg ethinyl estradiol with either nevirapine (NVP) or efavirenz (EFV) in 34 HIV-positive women." | 5.17 | Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives. ( Ahluwalia, J; Ananworanich, J; Chaithongwongwatthana, S; Gorowara, M; Kriengsinyot, R; Landolt, NK; Lange, JM; Phanuphak, N; Pinyakorn, S; Thammajaruk, N; Thongpaeng, P; Ubolyam, S, 2013) |
| "Nevirapine (NVP) resistance emerges in up to 70% of women exposed to single-dose (sd) NVP for prevention of mother-to-child transmission of human immunodeficiency virus (HIV)." | 5.17 | Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV. ( Bonhomme, J; Chan, ES; Halvas, EK; Hitti, J; Hong, F; Hughes, MD; Kabanda, J; Klingman, KL; Kumarasamy, N; McMahon, DK; Mellors, JW; Taulo, F; Wallis, CL; Zheng, L, 2013) |
| "Intrapartum single-dose (SD) nevirapine (NVP) reduces perinatal transmission of human immunodeficiency virus (HIV) infection but selects for NVP-resistant virus, which compromises subsequent NVP-based therapy." | 5.16 | A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine. ( Achalapong, J; Beck, IA; Britto, P; Chotivanich, N; Cressey, TR; Frenkel, L; Jourdain, G; Maupin, R; Mirochnick, M; Ngo-Giang-Huong, N; Prommas, S; Puthanakit, T; Rasri, W; Roongpisuthipong, A; Shapiro, DE; Van Dyke, RB; Yuthavisuthi, P, 2012) |
| "Women randomized to valacyclovir suppressive therapy during pregnancy and postpartum had greater increases in CD4 counts and smaller increases in plasma HIV-1 RNA levels than women in the placebo arm." | 5.16 | Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2. ( Drake, AL; Emery, S; Farquhar, C; John-Stewart, GC; Kiarie, JN; Matemo, DN; Ongecha-Owuor, F; Overbaugh, J; Richardson, B; Roxby, AC; Wald, A, 2012) |
| "In neonates whose mothers did not receive ART during pregnancy, prophylaxis with a two- or three-drug ART regimen is superior to zidovudine alone for the prevention of intrapartum HIV transmission; the two-drug regimen has less toxicity than the three-drug regimen." | 5.16 | Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. ( Bastos, FI; Bethel, J; Bryson, YJ; Camarca, M; Ceriotto, M; Dickover, R; Fonseca, R; Gray, G; Grinsztejn, B; Joao, EC; Kreitchmann, R; Machado, D; Mirochnick, M; Mofenson, LM; Moreira, RI; Morgado, MG; Moye, J; Mussi-Pinhata, MM; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Santos, B; Siberry, G; Theron, G; Veloso, VG; Watts, DH; Xu, J, 2012) |
| "eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400)." | 5.15 | Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. ( Back, D; Boffito, M; Byakika-Kibwika, P; Coakley, P; Colebunders, R; Kalemeera, F; Khoo, S; Lamorde, M; Merry, C; Namakula, R; Okaba-Kayom, V; Ryan, M, 2011) |
| "From the French Hospital Database on HIV, we selected 439 patients with undetectable viral load (VL) on a first-line boosted PI-containing cART regimen who switched to a PI-free combination including efavirenz, nevirapine or abacavir." | 5.15 | Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir. ( Abgrall, S; Bommenel, T; Costagliola, D; Gilquin, J; Katlama, C; Lascaux, AS; Launay, O; Mahamat, A; Martinez, V; Meynard, JL; Pradier, C; Rouveix, E; Simon, A, 2011) |
| "Nevirapine (NVP) can be safely and effectively administered once-daily but has not been assessed in human immunodeficiency virus (HIV)-infected patients with tuberculosis (TB)." | 5.15 | Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. ( Bhavani, PK; Dilip, M; Iliayas, S; Menon, PA; Narendran, G; Padmapriyadarsini, C; Ponnuraja, C; Pooranagangadevi, NP; Ramachandran, R; Ramesh Kumar, S; Selvaraju, S; Swaminathan, S; Venkatesan, P, 2011) |
| "Widespread use of lamivudine in antiretroviral therapy may lead to hepatitis B virus resistance in HIV-HBV coinfected patients from endemic settings where tenofovir is not readily available." | 5.15 | HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya. ( Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K, 2011) |
| "Artemether-lumefantrine and nevirapine-based antiretroviral therapy (ART) are the most commonly recommended first-line treatments for malaria and HIV, respectively, in Africa." | 5.15 | Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients. ( Barnes, KI; Cohen, K; Kredo, T; Maartens, G; Mauff, K; Smith, P; Van der Walt, JS; Wiesner, L, 2011) |
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 5.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "The aim was to develop a model to describe the population pharmacokinetics of nevirapine in South African human immunodeficiency virus (HIV)-infected patients who were taking nevirapine-based antiretroviral therapy concomitantly or in the absence of rifampicin-based tuberculosis therapy." | 5.14 | Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients. ( Cohen, K; Elsherbiny, D; Jansson, B; McIlleron, H; Simonsson, US; Smith, P, 2009) |
| "Daily nevirapine (NVP) prophylaxis to HIV-exposed infants significantly reduces breast-milk HIV transmission." | 5.14 | Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants. ( Balasubramaniam, U; Bharadwaj, R; Bhore, AV; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kagal, A; Kulkarni, S; Kulkarni, V; Moorthy, A; Patil, S; Persaud, D; Sastry, J; Suryavanshi, N; Thakar, M; Tripathy, S; Venkataramani, V; Ziemniak, C, 2009) |
| "To our knowledge, to date, no prospective, randomized, clinical trial has compared standard doses of efavirenz- and nevirapine-based antiretroviral therapy among patients with concurrent human immunodeficiency virus type 1 (HIV-1) infection and tuberculosis (TB) who are receiving rifampicin." | 5.14 | A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. ( Burapatarawong, S; Likanonsakul, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Prasithsirskul, W; Prommool, V; Ruxrungtham, K; Sungkanuparph, S; Tantanathip, P; Thawornwa, U; Thongyen, S, 2009) |
| "The aim of this study was to evaluate the pharmacokinetics of lamivudine (3TC), stavudine (d4T) and nevirapine (NVP) in HIV-infected Malawian children receiving quartered tablet multiples of Triomune 40 (generic tablet [GT]) compared with individual generic liquid (GL) and trade liquid (TL)." | 5.14 | Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R, 2010) |
| "For almost a decade, single-dose nevirapine (sdNVP) has been proven to be a safe and effective drug for the prevention of mother-to-child transmission (PMTCT) of HIV." | 5.14 | Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia. ( Bweupe, M; Dirks, R; Kabaso, M; Kasonde, P; Mandala, J; Sangiwa, G; Torpey, K, 2010) |
| "Among HIV-infected children previously exposed to nevirapine, switching to nevirapine-based therapy after achieving viral suppression with a ritonavir-boosted lopinavir regimen resulted in lower rates of viremia greater than 50 copies/mL than maintaining the primary ritonavir-boosted lopinavir regimen." | 5.14 | Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY, 2010) |
| "We aim here to determine the appropriate dose of nevirapine (NVP) in Thai HIV-tuberculosis (TB)-coinfected patients receiving rifampicin." | 5.13 | Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. ( Avihingsanon, A; Burger, D; Chuchotaworn, C; Cooper, DA; Gorowara, M; Ishikawa, N; Kantipong, P; Manosuthi, W; Mitarai, S; Moolphate, S; Phanuphak, P; Ruxrungtham, K; Sakornjun, W; Yamada, N; Yanai, H, 2008) |
| "Pregnant HIV-1 seropositive women (CD4+ T-cell count >250 and <500 cells/mm3) electing to breastfeed in Nairobi, Kenya were randomized to highly active antiretroviral therapy (HAART; zidovudine [ZDV], lamivudine and nevirapine [NVP]) during pregnancy and 6 months post-partum or to short-course ZDV plus single-dose NVP (ZDV/NVP)." | 5.13 | Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial. ( Chung, MH; John-Stewart, GC; Kiarie, JN; Kinuthia, J; Lehman, DA; Njiri, F; Overbaugh, J; Richardson, BA, 2008) |
| "In a setting of high perinatal nevirapine use, acute chorioamnionitis was not associated with vertical HIV-1 transmission." | 5.12 | Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission. ( Chi, BH; Goldenberg, RL; Levy, J; Mudenda, V; Sinkala, M; Stringer, JS, 2006) |
| "Nevirapine has been widely used in pregnancy for its efficacy, low pill burden, bioavailability and rapid transplacental transfer." | 5.12 | Safety of nevirapine in pregnancy. ( Anderson, J; de Ruiter, A; Edwards, SG; Hay, P; McDonald, C; Natarajan, U; Pym, A; Taylor, GP; Velisetty, P; Welch, J, 2007) |
| "Large numbers of women receive single-dose nevirapine (sdNVP) to prevent mother-to-child transmission (MTCT) of HIV; over time, an increasing proportion will return to prevention of MTCT programs for a second pregnancy." | 5.12 | Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire. ( Becquet, R; Dabis, F; Dhlamini, P; Ekouevi, DK; Gray, GE; Leroy, V; Lupodwana, P; Martinson, NA; McIntyre, JA; Morris, L; Steyn, JG; Tonwe-Gold, B; Viho, I, 2007) |
| "We conducted a randomized, double-blind trial of three treatment regimens in Thai women who were receiving zidovudine therapy during the third trimester of pregnancy." | 5.11 | Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. ( Jourdain, G; Kanshana, S; Koetsawang, S; Lallemant, M; Le Coeur, S; Mary, JY; McIntosh, K; Ngo-Giang-Huong, N; Thaineua, V, 2004) |
| "We randomly assigned 1844 women in Thailand who received zidovudine during the third trimester of pregnancy to receive intrapartum nevirapine or placebo." | 5.11 | Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. ( Ariyadej, S; Bowonwatanuwong, C; Hammer, S; Jourdain, G; Kantipong, P; Lallemant, M; Le Coeur, S; Leechanachai, P; Leenasirimakul, P; Ngo-Giang-Huong, N, 2004) |
| "To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy." | 5.10 | Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003) |
| " In a prospective study of 31 HIV-infected patients included in a salvage regimen with stavudine, nevirapine, nelfinavir, and saquinavir, viral load decreased a median of 1." | 5.09 | Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure. ( Antela, A; Casado, JL; Dehertogh, P; Dronda, F; Hertogs, K; Martí-Belda, P; Moreno, S; Sabido, R, 2001) |
| "To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study." | 5.09 | Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. ( Balagué, M; Bonjoch, A; Clotet, B; Domingo, P; Francia, E; Fumaz, CR; Gel, S; Johnston, S; Lange, J; Negredo, E; Paredes, R; Romeu, J; Ruiz, L, 2001) |
| " However, zidovudine administered with lamivudine and indinavir was associated with increased risk of preterm births, zidovudine administered with nevirapine was associated with increased risk of stillbirths, and lamivudine administered with stavudine and efavirenz was associated with increased risk of low birth weight." | 4.98 | Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs. ( Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA, 2018) |
| " Second, we discuss the existing clinical data on this topic, including the observational study from Kenya showing women using implants plus efavirenz-based ART had three-fold higher rates of pregnancy than women using implants plus nevirapine-based ART." | 4.95 | Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines. ( Cohen, CR; Kiarie, J; Morroni, C; Patel, RC; Scarsi, KK; Sripipatana, T, 2017) |
| " We aimed to establish whether pregnancy rates differ between HIV-positive women who use various contraceptive methods and either efavirenz-based or nevirapine-based antiretroviral therapy (ART) regimens." | 4.91 | Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. ( Blat, C; Bukusi, EA; Cohen, CR; Gandhi, M; Hagey, J; Newmann, SJ; Onono, M; Patel, RC; Shade, SB; Vittinghoff, E, 2015) |
| " Standard ART includes either nevirapine or efavirenz, however the efficacy of these drugs is limited in patients receiving rifampin treatment for tuberculosis (TB)." | 4.90 | Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis. ( Chen, HJ; Deng, M; Jiang, HY; Ruan, B; Yang, Y; Zhang, MN, 2014) |
| " Further, the addition of single-dose TDF to single-dose nevirapine (SD-NVP) during delivery following maternal ZDV use during pregnancy significantly reduces the frequency of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance." | 4.85 | Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine? ( Foster, C; Gibb, DM; Lyall, H; Olmscheid, B; Pearce, G; Zhang, S, 2009) |
| " Women appear to be at an especially high risk for lactic acidosis, nevirapine-associated rashes and hepatotoxicity, and fat redistribution after highly active antiretroviral therapy exposure." | 4.82 | Sex differences in antiretroviral therapy-associated intolerance and adverse events. ( Clark, R, 2005) |
| "Artemisinin-based combination therapies (ACTs) are the primary treatment for malaria." | 4.31 | Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda. ( Aweeka, F; Ehrlich, H; Freeman, T; French, J; Goodwin, J; Huang, L; Kajubi, R; Kay, K; Li, F; Mwebaza, N; Ou, J; Parikh, S; Riggs, M; Ruiz-Garcia, A; Wade, M; Wang, K, 2023) |
| "Maternal HIV drug resistance and maternal viral load were independent risk factors for vertical transmission during breastfeeding, suggesting that nevirapine alone may be insufficient infant prophylaxis against drug-resistant variants in maternal breast milk." | 4.12 | Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants. ( Beck, IA; Boyce, CL; DeMarrais, P; Flynn, PM; Fowler, MG; Frenkel, LM; Ko, D; Owor, M; Sils, T; Stranix-Chibanda, L; Styrchak, SM; Taha, TE; Tierney, C; Wong-On-Wing, A, 2022) |
| "Nevirapine (NVP) is an effective drug for the treatment of HIV infections, but its use is limited by a high incidence of severe skin rash and liver injury." | 4.12 | Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. ( Cao, Y; Kurogi, K; Liu, MC; Sakakibara, Y; Segawa, K; Suiko, M; Uetrecht, J, 2022) |
| " Younger age, male sex, less education, suboptimal adherence, receiving nevirapine, HIV non-disclosure, never having married and residing in Zimbabwe, Lesotho or Zambia were associated with higher odds of NVL." | 3.96 | Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys. ( Ao, TT; Barradas, DT; Bello, G; Birhanu, S; Brown, K; Frederix, K; Haas, AD; Hakim, AJ; Jahn, A; Jonnalagadda, S; Justman, JE; Kalua, T; Kim, E; Low, A; Mugurungi, O; Mulenga, LB; Musuka, G; Parekh, B; Patel, H; Philip, NM; Radin, E; Rogers, JH; Sachathep, K; Saito, S; Schwitters, AM; Sleeman, K; Thin, K; Tippett Barr, BA; Voetsch, AC; Williams, DB, 2020) |
| "Despite improved policies to prevent mother-to-child HIV transmission (MTCT), adherence to maternal antiretroviral therapy (ART) and infant Nevirapine prophylaxis (NVP) is low in South Africa." | 3.91 | Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa. ( Ayalew, K; Cheyip, M; Chirinda, W; Dinh, TH; Goga, A; Jackson, D; Kindra, G; Larsen, A; Lombard, C; Magasana, V; Ngandu, N, 2019) |
| "Nevirapine has an exceptional record for long-term tolerability with few side effects in human immunodeficiency virus (HIV) combined antiretroviral therapy (cART)." | 3.91 | Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management? ( Bregenzer, A; Kahlert, CR; Notter, J; Vernazza, P, 2019) |
| " This study utilized Bayesian logistic regression to examine maternal-level predictors of adherence to infant nevirapine prophylaxis, including intimate partner violence, maternal adherence, HIV serostatus disclosure reaction, recency of HIV diagnosis, and depression." | 3.88 | A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa. ( Cook, RR; Jones, DL; Peltzer, K; Rodriguez, VJ; Weiss, SM, 2018) |
| "Nevirapine is used in developing countries for the treatment of HIV infection, but its use is associated with rare serious adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)." | 3.88 | A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine. ( Borgiani, P; Ciccacci, C; Ciccacci, F; Lucaroni, F; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Politi, C, 2018) |
| " No baseline differences in depression or suicidal ideation were found between patients ever exposed to efavirenz and those never exposed to efavirenz and receiving nevirapine (P > 0." | 3.88 | Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study. ( Bangsberg, DR; Boum, Y; Bwana, M; Chang, JL; Haberer, JE; Hunt, PW; Martin, JN; Musinguzi, N; Muzoora, C; Siedner, MJ; Tsai, AC, 2018) |
| "Clinical trials demonstrated intermittent preventive treatment in pregnancy with mefloquine (MQ) reduced malaria rates among pregnant women, yet an unexpected higher risk of mother-to-child transmission (MTCT) of HIV among HIV-positive women receiving MQ has also been observed." | 3.88 | Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy. ( Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J, 2018) |
| " We report a case of successive gynecomastia and Stevens-Johnson syndrome (SJS) respectively induced by efavirenz and nevirapine in a single patient." | 3.88 | Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report. ( Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN, 2018) |
| "Syphilis is associated with increased human immunodeficiency virus acquisition and sexual transmission; we examined impact on human immunodeficiency virus mother-to-child transmission among mother-infant pairs enrolled in the India Six-Week Extended-Dose Nevirapine study." | 3.85 | Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission. ( Bharadwaj, R; Bhat, J; Bhosale, R; Bollinger, R; Gupta, A; Gupte, N; Kinikar, A; Kulkarni, V; Mave, V; McIntire, KN; Patil, S; Suryavanshi, N, 2017) |
| "All HIV-infected patients receiving a stable PI/r-based antiretroviral regimen, with persistently suppressed viremia, naïve to non-nucleoside analogues and to integrase strand transfer inhibitors, with mixed hyperlipidaemia, and who underwent a switch from PI/r to nevirapine (Group A) or raltegravir (Group B) or who started rosuvastatin at 10 mg daily (group C) with unchanged antiretroviral regimen were enrolled into the study." | 3.85 | Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study). ( Bon, I; Borderi, M; Bussini, L; Calza, L; Colangeli, V; Magistrelli, E; Re, MC; Viale, P, 2017) |
| "The antiretroviral nevirapine is associated with hypersensitivity reactions in 6%-10% of patients, including hepatotoxicity, maculopapular exanthema, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)." | 3.85 | Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population. ( Alfirevic, A; Borgiani, P; Bourgeois, S; Carr, DF; Castro, EM; Chaponda, M; Dandara, C; Deloukas, P; Haldenby, S; Heyderman, RS; Holden, A; Jones, AR; Kampira, E; Khoo, S; Lalloo, DG; Morris, AP; Munderi, P; Nelson, MR; Novelli, G; Pirmohamed, M; Rigden, DJ; Ssali, F; Takeshita, LY; van Oosterhout, JJ, 2017) |
| " Patients were allocated to 2groups according to exposure to nevirapine during pregnancy." | 3.83 | [Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy]. ( Figueras-Nadal, C; Fortuny-Guasch, C; Iveli, P; Martín-Nalda, A; Noguera-Julian, A; Rovira-Girabal, N; Soler-Palacín, P, 2016) |
| "We investigated the influence of efavirenz (EFV)- or nevirapine (NVP)-based antiretroviral therapy (ART) on lumefantrine plasma exposure in HIV-malaria-coinfected patients and implication of pharmacogenetic variations." | 3.83 | CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2016) |
| " Antiretroviral treatment-naive women started a nevirapine-based triple combination regimen from the third trimester of pregnancy until at least 6 months of exclusive breastfeeding." | 3.83 | Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children. ( Amici, R; Andreotti, M; Baroncelli, S; Galluzzo, CM; Giuliano, M; Jere, H; Mancinelli, S; Marazzi, MC; Palombi, L; Vella, S, 2016) |
| " In the study, women with baseline CD4(+) <350/mm(3) received a combination of stavudine, lamivudine, and nevirapine during pregnancy (from week 25 of gestation) and continued it indefinitely after delivery." | 3.83 | Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Pirillo, MF; Sagno, JB; Scarcella, P; Vella, S, 2016) |
| " We found that nevirapine use and pregnancy are independently associated with severe skin reaction." | 3.83 | Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis. ( Boulle, A; Cohen, K; de Waal, R; Lehloenya, R; Maartens, G; Stewart, A, 2016) |
| " We assessed the relationship between plasma lopinavir or nevirapine concentrations and the risk of subsequent viremia in children initially suppressed on antiretroviral therapy." | 3.83 | Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. ( Abrams, EJ; Castel, S; Coovadia, A; Kuhn, L; Maartens, G; McIlleron, H; Moholisa, RR; Patel, F; Pinillos, F; Schomaker, M; Strehlau, R; Wiesner, L, 2016) |
| "We describe nevirapine and efavirenz exposure on and off tuberculosis treatment and consequences for virological efficacy and tolerance in patients included in the ANRS 12146/12214-CARINEMO trial." | 3.81 | Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship. ( Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; da Silva, C; Furlan, V; Grinsztejn, B; Meggi, B; Taburet, AM, 2015) |
| " The present work envisages the development of a stealth anti-CD4 conjugated immunoliposomes containing two anti-retroviral drugs (nevirapine and saquinavir) that can selectively home into HIV infected cells through the CD4 receptor." | 3.81 | Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV. ( Krishnan, UM; Ramana, LN; Ranga, U; Sethuraman, S; Sharma, S, 2015) |
| "To determine the impact of nevirapine and subclinical mastitis on HIV-1 RNA in maternal plasma and breast milk after intrapartum single-dose nevirapine combined with either 1-week tail of Combivir (zidovudine/lamivudine) or single-dose Truvada (tenofovir/emtricitabine)." | 3.81 | Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis. ( Bygbjerg, IC; Chiduo, MG; Gerstoft, J; Katzenstein, TL; Lemnge, M; Lüneborg-Nielsen, M; Salado-Rasmussen, K; Theilgaard, ZP, 2015) |
| "HIV-malaria co-infected patients in most parts of sub-Saharan Africa are treated with both artemether-lumefantrine (AL) and efavirenz (EFV) or nevirapine (NVP)-based antiretroviral therapy (ART)." | 3.81 | The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. ( Aklillu, E; Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngaimisi, E, 2015) |
| "The objective of this study was to determine the prevalence of drug resistance mutations among HIV-positive women in Malawi 18 months after discontinuing nevirapine-based ART for the prevention of mother-to-child transmission." | 3.81 | Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi. ( Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Vella, S, 2015) |
| "An exit interview was conducted one year post-partum for 85 HIV-infected women who participated in a study of HIV-1 transmission rates among NVP-experienced compared with NVP-naïve women in "The Nevirapine Repeat Pregnancy (NVP-RP) Study" at the Makerere University-Johns Hopkins University Research Collaboration, Kampala-Uganda, between June 2004 and June 2006." | 3.81 | A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study". ( Bakaki, PM; Fowler, MG; Kiweewa, FM; Kusasira, F; McConnell, MS; Mubiru, MC; Musisi, M; Musoke, P; Nakayiwa, F; Nakintu, D; Namirembe, C, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| ", maternal zidovudine and infant ARV prophylaxis) of the World Health Organization's 2010 guidelines, no studies have assessed adherence to ARVs during pregnancy up to the postpartum period." | 3.81 | Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia. ( Chirwa, M; Ishikawa, N; Jimba, M; Kapyata, H; Komada, K; Miyano, S; Msiska, CY; Okawa, S; Syakantu, G; Yasuoka, J, 2015) |
| "We report a case in which an HIV-positive man developed general malaise, skin rash and biochemical hepatitis within days of starting a nevirapine-based antiretroviral treatment regimen." | 3.80 | Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both? ( Helbert, MR; Higgins, SP; Komolafe, AJ; Saxon, CJ, 2014) |
| "To determine whether residual plasma viremia in HIV(+) patients on nevirapine-including antiretroviral therapy (ART) is related to anti-HIV cellular immune responses, a case-control study was conducted comparing residual viremia in patients with detectable and undetectable Gag-specific T-cell responses." | 3.80 | Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response. ( Allavena, C; Billaud, E; Ferré, V; McIlroy, D; Raffi, F; Rodallec, A, 2014) |
| "Data from a prospective multisite cohort study were used to examine the effect of HIV exposure, untreated HIV infection, and single-dose nevirapine on infant growth velocity." | 3.80 | HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants. ( Chhagan, M; Doherty, T; Fadnes, LT; Goga, AE; Jackson, DJ; Lombard, C; Ramokolo, V; Van den Broeck, J, 2014) |
| "We modeled nevirapine (NVP) pharmacokinetics in HIV-infected Malawian patients to assess the relationship between drug exposure and patient characteristics, genetic polymorphisms, and development of hypersensitivity reaction (HSR)." | 3.80 | Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi. ( Carr, DF; Chaponda, M; Dickinson, L; Heyderman, RS; Khoo, SH; Kumwenda, J; Lalloo, DG; Pirmohamed, M; van Oosterhout, JJ, 2014) |
| "Artesunate plus amodiaquine is used for malaria treatment in regions with overlapping HIV endemicity." | 3.80 | Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy. ( Adedeji, WA; Adewole, IF; Akinola, IT; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, FA; Lindegardh, N; Ma, Q; Morse, GD; Murphy, RL; Ojengbede, O; Parikh, S; Scarsi, KK; Taiwo, B; Tarning, J, 2014) |
| "Data from cost studies and other published sources were used to determine the cost, per woman and per cohort (1000 breastfeeding and 1000 non-breastfeeding women), of switching from Option B (maternal triple antiretroviral [ARV] regimen during pregnancy and breastfeeding plus daily nevirapine for the infant for 6 weeks) to Option B+ (maternal triple ARV regimen initiated during pregnancy and continued for life)." | 3.80 | The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV. ( Abimbola, TO; O'Brien, L; Sangrujee, N; Shaffer, N, 2014) |
| "This was a prospective, non-randomized, open-label study conducted in Bagamoyo district, with three arms of HIV-infected adults: efavirenz-based treatment arm (EFV-arm) n = 66, nevirapine-based treatment arm (NVP-arm) n = 128, and control-arm n = 75, with uncomplicated malaria." | 3.80 | Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy. ( Kamuhabwa, AA; Maganda, BA; Minzi, OM; Ngasala, B; Sasi, PG, 2014) |
| "It has been proposed that hepatitis B virus (HBV) sub-genotype A1 infections have mild outcomes and a low risk of drug-resistance among patients infected with human immunodeficiency virus (HIV) receiving lamivudine-containing antiretroviral therapy (ART) without tenofovir in Africa." | 3.80 | Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi. ( Aoudjane, S; Beloukas, A; Chaponda, M; Geretti, AM; González Del Castillo, AA; Hopkins, M; Khoo, S; Noguera, M; O'Connor, J; van Oosterhout, JJ, 2014) |
| "We assessed the pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children while they were receiving nevirapine-containing fixed-dose combination tablets with rifampicin-based tuberculosis treatment and after discontinuation." | 3.78 | Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation. ( Capparelli, E; Chokephaibulkit, K; Cressey, TR; Lapphra, K; Prasitsuebsai, W; Vanprapar, N, 2012) |
| " We compared the pregnancy outcomes of women exposed to EFV and to nevirapine (NVP) during the first trimester." | 3.77 | Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire. ( Amani-Bosse, C; Anglaret, X; Coffie, PA; Dabis, F; Danel, C; Eholié, SP; Ekouevi, DK; Messou, E; Moh, R; Ouattara, E; Sissoko, M, 2011) |
| "To compare the level of HIV-1 residual viremia, defined by a viral load below 50 copies/ml in patients receiving a tenofovir/emtricitabine and nevirapine (NVP) or efavirenz (EFV)-containing regimen." | 3.77 | Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. ( Calvez, V; Flandre, P; Fourati, S; Girard, PM; Haïm-Boukobza, S; Katlama, C; Lavignon, M; Marcelin, AG; Morand-Joubert, L; Sayon, S; Simon, A; Valin, N, 2011) |
| "From the ATHENA cohort study, three scenarios were selected for which the guideline recommended TDM: 1) start of a combination of lopinavir/ritonavir + efavirenz or nevirapine (drug-drug interaction); 2) start of efavirenz (routine TDM); and 3) use of nelfinavir during pregnancy." | 3.77 | Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands. ( Burger, DM; de Wolf, F; Franssen, EJ; Kroon, F; Richter, C; Rigter, IM; Smit, C; van Luin, M; Wit, FW, 2011) |
| "Nevirapine resistance after failed prophylaxis to prevent mother-to-child human immunodeficiency virus (HIV) transmission can compromise subsequent nevirapine-based highly active antiretroviral therapy (HAART)." | 3.77 | Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children. ( Abrams, EJ; Chen, YH; Coovadia, A; Kuhn, L; Meyers, T; Moorthy, A; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2011) |
| "To evaluate the effect of a previous single dose of nevirapine given to prevent mother-to-child transmission of human immunodeficiency virus (HIV) on virologic and immunologic measures after months of an antiretroviral regimen containing either efavirenz or lopinavir-ritonavir." | 3.77 | Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir. ( Dewar, RL; Dlamini, JN; Follmann, DA; Highbarger, HC; Hu, Z; Pau, AK; Somaroo, H, 2011) |
| " Simulations of the nevirapine concentration profile were performed with dosing regimens of 200 mg twice daily and 400 mg once daily for individuals with body weights of 50, 70 and 90 kg in combination with CYP2B6 genetic variation." | 3.77 | Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. ( Back, DJ; Brockmeyer, NH; Davies, G; Egan, D; Fätkenheuer, G; Hendra, H; Johnson, MA; Khoo, S; Mahungu, T; Owen, A; Rockstroh, J; Schipani, A; Siccardi, M; Wyen, C; Youle, M, 2011) |
| " We compared five PMTCT regimens at a fixed level of PMTCT medication uptake: 1) no antenatal ARVs (comparator); 2) sdNVP; 3) WHO 2010 guidelines using "Option A" (zidovudine during pregnancy/infant NVP during breastfeeding for women without advanced HIV disease; lifelong 3-drug antiretroviral therapy (ART) for women with advanced disease); 4) WHO "Option B" (ART during pregnancy/breastfeeding without advanced disease; lifelong ART with advanced disease); and 5) "Option B+:" lifelong ART for all pregnant/breastfeeding, HIV-infected women." | 3.77 | WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers. ( Chu, J; Ciaranello, AL; Dabis, F; Engelsmann, B; Freedberg, KA; Keatinge, J; Maruva, M; Mugwagwa, R; Mushavi, A; Perez, F; Walensky, RP, 2011) |
| " Patients were offered nevirapine-based triple ART initiated in pregnancy until 6 months postpartum." | 3.77 | Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. ( Buonomo, E; Ceffa, S; Haswell, J; Liotta, G; Magid, NA; Marazzi, MC; Narciso, P; Nielsen-Saines, K; Palombi, L; Paturzo, G; Scarcella, P; Zimba, I, 2011) |
| " Unbooked HIV positive pregnant women, who had not received antiretroviral drugs during the antenatal period but received nevirapine in labour, referred to as untreated-maternal HIV infection, were compared with women who received HAART early in pregnancy." | 3.77 | Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection. ( Biodun, O; Joseph, O; Michael, E, 2011) |
| "Compare the risk of HIV drug resistance in women stopping suppressive nelfinavir (NFV)-based or Nevirapine (NVP)-based antiretroviral therapy (ART) after pregnancy." | 3.77 | Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum. ( Ellis, GM; Frenkel, LM; Hitti, J; Huang, S, 2011) |
| "The objective of this cross-sectional observational ('real-world') study was to investigate the effect of three HAART regimens plus stable nevirapine therapy on morphological and metabolic components of lipodystrophy in HIV-infected patients." | 3.77 | Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study. ( Adorni, F; Bagni, P; Carli, F; Garlassi, E; Guaraldi, G; Luzi, K; Menozzi, M; Orlando, G; Stentarelli, C; Zona, S, 2011) |
| " Nevirapine induced rash and SJ syndrome developed within first month of treatment followed by anemia, hepatitis and gastritis which developed within 6 months after initiation of ART." | 3.77 | HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India. ( Anwikar, SR; Bandekar, MS; Kshirsagar, NA; Pazare, AP; Smrati, B; Tatke, PA, 2011) |
| " Baseline median CD4 T-cell count: 417 cell/ųl; 98% received antiretroviral drugs during pregnancy [2 nucleoside analogs plus either nevirapine (55%) or a protease inhibitor (32%)]." | 3.77 | HIV and pregnancy: maternal and neonatal evolution. ( Cecchini, D; Mecikovsky, D; Trinidad, P; Urueña, A; Vesperoni, F, 2011) |
| " Infection with Plasmodium falciparum malaria was confirmed and treatment with quinine commenced together with amoxicillin/clavulanic acid and clarithromycin for possible respiratory infection." | 3.77 | Malaria therapy in HIV: drug interactions between nevirapine and quinine. ( Lewthwaite, P; Uriel, A, 2011) |
| " All women received zidovudine and lamivudine during pregnancy; 76% also received nelfinavir and 8." | 3.76 | Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy. ( Cheng, I; Kuritzkes, DR; Paredes, R; Tuomala, RE, 2010) |
| "To report on 1) clinical, immunological and virological outcomes and 2) safety among human immunodeficiency virus (HIV) infected patients with tuberculosis (TB) who received concurrent nevirapine (NVP) and rifampicin (RMP) based treatment." | 3.76 | Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. ( Bauerfeind, A; Foncha, C; Harries, AD; Kwanjana, J; Manzi, M; Misinde, D; Moses, M; Mwagomba, B; Tayler-Smith, K; Zachariah, R, 2010) |
| "Coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) in HIV-infected patients receiving a commonly used nevirapine-based antiretroviral therapy is a major concern for African clinicians owing to its high prevalence, the infrequent testing and treatment of viral hepatitis, and the impact of liver disease on the tolerability and effectiveness of anti-HIV treatment." | 3.76 | Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. ( Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Ducos, J; Gwet, H; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mbougua, JB; Molinari, N; Mpoudi-Ngolé, E, 2010) |
| "Conflicting data exist regarding the effect of pregnancy on steady-state nevirapine pharmacokinetics (PK), although steady-state nevirapine concentrations during pregnancy have never been characterized in sub-Saharan Africa." | 3.76 | Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women. ( Back, DJ; Boffito, M; Byakika-Kibwika, P; Flaherty, JP; Khoo, S; Lamorde, M; Merry, C; Nakabiito, C; Namakula, R; Okaba-Kayom, V; Ryan, M; Scarsi, KK, 2010) |
| "We describe a case of nevirapine-induced Stevens-Johnson Syndrome (SJS) and fulminant hepatic failure (FHF) requiring liver transplantation." | 3.76 | Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation. ( del Rio Martin, J; Fiel, MI; Huprikar, S; Jao, J; Schiano, T; Sturdevant, M, 2010) |
| "The concurrent use of nevirapine-based antiretroviral therapy (ART) and rifampin-containing anti-tuberculosis regimens for the treatment of HIV and tuberculosis (TB) is common in resource-limited countries." | 3.76 | Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study. ( Chimsuntorn, S; Eampokarap, B; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Tantanathip, P; Thongyen, S, 2010) |
| "This study assessed the effect of stavudine (d4T) 30 mg dosage on lipoatrophy in HIV-infected patients on antiretroviral treatment." | 3.76 | Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon. ( Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA, 2010) |
| "Use of single dose nevirapine (sdNVP) to prevent HIV mother-to-child transmission is associated with the emergence of NVP resistance in many infants who are HIV infected despite prophylaxis." | 3.75 | In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. ( Bagenda, D; Bakaki, P; Church, JD; Donnell, D; Eshleman, SH; Eure, C; Fowler, MG; Guay, LA; Jackson, JB; Matovu, F; McConnell, M; Musoke, P; Mwatha, A; Nakabiito, C; Omer, SB; Thigpen, MC, 2009) |
| "To estimate whether the association between nevirapine (NVP) and hepatotoxicity differs according to pregnancy status in HIV-infected women." | 3.75 | Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure. ( Brogly, SB; French, AL; Hershow, RC; Leighty, RM; Lu, M; Ouyang, DW; Shapiro, DE; Thompson, B; Tuomala, RE, 2009) |
| "Nevirapine (NVP) plasma levels are reduced in patients receiving rifampicin (RFM) for tuberculosis (TB) treatment." | 3.75 | Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. ( Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P, 2009) |
| "To determine the relationship between nutritional status and nevirapine exposure by comparing the pharmacokinetics of nevirapine in HIV-infected children of different ages with and without malnutrition receiving divided tablets of Triomune 30 (stavudine + lamivudine + nevirapine) in accordance with Malawi National Guidelines." | 3.75 | Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets. ( Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S, 2009) |
| "Limited information is currently available on the metabolic profile of nevirapine in pregnancy." | 3.75 | Plasma lipid profile in pregnant women with HIV receiving nevirapine. ( Anzidei, G; Dalzero, S; Floridia, M; Guaraldi, G; Guerra, B; Meloni, AM; Molinari, A; Pinnetti, C; Ravizza, M; Tamburrini, E; Tibaldi, C; Vimercati, A, 2009) |
| "The analysis included 2035 individuals who started antiretroviral therapy with efavirenz (1074 with concurrent tuberculosis) and 1935 with nevirapine (209 with concurrent tuberculosis)." | 3.74 | Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. ( Abrahams, M; Boulle, A; Coetzee, D; Cohen, K; Goemaere, E; Hilderbrand, K; Maartens, G; Mathee, S; Van Cutsem, G, 2008) |
| "Single-dose nevirapine (SD NVP) at birth plus NVP prophylaxis for the infant up to 6 weeks of age is superior to SD NVP alone for prevention of vertical transmission of human immunodeficiency virus (HIV) through breastfeeding." | 3.74 | Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. ( Church, JD; Eshleman, SH; Guay, LA; Huang, W; Jackson, JB; Lidstrom, J; Mmiro, F; Musoke, P; Omer, SB, 2008) |
| "PI substitution with nevirapine improved lipid profile in our patients, although this strategy did not show significant changes in body fat or lipodystrophy." | 3.74 | Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children. ( Amador, JT; Conejo, PR; Fontelos, PM; Gomez, ML; Gonzalez-Tome, MI; Peña, MJ, 2008) |
| "Single-dose nevirapine (SDNVP) for the prevention of mother-to-child HIV transmission (PMTCT) results in the selection of resistance mutants among HIV-infected mothers." | 3.74 | Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study. ( Aldrovandi, GM; Kankasa, C; Kuhn, L; Semrau, K; Sinkala, M; Thea, DM; Walter, J, 2008) |
| "a retrospective study was performed between January 2003 and December 2006 analysing all women prescribed nevirapine in pregnancy." | 3.74 | [Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital]. ( Astori, Ade A; Fernandes, Rde B; Gomes, Sel-K; Kondo, W; Sasaki, Md; Sbalqueiro, RL, 2008) |
| "Seventy patients with human immunodeficiency virus (HIV) and tuberculosis coinfection who initiated nevirapine-based antiretroviral therapy and had trough nevirapine levels determined while receiving rifampicin were enrolled in a study." | 3.74 | Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. ( Inthong, Y; Likanonsakul, S; Manosuthi, W; Phoorisri, T; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S, 2007) |
| "We prospectively followed 27 HIV-infected adult Malawians after starting Triomune (a generic fixed drug combination of stavudine, lamivudine and nevirapine) in the second week of tuberculosis treatment." | 3.74 | Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. ( Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE, 2007) |
| "Drug rash with eosinophilia and systemic symptoms (DRESS Syndrome) associated with nevirapine treatment has not been previously reported in children." | 3.74 | Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection. ( Barton, T; Ramilo, O; Santos, RP, 2007) |
| "Single-dose nevirapine (SDNVP) is widely used to prevent mother-to-child HIV transmission in resource-limited settings." | 3.74 | Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda. ( Bagenda, D; Bakaki, P; Downing, R; Eure, C; Fowler, MG; Greenberg, AE; Matovu, F; McConnell, M; Mubiru, M; Thigpen, MC, 2007) |
| "A previously healthy young man experienced several episodes of syncope while being treated with tenofovir, emtricitabine and nevirapine initiated during primary HIV-1 infection." | 3.74 | Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection. ( Larsen, CS; Lybaek, D, 2008) |
| "To determine the impact of pregnancy on the pharmacokinetics (PK) of nevirapine (NVP) during chronic dosing in HIV-infected women and appropriate NVP dosing in this population." | 3.74 | Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. ( Aweeka, F; Best, B; Burchett, SK; Capparelli, EV; Foca, M; Hitti, J; Hu, C; Jimenez, E; Mirochnick, M; Nachman, S; Read, JS; Shearer, WT; Smith, E; Spector, SA; Stek, A; Thorpe, EM; Watts, H, 2008) |
| "To determine incidence and risk factors of nevirapine (NVP)-associated severe hepatitis that led to NVP discontinuation among HIV-infected patients with CD4 < 250 cells/microL." | 3.74 | Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Mankatitham, W; Manosuthi, W; Moolasart, V; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S, 2008) |
| "There is limited comparative data between efavirenz (EFV) 600 mg/day and nevirapine (NVP) 400 mg/day-based antiretroviral therapy (ART) among HIV-1 patients with tuberculosis (TB) and receiving rifampicin." | 3.74 | Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. ( Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Sungkanuparph, S, 2008) |
| "In the Western Cape province of South Africa, an intensified regimen for the prevention-of-mother-to-child-transmission-of-HIV consisting of zidovudine (AZT) from 34 weeks of pregnancy plus single dose (sd) nevirapine (NVP) during labor was instituted in 2004." | 3.74 | Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa. ( Claassen, M; Cotton, MF; Engelbrecht, S; Laten, JD; Preiser, W; Theron, GB; van Zyl, GU, 2008) |
| "This study used Markov modeling to define the circumstances under which the following interventions would be cost-effective: BF for 6 months with daily infant nevirapine (NVP) prophylaxis; maternal combination antiretroviral therapy (ART) during pregnancy and for 6 months of BF; and maternal combination ART only for women who meet CD4 criteria." | 3.73 | Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding. ( Maclean, CC; Stringer, JS, 2005) |
| "Nelfinavir- or nevirapine-containing HAART regimens during pregnancy are well tolerated." | 3.73 | Nelfinavir and nevirapine side effects during pregnancy. ( Boer, K; de Wolf, F; Dieleman, J; Godfried, MH; Nellen, J; Schneider, ME; Sprenger, H; Tempelman, C; Timmermans, S; van der Ende, ME, 2005) |
| "The incidence of adverse events with nevirapine may be lower than previously reported (13% versus 29%) and may be primarily noted with initiating the drug late in pregnancy." | 3.73 | Third-trimester maternal toxicity with nevirapine use in pregnancy. ( Brady, MT; Fan-Havard, P; Hughes, L; Joy, S; Koletar, SL; Para, MF; Poi, M, 2005) |
| "In countries with high numbers of HIV/tuberculosis coinfection nevirapine and rifampin are used extensively." | 3.73 | Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis. ( Anekthananon, T; Autar, RS; Burger, DM; Cooper, DA; Lange, JM; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sankote, J; Sujaikaew, K; Wit, FW, 2005) |
| "To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity." | 3.73 | Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. ( Bergin, C; Geoghegan, J; Hopkins, S; Kelleher, B; Lyons, F; McCormick, PA; McGeary, A; Mulcahy, FM; Sheehan, G, 2006) |
| "The influence of nevirapine, efavirenz and tenofovir co-administration on ritonavir-boosted atazanavir pharmacokinetics was investigated in HIV (human immunodeficiency virus)-infected patients." | 3.73 | Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients. ( Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O, 2006) |
| " We describe a detailed case of fulminant hepatitis induced by nevirapine (Viramune) and treated by liver transplantation." | 3.73 | Liver transplantation for fulminant hepatitis related to nevirapine therapy. ( Antonini, T; Buyse, S; Castaing, D; Duclos-Vallée, JC; Ichai, P; Samuel, D; Sebagh, M; Vibert, E, 2006) |
| "Both chronic hepatitis C and nevirapine (NVP) use are risk factors for transaminase elevation under highly active antiretroviral therapy." | 3.72 | Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients. ( González-Lahoz, J; González-Requena, D; Núñez, M; Soriano, V, 2003) |
| " We report the case of a pregnant human immunodeficiency virus type 1-infected woman who developed drug rash with eosinophilia and systemic symptoms syndrome and renal failure shortly after initiation of a nevirapine-containing antiretroviral regimen at 27 weeks' gestation." | 3.72 | Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. ( Boswell, H; Fan-Havard, P; Knudtson, E; Para, M, 2003) |
| "At the defined period, 306 patients started a nevirapine-containing regimen, of whom eight developed an acute hepatitis (2." | 3.72 | Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment. ( Beijnen, JH; de Maat, MM; Mairuhu, AT; Mulder, JW; ter Heine, R; van Gorp, EC, 2003) |
| "HAART regimens including nevirapine are associated with faster liver fibrosis progression in HIV-infected patients with chronic hepatitis C." | 3.72 | Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. ( Castellano, V; García-García, JA; Gómez-Mateos, JM; Lozano, F; Macías, J; Merchante, N; Mira, JA; Palacios, RB; Pineda, JA; Sáez, C, 2004) |
| " The majority of the HIV positive mothers received nevirapine in labour while 35% had combination ARV drugs in pregnancy." | 3.72 | Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria. ( Audu, BM; Chama, CM; Kyari, O, 2004) |
| "The following were determined using data from eight African countries: national program costs and impact on infant infections; reductions in adult HIV prevalence and unintended pregnancies among HIV-infected women that would have equivalent impact on infant HIV infections averted as the nevirapine intervention; and the cost threshold for drugs with greater efficacy than nevirapine yielding an equivalent cost per DALY saved." | 3.72 | Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries. ( de Zoysa, I; Denison, J; O'Reilly, KR; Schmid, GP; Sweat, MD, 2004) |
| " In one case, a 43-year-old female health-care worker required liver transplantation after developing fulminant hepatitis and end-stage hepatic failure while taking NVP, zidovudine, and lamivudine as PEP following a needlestick injury (1)." | 3.71 | Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000. ( , 2001) |
| "To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN." | 3.71 | Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. ( Bouwes-Bavinck, JN; Fagot, JP; Mockenhaupt, M; Naldi, L; Roujeau, JC; Viboud, C, 2001) |
| "To describe the experience of four London HIV centres prescribing nevirapine (NVP) to HIV-1 infected pregnant women with respect to immunological and virological response, tolerability and pregnancy outcome." | 3.71 | Experience of nevirapine use in a London cohort of HIV-infected pregnant women. ( de Ruiter, A; Easterbrook, P; Edwards, SG; Hay, P; Larbalestier, N; Taylor, GP; Welch, J, 2001) |
| "To determine whether rifampicin reduces serum concentrations of nevirapine and whether nevirapine modifies serum concentrations of rifampicin, levels of these agents were determined at steady state by high-performance liquid chromatography in 10 HIV-infected patients with tuberculosis." | 3.71 | Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis. ( Crespo, M; Falco, V; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Ruiz, I, 2001) |
| " Risk factors were higher baseline alanine aminotransferase levels, chronic hepatitis B or C virus infection, antiretroviral therapy-naive patients undergoing their first HAART regimen, recent start of a regimen of nevirapine or high-dose ritonavir, and female sex." | 3.71 | Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. ( Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW, 2002) |
| "The nonnucleoside reverse transcriptase inhibitor nevirapine rapidly selects for mutant human immunodeficiency virus (HIV) in vivo." | 3.69 | Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. ( Eastman, S; Gamst, A; Havlir, DV; Richman, DD, 1996) |
| " As of September 1, 1996, ADAP began covering HIV protease inhibitors, viral load evaluations, and other crucial anti-HIV and opportunistic infection agents, including nevirapine for HIV, cidofovir for CMV, and DaunoXome for Kaposi's sarcoma." | 3.69 | New York ADAP to cover new AIDS drugs plus viral load testing. ( Link, D, 1996) |
| "Results of ACTG 076, a clinical trial funded by the National Institute of Allergy and Infectious Disease (NIAID), indicate that perinatal HIV transmission rates could be significantly reduced by treating HIV-positive pregnant women with an intensive zidovudine (AZT) regimen during the second half of pregnancy and during labor and delivery, and by treating the infants for the first six weeks of life." | 3.69 | Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases. ( , 1997) |
| " Participants provided sparse pharmacokinetic (PK) sampling at baseline and weeks 2 and 4 for trough nevirapine determination." | 3.01 | Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention. ( Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Hakim, J; Kanyama, C; Langat, D; Leon-Cruz, J; Mwelase, N; Omoz-Oarhe, A; Podany, AT; Supparatpinyo, K; Swindells, S, 2021) |
| "Nevirapine exposure was assessed in all patients with available blood samples and safety was assessed in all participants." | 3.01 | Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study. ( Bryson, Y; Bwakura-Dangarembizi, M; Capparelli, EV; Chadwick, EG; Coletti, A; Cotton, MF; Hazra, R; Jean-Philippe, P; LeBlanc, R; Mirochnick, M; Naidoo, KL; Nelson, BS; Persaud, D; Reding, C; Ruel, TD; Spector, SA; Tierney, C; Zimmer, B, 2021) |
| " Associations between patient genotype and etonogestrel pharmacokinetic parameters were determined through univariate and multivariate linear regression." | 2.90 | Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. ( Achilles, SL; Chappell, CA; Chen, BA; Lamorde, M; Matovu, J; Nakalema, S; Neary, M; Owen, A; Scarsi, KK; Siccardi, M, 2019) |
| "Nevirapine (NVP) is a key component of antiretroviral prophylaxis and treatment for neonates." | 2.84 | Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates. ( Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S, 2017) |
| " Absence of hypersensitivity reactions, superior resistance profile and once-daily dosing favours abacavir for African children, supporting WHO 2013 guidelines." | 2.82 | Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. ( Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS, 2016) |
| "Levonorgestrel implants were inserted at baseline in all women." | 2.82 | Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks. ( Back, DJ; Buzibye, A; Byakika-Kibwika, P; Cohn, SE; Darin, KM; Dilly Penchala, S; Else, LJ; Lamorde, M; Merry, C; Nakalema, S; Scarsi, KK, 2016) |
| " Hence, this study was aimed to determine population pharmacokinetic parameters in Malaysian HIV-infected patients with a non-parametric approach which allows detection of outliers or non-normal distribution contrary to the parametric approach." | 2.82 | Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach. ( Choon, TS; Hassan, NB; Mustafa, S; Woillard, JB; Yusuf, WN, 2016) |
| " Substituting nevirapine for rilpivirine resulted in ongoing virological suppression and did not have clinically relevant pharmacokinetic effects by cytochrome P450 interactions." | 2.80 | The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients. ( Blonk, M; Burger, D; Rijnders, BJ; Rokx, C; Verbon, A, 2015) |
| "Etravirine RAMs were detected in five (4%) individuals." | 2.80 | Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine. ( Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F, 2015) |
| "The metabolic pathways of dolutegravir and nevirapine suggest a potential pharmacokinetic interaction between these drugs." | 2.80 | Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. ( Allavena, C; Billaud, E; Bouchez, S; Bouquié, R; Dailly, E; Deslandes, G; Grégoire, M; Hall, N; Hernando, H; Jolliet, P; Raffi, F; Reliquet, V, 2015) |
| " There were no differences in adverse events between study arms." | 2.79 | Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial. ( Aizire, J; Allen, M; Andrew, P; Brown, E; Chetty, V; Chipato, T; Coovadia, H; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Herron, CM; Jackson, JB; Kisenge, R; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2014) |
| "To compare steady-state (ss) pharmacokinetic targets of nevirapine extended-release (NVP-XR) tablets once-daily (QD) with immediate-release (NVP-IR) tablet or oral suspension twice-daily in HIV-1-infected children and adolescents." | 2.79 | Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study. ( Anabwani, G; Feiterna-Sperling, C; Giaquinto, C; Königs, C; MacGregor, TR; Mensa, FJ; Mompati, K; Nguyen, T; Nuttall, J; Quinson, AM; Sabo, JP; Yong, CL, 2014) |
| "Etravirine is an NNRTI option for treatment-experienced paediatric patients." | 2.79 | Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study. ( Cahn, P; Chokephaibulkit, K; Dincq, S; Fourie, J; Kakuda, TN; Karatzios, C; Nijs, S; Opsomer, M; Tambuyzer, L; Tomaka, FL; Tudor-Williams, G, 2014) |
| "Bedaquiline is a novel drug for the treatment of multidrug-resistant (MDR) TB; combined use with antiretroviral drugs, nevirapine, or ritonavir-boosted lopinavir (LPV/r) is anticipated, but no clinical data from coinfected patients are available." | 2.79 | Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. ( Dooley, KE; Karlsson, MO; Svensson, EM, 2014) |
| " INH was associated with a 24% increase in median NVP area under the plasma concentration-time curve for the 12 h dosing interval, which was not statistically significant (P = 0." | 2.78 | The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. ( Decloedt, EH; Denti, P; Maartens, G; McIlleron, H; Mwansa-Kambafwile, J; Rangaka, M; Smith, P; van der Walt, JS; Wiesner, L; Wilkinson, RJ, 2013) |
| " In a pharmacokinetic investigation, breast milk and plasma samples of mothers and newborns were collected." | 2.78 | Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns. ( Frank, M; Harms, G; Kloft, C; Kunz, A, 2013) |
| "Nevirapine was assayed by high-performance liquid chromatography (HPLC)." | 2.78 | Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state. ( Barrail-Tran, A; Chou, M; Fan-Havard, P; Haas, DW; Ling, Y; Liu, Z; Taburet, AM, 2013) |
| "We evaluated disease progression among HIV-infected women not on ART with CD4⁺ lymphocyte counts above 200 cells per microliter at delivery." | 2.78 | HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial. ( Brown, ER; Chipato, T; Coovadia, H; Fawzi, W; Fowler, M; George, K; Herron, C; Maldonado, Y; Manji, K; Moodley, D; Nakabiito, C; Reddy, L; Richardson, P; Watts, DH; Zwerski, S, 2013) |
| " Subjects taking concomitant PIs exhibited increases in CsA and TAC exposure (AUC/dose) due to the increased apparent oral bioavailability and decreased apparent oral clearance." | 2.78 | Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. ( Barin, B; Benet, L; Browne, M; Carlson, L; Christians, U; Floren, L; Frassetto, L; Roland, M; Stock, P; Wolfe, A, 2013) |
| "Hepatotoxicity was a common adverse effect of NVP among men and women with CD4 >250 cells per microliter." | 2.78 | The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted. ( Ghanem, KG; Guo, F; Han, Y; Li, T; Li, Y; Qiu, Z; Wang, H; Wang, W; Xie, J; Zhang, C; Zhou, M, 2013) |
| " Adverse events (AEs) were recorded." | 2.77 | Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION). ( Arasteh, K; Cordes, C; Guo, J; Livrozet, JM; Orkin, C; Plettenberg, A; Quinson, A; Robinson, P; Wang, E; Ward, D; Yong, CL, 2012) |
| " The primary efficacy endpoint was HIV-1 infection in infants at 6 months and safety endpoints were adverse reactions in both groups." | 2.77 | Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. ( Andrew, P; Brown, ER; Chetty, V; Chipato, T; Coovadia, HM; Eshleman, SH; Fawzi, W; Fowler, MG; George, K; Guay, L; Kisenge, R; Lynn, DJ; Maldonado, Y; Manji, K; Mofenson, LM; Moodley, D; Msweli, L; Musoke, P; Mwatha, A; Nakabiito, C; Richardson, P; Stranix-Chibanda, L; Zwerski, S, 2012) |
| "Lamivudine resistance was detected by ASP in only 1 of 51 women who received CBV." | 2.77 | Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. ( Boltz, VF; Chow, JY; Coffin, JM; Gray, GE; Hall, DB; Hopley, MJ; Maldarelli, F; Martinson, NA; Mayers, D; McIntyre, JA; Mellors, JW; Palmer, S; Robinson, P, 2012) |
| "NVP pharmacokinetics were modeled by population pharmacokinetic analysis." | 2.77 | Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women. ( Aweeka, FT; Currier, JS; Dong, BJ; Frymoyer, A; Hughes, MD; Lizak, P; Lockman, S; Sawe, F; Verotta, D; Zheng, Y, 2012) |
| " However, long-term use poses adherence challenges, is associated with metabolic toxic effects, restricts second-line options, and is costly." | 2.77 | Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. ( Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Persaud, D; Sherman, G; Strehlau, R; Tsai, WY, 2012) |
| "Twenty-two children received antituberculosis and antiretroviral therapy (ART) concurrently for 4 weeks before pharmacokinetic sampling." | 2.77 | Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. ( Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS, 2012) |
| "Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions." | 2.77 | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. ( Back, D; Byakika-Kibwika, P; de Vries, PJ; Hanpithakpong, W; Katabira, E; Khoo, S; Lamorde, M; Lindegardh, N; Mayanja-Kizza, H; Mayito, J; Merry, C; Nabukeera, L; Namakula, R; Ntale, M; Pakker, N; Ryan, M; Tarning, J, 2012) |
| " Factors that may have contributed to the suboptimal results with nevirapine include elevated viral load at baseline, selection for nevirapine resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the standard ramp-up dosing strategy." | 2.77 | Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. ( Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A, 2012) |
| "42 women (37 VFs, five deaths; 17%) in the NVP and 50 (43 VFs, seven deaths; 20%) in the LPV/r arm reached the primary endpoint (HR 0." | 2.77 | Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. ( Alston-Smith, B; Amod, F; Asmelash, A; Chibowa, M; Chipato, T; Currier, J; Halvas, E; Hogg, E; Hosseinipour, M; Hughes, M; Kimaiyo, S; Lockman, S; McIntyre, J; Mellors, J; Mohapi, L; Rassool, M; Sawe, F; Schooley, R; Shaffer, D; Smith, L; Ssali, F; Zheng, Y, 2012) |
| "The nevirapine adducts were detected in 12/13 patient samples, and quantified in 11/12 samples (2." | 2.77 | Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity. ( Antunes, AM; Branco, T; Caixas, U; Godinho, AL; Grilo, NM; Marinho, AT; Marques, MM; Monteiro, EC; Oliveira, MC; Pereira, SA, 2012) |
| "46%), underweight (27% vs." | 2.77 | Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India. ( Bollinger, RC; Gupta, A; Gupte, N; Khandave, M; Kinikar, AA; Nayak, U; Ram, M; Sastry, J; Shankar, AV, 2012) |
| " A one-compartment model was used for mothers and neonates; the absorption rate constants for mothers and neonates were 0." | 2.76 | Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates. ( Arrivé, E; Avit, D; Benaboud, S; Blanche, S; Dabis, F; Ekouévi, DK; Gray, G; Hirt, D; McIntyre, J; Nerrienet, E; Rey, E; Sim, KL; Tréluyer, JM; Urien, S, 2011) |
| " Multivariate analyses were performed to compare, between the ddI and ZDV groups, the proportion of patients with a viral load <500 copies/ml during follow-up; the increase in the CD4 cell count; survival; treatment changes and severe adverse events." | 2.76 | Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal. ( Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB, 2011) |
| "Birth defects were evaluated among infants on the Pediatric AIDS Clinical Trials Group 316 trial that studied addition of peripartum nevirapine to established ARV regimen for prevention of mother-to-child transmission." | 2.76 | Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. ( Culnane, M; Cunningham, CK; Delfraissy, JF; Huang, S; Kaiser, KA; Mandelbrot, L; Mofenson, L; Newell, ML; Scheuerle, A; Stanley, K; Watts, DH, 2011) |
| " nevirapine on the same background, in naïve HIV-1-infected patients) study compared prospectively ritonavir-boosted atazanavir (ATZ/r) 300 mg/100 mg once daily (qd) with immediate release nevirapine (NVP) 200 mg twice daily or 400 mg qd, each combined with fixed-dose tenofovir 300 mg/emtricitabine 200 mg qd in 569 ARV-naïve HIV-1-infected patients." | 2.76 | Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). ( Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S, 2011) |
| "ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)." | 2.76 | Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. ( Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011) |
| "Severe hyperbilirubinemia (grade 3 or 4) occurred in 7 patients (5." | 2.76 | Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. ( Lueangniyomkul, A; Mankhatitham, W; Manosuthi, W, 2011) |
| " The safety profile of NVP XR was similar to NVP IR, but showed numerically fewer treatment-related adverse events." | 2.76 | Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients. ( Andrade-Villanueva, J; Bogner, J; Cahn, P; Drulak, M; Gathe, J; Horban, A; Nelson, M; Nguyen, T; Podzamczer, D; Quinson, AM; Santiago, S; Spencer, D; Yong, CL; Zhang, W, 2011) |
| " Similarly, the proportion of serious adverse events in the HIVIGLOB/sdNVP and sdNVP arms, respectively, for mothers (18." | 2.76 | Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). ( Antelman, G; Falksveden, L; Fowler, MG; Guay, L; Jackson, JB; Mmiro, F; Moulton, LH; Mubiru, M; Musoke, P; Nakabiito, C; Omer, SB; Onyango-Makumbi, C; Wahren, B; Wigzell, H; Zwerski, S, 2011) |
| "Nevirapine (NVP) is a widely used non-nucleoside reverse transcriptase inhibitor." | 2.76 | Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. ( Arasteh, K; Battegay, M; Berger, F; Bogner, JR; Livrozet, JM; Macha, S; Mossdorf, E; Plettenberg, A; Quinson, AM; Robinson, P; Stern, J; Witt, MD; Yong, CL; Zhang, W, 2011) |
| " Frequency of adverse events (AEs) was similar between arms, with 88." | 2.76 | A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. ( Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S, 2011) |
| "Differences in disease progression occurred from the third year on ART, whereas higher rates of switch to second-line treatment occurred in LCM from the second year." | 2.75 | Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. ( Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E, 2010) |
| "Nevirapine was added at a dose of 200 mg once daily from Days 0 to 14 and 200 mg twice daily from Days 14 to 28." | 2.75 | Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir. ( Cedeño, S; Clotet, B; Deig, E; Maria Llibre, J; Miranda, C; Moltó, J; Negredo, E; Valero, S; Valle, M, 2010) |
| " Six-point pharmacokinetic sampling (0, 2, 4, 6, 8, and 12 h) was undertaken after observed intake with a standardized breakfast." | 2.75 | Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults. ( Dickinson, L; Gibb, DM; Gilks, CF; Kayiwa, J; Khoo, S; Kityo, C; Lutwama, F; Munderi, P; Nalumenya, R; Reid, A; Ssali, F; Tumukunde, D; Walker, AS, 2010) |
| "The chewable FDC was safe and provided therapeutically adequate plasma drug exposures in human immunodeficiency virus-infected children." | 2.75 | A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand. ( Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R, 2010) |
| "Nevirapine clearance was shown to be affected by CYP2B6 516G>T genetic polymorphism and creatinine clearance, although this explained only part of the interpatient variability, which remains low compared to that for other antiretroviral drugs." | 2.75 | Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients. ( Becquemont, L; Bertrand, J; Borand, L; Chou, M; Comets, E; Le Tiec, C; Mentre, F; Ouk, V; Segeral, O; Taburet, AM; Verstuyft, C, 2010) |
| "Children were randomized to initiate antiretroviral therapy with full-dose (FD) nevirapine (Triomune Baby or Junior in the morning and evening) versus DE (half-dose nevirapine for 14 days [Triomune in the morning and stavudine-lamivudine {Lamivir-S} in the evening], then FD), in accordance with World Health Organization weight-band dosing tables." | 2.75 | Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial. ( Burger, D; Chijoka, C; Chintu, C; Cook, A; Ferrier, A; Gibb, DM; Kabamba, D; Kalengo, C; Kankasa, C; Kityo, C; Mulenga, V; Thomason, M; Walker, AS, 2010) |
| "Nevirapine is a nonnucleoside reverse transcriptase inhibitor used as part of combination therapy for human immunodeficiency virus (HIV) infection." | 2.74 | Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis. ( Cammett, AM; Felizarta, F; MacGregor, TR; Mallolas, J; Miailhes, P; Piliero, PJ; Wruck, JM, 2009) |
| "To investigate the pharmacokinetic interaction between darunavir/ritonavir (DRV/r) and nevirapine (NVP) in 19 HIV-infected patients." | 2.74 | Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients. ( De Pauw, M; Hoetelmans, RM; Lefebvre, E; Mariën, K; Pozniak, A; Sekar, V; Vangeneugden, T, 2009) |
| " Grade 3-4 adverse events occurred in 3 cases (2 peripheral neuropathy, and 1 suspected lactic acidosis)." | 2.74 | [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients]. ( Chen, Z; Gong, G; He, Y; Liu, C; Liu, M; Yin, W; Zheng, Y; Zhou, H, 2009) |
| "This home-based HIV-care strategy is as effective as is a clinic-based strategy, and therefore could enable improved and equitable access to HIV treatment, especially in areas with poor infrastructure and access to clinic care." | 2.74 | Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. ( Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW, 2009) |
| " Daily drug dosage was 300 mg Tenofovir, 200mg Emtricitabine and 400 mg Nevirapine once daily." | 2.74 | Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial). ( Flux, K; Gholam, P; Hartmann, M; Hueter, E; Weberschock, T, 2009) |
| "We aimed to compare the steady-state pharmacokinetic parameters and tolerability of Triomune 40 (stavudine 40 mg, lamivudine 150 mg and nevirapine 200 mg) and branded formulations of these drugs in HIV-infected Ugandans." | 2.73 | Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults. ( Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M, 2008) |
| "However, neutropenia was no longer associated with antenatal exposure to HAART after 1 month of age." | 2.73 | Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants. ( Bae, WH; Essex, M; Lockman, S; Onyait, K; Shapiro, RL; Smeaton, LM; Thior, I; Wester, C, 2008) |
| "Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor used in HIV patients and recently evaluated as a differentiating and antiproliferative agent in human malignancies." | 2.73 | Nevirapine toxicity in non-HIV cancer patients. ( Barone, C; Cignarelli, M; De Vis, K; Fabiano, A; Fersini, A; Landriscina, M; Lombardi, V; Piscazzi, A; Santodirocco, M, 2008) |
| " We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products." | 2.73 | Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. ( Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A, 2007) |
| " Mothers in the usZDV/sdNVP group received a loading dose of zidovudine (600 mg administered orally) and continued to receive 300-mg doses of zidovudine orally every 3 h while in labor, and their infants received zidovudine at a dosage of 2 mg per kg of body weight 4 times per day orally for 72 h." | 2.73 | A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe. ( Arbess, G; Boyle, E; Chipato, T; Chitsike, I; Glazier, RH; Gottesman, M; Pilon, R; Silverman, M; Simor, A; Spitzer, RF; Thistle, P, 2007) |
| " Patients taking Triomune had notably higher stavudine Cmax values." | 2.73 | Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. ( Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Mshali, I; Phakati, S; Rezk, NL; van der Horst, C, 2007) |
| "Disease progression was particularly rapid, 85% infants meeting WHO criteria for ART within 6 months." | 2.73 | High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. ( Blanckenberg, N; Goulder, P; Kiepiela, P; McCarthy, N; Mkhwanazi, N; Mphatswe, W; Prendergast, A; Thobakgale, C; Tudor-Williams, G; Walker, BD, 2007) |
| " Pharmacokinetic parameters were calculated using noncompartmental methods, and bioequivalence was assessed using an analysis of variance model." | 2.73 | Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products. ( Dimarco, M; Dodard, C; Guilbaud, R; Marier, JF; Monif, T; Morelli, G; Singla, AK; Thudi, NR; Tippabhotla, SK, 2007) |
| "For optimal adherence, once-daily dosing is best." | 2.73 | Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study. ( Arvieux, C; Chaillot, F; Le Moal, G; Massari, V; Parienti, JJ; Reliquet, V; Vabret, A; Verdon, R, 2007) |
| "HIV-infected women on selected ARV regimens or no ARV were administered DMPA 150 mg intramuscularly and evaluated for 12 weeks for adverse events, changes in CD4+ count and HIV RNA levels, and ovulation." | 2.73 | Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093. ( Clax, PA; Cohn, SE; Hitti, J; Lertora, JJ; Muderspach, L; Park, JG; Stek, A; Watts, DH; Yu, S, 2008) |
| " The primary endpoint was any serious adverse event (SAE) definitely/probably or uncertain whether related to blinded nevirapine/abacavir." | 2.73 | Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). ( , 2008) |
| "Nevirapine C12h was subtherapeutic (< 3." | 2.73 | Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets. ( Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS, 2008) |
| " However, pharmacokinetic knowledge is lacking for specific populations, especially patients with neglected tropical diseases and severe malnutrition." | 2.72 | Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review. ( Beijnen, JH; Dorlo, TPC; Huitema, ADR; Verrest, L; Wilthagen, EA, 2021) |
| "Nevirapine was detected in the cord blood of 244 of 259 (94%) infants whose mothers reported they took nevirapine in labor more than 1 h before delivery and in 12 of 13 (92%) infants whose mothers reported they took nevirapine less than 1 h before delivery." | 2.72 | Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. ( Donnell, D; Fleming, T; Fowler, MG; Guay, L; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Nakabiito, C; Parsons, T, 2006) |
| "Body weight was measured in kilograms with light clothes on." | 2.72 | The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients. ( Olatunji, PO; Olawumi, HO, 2006) |
| " Lower predose nevirapine concentrations were associated with lower cord blood concentrations and a shorter interval between maternal dosing and delivery." | 2.71 | Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose. ( Blanchard, S; Culnane, M; Cunningham, CK; Dorenbaum, A; Gelber, RD; Mirochnick, M; Mofenson, L; Sullivan, JL, 2003) |
| "Nevirapine was associated with a 41% (95% CI 16-59) reduction in relative risk of transmission through to age 18 months." | 2.71 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. ( Allen, M; Bagenda, D; Bakaki, P; Bray, D; Deseyve, M; Ducar, C; Duefield, C; Emel, L; Fleming, T; Fowler, MG; Gigliotti, M; Guay, LA; Jackson, JB; Miotti, P; Mirochnick, M; Mmiro, F; Mofenson, L; Musoke, P; Mwatha, A; Nakabiito, C; Owor, M; Sherman, J, 2003) |
| "The A/S/D regimen had a low efficacy and a high frequency of adverse events and cannot be recommended." | 2.71 | Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine. ( Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, L; Nielsen, H; Obel, N; Pedersen, C, 2003) |
| "Nevirapine was the most commonly prescribed NNRTI (96%)." | 2.71 | Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy. ( Alexander, C; Brumme, ZL; Harrigan, PR; Hertogs, K; Larder, B; Montaner, JS; O'Shaughnessy, MV; Tilley, J; Verbiest, W; Yip, B, 2003) |
| "Randomized, controlled, open-label trial of 233 protease inhibitor- and non-nucleoside reverse transcriptase inhibitor-naive HIV-infected patients allocated to a regimen of nelfinavir and nevirapine (1250/200 mg twice daily; n = 118) or ritonavir and saquinavir (400/400 mg twice daily; n = 115), both in combination with two nucleoside reverse transcriptase inhibitors." | 2.71 | A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors. ( Gerstoft, J; Katzenstein, TL; Kirk, O; Lundgren, JD; Mathiesen, LR; Nielsen, H; Obel, N; Pedersen, C, 2003) |
| "immediate allergy and increased hepatotoxicity (regardless of chronic infection with hepatitis B or C virus and methadone use) for nevirapine." | 2.71 | Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study. ( Calza, L; Chiodo, F; Manfredi, R, 2004) |
| "Cetirizine has no preventive effect on nevirapine-associated rash." | 2.71 | Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial. ( Allaert, FA; Boukli, N; Caumes, E; David, F; Devidas, A; Dupont, B; Launay, O; Lortholary, O; Patey, O; Piketty, C; Prévoteau du Clary, F; Rey, E; Roudière, L; Tréluyer, JM; Urbinelli, R, 2004) |
| " The one adverse event associated with nelfinavir occurred in a subject with a CD4 cell count less than 250 cells/microL." | 2.71 | Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. ( Baker, D; Foca, M; Frenkel, LM; Gandia, J; Gonzalez-Garcia, A; Hitti, J; Huang, S; McNamara, J; Nachman, SA; Paul, ME; Provisor, A; Stek, AM; Stevens, LM; Thorpe, EM; Watts, DH; Wei, LJ, 2004) |
| " Twelve subjects in the QD Group (14%) discontinued treatment due to adverse events, mainly nevirapine-related hepatitis (6%)." | 2.71 | Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach. ( Burger, D; Clotet, B; Galindos, MJ; Gel, S; Miralles, C; Moltó, J; Muñoz-Moreno, JA; Negredo, E; Pedrol, E; Puig, J; Ribera, E; Rodriguez Fumaz, C; Rodríguez, E; Ruiz, L; Viciana, P; Videla, S, 2004) |
| " Adjusting dosage by means of therapeutic drug monitoring would appear to be a reasonable way of maximising patient benefit from treatment." | 2.71 | Follow-up measurements of Nevirapine plasma levels over a prolonged period. ( Ebigbo, A; Klinker, H; Knipper, A; Langmann, P; Sienz, M; Winzer, R; Zilly, M, 2004) |
| "Rash is the most frequent adverse event associated with nevirapine." | 2.71 | Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study. ( Arranz, A; Arroyo, JA; Blanco, JL; Boix, V; Dalmau, D; De la Torre, J; Domingo, P; Force, L; González, A; Gonzalez, J; Knobel, H; Llibre, JM; Mahillo, B; Miró, JM; Montes, ML; Ribera, E; Rivero, A; Rodriguez, D; Sanz, J; Sarasa, M, 2004) |
| "The switching of a PI to nevirapine is a safe and well-tolerated option for maintaining long-term virological suppression and immunological control." | 2.71 | Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. ( Arranz, A; de Górgolas, M; Estrada, V; Fernández-Guerrero, M; García, R; Gil, P; Granizo, JJ; Rivas, P; Yera, C, 2004) |
| "In antiretroviral-experienced subjects with sustained viral suppression, dual therapy with NVP plus LPV/rtv at standard dosage was as potent and safe as standard-of-care HAART at 48 weeks of follow-up." | 2.71 | Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study). ( Burger, D; Clotet, B; Côté, H; López, S; Martínez, E; Miró, O; Moltó, J; Montaner, J; Negredo, E; Puig, J; Rey-Joly, C; Ribalta, J; Ruiz, L; Salazar, J, 2005) |
| "The median NVP level fell to 68 ng/mL (range: <50-228, n = 43) 8 to 14 days after dosing and to 51 ng/mL (range: <50-166, n = 25) between 15 and 21 days." | 2.71 | Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. ( Capparelli, E; Cressey, TR; Jackson, JB; Jourdain, G; Kunkeaw, S; Lallemant, MJ; Mirochnick, M; Musoke, P, 2005) |
| "The aim of this 2NN pharmacokinetic substudy was to investigate the population pharmacokinetics of nevirapine and efavirenz." | 2.71 | Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. ( Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F, 2005) |
| " The incidence of rash in the NVP group was significantly higher in female patients with higher CD4 cell counts, while adverse events in the EFV group were not associated with CD4 cell count." | 2.71 | The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. ( Andrews, S; Grinsztejn, B; Lange, JM; Lazanas, MK; Montaner, J; van Leth, F; Wilkins, E, 2005) |
| "Lipodystrophy was evaluated by clinical examination and morphological measurements." | 2.71 | Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. ( Crespo, M; Ferrer, E; Fisac, C; Fumero, E; Gatell, JM; Podzamczer, D; Ribera, E; Roson, B; Virgili, N, 2005) |
| " Our objective was to determine intracellular (or cell-associated) nevirapine concentrations over the full dosing interval and to relate protein binding and P-glycoprotein (P-gp) expression to intracellular exposure." | 2.71 | Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals. ( Almond, LM; Back, DJ; Bonington, A; Dalton, M; Edirisinghe, D; Khoo, SH, 2005) |
| " Therapy was discontinued in 18 patients due to virological failure in 11, adverse events in seven, loss to follow-up or withdrawal of consent in four and death in one." | 2.71 | Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients. ( Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A, 2005) |
| " Clinical assessment included plasma HIV-1 RNA, blood chemistry, haematology, lymphocyte counts and adverse events reports." | 2.71 | A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load. ( Arranz Caso, JA; Castilla, V; Estrada, V; Fernández Guerrero, M; Górgolas, M; López, JC; Molina, JP; Santos, I; Sanz, J, 2005) |
| " Intensive pharmacokinetic sampling occurred after 4 weeks of therapy." | 2.71 | Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403. ( Acosta, EP; Aldrovandi, G; Chen, J; Damle, B; Hodge, J; Hughes, MD; King, JR; Nachman, S; Wiznia, A; Yogev, R, 2005) |
| "Nevirapine resistance was more frequent in infants with subtype C than with subtypes A and D (87 versus 50%, P = 0." | 2.71 | Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. ( Chen, S; Eshleman, SH; Fiscus, SA; Guay, LA; Hoover, DR; Hudelson, SE; Jackson, JB; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, T, 2005) |
| " Population pharmacokinetic parameters (apparent clearance (CL/F), volume of distribution (V/F), absorption rate constant (k a)) were estimated, as were interindividual, interoccasion, and residual variability in the pharmacokinetics." | 2.70 | Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. ( Beijnen, JH; de Maat, MM; Huitema, AD; Meenhorst, PL; Mulder, JW; van Gorp, EC, 2002) |
| "Hydroxyurea has been administered with nucleoside analogues to modulate intracellular dNTP pools and thus the ratio of drug triphosphate:endogenous triphosphate." | 2.70 | Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea. ( Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R, 2002) |
| " The differences between the pharmacokinetic parameters of efavirenz with and without nevirapine were analyzed, and the pharmacokinetics of nevirapine were compared with those in historical control patients." | 2.70 | The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. ( Beijnen, JH; Carlier, H; Gazzard, B; Harris, M; Hoetelmans, RM; Johnson, M; Kwakkelstein, MO; Lange, JM; Montaner, JS; Moyle, G; Reiss, P; van Leeuwen, R; Veldkamp, AI; Youle, M, 2001) |
| "The purpose of the current study was to determine the efficacy and safety of nevirapine combined with nelfinavir and two nucleoside reverse transcriptase inhibitors (NRTIs) in patients previously exposed to highly active antiretroviral therapy (HAART)." | 2.70 | The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study. ( Black, FT; Jensen-Fangel, S; Larsen, L; Obel, N; Thomsen, HF, 2001) |
| "Limited data are available on antiretroviral drug concentrations in seminal plasma during a dosing interval." | 2.70 | Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. ( de Vries, JW; Hoetelmans, RM; Lange, JM; Prins, JM; Repping, S; van Praag, RM, 2001) |
| " Initial dose pharmacokinetic profiles in the pregnant women were similar to those seen in nonpregnant adults." | 2.70 | Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure. ( Fenton, T; Lugo, M; Mirochnick, M; Siminski, S; Sullivan, JL, 2001) |
| " Three patients discontinued therapy for drug-related adverse events." | 2.70 | Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. ( Benson, CA; Brun, SC; Deeks, SG; Eron, JJ; Feinberg, J; Gulick, RM; Hicks, C; Hsu, A; Japour, AJ; Kempf, D; Kessler, HA; King, M; Murphy, RL; Real, K; Riddler, S; Sax, PE; Stryker, R; Sun, E; Thompson, M; Wheeler, D, 2002) |
| " Overall, in 12 patients treated with hydroxyurea, 33 adverse events were reported versus 19 reported for 12 patients who did not receive hydroxyurea (p <." | 2.70 | Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection. ( Cahn, P; Federico, A; Kijak, G; Montaner, JS; Ochoa, C; Perez, H; Salomon, H; Zala, C, 2002) |
| "As part of an on-going clinical trial in Malawi, infants born to women who received (early presenters) or did not receive (late presenters) standard intrapartum nevirapine (NVP) dosing were randomized to receive orally either single dose NVP alone or NVP plus zidovudine (twice daily for 1 week)." | 2.70 | Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants. ( Broadhead, R; Fiscus, S; Gibbons, A; Hoover, D; Kumwenda, N; Lema, V; Liomba, G; Mukiibi, J; Taha, TE, 2002) |
| "Concomitant administration of NVP at steady state with EE/NET resulted in a significant (29%) median reduction in the area under the plasma concentration time curve (AUC(infinity)) and a significant reduction in mean residence time (MRT) and half-life (t(1/2)) of EE." | 2.70 | Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. ( Hutman, HW; Lamson, M; Marshak, A; McDonough, M; Mildvan, D; Robinson, P; Yarrish, R, 2002) |
| "Rates of disease progression or death were 23% (11/47), 25% (13/53), and 12% (6/51) for the zidovudine plus nevirapine, zidovudine plus didanosine, and triple drug therapy groups, respectively (P=." | 2.69 | A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. ( Conway, B; Cooper, D; Hall, D; Harris, M; Lange, JM; Montaner, JS; Myers, M; Reiss, P; Robinson, P; Smith, D; Vella, S; Wainberg, MA, 1998) |
| "Nevirapine plasma levels were within the expected range, while indinavir levels were lower than expected." | 2.69 | A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. ( Conway, B; Durakovic, C; Fransen, S; Harris, M; Montaner, JS; Raboud, J; Rae, S; Shillington, A, 1998) |
| "Nevirapine elimination was prolonged in both mothers and infants, with median half-lives ranging from 36." | 2.69 | Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. ( Beckerman, K; Fenton, T; Gagnier, P; Gwynne, M; Jimenez, E; Mirochnick, M; Pav, J; Siminski, S; Spector, SA; Sperling, RS; Sullivan, JL; Yogev, R, 1998) |
| " The relative bioavailability (F) of ZDV and ddI in the triple combination compared to that in the double combination was also evaluated." | 2.69 | Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. ( D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Myers, M; Sheiner, LB; Sommadossi, JP; Zhou, XJ, 1999) |
| " Nevirapine significantly reduced median indinavir Cmin (47." | 2.69 | Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. ( Dusek, A; Hall, DB; Lamson, M; Murphy, RL; Myers, M; Sommadossi, JP, 1999) |
| "Nevirapine, 200 mg, was given as a single dose during labor to 21 HIV-1-infected pregnant Ugandan women." | 2.69 | A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). ( Allen, M; Bagenda, D; Dransfield, K; Elliott, T; Fleming, T; Fowler, MG; Guay, LA; Hom, D; Horton, S; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, L; Murarka, A; Musoke, P; Nakabiito, C; Pav, JW, 1999) |
| "The dNN study evaluated the safety, efficacy and pharmacokinetic interactions of the combination of stavudine (2',3'-didehydro-2',3'-dideoxythymidine; D4T), nelfinavir and nevirapine in 25 HIV-infected subjects who received treatment for up to 29 weeks." | 2.69 | dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions. ( Skowron, G, 1998) |
| " Non-compartmental methods were used to calculate the area under the plasma concentration versus time curve (AUC[24h]), and the maximal (Cmax) and minimal plasma concentration (Cmin), the time to Cmax (t(max)), the plasma elimination half-life (t1/2), the apparent oral clearance (Cl/F) and the apparent volume of distribution (V/F)." | 2.69 | The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. ( Beijnen, JH; Danner, SA; Foudraine, NA; Hoetelmans, RM; Kwakkelstein, MO; Lange, JM; Meenhorst, PL; Mulder, JW; Reiss, P; van Heeswijk, RP; Veldkamp, AI; Wit, FW, 2000) |
| "The appearance of rash is one of the most frequent and limiting side-effects during the first 4 weeks of treatment with nevirapine (NVP)." | 2.69 | Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. ( Barreiro, P; Casas, E; de Requena, DG; Estrada, V; González-Lahoz, J; Hoetelmans, R; Jimenéz-Nácher, I; Soriano, V; Téllez, MJ, 2000) |
| " This pharmacokinetic interaction study was nested within a larger Phase III clinical trial conducted to characterize the safety and efficacy of coadministered nevirapine and lamivudine." | 2.69 | Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection. ( Lamson, MJ; Leitz, G; MacGregor, TR; Sabo, JP; Yong, CL, 2000) |
| "Nevirapine was well tolerated in the doses tested." | 2.68 | Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. ( Cheeseman, SH; Greenough, TC; Hall, D; Hattox, SE; Havlir, D; McLaughlin, MM; Myers, M; Spector, SA; Stein, DS; Sullivan, JL, 1995) |
| "Risk for disease progression did not differ between the two groups (relative hazard of the triple-combination group, 1." | 2.68 | Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco ( Basgoz, N; D'Aquila, RT; Fischl, MA; Hirsch, MS; Hughes, MD; Johnson, VA; Liou, SH; Myers, M; Niu, M; Sommadossi, JP; Timpone, J, 1996) |
| "Nevirapine is a non-nucleoside reverse transcriptase inhibitor of HIV-1 which exhibits synergy in vitro with zidovudine (ZDV) and also is active against ZDV-resistant HIV." | 2.68 | A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group. ( Boucher, CA; Carr, A; Cooper, DA; de Jong, MD; Imrie, A; Sorice, F; Vella, S, 1996) |
| "To determine which non-nucleoside reverse transcriptase inhibitor, either EFV or NVP, is more effective in suppressing viral load when given in combination with two nucleoside reverse transcriptase inhibitors as part of initial antiretroviral therapy for HIV infection in adults and children." | 2.53 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. ( Irlam, JH; Mbuagbaw, L; Mursleen, S; Rutherford, GW; Siegfried, N; Spaulding, AB, 2016) |
| " However, there are challenges to initiation of ART in early life, including the possibility of drug resistance in the context of prevention of mother-to-child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long-term toxicities." | 2.50 | Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. ( Abrams, E; Muhe, LM; Penazzato, M; Prendergast, AJ; Tindyebwa, D, 2014) |
| "Regimen simplification can be defined as a change in established effective therapy to reduce pill burden and dosing frequency, to enhance tolerability, or to decrease specific food and fluid requirements." | 2.49 | Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV. ( Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G, 2013) |
| "We systematically reviewed adverse events among treatment-naive HIV-positive adults and children receiving either NVP or EFV as part of first-line antiretroviral therapy." | 2.49 | Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis. ( Andrieux-Meyer, I; Calmy, A; Ford, N; Hargreaves, S; Mills, EJ; Renaud-Théry, F; Shaffer, N; Shubber, Z; Vitoria, M, 2013) |
| " However, there are challenges to initiate ART in early life, including the possibility of drug resistance in the context of prevention of mother-to-child transmission (PMTCT) programs, a paucity of drug choices , uncertain dosing for some medications and long-term toxicities." | 2.48 | Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. ( Cotton, M; Gibb, D; Penazzato, M; Prendergast, A; Tierney, J, 2012) |
| "We reviewed studies comparing serious adverse NVP-related events among ART-naive pregnant women who commenced therapy at higher v." | 2.48 | Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis. ( Bera, E; Mia, R, 2012) |
| " Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more convenient once-a-day antiretroviral combination." | 2.47 | Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation. ( Parienti, JJ; Peytavin, G, 2011) |
| " The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial." | 2.47 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, N; Sint, TT; van der Merwe, L, 2011) |
| "Nevirapine (NVP) was the first non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for the treatment of HIV infection and quickly became one of the most extensively used antiretrovirals (ARVs) worldwide." | 2.47 | Guidelines for the use of extended-release nevirapine in HIV-infected patients. ( Corbett, AH; Heil, EL, 2011) |
| " More comprehensive in vivo pharmacokinetic data are required to justify the potential use of these agents as safe and effective options during pregnancy." | 2.47 | Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid). ( Back, DJ; Else, LJ; Khoo, SH; Taylor, S, 2011) |
| "To determine which NNRTI, EFV or NVP, is more efficacious when given in combination with two NRTIs as part of initial ART for HIV infection in adults and children." | 2.46 | Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. ( Irlam, JH; Mbuagbaw, LC; Rutherford, GW; Siegfried, N; Spaulding, A, 2010) |
| " Sources included adverse event reports from pharmaceutical manufacturers and the US FDA, reports from peer-reviewed journals/scientific meetings and the Research on Adverse Drug events And Reports (RADAR) project." | 2.45 | Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project. ( Bennett, CL; Chandler, KL; Differding, V; Johnson, S; McKoy, JM; Obadina, E; Palella, F; Parada, JP; Raisch, DW; Scarsi, KK; Scheetz, MH; Sutton, S; Yarnold, PR, 2009) |
| " The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial." | 2.44 | Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. ( Brocklehurst, P; Siegfried, NL; van der Merwe, L; Volmink, J, 2007) |
| " Both drugs have demonstrated interindividual pharmacokinetic variability." | 2.44 | Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring? ( Dahri, K; Ensom, MH, 2007) |
| "Nevirapine has a long half-life and achieves high steady-state plasma concentrations relative to the concentration required to inhibit 50% viral replication in vitro (IC(50)) in patients." | 2.44 | Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review. ( Cooper, CL; van Heeswijk, RP, 2007) |
| "Nevirapine resistance has been detected in a considerable proportion of women after single-dose nevirapine (SD-NVP) for the prevention of mother-to-child human immunodeficiency virus-1 transmission." | 2.44 | Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter? ( Eshleman, SH; Kourtis, AP; McConnell, MS; Stringer, JS; Weidle, PJ, 2007) |
| " All papers, abstracts, or presentations, regardless of study design, that made reference to the response of patients who were switched from one NNRTI to another as a result of an adverse drug reaction were included." | 2.44 | Is it safe to switch between efavirenz and nevirapine in the event of toxicity? ( Maartens, G; Mehta, U, 2007) |
| "Ideally, an anti-HIV drug should (1) be highly active against wild-type and mutant HIV without allowing breakthrough; (2) have high oral bioavailability and long elimination half-life, allowing once-daily oral treatment at low doses; (3) have minimal adverse effects; and (4) be easy to synthesize and formulate." | 2.43 | In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). ( Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P, 2005) |
| " These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice." | 2.43 | Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005) |
| " Based on current knowledge, the immense benefits of antiretroviral prophylaxis in reducing the risk of MTCT, far outweigh the potential for adverse effects." | 2.43 | The safety of antiretroviral drugs in pregnancy. ( Newell, ML; Thorne, C, 2005) |
| " There was no statistically significant difference between once daily or twice-daily dosing of NVP, when used in combination with 3TC and d4T (RR = 1." | 2.43 | Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. ( Mahomed, FA; Rutherford, GW; Siegfried, NL; Van Deventer, PJ, 2006) |
| " To minimize toxicity, clinicians must adhere to dosing guidelines, avoid prescribing the drug in patients with known increased risk of toxicity, and promptly recognize toxicities, which are mainly cutaneous and hepatic." | 2.43 | Nevirapine toxicity. ( Taiwo, BO, 2006) |
| "Despite the benefits of protease inhibitor (PI)-based HIV treatment, issues of tolerability, dosing frequency, pill count and long-term metabolic complications necessitate evaluation of alternate treatment strategies." | 2.43 | Evaluation of nevirapine-switch strategies for HIV treatment. ( Cooper, CL, 2006) |
| " PI-based therapies often fail due to poor adherence caused by heavy pill burden, complex dosing schedules and undesirable side effects." | 2.42 | Clinical utility of current NNRTIs and perspectives of new agents in this class under development. ( Hamatake, R; Hong, Z; Zhang, Z, 2004) |
| "Nevirapine has a beneficial effect on the lipid profile in both treatment-naive and -experienced patients." | 2.42 | Nevirapine in the treatment of HIV. ( Martínez, E; Milinkovic, A, 2004) |
| "Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase." | 2.41 | Nevirapine: pharmacokinetic considerations in children and pregnant women. ( Clarke, DF; Dorenbaum, A; Mirochnick, M, 2000) |
| " Although possessing a common mechanism of action, these agents can be differentiated by both molecular and pharmacokinetic characteristics." | 2.41 | Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. ( DiCenzo, R; Morse, GD; Smith, PF, 2001) |
| "We describe two cases of toxic epidermal necrolysis developed during an antiretroviral therapy regimen containing nevirapine." | 2.41 | Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature. ( Cattelan, AM; Lanzafame, M; Meneghetti, F; Sasset, L; Sgarabotto, D; Trevenzoli, M, 2001) |
| "Nevirapine is a potent antiretroviral agent whose use, especially as monotherapy, may be limited by rapid onset of resistance as well as by hypersensitivity reactions." | 2.39 | Current clinical experience with nevirapine for HIV infection. ( Carr, A; Cooper, DA, 1996) |
| "Thrombocytopenia was higher in children with WHO Stage III/IV, lower in children on zidovudine, and had no association with use of lamivudine or nevirapine, CD4 + suppression, age, and nutrition status." | 1.91 | Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy. ( Airewele, G; Bulsara, S; Despotovic, J; Elyanu, P; Grimes, A; Haq, H; Kekitiinwa, A; Kim, TO; Lubega, J; Lumumba, M; Matshaba, M; Musoke, P; Peckham, E; Scheurer, M; Wanless, SR, 2023) |
| "Abacavir was found at high concentrations to a maximum of 40." | 1.91 | Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits. ( Kunene, PN; Mahlambi, PN, 2023) |
| "Abacavir was dominant in water while efavirenz was dominant in soil/sediments." | 1.91 | Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment. ( Mahlambi, P; Ngwenya, N, 2023) |
| "Nevirapine was the only ARVD detected in crops grown with NUC and struvite on both soils, but the concentrations were below the limit of quantification." | 1.91 | Uptake of selected antiretrovirals by pepper (Capsicum annum), radish (Raphanus sativus), and ryegrass (Lolium perenne) grown on two contrasting soils and fertilized with human urine-derived fertilizers. ( Abafe, OA; Badza, T; Hughes, JC; Lawal, MA; Martincigh, BS; Migeri, S; Odindo, AO, 2023) |
| " This study aimed to develop a population pharmacokinetic model to characterize the disposition of maraviroc in neonates to inform dosing regimens and expand available options." | 1.72 | Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life. ( Best, BM; Bradford, S; Capparelli, EV; Chadwick, EG; Jean-Philippe, P; Liyanage, M; McFadyen, L; Mirochnick, M; Moye, J; Nikanjam, M; Rogg, L; Vourvahis, M; Whitson, K, 2022) |
| "Buprenorphine CL/F was 76% higher in HIV+ patients (n = 17) than HIV- patients (n = 37)." | 1.72 | Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability. ( Bart, G; Brundage, RC; Giang, LM; Jaber, M; Korthuis, PT, 2022) |
| "Methadone treatment of opioid use disorder in HIV-infected individuals is complicated by drug-drug interactions." | 1.62 | Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study. ( Bart, G; Brundage, RC; Giang, LM; Hodges, JS; Yen, H, 2021) |
| "Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that retains activity against common NNRTI resistance mutations." | 1.62 | Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients. ( Bociąga-Jasik, M; Hlebowicz, M; Jakubowski, P; Parczewski, M; Raczyńska, A; Scheibe, K; Szetela, B; Szymczak, A; Urbańska, A; Łojewski, W, 2021) |
| "NVP/ZDV/3TC started in the first week of life was safe and effective, even when trough NVP levels were below target." | 1.62 | Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life. ( Ajibola, G; Batlang, O; Bennett, K; Capparelli, EV; Hughes, MD; Jean-Philippe, P; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Mohammed, T; Moyo, S; Sakoi, M; Shapiro, RL, 2021) |
| "2% (30/185) with improper dosage or prescription errors." | 1.62 | Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS. ( Morales-Pérez, M, 2021) |
| "Lopinavir was mostly requested in patients when adherence measures did not correlate with the clinical picture, suspected non-adherence, lopinavir-rifampicin interactions and for neonatal safety monitoring." | 1.56 | Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital. ( Decloedt, EH; Engelbrecht, AE; Norman, J; Rabie, H; Wiesner, L, 2020) |
| " There were no clinically relevant toxicities nor adverse events in both control and test arms." | 1.56 | Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria. ( Abideen, G; Adeniji, H; Adeuja, O; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, AA; Busari, AW; Hassan, OO; Ken-Owotor, C; Kogbe, S; Ogunfowokan, T; Onwujuobi, AG; Oreagba, IA; Owolabi, ET; Usman, SO, 2020) |
| " We evaluated the adverse events associated with the use of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP) for neonatal PEP during the first 6 weeks of life." | 1.51 | Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. ( Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P, 2019) |
| "Nevirapine has been used as antiretroviral agent since early '90." | 1.48 | Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. ( Cattaneo, D; Cheli, S; Clementi, E; Di Cristo, V; Falvella, FS; Galli, M; Giacomelli, A; Lupo, A; Oreni, ML; Renisi, G; Ridolfo, AL; Riva, A; Rusconi, S, 2018) |
| " Secondary endpoints were time to loss of virological response and adverse events." | 1.46 | Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan. ( Chang, HM; Chen, YS; Kunin, CM; Lee, CY; Lee, SS; Tsai, HC, 2017) |
| "Traditional medication adherence measures do not account for the pharmacokinetic (PK) properties of the drugs, potentially misrepresenting true therapeutic exposure." | 1.46 | Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children. ( Ayaya, SO; Liu, H; Nyandiko, WM; Scanlon, ML; Slaven, JE; Tu, W; Vreeman, RC, 2017) |
| "Sparse pharmacokinetic sampling of ENG, NVP, or EFV were performed at screening, entry, and then 1, 4, 12, and 24-week postimplant insertion." | 1.46 | Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy. ( Achilles, SL; Chappell, CA; Chen, BA; Cohn, SE; Darin, KM; Lamorde, M; Mackline, H; Nakalema, S; Riddler, SA; Scarsi, KK, 2017) |
| " However, studies have shown that this dosing strategy based on adult studies may not be appropriate in children, given that younger children have higher drug clearance rates." | 1.46 | Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring. ( A K, HK; D'souza, RR; Gopalan, BP; Mehta, K; Rajnala, N; Ramachandran, G; Shet, A, 2017) |
| "zidovudine (AZT)) were associated with earlier VF." | 1.46 | Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam. ( Cuong, DD; Dung, NT; Dung, NTH; Haneuse, S; Kinh, NV; Matsumoto, S; Oka, S; Tanuma, J; Thuy, PTT; Trung, NV; Vu, TV, 2017) |
| " Here we aimed to quantify nevirapine and LPV/r drug-drug interaction effects on bedaquiline and M2 in patients co-infected with HIV and multidrug-resistant tuberculosis (MDR-TB) using population pharmacokinetic (PK) analysis and compare these with model-based predictions from single-dose studies in subjects without TB." | 1.46 | Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. ( Brill, MJ; Karlsson, MO; Maartens, G; Pandie, M; Svensson, EM, 2017) |
| " The most common adverse events potentially attributable to combination antiretroviral therapy were transient asymptomatic hyperlactatemia (26%), anemia (24." | 1.46 | Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission. ( Bitnun, A; Brophy, J; Campbell, DM; Colantonio, D; Kakkar, F; Lau, E; Murphy, K; Read, SE; Samson, L; Seto, W; Yudin, MH, 2017) |
| " Blood plasma was collected at 1, 4 and 24 hours post-ART dosing from 58 subjects receiving NVP-containing ART and used to determine cNVP and viral load (VL)." | 1.46 | Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. ( Aman, RA; Kimulwo, MJ; Kokwaro, GO; Muigai, AW; Ochieng, DJ; Ochieng, W; Ogutu, BR; Okendo, J; Oloo, FA, 2017) |
| " The form is designed to obtain information on the demographics of the patients, WHO clinical stage of their HIV infection, HAART regimen for the patients, and suspected adverse events associated with the antiretroviral drugs used by the patients." | 1.43 | A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria. ( Awodele, O; Oshikoya, KA; Popoola, TD, 2016) |
| " Plasma concentrations were measured as therapeutic drug monitoring while a subset of patients underwent intensive 12-hour pharmacokinetic evaluation." | 1.43 | Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. ( Bonora, S; Calcagno, A; Calza, L; Capetti, A; Cenderello, G; D'Avolio, A; Di Perri, G; Guaraldi, G; Lanzafame, M; Marinaro, L; Montrucchio, C; Tettoni, MC; Trentini, L, 2016) |
| "Compared with zidovudine-lamivudine, the use of tenofovir-lamivudine or emtricitabine in combination with nevirapine was a strong predictor of virologic failure in our cohort, which was not explained by other risk factors or criteria for regimen selection." | 1.43 | Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. ( Agbaji, OO; Darin, KM; Eisen, G; Gashau, W; Kanki, PJ; Meloni, ST; Murphy, RL; Nkado, R; Okonkwo, P; Onwujekwe, DI; Rawizza, HE; Scarsi, KK; Tchetgen Tchetgen, EJ, 2016) |
| "Bedaquiline is a new anti-TB drug, which is metabolized by cytochrome P450 (CYP) 3A4." | 1.43 | Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. ( Conradie, F; Hughes, J; Maartens, G; McIlleron, H; Pandie, M; Siwendu, S; Variava, E; Wiesner, L, 2016) |
| "Universal multi drug antiretroviral treatment in pregnancy is a global priority in our bid to eliminate paediatric HIV infections although few studies have documented the impact of antiretroviral coverage on overall pregnancy outcomes." | 1.43 | Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa. ( Maharaj, N; Moodley, D; Moodley, T; Sartorius, B; Sebitloane, M, 2016) |
| " The aim of this study was to compare the rate of any discontinuation of antiretroviral (ARV) regimen because of virologic failure (VF), and/or adverse drug reaction (ADR) among patients receiving stable ARV regimens for at least 6 months." | 1.43 | Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study. ( Bani-Sadr, F; Cabie, A; Cotte, L; de Boissieu, P; Delobel, P; Dramé, M; Garraffo, R; Huleux, T; Poizot-Martin, I; Raffi, F; Rey, D, 2016) |
| "Nevirapine (39." | 1.43 | Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China. ( Bai, JS; Chen, JH; He, LP; Jin, YM; Kuang, YQ; Li, YY; Liu, J; Wen, J; Yu, M, 2016) |
| "Nevirapine is a reverse-transcriptase inhibitor widely used in combination therapy to treat HIV infection." | 1.43 | Exploring CYP2B6 activity by measuring the presence ofnevirapine hydroxy metabolites in plasma. ( Ab Rahman, AK; Hassan, NB; Low, LL; Mustafa, S; Tan, SC; Wan Yusuf, WN, 2016) |
| " In conclusion, this genotypic resistance analysis strongly suggests that the latest NNRTI, rilpivirine, may retain activity in a large proportion of HIV-1 patients in whom resistance failed while they were on an efavirenz- or nevirapine-containing regimen, and may present an attractive option for second-line treatment given its good safety profile and dosing convenience." | 1.42 | Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine. ( Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM, 2015) |
| " Compared to RRC, Ugandan children exhibited reduced bioavailability of EFV and LPV; 11% (P=0." | 1.42 | The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. ( Achan, J; Aweeka, F; Bartelink, IH; Capparelli, E; Charlebois, E; Dorsey, G; Gingrich, D; Havlir, D; Jullien, V; Kamya, M; Plenty, A; Ruel, T; Savic, RM; Scherpbier, HJ; Young, SL, 2015) |
| "Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are severe adverse drug reactions, characterized by extensive epidermal detachment and erosions of mucous membrane." | 1.42 | A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility. ( Borgiani, P; Buonomo, E; Ciccacci, C; Giardina, E; Mancinelli, S; Marazzi, MC; Novelli, G; Palombi, L; Rufini, S; Scarcella, P, 2015) |
| "Data on AIDS patients initially starting antiretroviral therapy during 2008 and 2013 were collected from Chinese HIV/AIDS integrated control system." | 1.42 | [Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013]. ( Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q, 2015) |
| " Stavudine and lamivudine are administered as fixed combination while nevirapine as separate dosage form which often results in poor compliance and adherence to therapy by patients and therefore, there is a need to develop dosage forms that can overcome the problems of currently available dosage forms for treatment of HIV infection." | 1.42 | Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy. ( Priya, MR; Rajendran, NN, 2015) |
| "HIV-associated Kaposi sarcoma (HIV-KS) is the most common cancer in Malawi." | 1.42 | Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi. ( Bazile, J; Beste, JA; Chingoli, F; Crocker, JT; Elmore, SN; Gopal, S; Herce, ME; Kalanga, N; Keck, JW; Mailosi, B; Phiri, A; Rigodon, J; Tengatenga, L; Wroe, EB, 2015) |
| "Nevirapine was the offending drug in 21/22 (95%) cases." | 1.42 | Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women. ( Knight, L; Lehloenya, RJ; Matjila, M; Muloiwa, R; Todd, G, 2015) |
| "983T>C could be important sources of nevirapine pharmacokinetic variability that could be considered for dosage optimization, while CYP1A2 g." | 1.42 | Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients. ( Castel, S; Dandara, C; Lacerda, M; Mhandire, D; Mhandire, K; Musingwini, T; Shamu, T; Smith, P; Stray-Pedersen, B; Swart, M; Wiesner, L; Zhou, D, 2015) |
| "Nevirapine exposure was unchanged before and after artemether-lumefantrine administration." | 1.42 | Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy. ( Adedeji, WA; Adewole, IF; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, F; Huang, L; Morse, GD; Murphy, RL; Olson, A; Parikh, S; Scarsi, KK; Taiwo, BO, 2015) |
| "Only zidovudine has adequate dosing recommendations for treating term and preterm infants and has an intravenous formulation, essential if feeding intolerance occurs." | 1.42 | The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants. ( Cotton, MF; Holgate, S; Mirochnick, M; Nelson, A; Rabie, H; Wedderburn, C, 2015) |
| " The purpose of the current study was to determine the population mean pharmacokinetic parameters and identify factors that influence pharmacokinetic parameters of nevirapine in Thai HIV-infected patients." | 1.40 | Population pharmacokinetics of nevirapine in Thai HIV-infected patients. ( Avihingsanon, A; Manosuthi, W; Punyawudho, B; Wattanakul, T, 2014) |
| "Nevirapine (NVP) was loaded in polycaprolactone (PCL) matrices to produce vaginal inserts with the aim of preventing HIV transmission." | 1.40 | Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission. ( Coombes, AGA; Dang, N; Harrich, D; Shaw, PN; Sivakumaran, H, 2014) |
| "Nevirapine is an inducer of hepatic metabolism." | 1.40 | Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects. ( Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V, 2014) |
| "Stavudine was prescribed to 5." | 1.40 | Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. ( Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, C; Li, CK; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Sohn, A; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F, 2014) |
| "We document our experience with therapeutic drug monitoring (TDM) of antiretroviral agents (1807 determinations) carried out as day-by-day clinical practice for the optimization of drug dosing in HIV-infected patients." | 1.40 | Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint. ( Baldelli, S; Castoldi, S; Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Fucile, S, 2014) |
| "Nevirapine (NVP) is an effective nonnucleoside reverse transcriptase inhibitor (NNRTI) of particular interest as it is often used in resource limited countries." | 1.40 | Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine. ( Janphen, K; Kumrapich, B; Praparattanapan, J; Roytrakul, S; Smith, DR; Supparatpinyo, K; Thongtan, T; Wongtrakul, J, 2014) |
| " We conducted a cross-sectional study of HIV-positive women to determine if protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) C(min) and Cmax values were significantly different than historical general population (predominantly male) averages and to evaluate correlates of higher concentrations." | 1.39 | Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study. ( Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL, 2013) |
| " SJS can occur in children at any age, with any level of immunosuppression, and can occur during the lead-in dosing period of NVP." | 1.39 | Stevens-Johnson syndrome and HIV in children in Swaziland. ( Blank, DA; Draper, HR; Dziuban, EJ; Hughey, AB; Kochelani, D; Schutze, GE; Stewart, DA, 2013) |
| "Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor, widely prescribed for type 1 human immunodeficiency virus infection." | 1.39 | Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study. ( Borgiani, P; Ciccacci, C; Di Fusco, D; Erba, F; Liotta, G; Marazzi, MC; Novelli, G; Palombi, L; Zimba, I, 2013) |
| " Our results demonstrate that the HIV PI lopinavir inhibits liver stage parasites at clinically relevant concentrations, that is, at drug levels achieved in HIV-infected patients on standard dosing regimens." | 1.39 | The effect of antiretrovirals on Plasmodium falciparum liver stages. ( Borkowsky, W; De La Vega, P; Duffy, PE; Hobbs, CV; Krzych, U; Penzak, SR; Sinnis, P; Van Vliet, J, 2013) |
| "To investigate if pregnancy is a risk factor for SJS among HIV-infected women taking NVP-containing regimens and registered within the Medunsa National Pharmacovigilance Centre database." | 1.39 | Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012. ( Adewusi, E; Dube, N; Summers, R, 2013) |
| "Nevirapine is an important component of highly active antiretroviral therapy used in the treatment of HIV infection." | 1.39 | Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? ( Bangsberg, DR; Chinn, LW; Kroetz, DL; Martin, JN; Micheli, JE; Patel, A; Shugarts, SB, 2013) |
| " After adjusting for age, gender, HIV risk factor, current CD4 count, pill burden and dosing interval, adherence was higher in patients with undetectable HIV RNA (P < 0." | 1.39 | Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy. ( Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D, 2013) |
| "Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used for chronic human immunodeficiency virus infections in adults and children." | 1.39 | Evaluation of nevirapine dosing recommendations in HIV-infected children. ( Benaboud, S; Blanche, S; Bouazza, N; Dollfus, C; Faye, A; Foissac, F; Frange, P; Hirt, D; Lachassinne, E; Treluyer, JM; Urien, S, 2013) |
| "Nevirapine (NVP) treatment is associated with serious skin rashes that appear to be immune-mediated." | 1.39 | Nevirapine bioactivation and covalent binding in the skin. ( Klarskov, K; Sharma, AM; Uetrecht, J, 2013) |
| "Demographic, treatment and pregnancy related data were collected." | 1.38 | Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy. ( Boer, K; de Wolf, F; Godfried, MH; Nellen, JF; Smit, C; Snijdewind, IJ; van der Ende, ME, 2012) |
| "To propose a modelling strategy to efficiently integrate data from different sources in one simultaneous analysis, using nevirapine population pharmacokinetic data as an example." | 1.38 | Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. ( Barnes, KI; Cohen, K; Denti, P; Huitema, A; Karlsson, MO; Kredo, T; Nachega, JB; Svensson, E; van der Walt, JS, 2012) |
| "We compared adverse events among breast-feeding neonates born to Kenyan mothers receiving triple-antiretroviral therapy, including either nevirapine or nelfinavir." | 1.38 | Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission. ( Akoth, B; Angira, F; Masaba, R; Mills, LA; Minniear, TD; Ndivo, R; Oyaro, B; Peters, PJ; Polle, N; Thomas, TK; Zeh, C, 2012) |
| "Nevirapine was given at delivery to 93/135 (69%) women, and to 128/135 (95%) children." | 1.38 | HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study. ( Anh, NM; Bao, NH; Cam, PD; Caridha, R; Ehrnst, A; Gaseitsiwe, S; Ha, TT; Hien, NT; Tuan, PL, 2012) |
| " The population pharmacokinetic approach represents a very useful tool for the description of the dose-concentration relationship, the quantification of variability in the target population of patients and the identification of influencing factors." | 1.38 | Dosage optimization of treatments using population pharmacokinetic modeling and simulation. ( Aouri, M; Arab-Alameddine, M; Buclin, T; Csajka, C; Decosterd, LA; Guidi, M; Rotger, M; Telenti, A, 2012) |
| "Nevirapine (NVP) is a nonnucleoside reverse transcriptase inhibitor (NNRTI) used worldwide as part of combination antiretroviral therapy in infants and children to treat HIV infection." | 1.38 | Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience. ( Acosta, EP; Aweeka, FT; Burger, D; Capparelli, EV; Cressey, TR; Kabamba, D; Nikanjam, M; Spector, SA, 2012) |
| " Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes." | 1.37 | Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. ( Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ, 2011) |
| "Ritonavir (RTV) was used initially for 138 children who were <6 months old or receiving antimycobacterial therapy; otherwise children received lopinavir/ritonavir (LPV/r)-based ART." | 1.37 | Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. ( Abrams, EJ; Coovadia, A; Hunt, G; Kuhn, L; Meyers, T; Morris, L; Sherman, G; Strehlau, R; Taylor, BS, 2011) |
| "Nevirapine is an important component of paediatric combination HIV therapy." | 1.37 | Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India. ( Agibothu Kupparam, HK; Karunaianandham, R; Mahalingam, V; Navaneethapandian, PG; Perumal Kannabiran, B; Ramachandran, G; Shah, I; Sikhamani, R; Soundararajan, L; Swaminathan, S, 2011) |
| " We characterized relationships between nevirapine-associated cutaneous and hepatic adverse events and genetic variants among HIV-infected adults." | 1.37 | Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. ( Cammett, AM; Distel, M; Guo, S; Haas, DW; Hall, D; Huang, Z; Jayadev, S; Mootsikapun, P; Podzamczer, D; Ruxrungtham, K; Storfer, S; Yuan, J, 2011) |
| "We retrospectively evaluated the durability and reasons for discontinuation of nevirapine (NVP) in combination with a tenofovir (TDF) and emtricitabine (FTC) or lamivudine (3TC)-containing antiretroviral therapy (ART) regimen in an Australian outpatient setting." | 1.37 | Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects. ( Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE, 2011) |
| " Pharmacokinetic parameter estimates and model-predicted HIV-1 transmission rates were very consistent with other studies." | 1.37 | Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes. ( Frank, M; Harms, G; Kloft, C; Kunz, A; Schütte, C; von Kleist, M, 2011) |
| " The correlation between nevirapine concentrations, efficacy and hepatotoxicity suggests the benefit of dosage adjustment based on therapeutic drug monitoring among Chinese HIV-infected patients to optimize nevirapine containing antiretroviral therapy." | 1.37 | Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection. ( Fu, Q; Han, Y; Kou, H; Li, T; Li, Y; Ma, Q; Qiu, Z; Wang, J; Ye, M; Zhu, Z; Zuo, L, 2011) |
| "7% oral bioavailability in rat, tolerated oral single dose toxicity in mice, and especially the feature of highly efficient suppression of the wild-type HIV-1 and Y181C mutant HIV-1 at an EC(50) = 7." | 1.36 | Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile. ( Chen, Z; Han, C; Hu, J; Li, Y; Liu, G; Liu, L; Liu, Z; Lu, X; Ma, T; Wang, L; Xue, H; Zheng, P, 2010) |
| "Etravirine (ETV) is a second-generation nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) introduced recently for salvage antiretroviral treatment after the emergence of NNRTI-resistant human immunodeficiency virus type 1 (HIV-1)." | 1.36 | Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine. ( Gatanaga, H; Hachiya, A; Hayashida, T; Ode, H; Oka, S; Sato, H, 2010) |
| "Nevirapine is widely used to treat HIV-1 infection to prevent mother-to-child transmission; unfortunately adverse drug reactions have been reported." | 1.36 | Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique. ( Altan, AM; Borgiani, P; Bramanti, P; Ceffa, S; Ciccacci, C; Marazzi, MC; Novelli, G; Palombi, L; Paturzo, G; Sirianni, E, 2010) |
| "Etravirine has compromised activity in approximately half of the patients failing nevirapine-based first-line treatment in this cohort, which supports guidelines that caution against using it with NRTIs alone in such patients." | 1.36 | Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1. ( Adewole, I; Akanmu, S; Chaplin, B; Gashau, W; Idoko, J; Kanki, P; Meloni, S; Murphy, R; Penugonda, S; Taiwo, B, 2010) |
| "To investigate uptake and provision of antenatal care (ANC) services in the Uzazi Bora project: a demonstration-intervention project for Safe Motherhood and prevention of mother-to-child transmission of HIV in Kenya." | 1.36 | A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT. ( Chersich, MF; Delva, W; Luchters, S; Muigai, E; Oyier, V; Temmerman, M; Yard, E, 2010) |
| "We describe a 51-year-old female with acquired immunodeficiency syndrome (AIDS) and HIV-associated PAH." | 1.36 | Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension. ( Backman, ES; Farber, HW; Hardy, H, 2010) |
| "Full 12-hour pharmacokinetic profiles of nevirapine, stavudine, and lamivudine in HIV-infected children taking fixed-dose combination antiretroviral tablets have been reported previously by us." | 1.36 | Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets. ( Burger, D; Chintu, C; Ewings, F; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, R; Mulenga, V; Thomason, M; Walker, AS, 2010) |
| "CHAP2 (Children with HIV Antibiotic Prophylaxis 2) is a prospective cohort of Zambian children using d4T/3TC/NVP adult Triomune30 dosed according to WHO guidelines." | 1.36 | Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine. ( Chintu, C; Ferrier, A; Ford, D; Gibb, DM; Grant, PR; Gupta, RK; Kabamba, D; Kalumbi, M; Mulenga, V; Pillay, D; Walker, AS, 2010) |
| " Children taking T30 for > 6 weeks from each dosing weight band (<5, 5-<8, 8-<12, 12-<14, 14-<19, 19-<26, 26-<30 and > or = 30 kg) were recruited." | 1.36 | Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets. ( Burger, D; Chesshyre, E; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L, 2010) |
| "In resource-limited settings where nevirapine-containing regimen is the preferred regimen in women, data on severe adverse events (SAEs) according to CD4 cell count are limited." | 1.36 | Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire. ( Abrams, EJ; Amani-Bosse, C; Bédikou, G; Coffie, PA; Dabis, F; Ekouevi, DK; Tanon, AK; Tonwe-Gold, B, 2010) |
| "Nevirapine-based ART was initiated in 820 women and baseline ALT or AST results were abnormal (≥ grade 1) in 113 (14%) women." | 1.36 | Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya. ( Bolu, O; Borkowf, CB; Brooks, JT; Intalapaporn, P; Kiarie, J; McConnell, MS; Mutsotso, W; Peters, PJ; Potter, D; Ratanasuwan, W; Stringer, J; Weidle, PJ; Zulu, I, 2010) |
| "Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used against human immunodeficiency virus type-1 (HIV-1), mostly to prevent mother-to-child HIV-1 transmission in developing countries." | 1.36 | Protein adducts as prospective biomarkers of nevirapine toxicity. ( Antunes, AM; Beland, FA; Coelho, AV; Godinho, AL; Gomes, RA; Marques, MM; Martins, IL; Oliveira, MC, 2010) |
| "Predictors of adverse events (AE) associated with nevirapine use are needed to better understand reports of severe rash or liver enzyme elevation (LEE) in HIV+ women." | 1.36 | Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication. ( Aaron, E; Bachmann, LH; Criniti, S; Gracely, E; Kempf, MC; Kumar, R; Tedaldi, E; Warriner, A, 2010) |
| "There are few studies from India documenting the adverse effects of generic HAART (Highly Active Anti-retroviral Therapy)." | 1.36 | Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. ( Dasegowda, V; Sreenivasan, S, 2010) |
| "The aim of this study was to measure the cumulative incidence of adverse events (AEs) related to nevirapine in patients switched from efavirenz to immediate full-dose nevirapine (FDN)." | 1.35 | Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia. ( Chhneang, V; Fernandez, M; Laureillard, D; Moeung, S; Ngeth, C; Piketty, C; Prak, N; Quillet, C; Riel, V; Song, S, 2008) |
| "The aim of this study was to develop and validate a population pharmacokinetic model for nevirapine in a population of HIV-infected adults and to evaluate the influence of nevirapine dosing regimen and patient characteristics on nevirapine trough concentration." | 1.35 | Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach. ( Cedeño, S; Clotet, B; Costa, J; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M; Vilaró, J, 2008) |
| "to give a description of HIV-AIDS and tuberculosis co-infection in Jakarta, viewed from the perspective of virologic and immunologic status and the correct selection of antiretrovirals." | 1.35 | Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital. ( Djoerban, Z; Sumantri, S, 2008) |
| "Zidovudine was not detectable in any infant plasma samples obtained after the day of delivery, while the median concentrations in infant plasma samples from postpartum weeks 2, 6, and 14 were 67 ng/ml, 32 ng/ml, and 24 ng/ml for lamivudine and 987 ng/ml, 1,032 ng/ml, and 734 ng/ml for nevirapine, respectively." | 1.35 | Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. ( Capparelli, E; Fowler, MG; Holland, D; Masaba, R; Mirochnick, M; Odhiambo, P; Thigpen, MC; Thomas, T; Weidle, PJ; Zeh, C, 2009) |
| " The latter association was maintained with both 200 mg twice daily (bid) and 400 mg once daily (qd) dosing [GG, 3527 ng/mL (n=30); GT, 4525 ng/mL (n=32); TT, 7020 ng/mL (n=2); P(anova)=0." | 1.35 | Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population. ( Back, Dj; Egan, D; Johnson, M; Khoo, S; Mahungu, T; Owen, A; Smith, C; Turner, F; Youle, M, 2009) |
| "By logistic regression, history of drug allergy apart from NVP (odds ratio [OR] 11." | 1.35 | Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash. ( Kiertiburanakul, S; Malathum, K; Sathapatayavongs, B; Sungkanuparph, S; Watcharananan, S, 2009) |
| "A 12 h pharmacokinetic analysis was performed in 18 patients: 7 HIV/HCV-coinfected and 11 HIV-monoinfected." | 1.35 | Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. ( Bertram, N; Fätkenheuer, G; Reichel, C; Rockstroh, JK; Schwarze-Zander, C; Sudhop, T; Vogel, M; Voigt, E; Wasmuth, JC; Wyen, C, 2009) |
| "Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections." | 1.35 | The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008) |
| "Small intensive pharmacokinetic (PK) studies of medications in early-phase trials cannot identify the range of factors that influence drug exposure in heterogenous populations." | 1.35 | Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women. ( Anastos, K; Bacchetti, P; Benet, LZ; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Kalinowski, A; Minkoff, H; Wolfe, AR; Young, M, 2009) |
| " We investigated the relationship of NVP dosing with safety and efficacy." | 1.35 | Safety and efficacy of once-daily nevirapine dosing: a multicohort study. ( Battegay, M; Calmy, A; de Wolf, F; Hirschel, B; Hogg, RS; Lange, JM; Lima, VD; Montaner, JS; Nguyen, A; Reiss, P; Vallier, N; Wit, FW; Yip, B, 2009) |
| " Hepatitis C virus (HCV) coinfection, adverse events, and reasons for using nevirapine were also recorded." | 1.35 | Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine. ( Aguirrebengoa, K; Clotet, B; García, MA; Goikoetxea, J; Iribarren, JA; Martínez, E; Muñoz, J; Negredo, E; Perez-Alvarez, N; Portu, J; Rodríguez-Arrondo, F, 2009) |
| " Simplification of dosing schedules has prompted investigations into once-daily dosing regimens; nevirapine once-daily dosing strategies are currently under investigation." | 1.35 | Once-daily dosing of nevirapine in HAART. ( Clotet, B, 2008) |
| "Nevirapine Cmin was subtherapeutic (<3 mg/L) in six patients during antitubercular therapy (one of whom developed virological failure) and in none afterwards." | 1.35 | Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. ( Boulle, A; Cohen, K; Goemaere, E; Maartens, G; McIlleron, H; Smith, PJ; van Cutsem, G, 2008) |
| "The aim of this article is to present the clinical characteristics and management of an oral adverse effect stemming from the use of the antiretroviral medication Nevirapine (NVP)." | 1.35 | Oral adverse effects due to the use of Nevirapine. ( Fonseca, LM; Madureira, DF; Mesquita, RA; Moura, MD; Senna, MI, 2008) |
| "The influence of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics was investigated in HIV-infected patients with a population pharmacokinetic approach." | 1.35 | Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients. ( Allavena, C; Biron, C; Dailly, E; Jolliet, P; Raffi, F, 2008) |
| "We assessed the 18-month effectiveness of short-course (sc) antiretroviral peripartum regimens combined with alternatives to prolonged breastfeeding to prevent mother-to-child transmission (MTCT) of HIV-1 in Abidjan, Côte d'Ivoire." | 1.35 | 18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission. ( Becquet, R; Dabis, F; Dequae-Merchadou, L; Ekouevi, DK; Horo, A; Leroy, V; Rouet, F; Rouzioux, C; Sakarovitch, C; Timité-Konan, M; Tonwe-Gold, B; Viho, I, 2008) |
| "By logistic regression, history of drug allergy (OR, 3." | 1.35 | Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings. ( Chantratita, W; Charoenyingwattana, A; Kiertiburanakul, S; Mahasirimongkol, S; Sungkanuparph, S; Sura, T, 2008) |
| "Non-nevirapine regimens were initiated following biochemical and symptomatic improvement; symptoms did not recur." | 1.35 | Incidence of nevirapine-associated hepatitis in an antenatal clinic. ( Black, V; Rees, H, 2008) |
| "Fibrinogen is an inflammatory factor associated with atherosclerosis." | 1.35 | Association of antiretroviral therapy with fibrinogen levels in HIV-infection. ( Bacchetti, P; Grunfeld, C; Heymsfield, S; Kotler, DP; Lee, G; Lewis, CE; Madden, E; Scherzer, R; Shlipak, MG; Tracy, R; Wanke, C, 2008) |
| "Pregnancy has a moderate but significant lowering effect on NVP plasma concentrations." | 1.35 | Steady-state nevirapine plasma concentrations are influenced by pregnancy. ( Boer, K; Burger, DM; Damming, M; de Wolf, F; Godfried, MH; Nellen, JF; Prins, JM; van der Ende, ME; Wit, FW, 2008) |
| "To determine the incidence of clinically significant adverse events after long-term, fixed-dose, generic highly active antiretroviral therapy (HAART) use among HIV-infected individuals in South India, we examined the experiences of 3154 HIV-infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India." | 1.35 | Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients. ( Balakrishnan, P; Cecelia, AJ; Devaleenal, B; Flanigan, TP; Kumarasamy, N; Lai, AR; Mayer, KH; Poongulali, S; Saghayam, S; Solomon, S; Venkatesh, KK; Yepthomi, T, 2008) |
| "0001 in both cases) influenced by the patient's status (mean KM estimate of 812 days for virological failures, 1294 for naive patients and 1657 for treatment simplifications) and by the dosing schedule (once-daily 1315 days; twice-daily 1198 days)." | 1.34 | Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort. ( Airoldi, M; Arici, C; Bombana, E; Gregis, G; Maggiolo, F; Quinzan, G; Ravasio, V; Ripamonti, D; Suter, F, 2007) |
| "Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency." | 1.34 | Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. ( Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V, 2007) |
| " The objectives were to compare NVP levels, adverse events, and 36-week efficacy of NVP-based ART between patients who did not receive FLU (group A) and those who received FLU 200 mg/day or 400 mg/day (group B)." | 1.34 | Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. ( Athichathanabadi, C; Manosuthi, W; Phoorisri, T; Sungkanuparph, S; Uttayamakul, S, 2007) |
| "Nevirapine was detected in 15/18 (83%) patients at 1 week, and 5/19 (26%) patients at 2 weeks but was not found any samples collected after 2 weeks." | 1.34 | Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. ( Gibb, DM; Grosskurth, H; Khoo, S; Kikaire, B; Mugyenyi, P; Munderi, P; Namale, L; Reid, A; Ssali, F; Walker, AS, 2007) |
| " Noncompartmental pharmacokinetic analysis was performed." | 1.34 | Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily. ( Arroyo, E; Climent-Grana, E; Merino, E; Pérez-Ruixo, JJ; Portilla, J; Valenzuela, B, 2007) |
| " Neutropenia (usually transient) was the most common severe adverse event." | 1.34 | Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India. ( Bethel, J; Dharmarajan, S; Jacob, SM; Junankar, V; Parameshwari, S; Read, JS; Samuel, NM; Stoszek, SK; Van Hook, HM; Xu, J, 2007) |
| "Nevirapine was quantifiable for up to 17 days after discontinuation of therapy; total nevirapine concentrations remained above the 90% inhibitory concentration for 6 days, and no differences were observed between breasts." | 1.34 | Persistence of nevirapine in breast milk after discontinuation of treatment. ( Acosta, EP; Aldrovandi, GM; Ashouri, N; Bennetto-Hood, C; King, JR; Woodman, K, 2007) |
| "In conclusion, NVP-associated skin rashes that lead to NVP discontinuation are common among HIV-infected patients with baseline CD4 <250 cells/microL." | 1.34 | Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL. ( Chaovavanich, A; Chimsuntorn, S; Chottanapund, S; Chumpathat, N; Inthong, Y; Mankatitham, W; Manosuthi, W; Moolasart, V; Prasithsirikul, W; Sittibusaya, C; Sungkanuparph, S; Tansuphaswadikul, S; Termvises, P, 2007) |
| " Newer HAART regimens have less toxicity and better dosing characteristics than first-generation regimens, but it is not known whether they are associated with improved clinical outcomes." | 1.34 | Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine. ( Crane, HM; Kitahata, MM; Van Rompaey, SE, 2007) |
| " Pharmacokinetic variables were compared between patients divided based on CD4 cell counts, sex, and BMI." | 1.34 | Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India. ( Anitha, S; Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Rajasekaran, S; Ramachandran, G; Subramanyam, S; Swaminathan, S, 2007) |
| "All nevirapine side effects were developed in less than seven weeks." | 1.34 | Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital. ( Carraro, EA; Cornelsen, TC; Dias, JM; Kondo, W; Macedo, RL; Perini, J; Prandel, E; Sasaki, Md; Sbalquiero, R, 2007) |
| "Chronic viral hepatitis is common among persons with HIV-1 infection, because of shared modes of transmission, and coinfection results in accelerated liver damage, compared with persons with chronic viral hepatitis alone." | 1.33 | Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. ( Gerber, JG; Wyles, DL, 2005) |
| "Nevirapine plasma levels were remarkably high and associated with successful virological treatment results." | 1.33 | Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. ( Bodasing, N; Burger, DM; Cleary, PR; de Baar, MP; Kumwenda, JJ; Mallewa, J; Nyirenda, C; Schuurman, R; van Oosterhout, JJ; Zijlstra, EE, 2005) |
| "We have investigated the pharmacokinetics of nevirapine and paclitaxel in a patient who used both drugs concomitantly, as there are strong theoretical indications for a potential pharmacokinetic drug-drug interaction." | 1.33 | No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel. ( Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH, 2005) |
| "Nevirapine plasma levels were determined by a validated high-performance liquid chromatography method with a lower limit of quantification of 0." | 1.33 | Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. ( Bosch, M; Burger, DM; Dolmans, W; Droste, JA; Hofstede, HT; Muro, E, 2005) |
| "The relationships between adverse events (AEs) and plasma concentrations of nevirapine (NVP) and efavirenz (EFV) were investigated as part of the large, international, randomized 2NN study." | 1.33 | Are adverse events of nevirapine and efavirenz related to plasma concentrations? ( Baraldi, E; Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, JM; MacGregor, TR; Montella, F; Robinson, PA; Russell, DB; Thompson, MA; Uip, DE; van Leth, F, 2005) |
| "To compare the adverse events after initiation of NVP-based ART among HIV-infected patients who did not receive fluconazole (group A), received fluconazole 400 mg/week (group B), and received fluconazole 200 mg/day (group C)." | 1.33 | Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study. ( Chaovavanich, A; Chumpathat, N; Manosuthi, W; Sungkanuparph, S, 2005) |
| "Zidovudine (AZT) was provided antenatally from week 34 of gestation and during labour." | 1.33 | Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa. ( Abdullah, F; Boulle, A; Coetzee, D; Draper, B; Goemaere, E; Hilderbrand, K, 2005) |
| "Tenofovir disoproxil fumarate (DF) has been studied in combination with efavirenz in healthy volunteers and no interaction was found." | 1.33 | Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. ( Burger, DM; Droste, JA; Hekster, YA; Kearney, BP, 2006) |
| " Multivariate logistic regression was used to test independent association of CD4 and hepatitis C virus (HCV) infection related to the outcome of toxic effects of NVP." | 1.33 | Nevirapine toxicity in a cohort of HIV-1-infected pregnant women. ( Calvet, GA; Cruz, ML; D'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LA, 2006) |
| " The objective was to find cutoff values of the Cmin and AUC24 below which the risk of virologic failure increased." | 1.33 | Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. ( Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW, 2006) |
| "7% of all adverse events reported during the investigation were attributable to NVP." | 1.33 | Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients. ( Bonjoch, A; Cervantes, M; Cinquegrana, D; Clotet, B; Cucurull, J; Dalmau, D; Domingo, P; Force, L; Llibre, JM; Masabeu, A; Mascaró, J; Paredes, R; Pedrol, E; Pérez-Alvarez, N; Puig, J; Ribera, E; Vilaró, J, 2006) |
| " Our findings suggest that decreased bioavailability of nevirapine because of rifampicin coadministration could be overcome by increasing the dose of nevirapine from 200 to 300 mg twice daily without short-term adverse events." | 1.33 | Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration. ( Hemanthkumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Raja, K; Rajasekaran, S; Ramachandran, G; Sathishnarayan, S; Sukumar, B; Swaminathan, S, 2006) |
| "The stage of liver fibrosis was assessed by liver biopsy and/or elastography." | 1.33 | Severe liver disease associated with prolonged exposure to antiretroviral drugs. ( Babudieri, S; Barreiro, P; Garcia-Samaniego, J; González-Lahoz, J; Maida, I; Martín-Carbonero, L; Mura, MS; Núñez, M; Ríos, MJ; Rivas, P; Soriano, V; Sotgiu, G; Toro, C, 2006) |
| " In a multivariate model, K103N detection was associated with HIV-1 subtype (C > A), after adjusting for log10 delivery viral load, the number of days between NVP dosing and sample collection, age, and parity." | 1.33 | Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. ( Chen, S; Church, JD; Eshleman, SH; Fiscus, SA; Flys, TS; Guay, LA; Hoover, DR; Jackson, JB; Jones, DC; Kumwenda, N; Mmiro, F; Musoke, P; Mwatha, A; Taha, TE, 2006) |
| " This is a retrospective analysis of virologic efficacy and changes in adverse neuropsychiatric effects and serum lipid levels after this switch." | 1.33 | Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. ( Curtin, JM; Ward, DJ, 2006) |
| " A pre-dose to 6 h post-dose steady-state pharmacokinetic analysis (n = 35) of the drugs on the day of the scheduled Caesarean section was performed." | 1.33 | Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. ( Belohradsky, BH; Eberle, J; Friese, K; Gingelmaier, A; Grubert, TA; Kästner, R; Kurowski, M; Mylonas, I, 2006) |
| "To assess the incidence and consequences of adverse reactions among African HIV-positive pregnant women treated with fixed-dose combinations of a nevirapine-containing antiretroviral (ARV) triple therapy." | 1.33 | Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. ( da Cruz Gomes, A; Germano, P; Guidotti, G; Liotta, G; Loureiro, S; Mancinelli, S; Marazzi, MC; Narciso, P; Palombi, L; Perno, CF; Valls Blazquez, MC, 2006) |
| "To reduce mother-to-child transmission (MTCT) of HIV, we assessed the stability of nevirapine suspension in an oral dosing syringe over a range of storage conditions." | 1.33 | Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission. ( Dreyfuss, ML; Gray, RH; Hamzeh, FM; Li, X; Parsons, TL; Rexroad, VE; Stamper, PD, 2006) |
| " The influence of gender, age, body weight and comedication on minimum and maximum concentrations (C(min), C(max)), area under the concentration-time curve (AUC), total clearance (CL(tot)), half-life (t(1/2)) and volume of distribution (V(d)) was analysed by multivariate techniques." | 1.33 | A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. ( Carlebach, A; Gute, P; Haberl, A; Harder, S; Klauke, S; Knecht, G; Kurowski, M; Rohrbacher, M; Staszewski, S; Stocker, H; von Hentig, N, 2006) |
| "Simplification is safe and effective, but it should be offered to patients with shorter treatment duration, and in good clinical and immunovirological conditions." | 1.32 | Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. ( Adorni, F; Bini, T; Bongiovanni, M; Capetti, A; Castelnuovo, B; Chiesa, E; Cicconi, P; d'Arminio Monforte, A; Faggion, I; Melzi, S; Mussini, C; Rizzardini, G; Rusconi, S; Sollima, S; Tordato, F, 2003) |
| "Nevirapine was dosed according to the manufacturer's guidelines." | 1.32 | Nevirapine use in HIV-1-infected children. ( Ball, C; Dumont, G; Gibb, DM; Lyall, H; Novelli, V; Sharland, M; Tudor-Williams, G; Verweel, G; Walters, S; Wilkins, E, 2003) |
| " To have any understanding of drug-drug interactions in HIV treatment we need to appreciate the importance of key pharmacological areas including: 1) how each drug in a regimen is eliminated; 2) the potential for a drug to either induce or inhibit metabolic enzymes and/or transporters; 3) the therapeutic index of each drug." | 1.32 | Pharmacokinetic drug interactions with nevirapine. ( Back, D; Gibbons, S; Khoo, S, 2003) |
| " Using the recommended lead-in dosing schedule in conjunction with good health care management, this adverse event can be controlled in the vast majority of patients." | 1.32 | Defining the toxicity profile of nevirapine and other antiretroviral drugs. ( Murphy, RL, 2003) |
| "Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was first reported in the scientific literature in 1990." | 1.32 | Efficacy and durability of nevirapine in antiretroviral drug näive patients. ( Lange, JM, 2003) |
| " Assessment consisted of CD4+ cell count, plasma HIV-1 RNA load, and adverse effects of study medications." | 1.32 | Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection. ( Carroll, H; Conlon, V; Green, A; Green, DC; Green, R; Jefferson, R; Jordan, WC; Tolbert, L; Yemofio, F, 2003) |
| "In HIV-infected women receiving prenatal care and ART, adverse events were uncommon." | 1.32 | Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. ( Balasubramanian, R; Culnane, M; Cunningham, CK; Delfraissy, JF; Delke, I; Dorenbaum, A; Fiore, S; Gelber, RD; Maupin, RT; Mofenson, LM; Newell, ML; Watts, DH, 2004) |
| " Labor ward dosing to enhance nevirapine coverage should be considered as an adjunct to antenatal nevirapine administration for prevention of mother-to-child transmission of HIV." | 1.32 | Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings. ( Acosta, EP; Aldrovandi, GM; Goldenberg, RL; Kumwenda, R; Sinkala, M; Stout, JP; Stringer, JS; Vermund, SH, 2004) |
| "Evaluate pharmacokinetic interaction, short-term safety, and antiretroviral activity of stavudine (d4T), nevirapine (NVP), and nelfinavir (NFV) as combination HIV-1 therapy." | 1.32 | Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults. ( Fisher, A; Grosso, R; Hall, DB; Jacobs, M; Kerr, B; Leoung, G; Lewis, R; MacGregor, T; Odgen, R; Robinson, P; Skowron, G; Stevens, M; Yen-Lieberman, B, 2004) |
| "The prolonged elimination half-life of NVP compared with NRTIs, which persists even after 20 weeks of therapy, raises concern over the development of NNRTI resistance if all three drugs are stopped together." | 1.32 | Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance. ( Back, D; Clarke, JR; Fidler, S; Mackie, NE; Tamm, N; Taylor, GP; Weber, JN, 2004) |
| "Insulin sensitivity was evaluated by the HOMA model assessment." | 1.32 | Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. ( Bour, JB; Brindisi, MC; Buisson, M; Duong, M; Duvillard, L; Galland, F; Gambert, P; Guiguet, M; Masson, D; Petit, JM; Portier, H; Vergès, B, 2004) |
| "Nevirapine is a non-nucleoside reverse transcriptase inhibitor used in the treatment of human immunodeficiency virus (HIV)-infected patients and in post-exposure prophylaxis." | 1.32 | Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine. ( Krivoy, N; Pollack, S; Shahar, E; Weltfriend, S, 2004) |
| "Nevirapine was given as 200 mg once daily for the first 2 weeks." | 1.32 | Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study. ( Anekthananon, T; Ratanasuwan, W; Sonjai, A; Suwanagool, S; Techasathit, W, 2004) |
| "Nevirapine was provided to HIV-1-seropositive women and condoms distributed to all participants." | 1.32 | Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission. ( Farquhar, C; John, FN; John-Stewart, GC; Kabura, MN; Kiarie, JN; Mbori-Ngacha, DA; Nduati, RW; Richardson, BA, 2004) |
| "Prednisone is commonly used to treat rash, a potentially harmful side effect of nevirapine." | 1.31 | Nevirapine, prednisone and rash. ( , 2000) |
| "Mass treatment of nevirapine would increase access to antiretroviral drugs among pregnant women because they can access nevirapine without volunteer counseling and testing, which 31% of pregnant women in developing countries refused to accept due to the fear of stigmatization." | 1.31 | Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries. ( Hashimoto, H; Kapiga, SH; Murata, Y, 2002) |
| "Nevirapine (NVP) is a non-nucleoside reverse transcriptase inhibitor used as part of combination antiretroviral therapy for the treatment of HIV infection." | 1.31 | Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy. ( Clarke, S; Condon, C; Harrington, P; Kelleher, D; Mulcahy, F; Smith, OP, 2000) |
| " RT sequences from plasma collected prior to NVP dosing were also analyzed." | 1.31 | Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. ( Becker-Pergola, G; Eshleman, SH; Fowler, MG; Guay, LA; Jackson, JB; Mirochnick, M; Mmiro, F; Mofenson, LM; Mracna, M; Musoke, P, 2000) |
| "NVP reaches concentrations in the semen approximately 60% of those in the blood plasma throughout the 12 h dosing period." | 1.31 | Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. ( Drake, SM; Hoetelmans, RM; Pillay, D; Taylor, S; van Heeswijk, RP; White, DJ; Workman, J, 2000) |
| "Eight patients who were infected with human immunodeficiency virus, and who had each sustained an adverse drug reaction while following a regimen including nevirapine, were switched to a regimen including efavirenz." | 1.31 | The tolerability of efavirenz after nevirapine-related adverse events. ( Barry, M; Clarke, S; Harrington, P; Mulcahy, F, 2000) |
| "Nevirapine is a nonnucleoside reverse transcriptase inhibitor (NNRTI) that has the most common treatment limiting side effect of rash." | 1.31 | Sex differences in nevirapine rash. ( Aberg, JA; Bersoff-Matcha, SJ; Hamrick, HJ; Miller, WC; Mundy, LM; Powderly, WG; van Der Horst, C, 2001) |
| " Nevirapine is well absorbed during labor, and sufficient drug for prophylaxis against perinatal transmission crosses the placenta if an oral dose is administered to the mother at least 1 hour before delivery." | 1.31 | Antiretroviral pharmacology in pregnant women and their newborns. ( Mirochnick, M, 2000) |
| "Nevirapine is a non-nucleoside reverse transcriptase inhibitor widely used in combination with other antiretroviral agents for the treatment of HIV infection." | 1.31 | Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. ( Farmer, KL; Hebert, AA; Lahart, CJ; Metry, DW, 2001) |
| "Nevirapine is a nonnucleoside reverse transcription inhibitor that is used as part of highly active antiretroviral therapeutic combinations." | 1.31 | Jaundice and hepatocellular damage associated with nevirapine therapy. ( Bonacini, M; Poreddy, V; Prakash, M; Tiyyagura, L, 2001) |
| "Cutaneous and hepatic adverse reactions and clinical hepatitis were assessed." | 1.31 | Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. ( Arnaiz, JA; Blanco, JL; Carné, X; Cruceta, A; García-Viejo, MA; Gatell, JM; Mallolas, J; Marcos, MA; Martínez, E; Milinkovic, A; Mocroft, A; Pérez-Cuevas, JB; Phillips, A, 2001) |
| "Nevirapine plasma levels were measured in 70 HIV-infected patients, 33 of whom developed transaminase elevations." | 1.31 | Liver toxicity caused by nevirapine. ( González de Requena, D; Jiménez-Nácher, I; Núñez, M; Soriano, V, 2002) |
| "Blood samples were obtained at 0, 1, 2, 3, 4, 6 and 8 h after dosing on both study days." | 1.30 | The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. ( Back, DJ; Barry, MG; Breckenridge, AM; Halifax, KL; Merry, C; Mulcahy, F; Ryan, M; Tjia, JF, 1998) |
| "Antiretroviral therapy including zidovudine may yield replicating viruses with a two amino-acid insertion in RT in combination with amino-acid changes at codons 67 and 215, which are highly resistant to lamivudine and stavudine on top of zidovudine and have unpredictable susceptibility to didanosine and zalcitabine despite lack of previously reported corresponding resistance-associated amino-acid changes." | 1.30 | Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. ( Baan, E; Danner, SA; de Jong, JJ; de Wolf, F; Goudsmit, J; Hillebrand, ME; Huismans, R; Jurriaans, S; Lukashov, VV; ten Veen, JH, 1999) |
| "Methadone has two roles in human immunodeficiency viral infection: pain management and treatment of opioid abuse." | 1.30 | Methadone withdrawal when starting an antiretroviral regimen including nevirapine. ( Heelon, MW; Meade, LB, 1999) |
| "(4) Nevirapine is a liver enzyme inducer, hence the possibility of drug interactions, especially with protease inhibitors of HIV; the clinical consequences are poorly known." | 1.30 | Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens. ( , 1998) |
| "Nevirapine was shown to be most effective in trials with triple combination regimens." | 1.30 | NNRTIs: a neglected class. ( Cadman, J, 1998) |
| " Several studies of regimens that include protease inhibitors compare dosing twice daily to three times a day." | 1.30 | Antivirals update. ( , 1998) |
| "Genital warts are caused by the human papillomavirus (HPV) and are very common among the general population." | 1.30 | HIV transmission. ( Bartnof, HS, 1999) |
| "Nevirapine was rapidly absorbed at all doses from a tablet formulation." | 1.29 | Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. ( Andrews, C; Bova, CA; Cheeseman, SH; Hattox, SE; Keirns, JJ; Koup, RA; McLaughlin, MM; Pav, JW; Roy, T; Sullivan, JL, 1993) |
| "Nevirapine is a nonnucleoside inhibitor of reverse transcriptase (RT) which decreases the level of HIV-1 viral particles in the blood plasma of infected individuals." | 1.29 | Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo. ( Dornadula, G; Havlir, D; Pomerantz, RJ; Richman, DD; Wu, Y; Zhang, H, 1996) |
| "Nevirapine was added to the drug regiment of eight children with HIV infection treated with the combination of zidovudine and didanosine who had increasing levels of serum p24 antigen." | 1.29 | Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus. ( Anderson, B; Farley, M; Fox, C; Luzuriaga, K; Mueller, BU; Pizzo, PA; Schwartzentruber, DJ; Sei, S; Sullivan, JL; Tudor-Williams, G; Venzon, DJ, 1996) |
| " This small-animal model should be particularly useful in the preclinical prioritization of lead compounds within a common chemical class, in the evaluation of alternative in vivo dosing regimens, and in the determination of appropriate combination therapy in vivo." | 1.29 | Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds. ( Charpiot, B; Datema, R; Hincenbergs, M; Kaneshima, H; Linquist, V; McCune, JM; Moreno, MB; Rabin, L; Seifert, J; Warren, S, 1996) |
| "Nevirapine is a non-nucleoside HIV reverse transcriptase inhibitor." | 1.29 | Nevirapine: ethical dilemmas and care for HIV-infected mothers. ( Benson, M; Shannon, M, 1995) |
| "When nevirapine was combined with zidovudine (AZT) and didanosine (ddI), patients' CD4 counts rose significantly and viral load was reduced to below detectable levels." | 1.29 | FDA approves first new class of HIV drugs. Food and Drug Administration. ( , 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 176 (8.84) | 18.2507 |
| 2000's | 986 (49.50) | 29.6817 |
| 2010's | 749 (37.60) | 24.3611 |
| 2020's | 81 (4.07) | 2.80 |
| Authors | Studies |
|---|---|
| Janssen, PA | 1 |
| Lewi, PJ | 1 |
| Arnold, E | 2 |
| Daeyaert, F | 1 |
| de Jonge, M | 1 |
| Heeres, J | 1 |
| Koymans, L | 1 |
| Vinkers, M | 1 |
| Guillemont, J | 1 |
| Pasquier, E | 1 |
| Kukla, M | 1 |
| Ludovici, D | 1 |
| Andries, K | 1 |
| de Béthune, MP | 3 |
| Pauwels, R | 1 |
| Das, K | 2 |
| Clark, AD | 1 |
| Frenkel, YV | 1 |
| Hughes, SH | 1 |
| Medaer, B | 1 |
| De Knaep, F | 1 |
| Bohets, H | 1 |
| De Clerck, F | 1 |
| Lampo, A | 1 |
| Williams, P | 1 |
| Stoffels, P | 1 |
| Jorgensen, WL | 2 |
| Ruiz-Caro, J | 2 |
| Tirado-Rives, J | 1 |
| Basavapathruni, A | 3 |
| Anderson, KS | 3 |
| Hamilton, AD | 2 |
| Kim, JT | 1 |
| Bailey, CM | 2 |
| Wang, L | 7 |
| Zhang, Z | 3 |
| Xu, W | 2 |
| Koh, YH | 1 |
| Shim, JH | 1 |
| Girardet, JL | 1 |
| Yeh, LT | 1 |
| Hamatake, RK | 1 |
| Hong, Z | 2 |
| Zhan, P | 12 |
| Liu, X | 14 |
| Cao, Y | 3 |
| Wang, Y | 4 |
| Pannecouque, C | 17 |
| De Clercq, E | 14 |
| Van Neck, T | 1 |
| Vanstreels, E | 1 |
| Stevens, M | 2 |
| Dehaen, W | 1 |
| Daelemans, D | 4 |
| Fletcher, P | 1 |
| Harman, S | 1 |
| Azijn, H | 2 |
| Armanasco, N | 1 |
| Manlow, P | 1 |
| Perumal, D | 1 |
| Nuttall, J | 2 |
| Romano, J | 1 |
| Shattock, R | 1 |
| Varghese, V | 2 |
| Mitsuya, Y | 1 |
| Shahriar, R | 1 |
| Bachmann, MH | 1 |
| Fessel, WJ | 2 |
| Kagan, RM | 2 |
| Shafer, RW | 7 |
| Fang, Z | 2 |
| Li, Z | 2 |
| Tirry, I | 1 |
| Vingerhoets, J | 1 |
| Kraus, G | 1 |
| Boven, K | 1 |
| Jochmans, D | 1 |
| Van Craenenbroeck, E | 1 |
| Picchio, G | 1 |
| Rimsky, LT | 1 |
| Maïga, AI | 2 |
| Descamps, D | 4 |
| Morand-Joubert, L | 7 |
| Malet, I | 1 |
| Derache, A | 2 |
| Cisse, M | 2 |
| Koita, V | 1 |
| Akonde, A | 1 |
| Diarra, B | 1 |
| Wirden, M | 2 |
| Tounkara, A | 2 |
| Verlinden, Y | 1 |
| Katlama, C | 12 |
| Costagliola, D | 7 |
| Masquelier, B | 6 |
| Calvez, V | 9 |
| Marcelin, AG | 7 |
| Xue, H | 1 |
| Lu, X | 5 |
| Zheng, P | 2 |
| Liu, L | 3 |
| Han, C | 1 |
| Hu, J | 1 |
| Liu, Z | 5 |
| Ma, T | 1 |
| Li, Y | 6 |
| Chen, Z | 5 |
| Liu, G | 3 |
| Gatanaga, H | 5 |
| Ode, H | 1 |
| Hachiya, A | 4 |
| Hayashida, T | 1 |
| Sato, H | 1 |
| Oka, S | 8 |
| Chauthe, SK | 1 |
| Bharate, SB | 1 |
| Sabde, S | 1 |
| Mitra, D | 1 |
| Bhutani, KK | 1 |
| Singh, IP | 1 |
| Gupta, S | 1 |
| Fransen, S | 2 |
| Paxinos, EE | 1 |
| Stawiski, E | 1 |
| Huang, W | 3 |
| Petropoulos, CJ | 2 |
| Qin, B | 1 |
| Jiang, X | 2 |
| Lu, H | 3 |
| Tian, X | 1 |
| Barbault, F | 1 |
| Huang, L | 4 |
| Qian, K | 1 |
| Chen, CH | 2 |
| Huang, R | 1 |
| Jiang, S | 2 |
| Lee, KH | 2 |
| Xie, L | 1 |
| Zeng, ZS | 1 |
| He, QQ | 1 |
| Liang, YH | 1 |
| Feng, XQ | 1 |
| Chen, FE | 1 |
| Balzarini, J | 4 |
| Casano, G | 1 |
| Dumètre, A | 1 |
| Hutter, S | 1 |
| Azas, N | 1 |
| Robin, M | 1 |
| Banerjee, D | 1 |
| Yogeeswari, P | 1 |
| Bhat, P | 1 |
| Thomas, A | 1 |
| Srividya, M | 1 |
| Sriram, D | 1 |
| He, YP | 1 |
| Long, J | 1 |
| Zhang, SS | 1 |
| Li, C | 2 |
| Lai, CC | 1 |
| Zhang, CS | 1 |
| Li, DX | 1 |
| Zhang, DH | 1 |
| Wang, H | 2 |
| Cai, QQ | 1 |
| Zheng, YT | 1 |
| Chen, X | 6 |
| Li, X | 6 |
| Li, D | 3 |
| Tian, Y | 5 |
| Chen, W | 5 |
| Kim, J | 2 |
| Park, C | 1 |
| Ok, T | 1 |
| So, W | 1 |
| Jo, M | 1 |
| Seo, M | 1 |
| Kim, Y | 1 |
| Sohn, JH | 1 |
| Park, Y | 1 |
| Ju, MK | 1 |
| Han, SJ | 1 |
| Kim, TH | 1 |
| Cechetto, J | 1 |
| Nam, J | 1 |
| Sommer, P | 1 |
| No, Z | 1 |
| Clercq, ED | 1 |
| Parrish, J | 1 |
| Tong, L | 1 |
| Wang, M | 2 |
| Lansdon, EB | 1 |
| Cannizzaro, C | 1 |
| Zheng, X | 1 |
| Desai, MC | 1 |
| Xu, L | 2 |
| Liu, H | 4 |
| Rai, D | 1 |
| Zhang, L | 6 |
| Guo, J | 2 |
| Patel, RV | 1 |
| Park, SW | 1 |
| Yang, J | 2 |
| Kang, D | 4 |
| Huang, B | 3 |
| Devale, TL | 1 |
| Parikh, J | 1 |
| Miniyar, P | 1 |
| Sharma, P | 1 |
| Shrivastava, B | 1 |
| Murumkar, P | 1 |
| Curreli, F | 1 |
| Kwon, YD | 1 |
| Belov, DS | 1 |
| Ramesh, RR | 1 |
| Kurkin, AV | 1 |
| Altieri, A | 1 |
| Kwong, PD | 1 |
| Debnath, AK | 1 |
| Xue, P | 1 |
| Lu, HH | 1 |
| Zhu, YY | 1 |
| Ju, XL | 1 |
| Zheng, XJ | 1 |
| Liu, GY | 1 |
| Zhang, XL | 1 |
| Gu, SX | 1 |
| Zhang, H | 5 |
| Xu, H | 2 |
| Huo, Z | 1 |
| Zhou, Z | 1 |
| Yu, Z | 1 |
| Meng, Q | 1 |
| Wu, G | 1 |
| Ding, X | 1 |
| Liu, J | 6 |
| Namasivayam, V | 1 |
| Vanangamudi, M | 1 |
| Kramer, VG | 1 |
| Kurup, S | 1 |
| Kongsted, J | 1 |
| Byrareddy, SN | 1 |
| Sang, Y | 1 |
| Han, S | 1 |
| Zhuang, C | 1 |
| Chen, F | 1 |
| Zhu, M | 1 |
| Ma, L | 3 |
| Wen, J | 2 |
| Dong, B | 1 |
| Wang, Z | 7 |
| Zhou, J | 3 |
| Zhang, G | 2 |
| Wang, J | 5 |
| Guo, Y | 2 |
| Liang, C | 1 |
| Cen, S | 1 |
| Cherukupalli, S | 1 |
| Xie, M | 1 |
| Wang, W | 7 |
| Jia, R | 1 |
| Boyce, CL | 1 |
| Sils, T | 1 |
| Ko, D | 1 |
| Wong-On-Wing, A | 1 |
| Beck, IA | 8 |
| Styrchak, SM | 1 |
| DeMarrais, P | 1 |
| Tierney, C | 4 |
| Stranix-Chibanda, L | 9 |
| Flynn, PM | 3 |
| Taha, TE | 23 |
| Owor, M | 8 |
| Fowler, MG | 44 |
| Frenkel, LM | 14 |
| Bart, G | 4 |
| Giang, LM | 4 |
| Yen, H | 1 |
| Hodges, JS | 1 |
| Brundage, RC | 5 |
| Kwara, A | 3 |
| Pressiat, C | 1 |
| Toni, TD | 3 |
| Treluyer, JM | 6 |
| Yonaba, C | 1 |
| Dahourou, DL | 1 |
| Malateste, K | 1 |
| Seguin-Devaux, C | 2 |
| Leroy, V | 13 |
| Hirt, D | 4 |
| Ngayo, MO | 2 |
| Oluka, M | 1 |
| Bulimo, WD | 1 |
| Okalebo, FA | 1 |
| Chaúque, S | 1 |
| Mohole, J | 1 |
| Zucula, H | 1 |
| Lambo, L | 1 |
| Lisboa, A | 1 |
| Ferreira, D | 1 |
| Nguyen, H | 1 |
| Chowdhary, H | 1 |
| Macmillian, B | 1 |
| Elias, B | 1 |
| Seni, A | 1 |
| Buck, WC | 3 |
| Dollfus, C | 2 |
| Le Chenadec, J | 1 |
| Mandelbrot, L | 2 |
| Tubiana, R | 2 |
| Faye, A | 4 |
| Brossard, M | 1 |
| Frange, P | 2 |
| Blanche, S | 5 |
| Warszawski, J | 1 |
| Cuco, RM | 1 |
| Loquiha, O | 1 |
| Juga, A | 1 |
| Couto, A | 2 |
| Meggi, B | 3 |
| Vubil, A | 1 |
| Sevene, E | 1 |
| Osman, N | 2 |
| Temermam, M | 1 |
| Degomme, O | 1 |
| Sidat, M | 2 |
| Bhatt, N | 3 |
| Abdullahi, ST | 2 |
| Soyinka, JO | 2 |
| Bolarinwa, RA | 2 |
| Olarewaju, OJ | 2 |
| Salami, AK | 1 |
| Bakare-Odunola, MT | 2 |
| Scheibe, K | 1 |
| Urbańska, A | 1 |
| Jakubowski, P | 1 |
| Hlebowicz, M | 1 |
| Bociąga-Jasik, M | 1 |
| Raczyńska, A | 1 |
| Szymczak, A | 1 |
| Szetela, B | 1 |
| Łojewski, W | 1 |
| Parczewski, M | 2 |
| Maseng, MJ | 1 |
| Tawe, L | 2 |
| Thami, PK | 1 |
| Moyo, S | 8 |
| Kasvosve, I | 2 |
| Novitsky, V | 8 |
| Essex, M | 17 |
| Russo, G | 3 |
| Gaseitsiwe, S | 4 |
| Paganotti, GM | 2 |
| Opoku, S | 1 |
| Sakyi, SA | 1 |
| Ayisi-Boateng, NK | 1 |
| Enimil, AK | 1 |
| Senu, E | 1 |
| Ansah, RO | 1 |
| Aning, BD | 1 |
| Ojuang, DA | 1 |
| Wekesa, DN | 1 |
| Ahmed, FO | 1 |
| Okeke, CB | 1 |
| Sarfo, AD | 1 |
| Chua, KY | 1 |
| Tey, KE | 1 |
| Pham, MM | 1 |
| Podany, AT | 4 |
| Mwelase, N | 3 |
| Supparatpinyo, K | 4 |
| Mohapi, L | 4 |
| Gupta, A | 10 |
| Samaneka, W | 2 |
| Omoz-Oarhe, A | 2 |
| Langat, D | 2 |
| Benson, CA | 4 |
| Chaisson, RE | 6 |
| Swindells, S | 3 |
| Fletcher, CV | 4 |
| Liyanage, M | 1 |
| Nikanjam, M | 2 |
| McFadyen, L | 1 |
| Vourvahis, M | 1 |
| Rogg, L | 1 |
| Moye, J | 6 |
| Chadwick, EG | 2 |
| Jean-Philippe, P | 7 |
| Mirochnick, M | 23 |
| Whitson, K | 1 |
| Bradford, S | 1 |
| Capparelli, EV | 9 |
| Best, BM | 1 |
| Adedeji, TA | 1 |
| Adedeji, NO | 1 |
| Ajeigbe, AK | 1 |
| Smith, OS | 1 |
| Jeje, OA | 1 |
| Fawale, MB | 1 |
| Ajose, AO | 1 |
| Adebisi, SA | 1 |
| Akande, AA | 1 |
| Okesina, BA | 1 |
| Stalter, RM | 2 |
| Amorim, G | 1 |
| Mocello, AR | 1 |
| Jakait, B | 2 |
| Shepherd, BE | 2 |
| Musick, B | 1 |
| Bernard, C | 1 |
| Bukusi, EA | 4 |
| Wools-Kaloustian, K | 4 |
| Cohen, CR | 6 |
| Yiannoutsos, CT | 3 |
| Patel, RC | 5 |
| Kurogi, K | 1 |
| Segawa, K | 1 |
| Sakakibara, Y | 1 |
| Suiko, M | 1 |
| Uetrecht, J | 2 |
| Liu, MC | 1 |
| Lubega, J | 1 |
| Kim, TO | 1 |
| Airewele, G | 1 |
| Grimes, A | 1 |
| Bulsara, S | 1 |
| Peckham, E | 1 |
| Wanless, SR | 1 |
| Haq, H | 1 |
| Elyanu, P | 1 |
| Musoke, P | 42 |
| Lumumba, M | 1 |
| Kekitiinwa, A | 8 |
| Matshaba, M | 1 |
| Scheurer, M | 1 |
| Despotovic, J | 1 |
| Mukhatayeva, A | 1 |
| Mustafa, A | 1 |
| Dzissyuk, N | 1 |
| Issanov, A | 1 |
| Mukhatayev, Z | 1 |
| Bayserkin, B | 1 |
| Vermund, SH | 16 |
| Ali, S | 1 |
| Jao, J | 4 |
| Sun, S | 1 |
| Bonner, LB | 1 |
| Legbedze, J | 1 |
| Mmasa, KN | 1 |
| Makhema, J | 13 |
| Mmalane, M | 1 |
| Kgole, S | 1 |
| Masasa, G | 1 |
| Gerschenson, M | 2 |
| Mohammed, T | 3 |
| Abrams, EJ | 26 |
| Kurland, IJ | 3 |
| Geffner, ME | 3 |
| Powis, KM | 2 |
| Kay, K | 1 |
| Goodwin, J | 1 |
| Ehrlich, H | 1 |
| Ou, J | 1 |
| Freeman, T | 1 |
| Wang, K | 1 |
| Li, F | 1 |
| Wade, M | 1 |
| French, J | 1 |
| Aweeka, F | 4 |
| Mwebaza, N | 1 |
| Kajubi, R | 1 |
| Riggs, M | 1 |
| Ruiz-Garcia, A | 1 |
| Parikh, S | 4 |
| Penda, CI | 1 |
| Moukoko Mbonjo, M | 1 |
| Fokam, J | 2 |
| Djeuda, ABD | 1 |
| Grace, N | 1 |
| Ateba Ndongo, F | 1 |
| Bilong, S | 1 |
| Eyoum Bille, B | 1 |
| Koki Ndombo, P | 1 |
| Aghokeng, A | 2 |
| Ndjolo, A | 2 |
| Eboumbou Moukoko, CE | 1 |
| Namara-Lugolobi, E | 1 |
| Namukwaya, Z | 3 |
| Ouma, J | 1 |
| Namale-Matovu, J | 1 |
| Nakabiito, C | 15 |
| Ndugwa, C | 1 |
| Jaber, M | 3 |
| Korthuis, PT | 3 |
| Omondi, EO | 1 |
| Muigai, A | 1 |
| Mungiria, J | 1 |
| Lihana, R | 1 |
| Kunene, PN | 1 |
| Mahlambi, PN | 1 |
| Chen, M | 1 |
| Wu, M | 1 |
| Zeng, L | 1 |
| Zhang, Y | 2 |
| Huobu-Mo, M | 1 |
| Li, J | 4 |
| Xiao, H | 1 |
| Ajibola, G | 2 |
| Maswabi, K | 2 |
| Hughes, MD | 19 |
| Bennett, K | 2 |
| Pretorius-Holme, M | 1 |
| Batlang, O | 2 |
| Sakoi, M | 2 |
| Ricci, L | 1 |
| Lockman, S | 29 |
| Kuritzkes, DR | 5 |
| Lichterfeld, M | 2 |
| Shapiro, RL | 12 |
| Penazzato, M | 6 |
| Kasirye, I | 1 |
| Ruel, T | 4 |
| Mukui, I | 1 |
| Bekker, A | 1 |
| Archary, M | 2 |
| Essajee, S | 3 |
| Siberry, GK | 4 |
| Mahy, M | 1 |
| Simnoue, D | 1 |
| Simione, B | 1 |
| Zech, JM | 1 |
| Mushavi, A | 2 |
| Do, NT | 1 |
| Boupha, P | 1 |
| Newton, PN | 1 |
| Caillet, C | 1 |
| Ngwenya, N | 1 |
| Mahlambi, P | 1 |
| Elwitigala, J | 1 |
| Rajapaksa, L | 1 |
| Inzaule, SC | 1 |
| Ariyaratne, KAM | 1 |
| Jayasena, S | 1 |
| Kurle, S | 1 |
| Patil, A | 1 |
| Kale, D | 1 |
| Siriwardna, L | 1 |
| Samaraweera, G | 1 |
| Perera, H | 1 |
| Jayakody, C | 1 |
| de Wet, JJ | 1 |
| Ban, JK | 1 |
| Verdier, G | 1 |
| Ling, J | 1 |
| Eberg, M | 1 |
| Bunko, A | 1 |
| McKimm, M | 1 |
| Vhembo, T | 2 |
| Baltrusaitis, K | 1 |
| Dadabhai, S | 1 |
| Violari, A | 8 |
| Theron, G | 5 |
| Moodley, D | 16 |
| Mukwasi-Kahari, C | 1 |
| George, K | 7 |
| Shepherd, J | 1 |
| Browning, R | 3 |
| Migeri, S | 1 |
| Lawal, MA | 1 |
| Hughes, JC | 1 |
| Badza, T | 1 |
| Abafe, OA | 1 |
| Martincigh, BS | 1 |
| Odindo, AO | 1 |
| Tukei, VJ | 1 |
| Herrera, N | 2 |
| Masitha, M | 1 |
| Masenyetse, L | 1 |
| Mokone, M | 2 |
| Maile, L | 1 |
| Gill, MM | 1 |
| Rattanabunyong, S | 1 |
| Choengpanya, K | 1 |
| Suwattanasophon, C | 1 |
| Kiriwan, D | 1 |
| Wolschann, P | 2 |
| Lamtha, T | 1 |
| Shaikh, AR | 1 |
| Rattanasrisomporn, J | 1 |
| Choowongkomon, K | 1 |
| Weng, YW | 1 |
| Chen, IT | 1 |
| Tsai, HC | 3 |
| Wu, KS | 1 |
| Tseng, YT | 2 |
| Sy, CL | 1 |
| Chen, JK | 1 |
| Lee, SS | 4 |
| Chen, YS | 3 |
| Boltz, VF | 4 |
| Shao, W | 1 |
| Bale, MJ | 1 |
| Halvas, EK | 4 |
| Luke, B | 1 |
| McIntyre, JA | 10 |
| Schooley, RT | 4 |
| Currier, JS | 9 |
| Sawe, F | 7 |
| Hogg, E | 5 |
| Kearney, MF | 2 |
| Coffin, JM | 4 |
| Mellors, JW | 7 |
| Favarel-Garrigues, M | 1 |
| Hentzien, M | 1 |
| Berger, JL | 1 |
| Brunet, A | 1 |
| Bani-Sadr, F | 2 |
| Larsen, A | 1 |
| Magasana, V | 1 |
| Dinh, TH | 2 |
| Ngandu, N | 1 |
| Lombard, C | 3 |
| Cheyip, M | 1 |
| Ayalew, K | 1 |
| Chirinda, W | 1 |
| Kindra, G | 1 |
| Jackson, D | 3 |
| Goga, A | 3 |
| Onyango-Makumbi, C | 2 |
| Owora, AH | 1 |
| Mwiru, RS | 1 |
| Mwatha, A | 18 |
| Young, AM | 1 |
| Coovadia, HM | 6 |
| Manji, K | 4 |
| Maldonado, Y | 6 |
| Richardson, P | 5 |
| Andrew, P | 3 |
| Fawzi, W | 5 |
| Hompe, ED | 1 |
| Jacobson, DL | 1 |
| Eudailey, JA | 1 |
| Butler, K | 2 |
| Edwards, W | 1 |
| Pollara, J | 1 |
| Brummel, SS | 1 |
| Fouda, GG | 1 |
| Chinula, L | 1 |
| Kamanga, M | 1 |
| Kinikar, A | 4 |
| Permar, SR | 2 |
| Engelbrecht, AE | 1 |
| Wiesner, L | 11 |
| Norman, J | 2 |
| Rabie, H | 4 |
| Decloedt, EH | 2 |
| Venkatesh, KK | 4 |
| Farhad, M | 1 |
| Fenton, T | 5 |
| Naik, S | 1 |
| Fairlie, L | 3 |
| Stringer, JSA | 1 |
| Chi, BH | 19 |
| Lanzafame, M | 8 |
| Lattuada, E | 5 |
| Vincenzi, M | 1 |
| Vecchi, M | 1 |
| Luise, D | 1 |
| Diani, E | 1 |
| Gibellini, D | 1 |
| Couffignal, C | 1 |
| Kolta, S | 1 |
| Flamant, M | 1 |
| Cazanave, C | 1 |
| Haymann, JP | 1 |
| Mentré, F | 3 |
| Duval, X | 2 |
| Leport, C | 2 |
| Raffi, F | 25 |
| Ogar, CK | 1 |
| Abiola, A | 1 |
| Yuah, D | 1 |
| Ibrahim, A | 1 |
| Oreagba, IA | 2 |
| Amadi, EC | 1 |
| Adeyeye, MC | 1 |
| Oshikoya, KA | 2 |
| Teshale, AB | 1 |
| Tsegaye, AT | 1 |
| Wolde, HF | 1 |
| Hasan, M | 1 |
| Yunihastuti, E | 3 |
| Teguh H, K | 1 |
| Abdullah, M | 1 |
| Lallemant, M | 15 |
| Amzal, B | 2 |
| Sripan, P | 1 |
| Urien, S | 4 |
| Cressey, TR | 16 |
| Ngo-Giang-Huong, N | 12 |
| Klinbuayaem, V | 5 |
| Rawangban, B | 1 |
| Sabsanong, P | 3 |
| Siriwachirachai, T | 1 |
| Jarupanich, T | 2 |
| Kanjanavikai, P | 2 |
| Wanasiri, P | 1 |
| Koetsawang, S | 4 |
| Jourdain, G | 13 |
| Le Coeur, S | 7 |
| Zulu, SS | 1 |
| Abboussi, O | 1 |
| Simola, N | 1 |
| Mabandla, MV | 1 |
| Daniels, WMU | 1 |
| Suryavanshi, N | 5 |
| Kadam, A | 1 |
| Gupte, N | 9 |
| Hegde, A | 1 |
| Kanade, S | 1 |
| Sivalenka, S | 1 |
| Kumar, VS | 1 |
| Bollinger, RC | 6 |
| Shankar, A | 2 |
| McKenzie-White, J | 1 |
| Mave, V | 3 |
| De Benedetto, I | 1 |
| Trunfio, M | 1 |
| Guastamacchia, G | 1 |
| Bonora, S | 6 |
| Calcagno, A | 4 |
| Haas, DW | 9 |
| Bao, Y | 3 |
| Baker, P | 1 |
| Lain, MG | 1 |
| Chicumbe, S | 1 |
| de Araujo, AR | 1 |
| Karajeanes, E | 1 |
| Giaquinto, C | 5 |
| Vaz, P | 2 |
| Usman, SO | 1 |
| Akinyede, AA | 1 |
| Agbaje, EO | 1 |
| Akinleye, MO | 1 |
| Onwujuobi, AG | 1 |
| Ken-Owotor, C | 1 |
| Adeuja, O | 1 |
| Ogunfowokan, T | 1 |
| Kogbe, S | 1 |
| Owolabi, ET | 1 |
| Adeniji, H | 1 |
| Busari, AW | 1 |
| Hassan, OO | 1 |
| Abideen, G | 1 |
| Akanmu, AS | 1 |
| Kahlert, CR | 2 |
| Cipriani, M | 1 |
| Vernazza, P | 3 |
| Napyo, A | 1 |
| Tylleskär, T | 1 |
| Mukunya, D | 1 |
| Tumuhamye, J | 1 |
| Musaba, MW | 1 |
| Ojok Arach, AA | 1 |
| Waako, P | 1 |
| Tumwine, JK | 2 |
| Ndeezi, G | 1 |
| Yoon, HY | 1 |
| Cho, YA | 1 |
| Yee, J | 1 |
| Gwak, HS | 1 |
| Rich, SN | 1 |
| Cook, RL | 1 |
| Yaghjyan, L | 1 |
| Francois, K | 1 |
| Puttkammer, N | 1 |
| Robin, E | 1 |
| Bae, J | 1 |
| Joseph, N | 1 |
| Pessoa-Brandão, L | 1 |
| Delcher, C | 1 |
| Mulisa, D | 1 |
| Tolossa, T | 1 |
| Wakuma, B | 1 |
| Etafa, W | 1 |
| Yadesa, G | 1 |
| Bhattacharya, D | 1 |
| Guo, R | 1 |
| Tseng, CH | 1 |
| Emel, L | 4 |
| Sun, R | 1 |
| Chiu, SH | 1 |
| Chipato, T | 12 |
| Mohtashemi, NZ | 1 |
| Kintu, K | 1 |
| Manji, KP | 1 |
| Thio, CL | 2 |
| Haas, AD | 1 |
| Radin, E | 1 |
| Hakim, AJ | 1 |
| Jahn, A | 4 |
| Philip, NM | 1 |
| Jonnalagadda, S | 1 |
| Saito, S | 1 |
| Low, A | 1 |
| Patel, H | 1 |
| Schwitters, AM | 1 |
| Rogers, JH | 1 |
| Frederix, K | 2 |
| Kim, E | 1 |
| Bello, G | 2 |
| Williams, DB | 1 |
| Parekh, B | 1 |
| Sachathep, K | 1 |
| Barradas, DT | 1 |
| Kalua, T | 1 |
| Birhanu, S | 1 |
| Musuka, G | 1 |
| Mugurungi, O | 3 |
| Tippett Barr, BA | 1 |
| Sleeman, K | 1 |
| Mulenga, LB | 1 |
| Thin, K | 1 |
| Ao, TT | 1 |
| Brown, K | 1 |
| Voetsch, AC | 1 |
| Justman, JE | 1 |
| Mehta, G | 1 |
| Sharma, A | 1 |
| Arora, SK | 1 |
| Leon-Cruz, J | 1 |
| Hakim, J | 6 |
| Kanyama, C | 5 |
| Waitt, C | 1 |
| Myer, L | 1 |
| Khoo, S | 20 |
| Ruel, TD | 1 |
| Nelson, BS | 1 |
| Coletti, A | 1 |
| Bryson, Y | 3 |
| Cotton, MF | 8 |
| Spector, SA | 8 |
| LeBlanc, R | 1 |
| Reding, C | 1 |
| Zimmer, B | 2 |
| Persaud, D | 5 |
| Bwakura-Dangarembizi, M | 4 |
| Naidoo, KL | 1 |
| Hazra, R | 1 |
| Celerino da Silva, R | 1 |
| Segat, L | 1 |
| Kuhn, L | 25 |
| Chies, JAB | 1 |
| Crovella, S | 1 |
| Yang, H | 1 |
| Chu, L | 1 |
| Wu, Y | 2 |
| Zhang, Q | 2 |
| Qiao, S | 1 |
| Shen, Z | 2 |
| Zhou, Y | 2 |
| Liu, S | 2 |
| Deng, H | 2 |
| Menegotto, M | 1 |
| Magdaleno, AM | 1 |
| da Silva, CLO | 1 |
| Friedrich, L | 1 |
| da Silva, CH | 1 |
| Marinho, AT | 2 |
| Batuca, JR | 1 |
| Miranda, JP | 1 |
| Caixas, U | 2 |
| Dias, CG | 1 |
| Branco, T | 2 |
| Soto, K | 1 |
| Pinheiro, P | 1 |
| Bourbon, M | 1 |
| Marques, MM | 4 |
| Antunes, AM | 4 |
| Monteiro, EC | 2 |
| Pereira, SA | 2 |
| Aguti, I | 1 |
| Kimbugwe, C | 1 |
| Apai, P | 1 |
| Munyaga, S | 1 |
| Nyeko, R | 1 |
| Bitarakwate, E | 2 |
| Ashburn, K | 1 |
| Kazooba, P | 1 |
| Khamasi, R | 1 |
| Natumanya, E | 1 |
| Owomugisha, B | 1 |
| Malkin, RA | 2 |
| Kisaakye, L | 1 |
| Kubota Kilengelela, J | 1 |
| Jarreau, PH | 1 |
| Marcou, V | 1 |
| Kebaya, LMN | 1 |
| Wamalwa, D | 4 |
| Kariuki, N | 1 |
| Admani, B | 1 |
| Ayieko, P | 1 |
| Nduati, R | 1 |
| Morales-Pérez, M | 1 |
| Nibamureke, UMC | 1 |
| Wagenaar, GM | 1 |
| Verrest, L | 1 |
| Wilthagen, EA | 1 |
| Beijnen, JH | 19 |
| Huitema, ADR | 1 |
| Dorlo, TPC | 1 |
| Cababasay, M | 1 |
| Mofenson, LM | 24 |
| Fiscus, S | 6 |
| Coutsoudis, A | 4 |
| Gnanashanmugam, D | 2 |
| Chakhtoura, N | 1 |
| McCarthy, K | 1 |
| Frenkel, L | 4 |
| Beck, I | 2 |
| Mukuzunga, C | 1 |
| Makanani, B | 1 |
| Nematadzira, T | 2 |
| Kusakara, B | 2 |
| Patil, S | 4 |
| Bobat, R | 5 |
| Mmbaga, BT | 4 |
| Masenya, M | 1 |
| Nyati, M | 1 |
| Mulenga, H | 1 |
| Shapiro, DE | 6 |
| Afrane, AKA | 1 |
| Goka, BQ | 1 |
| Renner, L | 1 |
| Yawson, AE | 1 |
| Alhassan, Y | 1 |
| Owiafe, SN | 1 |
| Agyeman, S | 1 |
| Sagoe, KWC | 1 |
| Pinilla, M | 1 |
| Aizire, J | 4 |
| Chipoka, G | 1 |
| Mallewa, M | 1 |
| Naidoo, M | 1 |
| Mbengeranwa, T | 2 |
| Njau, B | 1 |
| Mubiana-Mbewe, M | 1 |
| Khadse, S | 3 |
| Mechi, A | 1 |
| Al-Khalidi, A | 1 |
| Al-Darraji, R | 1 |
| Al-Dujaili, MN | 1 |
| Al-Buthabhak, K | 1 |
| Alareedh, M | 1 |
| Shaghee, F | 1 |
| Nafakhi, H | 1 |
| Neto, FR | 1 |
| Dorneles, JR | 1 |
| Carneiro Leão Veloso, JH | 1 |
| Gonçalves, CW | 1 |
| Gomes Costa, RR | 1 |
| Velaer, KN | 1 |
| Welk, B | 1 |
| Ginsberg, D | 1 |
| Myers, J | 1 |
| Shem, K | 1 |
| Elliott, C | 1 |
| Shi, Y | 1 |
| Meng, D | 1 |
| Wang, S | 1 |
| Geng, P | 1 |
| Xu, T | 1 |
| Zhou, Q | 1 |
| Li, W | 2 |
| Wakene, W | 1 |
| Asmamaw, S | 1 |
| Kahaliw, W | 1 |
| Zenebe, E | 1 |
| Washo, A | 1 |
| Addis Gesese, A | 1 |
| Halley, E | 1 |
| Giai, J | 1 |
| Chappuis, M | 1 |
| Tomasino, A | 1 |
| Henaine, R | 1 |
| Letrilliart, L | 1 |
| Nikolaus, S | 1 |
| Wittsack, HJ | 1 |
| Antke, C | 1 |
| Beu, M | 1 |
| Hautzel, H | 1 |
| Decheva, C | 1 |
| Mamlins, E | 1 |
| Mori, Y | 1 |
| Huston, JP | 1 |
| Antoch, G | 1 |
| Müller, HW | 1 |
| Li, R | 1 |
| Qi, Y | 1 |
| Shi, L | 1 |
| Zhang, A | 1 |
| Luo, Y | 1 |
| Kung, WK | 1 |
| Jiao, Z | 1 |
| Li, H | 3 |
| Dalkner, N | 1 |
| Bengesser, SA | 1 |
| Birner, A | 1 |
| Fellendorf, FT | 1 |
| Fleischmann, E | 1 |
| Großschädl, K | 1 |
| Lenger, M | 1 |
| Maget, A | 1 |
| Platzer, M | 1 |
| Queissner, R | 1 |
| Schönthaler, E | 1 |
| Tmava-Berisha, A | 1 |
| Reininghaus, EZ | 1 |
| Sun, Y | 1 |
| Song, Z | 1 |
| Zheng, W | 1 |
| Xiong, W | 1 |
| Yang, Y | 3 |
| Yuan, L | 1 |
| Chiu, PY | 1 |
| Wei, CY | 1 |
| Hung, GU | 1 |
| Wu, SL | 1 |
| Qi, Z | 1 |
| Cao, F | 1 |
| Zhao, L | 1 |
| Fang, X | 1 |
| Lu, Y | 1 |
| Chen, H | 2 |
| Zhang, J | 4 |
| Tang, B | 1 |
| Ma, C | 1 |
| Tang, X | 1 |
| Li, L | 3 |
| Wu, J | 1 |
| Wei, J | 1 |
| Li, S | 1 |
| Yang, L | 1 |
| Han, L | 1 |
| Lu, C | 1 |
| Jin, G | 1 |
| Yao, K | 1 |
| Chang, R | 1 |
| Zhu, Z | 3 |
| Jin, X | 2 |
| Yin, J | 1 |
| Zhu, H | 1 |
| Yu, K | 1 |
| Liu, M | 4 |
| Zhang, X | 2 |
| Lu, M | 3 |
| Wan, Z | 1 |
| Huang, X | 2 |
| Hu, S | 1 |
| Liu, Y | 2 |
| Huang, J | 2 |
| Hong, W | 1 |
| Fang, J | 1 |
| Kulikov, A | 1 |
| Shipaeva, E | 1 |
| Dmitrieva, A | 1 |
| Batrak, V | 1 |
| Shipunov, G | 1 |
| Guy, C | 1 |
| Smith, J | 1 |
| Zhang, R | 1 |
| Zhang, M | 2 |
| Duan, J | 2 |
| Chestukhin, A | 1 |
| Barbashov, S | 1 |
| Samsonov, M | 1 |
| Lavrovsky, Y | 1 |
| Qu, Q | 1 |
| Cui, W | 1 |
| Xing, X | 1 |
| Zou, R | 1 |
| Wang, X | 4 |
| Wu, T | 1 |
| Bello-Onaghise, G | 1 |
| Yuan, S | 1 |
| Li, T | 4 |
| Wang, PJ | 1 |
| Zhang, ZW | 1 |
| Huang, JQ | 1 |
| Elzayat, MT | 1 |
| Markofski, MM | 1 |
| Simpson, RJ | 1 |
| Laughlin, M | 1 |
| LaVoy, EC | 1 |
| Ntamatungiro, AJ | 1 |
| Muri, L | 1 |
| Glass, TR | 1 |
| Erb, S | 2 |
| Battegay, M | 7 |
| Furrer, H | 4 |
| Hatz, C | 2 |
| Tanner, M | 2 |
| Felger, I | 1 |
| Klimkait, T | 2 |
| Letang, E | 2 |
| Lee, CY | 1 |
| Chang, HM | 2 |
| Kunin, CM | 1 |
| Girma, M | 1 |
| Wendaferash, R | 1 |
| Shibru, H | 1 |
| Berhane, Y | 1 |
| Hoelscher, M | 1 |
| Kroidl, A | 1 |
| Murnane, PM | 1 |
| Strehlau, R | 10 |
| Shiau, S | 6 |
| Patel, F | 5 |
| Mbete, N | 1 |
| Hunt, G | 8 |
| Coovadia, A | 14 |
| McIlleron, H | 11 |
| Denti, P | 4 |
| Cohn, S | 1 |
| Mashabela, F | 1 |
| Hoffmann, JD | 1 |
| Shembe, S | 1 |
| Msandiwa, R | 1 |
| Velaphi, S | 2 |
| Lala, SG | 2 |
| Martinson, N | 7 |
| Dooley, KE | 3 |
| Punyawudho, B | 2 |
| Saenjum, C | 1 |
| Jittayanun, K | 1 |
| Phanomcheong, S | 1 |
| Luvira, A | 1 |
| Borkird, T | 1 |
| Puangsombat, A | 1 |
| Aarons, L | 1 |
| Sukrakanchana, PO | 1 |
| Bhat, J | 1 |
| Bharadwaj, R | 3 |
| Kulkarni, V | 4 |
| Bhosale, R | 6 |
| McIntire, KN | 1 |
| Bollinger, R | 2 |
| Szubert, AJ | 2 |
| Spyer, M | 3 |
| Katuramu, R | 1 |
| Musiime, V | 6 |
| Mhute, T | 1 |
| Bakeera-Kitaka, S | 2 |
| Senfuma, O | 1 |
| Walker, AS | 23 |
| Gibb, DM | 27 |
| Morroni, C | 1 |
| Scarsi, KK | 11 |
| Sripipatana, T | 2 |
| Kiarie, J | 6 |
| Svärd, J | 1 |
| Mugusi, S | 1 |
| Mloka, D | 1 |
| Neogi, U | 1 |
| Meini, G | 1 |
| Mugusi, F | 1 |
| Incardona, F | 1 |
| Zazzi, M | 2 |
| Sönnerborg, A | 2 |
| Tu, W | 2 |
| Nyandiko, WM | 3 |
| Slaven, JE | 2 |
| Scanlon, ML | 3 |
| Ayaya, SO | 3 |
| Vreeman, RC | 3 |
| Mukeba-Tshialala, D | 2 |
| Nachega, JB | 5 |
| Mutombo-Tshingwali, M | 1 |
| Arendt, V | 4 |
| Gilson, G | 1 |
| Moutschen, M | 3 |
| Birlie, B | 1 |
| Braekers, R | 1 |
| Awoke, T | 1 |
| Kasim, A | 3 |
| Shkedy, Z | 2 |
| Calza, L | 8 |
| Magistrelli, E | 2 |
| Colangeli, V | 3 |
| Borderi, M | 2 |
| Bussini, L | 1 |
| Bon, I | 1 |
| Re, MC | 2 |
| Viale, P | 2 |
| Chappell, CA | 2 |
| Lamorde, M | 10 |
| Nakalema, S | 3 |
| Chen, BA | 2 |
| Mackline, H | 1 |
| Riddler, SA | 1 |
| Cohn, SE | 4 |
| Darin, KM | 6 |
| Achilles, SL | 2 |
| Canals, F | 1 |
| Masiá, M | 1 |
| Gutiérrez, F | 2 |
| Dow, DE | 3 |
| Schimana, W | 7 |
| Nyombi, BM | 1 |
| Shayo, AM | 1 |
| Bartlett, JA | 7 |
| Massambu, CG | 2 |
| Kifaro, EG | 1 |
| Turner, EL | 1 |
| DeMarco, T | 1 |
| Cai, F | 2 |
| Cunningham, CK | 8 |
| Buchanan, AM | 2 |
| Gopalan, BP | 1 |
| Mehta, K | 1 |
| D'souza, RR | 1 |
| Rajnala, N | 1 |
| A K, HK | 1 |
| Ramachandran, G | 11 |
| Shet, A | 2 |
| Ayele, TA | 1 |
| Worku, A | 1 |
| Kebede, Y | 1 |
| Alemu, K | 1 |
| Mwau, M | 1 |
| Bwana, P | 1 |
| Kithinji, L | 1 |
| Ogollah, F | 1 |
| Ochieng, S | 1 |
| Akinyi, C | 1 |
| Adhiambo, M | 1 |
| Ogumbo, F | 1 |
| Sirengo, M | 1 |
| Boeke, C | 1 |
| De Luca, A | 5 |
| Sidumo, ZJ | 1 |
| Zanelli, G | 1 |
| Magid, NA | 3 |
| Luhanga, R | 3 |
| Brambilla, D | 1 |
| Liotta, G | 9 |
| Mancinelli, S | 9 |
| Marazzi, MC | 14 |
| Palombi, L | 14 |
| Ceffa, S | 4 |
| Kirmse, B | 3 |
| Yu, C | 2 |
| Epie, F | 2 |
| Nshom, E | 2 |
| Sperling, RS | 3 |
| Leroith, D | 2 |
| Côté, HCF | 1 |
| Eloy, P | 1 |
| Tessier, A | 1 |
| Fan-Havard, P | 4 |
| Chou, M | 4 |
| Verstuyft, C | 5 |
| Taburet, AM | 8 |
| Bertrand, J | 3 |
| Padmapriyadarsini, C | 6 |
| Ramesh, K | 4 |
| Sekar, L | 1 |
| Reddy, D | 1 |
| Narendran, G | 7 |
| Sekar, S | 1 |
| Chandrasekar, C | 2 |
| Anbarasu, D | 1 |
| Wanke, C | 4 |
| Swaminathan, S | 15 |
| Nakku, D | 1 |
| Nyaiteera, V | 1 |
| Llowet, E | 1 |
| Nanseera, D | 1 |
| Nakalema, G | 1 |
| Westerberg, B | 1 |
| Bajunirwe, F | 6 |
| Boyd, MA | 2 |
| Cooper, DA | 11 |
| Gilks, CF | 10 |
| Su, S | 1 |
| Fairley, CK | 1 |
| Sasadeusz, J | 1 |
| He, J | 1 |
| Wei, X | 2 |
| Zeng, H | 1 |
| Jing, J | 1 |
| Mao, L | 1 |
| Dimala, CA | 1 |
| Bechem, NN | 1 |
| Aroke, D | 1 |
| Kadia, BM | 1 |
| Tanuma, J | 2 |
| Matsumoto, S | 1 |
| Haneuse, S | 1 |
| Cuong, DD | 2 |
| Vu, TV | 1 |
| Thuy, PTT | 1 |
| Dung, NT | 1 |
| Dung, NTH | 1 |
| Trung, NV | 1 |
| Kinh, NV | 1 |
| Sinha, S | 2 |
| Gupta, K | 1 |
| Tripathy, S | 5 |
| Dhooria, S | 2 |
| Ranjan, S | 2 |
| Pandey, RM | 2 |
| Cook, RR | 1 |
| Peltzer, K | 3 |
| Weiss, SM | 1 |
| Rodriguez, VJ | 1 |
| Jones, DL | 1 |
| Sousa, MJ | 1 |
| Cadinha, S | 1 |
| Mota, M | 1 |
| Teixeira, T | 1 |
| Malheiro, D | 1 |
| Moreira da Silva, JP | 1 |
| Popoola, TD | 1 |
| Awodele, O | 2 |
| Castelnuovo, B | 6 |
| Mubiru, F | 2 |
| Kiragga, AN | 2 |
| Musomba, R | 1 |
| Mbabazi, O | 1 |
| Gonza, P | 1 |
| Kambugu, A | 6 |
| Ratanshi, RP | 1 |
| Tchetnya, X | 1 |
| Ngwasiri, CA | 1 |
| Munge, T | 1 |
| Aminde, LN | 1 |
| Sikhondze, N | 1 |
| Mahomed, OH | 1 |
| Diphoko, T | 1 |
| Okatch, H | 1 |
| Musonda, R | 2 |
| Wainberg, M | 1 |
| Marlink, R | 3 |
| Ciccacci, C | 4 |
| Politi, C | 1 |
| Ciccacci, F | 1 |
| Lucaroni, F | 1 |
| Novelli, G | 5 |
| Borgiani, P | 5 |
| Bokore, A | 1 |
| Korme, B | 1 |
| Bayisa, G | 1 |
| Veroniki, AA | 1 |
| Antony, J | 2 |
| Straus, SE | 1 |
| Ashoor, HM | 1 |
| Finkelstein, Y | 1 |
| Khan, PA | 1 |
| Ghassemi, M | 1 |
| Blondal, E | 1 |
| Ivory, JD | 1 |
| Hutton, B | 1 |
| Gough, K | 2 |
| Hemmelgarn, BR | 1 |
| Lillie, E | 1 |
| Vafaei, A | 1 |
| Tricco, AC | 1 |
| Piacentini, D | 1 |
| Rizzardo, S | 1 |
| Chiesi, S | 1 |
| Vento, S | 4 |
| Chang, JL | 1 |
| Tsai, AC | 1 |
| Musinguzi, N | 1 |
| Haberer, JE | 2 |
| Boum, Y | 1 |
| Muzoora, C | 1 |
| Bwana, M | 1 |
| Martin, JN | 4 |
| Hunt, PW | 3 |
| Bangsberg, DR | 6 |
| Siedner, MJ | 1 |
| Duthaler, U | 1 |
| Berger, B | 1 |
| Gaugler, S | 1 |
| Natamatungiro, A | 1 |
| Mnzava, D | 1 |
| Donzelli, M | 1 |
| Krähenbühl, S | 1 |
| Haschke, M | 1 |
| Ahir-Bist, S | 1 |
| Chavan, V | 1 |
| Samant-Mavani, P | 1 |
| Nanavati, R | 1 |
| Mehta, P | 1 |
| Mania-Pramanik, J | 1 |
| Nkenfou, CN | 1 |
| Temgoua, ES | 1 |
| Ndzi, EN | 1 |
| Mekue, LCM | 1 |
| Ngoufack, MN | 1 |
| Dambaya, B | 1 |
| Anoubissi, JD | 1 |
| Domkam, I | 1 |
| Elong, E | 1 |
| Fainguem, N | 1 |
| Thèze, J | 1 |
| Colizzi, V | 2 |
| Bissek, ACZK | 1 |
| Nasuuna, E | 1 |
| Kigozi, J | 4 |
| Babirye, L | 1 |
| Muganzi, A | 2 |
| Sewankambo, NK | 2 |
| Nakanjako, D | 2 |
| Haaland, RE | 1 |
| Otieno, K | 1 |
| Martin, A | 1 |
| Katana, A | 1 |
| Dinh, C | 1 |
| Slutsker, L | 1 |
| Menendez, C | 2 |
| Gonzalez, R | 1 |
| Williamson, J | 1 |
| Heneine, W | 6 |
| Desai, M | 1 |
| Anugulruengkitt, S | 2 |
| Suntarattiwong, P | 2 |
| Ounchanum, P | 2 |
| Srirompotong, U | 2 |
| Jantarabenjakul, W | 2 |
| Sophonphan, J | 2 |
| Tawon, Y | 3 |
| Punnahitanon, S | 2 |
| Pancharoen, C | 3 |
| Chokephaibulkit, K | 10 |
| Puthanakit, T | 6 |
| Saka, B | 4 |
| Akakpo, AS | 1 |
| Bassowa, A | 1 |
| Dapam, AN | 1 |
| Mahamadou, G | 1 |
| Teclessou, JN | 1 |
| Mouhari-Toure, A | 5 |
| Laouali, AY | 1 |
| Mensah, E | 1 |
| Kombaté, K | 3 |
| Pitché, P | 6 |
| Ogalo, EA | 1 |
| Adina, JO | 1 |
| Ooko, H | 1 |
| Batuka, J | 1 |
| Kimaiyo, S | 3 |
| Aliu, R | 1 |
| Ali, I | 1 |
| Oni, Y | 1 |
| Adeyeye, CM | 1 |
| Singh, H | 1 |
| Lata, S | 1 |
| Gangakhedkar, RR | 2 |
| Bila, D | 1 |
| Auld, A | 1 |
| Houston, J | 1 |
| Cossa, L | 1 |
| Alfredo, C | 1 |
| Jobarteh, K | 1 |
| Sabatier, J | 1 |
| Macassa, E | 1 |
| Sousa, A | 1 |
| DeVos, J | 1 |
| Jani, I | 2 |
| Yang, C | 2 |
| Ramalingam, VV | 1 |
| Demosthenes, JP | 1 |
| Ghale, BC | 1 |
| Rupali, P | 1 |
| Varghese, GM | 1 |
| Abraham, OC | 1 |
| Kannangai, R | 1 |
| Giacomelli, A | 1 |
| Riva, A | 1 |
| Falvella, FS | 1 |
| Oreni, ML | 1 |
| Cattaneo, D | 2 |
| Cheli, S | 1 |
| Renisi, G | 1 |
| Di Cristo, V | 1 |
| Lupo, A | 1 |
| Clementi, E | 2 |
| Rusconi, S | 2 |
| Galli, M | 1 |
| Ridolfo, AL | 1 |
| Olagunju, A | 2 |
| Owen, A | 7 |
| Allavena, C | 15 |
| Volteau, C | 1 |
| André-Garnier, E | 4 |
| Guimard, T | 1 |
| Hall, N | 2 |
| Khatchatourian, L | 1 |
| Morrier, M | 1 |
| Billaud, E | 8 |
| Rodallec, A | 3 |
| Reliquet, V | 15 |
| Jovelin, T | 1 |
| Le Guen, L | 1 |
| Perré, P | 8 |
| Grégoire, M | 2 |
| Liu, JX | 1 |
| Shen, J | 1 |
| Wilson, N | 1 |
| Janumpalli, S | 1 |
| Stadler, P | 1 |
| Padian, N | 1 |
| Guo, G | 1 |
| Zheng, J | 1 |
| Lu, L | 1 |
| Sterrantino, G | 1 |
| Borghi, V | 1 |
| Callegaro, AP | 1 |
| Bruzzone, B | 1 |
| Saladini, F | 1 |
| Maggiolo, F | 3 |
| Maffongelli, G | 2 |
| Andreoni, M | 3 |
| De Gennaro, M | 1 |
| Gianotti, N | 3 |
| Bagnarelli, P | 1 |
| Vergori, A | 1 |
| Antinori, A | 5 |
| Zaccarelli, M | 4 |
| Mohamed Saleem, TS | 1 |
| Jyothi, K | 1 |
| Babu, SC | 1 |
| Chendi, BH | 1 |
| Okomo Assoumou, MC | 1 |
| Jacobs, GB | 1 |
| Yekwa, EL | 1 |
| Lyonga, E | 1 |
| Mesembe, M | 1 |
| Eyoh, A | 1 |
| Ikomey, GM | 1 |
| O'Donnell, MR | 1 |
| Padayatchi, N | 1 |
| Daftary, A | 1 |
| Orrell, C | 2 |
| Rivet Amico, K | 1 |
| Friedland, G | 1 |
| Ji, S | 1 |
| Xu, Y | 1 |
| Han, D | 1 |
| Peng, X | 1 |
| Brockmeyer, NH | 3 |
| Wu, N | 1 |
| Britto, GR | 1 |
| Augustine, M | 1 |
| Luo, XL | 1 |
| Mo, LD | 1 |
| Su, GS | 1 |
| Huang, JP | 1 |
| Wu, JY | 1 |
| Su, HZ | 1 |
| Huang, WH | 1 |
| Luo, SD | 1 |
| Ni, ZY | 1 |
| Potty, RS | 1 |
| Sinha, A | 1 |
| Sethumadhavan, R | 1 |
| Isac, S | 1 |
| Washington, R | 1 |
| Notter, J | 1 |
| Bregenzer, A | 1 |
| Apangu, P | 1 |
| Izudi, J | 2 |
| Mulogo, E | 1 |
| Batwala, V | 1 |
| Shiferaw, MB | 1 |
| Endalamaw, D | 1 |
| Hussien, M | 1 |
| Agegne, M | 1 |
| Amare, D | 1 |
| Estifanos, F | 1 |
| Temesgen, D | 1 |
| Paximadis, M | 2 |
| Burke, M | 2 |
| Technau, KG | 2 |
| Sherman, GG | 5 |
| Ledwaba, J | 3 |
| Mazanderani, AH | 2 |
| Tiemessen, CT | 5 |
| Sudjaritruk, T | 1 |
| Boettiger, DC | 2 |
| Nguyen, LV | 1 |
| Mohamed, TJ | 1 |
| Wati, DK | 1 |
| Bunupuradah, T | 4 |
| Hansudewechakul, R | 1 |
| Ly, PS | 1 |
| Lumbiganon, P | 2 |
| Nallusamy, RA | 1 |
| Fong, MS | 1 |
| Nik Yusoff, NK | 1 |
| Truong, KH | 1 |
| Do, VC | 1 |
| Sohn, AH | 1 |
| Sirisanthana, V | 6 |
| Murray, TY | 1 |
| Snyman, T | 1 |
| George, J | 1 |
| Avenant, T | 1 |
| Goga, AE | 2 |
| Pepper, MS | 2 |
| du Plessis, N | 1 |
| Thomas, K | 1 |
| Yiannoutsos, C | 1 |
| Onono, M | 2 |
| Wools-Kaloustian, KK | 1 |
| Omooja, J | 1 |
| Nannyonjo, M | 1 |
| Sanyu, G | 1 |
| Nabirye, SE | 1 |
| Nassolo, F | 1 |
| Lunkuse, S | 1 |
| Kapaata, A | 1 |
| Segujja, F | 1 |
| Kateete, DP | 1 |
| Ssebaggala, E | 1 |
| Bbosa, N | 1 |
| Aling, E | 1 |
| Nsubuga, RN | 1 |
| Kaleebu, P | 8 |
| Ssemwanga, D | 1 |
| Hu, K | 1 |
| Xiang, Q | 1 |
| Mu, GY | 1 |
| Ma, LY | 1 |
| Xie, QF | 1 |
| Chen, SQ | 1 |
| Zhou, S | 1 |
| Zhang, XD | 1 |
| Cui, YM | 1 |
| Neary, M | 2 |
| Matovu, J | 2 |
| Siccardi, M | 4 |
| Thomas, KK | 1 |
| Tamraz, B | 1 |
| Blue, SW | 1 |
| Erikson, DW | 1 |
| Kim, CJ | 1 |
| Kelly, EJ | 1 |
| Nanda, K | 2 |
| Kourtis, AP | 9 |
| Lingappa, JR | 1 |
| Mugo, N | 1 |
| Baeten, JM | 1 |
| Mwansa-Kambafwile, J | 1 |
| van der Walt, JS | 3 |
| Smith, P | 5 |
| Rangaka, M | 1 |
| Wilkinson, RJ | 2 |
| Maartens, G | 14 |
| Prendergast, AJ | 3 |
| Hermans, SM | 1 |
| Manabe, YC | 1 |
| Hoepelman, AI | 1 |
| Lange, JM | 38 |
| van Leth, F | 13 |
| Ton, Q | 1 |
| Bonnet, M | 3 |
| Baudin, E | 3 |
| Silva, C | 2 |
| Michon, C | 1 |
| Ciaffi, L | 6 |
| Sobry, A | 1 |
| Bastos, R | 1 |
| Nunes, E | 1 |
| Rouzioux, C | 8 |
| Calmy, A | 10 |
| Bayonne Kombo, ES | 1 |
| Gathse, A | 1 |
| Frank, M | 3 |
| Harms, G | 10 |
| Kunz, A | 10 |
| Kloft, C | 3 |
| Meng, X | 1 |
| Howarth, A | 1 |
| Earnshaw, CJ | 1 |
| Jenkins, RE | 1 |
| French, NS | 1 |
| Back, DJ | 13 |
| Naisbitt, DJ | 1 |
| Park, BK | 1 |
| Reynolds, HW | 2 |
| Gachuno, O | 1 |
| Kayita, J | 2 |
| Hays, MA | 1 |
| Otterness, C | 1 |
| Rakwar, J | 1 |
| Tapsfield, J | 1 |
| Mathews, T | 1 |
| Lungu, M | 1 |
| van Oosterhout, JJ | 11 |
| Ling, Y | 1 |
| Barrail-Tran, A | 3 |
| Darak, S | 1 |
| Darak, T | 1 |
| Kulkarni, S | 3 |
| Parchure, R | 1 |
| Hutter, I | 1 |
| Janssen, F | 1 |
| Wang, R | 2 |
| Weng, J | 1 |
| Pain, D | 1 |
| Barr, CD | 1 |
| Maruapula, D | 1 |
| Mongwato, D | 1 |
| Iqbal, HS | 1 |
| Solomon, SS | 1 |
| Saravanan, S | 1 |
| Vidya, M | 1 |
| Kumarasamy, N | 12 |
| Solomon, S | 6 |
| Balakrishnan, P | 5 |
| Audureau, E | 2 |
| Kahn, JG | 4 |
| Besson, MH | 2 |
| Saba, J | 2 |
| Ladner, J | 2 |
| Lilian, RR | 1 |
| Kalk, E | 1 |
| Kiage, JN | 1 |
| Heimburger, DC | 1 |
| Nyirenda, CK | 1 |
| Wellons, MF | 1 |
| Bagchi, S | 1 |
| Koethe, JR | 1 |
| Arnett, DK | 1 |
| Kabagambe, EK | 1 |
| Fillekes, Q | 5 |
| Mulenga, V | 11 |
| Kabamba, D | 7 |
| Kankasa, C | 14 |
| Thomason, MJ | 4 |
| Cook, A | 6 |
| Chintu, C | 8 |
| Burger, DM | 21 |
| Bannaga, A | 1 |
| Rahama, O | 1 |
| Barlow, G | 1 |
| Lowenthal, ED | 1 |
| Ellenberg, JH | 1 |
| Machine, E | 1 |
| Sagdeo, A | 1 |
| Boiditswe, S | 1 |
| Steenhoff, AP | 1 |
| Rutstein, R | 1 |
| Anabwani, G | 3 |
| Gross, R | 1 |
| Holmes, D | 1 |
| Patel, K | 3 |
| Panchasara, A | 1 |
| Purohit, B | 1 |
| Tripathi, CB | 1 |
| Pombo, M | 1 |
| Olalla, J | 1 |
| Del Arco, A | 1 |
| De La Torre, J | 3 |
| Urdiales, D | 1 |
| Aguilar, A | 1 |
| Prada, JL | 1 |
| García-Alegría, J | 1 |
| Ruiz-Mateas, F | 1 |
| Taverne, B | 1 |
| Desclaux, A | 1 |
| Koita Fall, MB | 1 |
| Delaporte, E | 8 |
| Ndoye, I | 3 |
| Otegbayo, JA | 1 |
| Kuti, MA | 1 |
| Ogunbode, O | 1 |
| Irabor, AE | 1 |
| Adewoles, IF | 1 |
| Balkus, JE | 1 |
| Richardson, BA | 10 |
| Mochache, V | 1 |
| Chohan, V | 1 |
| Chan, JD | 1 |
| Masese, L | 2 |
| Shafi, J | 1 |
| Marrazzo, J | 1 |
| Farquhar, C | 5 |
| McClelland, RS | 2 |
| Vardhanabhuti, S | 1 |
| Acosta, EP | 10 |
| Ribaudo, HJ | 3 |
| Severe, P | 1 |
| Lalloo, U | 1 |
| Taulo, F | 2 |
| Kabanda, J | 3 |
| Oneko, O | 1 |
| Ive, P | 1 |
| Sambarey, P | 2 |
| Chan, ES | 2 |
| Hitti, J | 9 |
| Hong, F | 3 |
| McMahon, D | 1 |
| Tang, MW | 2 |
| Rhee, SY | 3 |
| Bertagnolio, S | 1 |
| Ford, N | 6 |
| Holmes, S | 1 |
| Sigaloff, KC | 2 |
| Hamers, RL | 3 |
| de Wit, TF | 3 |
| Fleury, HJ | 6 |
| Kanki, PJ | 4 |
| Ruxrungtham, K | 11 |
| Hawkins, CA | 1 |
| Wallis, CL | 2 |
| Stevens, W | 2 |
| van Zyl, GU | 4 |
| Manosuthi, W | 28 |
| Hosseinipour, MC | 11 |
| Belec, L | 2 |
| Peeters, M | 2 |
| Burda, S | 1 |
| Cane, P | 1 |
| Cappelli, G | 1 |
| Charpentier, C | 2 |
| Dagnra, AY | 1 |
| Deshpande, AK | 1 |
| El-Katib, Z | 1 |
| Eshleman, SH | 39 |
| Gody, JC | 2 |
| Katzenstein, D | 2 |
| Koyalta, DD | 1 |
| Kumwenda, JJ | 4 |
| Lynen, L | 5 |
| Marconi, VC | 2 |
| Margot, NA | 1 |
| Moussa, S | 1 |
| Ndung'u, T | 4 |
| Nyambi, PN | 1 |
| Schapiro, JM | 2 |
| Schuurman, R | 5 |
| Sirivichayakul, S | 3 |
| Smith, D | 3 |
| Zolfo, M | 2 |
| Jordan, MR | 1 |
| Kyaw, NL | 2 |
| Thanachartwet, V | 2 |
| Kiertiburanakul, S | 13 |
| Desakorn, V | 4 |
| Chamnanchanunt, S | 1 |
| Chierakul, W | 1 |
| Pitisuttithum, P | 5 |
| Sungkanuparph, S | 25 |
| Abgrall, S | 4 |
| Ingle, SM | 1 |
| May, MT | 1 |
| Mercie, P | 1 |
| Cavassini, M | 3 |
| Reekie, J | 2 |
| Samji, H | 1 |
| Gill, MJ | 2 |
| Crane, HM | 2 |
| Tate, J | 1 |
| Sterling, TR | 2 |
| Reiss, P | 27 |
| Saag, MS | 4 |
| Mugavero, MJ | 1 |
| Phillips, A | 3 |
| Manzardo, C | 1 |
| Wasmuth, JC | 2 |
| Stephan, C | 2 |
| Guest, JL | 1 |
| Gomez Sirvent, JL | 1 |
| Sterne, JA | 1 |
| Werayingyong, P | 1 |
| Phanuphak, N | 5 |
| Tantivess, S | 1 |
| Kullert, N | 1 |
| Tosanguan, K | 1 |
| Butchon, R | 1 |
| Voramongkol, N | 1 |
| Boonsuk, S | 1 |
| Pilasant, S | 1 |
| Kulpeng, W | 1 |
| Teerawattananon, Y | 2 |
| Loutfy, MR | 1 |
| Walmsley, SL | 1 |
| Klein, MB | 1 |
| Raboud, J | 2 |
| Tseng, AL | 1 |
| Blitz, SL | 1 |
| Pick, N | 1 |
| Conway, B | 9 |
| Angel, JB | 1 |
| Rachlis, AR | 1 |
| Cohen, J | 6 |
| Haase, D | 1 |
| Burdge, D | 1 |
| Smaill, FM | 1 |
| de Pokomandy, A | 1 |
| Loemba, H | 1 |
| Trottier, S | 1 |
| la Porte, CJ | 1 |
| Vispo, E | 2 |
| Fernández-Montero, JV | 1 |
| Labarga, P | 3 |
| Barreiro, P | 7 |
| Soriano, V | 15 |
| Cruciani, M | 1 |
| Mengoli, C | 1 |
| Serpelloni, G | 1 |
| Parisi, SG | 2 |
| Malena, M | 1 |
| Bosco, O | 1 |
| Dziuban, EJ | 1 |
| Hughey, AB | 1 |
| Stewart, DA | 1 |
| Blank, DA | 1 |
| Kochelani, D | 1 |
| Draper, HR | 1 |
| Schutze, GE | 2 |
| Mghamba, FW | 1 |
| Minzi, OM | 5 |
| Massawe, A | 1 |
| Sasi, P | 1 |
| Chijioke-Nwauche, I | 1 |
| van Wyk, A | 1 |
| Nwauche, C | 1 |
| Beshir, KB | 1 |
| Kaur, H | 1 |
| Sutherland, CJ | 1 |
| Di Fusco, D | 1 |
| Zimba, I | 2 |
| Erba, F | 1 |
| Bendle, M | 1 |
| Bajpai, S | 1 |
| Choudhary, A | 2 |
| Pazare, A | 1 |
| Bach-Ngohou, K | 1 |
| Sécher, S | 2 |
| Dejoie, T | 1 |
| Fakhouri, F | 1 |
| Watts, DH | 9 |
| Brown, ER | 6 |
| Herron, C | 1 |
| Reddy, L | 1 |
| Zwerski, S | 7 |
| Coovadia, H | 8 |
| Fowler, M | 1 |
| Gupta-Wright, A | 1 |
| Wood, R | 10 |
| Bekker, LG | 1 |
| Lawn, SD | 1 |
| Takuva, S | 1 |
| Evans, D | 1 |
| Zuma, K | 1 |
| Okello, V | 1 |
| Louwagie, G | 1 |
| Baffoin, S | 1 |
| Ferré, V | 5 |
| Muro, EP | 4 |
| Chunda, C | 1 |
| Aitken, S | 1 |
| Kisanga, ER | 3 |
| Geretti, AM | 5 |
| Fox, Z | 1 |
| Johnson, JA | 6 |
| Booth, C | 1 |
| Lipscomb, J | 2 |
| Stuyver, LJ | 1 |
| Tachedjian, G | 3 |
| Baxter, J | 1 |
| Touloumi, G | 1 |
| Lehmann, C | 1 |
| Pillay, P | 1 |
| Shubber, Z | 2 |
| Ferrand, RA | 1 |
| Hobbs, CV | 2 |
| De La Vega, P | 1 |
| Penzak, SR | 2 |
| Van Vliet, J | 1 |
| Krzych, U | 1 |
| Sinnis, P | 1 |
| Borkowsky, W | 2 |
| Duffy, PE | 2 |
| Cohan, D | 1 |
| Mwesigwa, J | 1 |
| Natureeba, P | 1 |
| Aliba Luwedde, F | 1 |
| Ades, V | 1 |
| Plenty, A | 2 |
| Kakuru, A | 3 |
| Achan, J | 3 |
| Clark, T | 1 |
| Osterbauer, B | 1 |
| Kamya, M | 4 |
| Havlir, D | 9 |
| Salazar, MG | 1 |
| Gao, F | 1 |
| Learn, GH | 1 |
| Kalilani, L | 1 |
| Hahn, BH | 1 |
| Shaw, GM | 2 |
| Salazar-Gonzalez, JF | 1 |
| Saxon, CJ | 1 |
| Helbert, MR | 1 |
| Komolafe, AJ | 1 |
| Higgins, SP | 1 |
| Dube, N | 1 |
| Adewusi, E | 1 |
| Summers, R | 1 |
| Nii-Trebi, NI | 1 |
| Ibe, S | 1 |
| Barnor, JS | 1 |
| Ishikawa, K | 1 |
| Brandful, JA | 1 |
| Ofori, SB | 1 |
| Yamaoka, S | 1 |
| Ampofo, WK | 1 |
| Sugiura, W | 3 |
| Gedefaw, L | 1 |
| Yemane, T | 1 |
| Sahlemariam, Z | 1 |
| Yilma, D | 2 |
| Micheli, JE | 1 |
| Chinn, LW | 2 |
| Shugarts, SB | 1 |
| Patel, A | 1 |
| Kroetz, DL | 2 |
| Manasa, J | 1 |
| Lessells, RJ | 1 |
| Skingsley, A | 1 |
| Naidu, KK | 1 |
| Newell, ML | 15 |
| McGrath, N | 1 |
| de Oliveira, T | 2 |
| Sarfo, FS | 1 |
| Sarfo, MA | 1 |
| Phillips, R | 1 |
| Booth, M | 1 |
| Chadwick, D | 1 |
| Bock, P | 1 |
| Fatti, G | 1 |
| Grimwood, A | 1 |
| Frassetto, L | 1 |
| Floren, L | 1 |
| Barin, B | 1 |
| Browne, M | 1 |
| Wolfe, A | 1 |
| Roland, M | 1 |
| Stock, P | 1 |
| Carlson, L | 1 |
| Christians, U | 1 |
| Benet, L | 1 |
| Blanco, J | 1 |
| Gunda, DW | 1 |
| Kasang, C | 1 |
| Kidenya, BR | 1 |
| Kabangila, R | 1 |
| Mshana, SE | 1 |
| Kidola, J | 1 |
| Kalluvya, SE | 1 |
| Kongola, GW | 1 |
| Klinker, H | 7 |
| Delany-Moretlwe, S | 1 |
| Dubé, K | 1 |
| Lendvay, A | 1 |
| Kwok, C | 1 |
| Molife, L | 1 |
| Nakubulwa, S | 1 |
| Edward, VA | 1 |
| Mpairwe, B | 1 |
| Mirembe, FM | 1 |
| León, W | 1 |
| McIlroy, D | 1 |
| Kawalec, P | 1 |
| Kryst, J | 1 |
| Mikrut, A | 1 |
| Pilc, A | 1 |
| Bhavani, PK | 2 |
| Tang, A | 1 |
| Kumar, H | 1 |
| Ponnuraja, C | 3 |
| Hannah, E | 1 |
| Ramesh, C | 1 |
| Donnell, D | 6 |
| Mmiro, F | 28 |
| Allen, M | 5 |
| Jackson, JB | 39 |
| Guay, LA | 26 |
| Raghunandan, P | 1 |
| Chandrashekhar, R | 1 |
| Sharma, SK | 1 |
| Kumar, S | 1 |
| Ekka, M | 1 |
| Velpandian, T | 2 |
| Ahmad, H | 1 |
| Samantaray, JC | 1 |
| Venkatesh, S | 1 |
| Rewari, BB | 4 |
| Khan, NH | 1 |
| Chirouze, C | 1 |
| Muret, P | 1 |
| Peytavin, G | 14 |
| Bettinger, D | 2 |
| Hoen, B | 3 |
| Fortes Déguénonvo, L | 1 |
| Diop, SA | 1 |
| Leye, MM | 1 |
| Seydi, M | 2 |
| Dieng, AB | 1 |
| Bentaleb, H | 1 |
| Diouf, A | 2 |
| Lakhe, NA | 1 |
| Ka, D | 1 |
| Cisse, VM | 1 |
| Dia Badiane, NM | 2 |
| Manga, MN | 1 |
| Ndour, CT | 2 |
| Soumaré, M | 2 |
| Diop, BM | 2 |
| Sow, PS | 5 |
| Gandhi, M | 7 |
| Yang, Q | 2 |
| Bacchetti, P | 6 |
| Huang, Y | 4 |
| Herron, CM | 1 |
| Chetty, V | 2 |
| Msweli, L | 2 |
| Kisenge, R | 3 |
| Brown, E | 3 |
| Sartorius, BK | 1 |
| Chersich, MF | 4 |
| Mwaura, M | 1 |
| Meda, N | 1 |
| Temmerman, M | 6 |
| Farley, TM | 1 |
| Luchters, S | 2 |
| Ramokolo, V | 2 |
| Fadnes, LT | 1 |
| Doherty, T | 4 |
| Jackson, DJ | 1 |
| Chhagan, M | 1 |
| Van den Broeck, J | 1 |
| Dickinson, L | 2 |
| Chaponda, M | 5 |
| Carr, DF | 4 |
| Kumwenda, J | 4 |
| Lalloo, DG | 5 |
| Pirmohamed, M | 4 |
| Heyderman, RS | 4 |
| Khoo, SH | 7 |
| Li, JZ | 2 |
| George, L | 1 |
| Ndaro, A | 1 |
| Dolmans, W | 3 |
| Shen, Y | 1 |
| Qi, T | 1 |
| Feiterna-Sperling, C | 2 |
| Mompati, K | 1 |
| Königs, C | 2 |
| Mensa, FJ | 1 |
| Sabo, JP | 3 |
| Yong, CL | 5 |
| MacGregor, TR | 6 |
| Nguyen, T | 2 |
| Quinson, AM | 3 |
| Cain, LE | 1 |
| Hernán, MA | 1 |
| Perry, SH | 1 |
| Swamy, P | 1 |
| Preidis, GA | 1 |
| Mwanyumba, A | 1 |
| Motsa, N | 1 |
| Sarero, HN | 1 |
| Kayentao, K | 1 |
| Guirou, EA | 1 |
| Doumbo, OK | 1 |
| Venkatesan, M | 1 |
| Plowe, CV | 1 |
| Parsons, TL | 4 |
| Hendrix, CW | 1 |
| Nyunt, MM | 1 |
| Mwafongo, A | 1 |
| Nkanaunena, K | 5 |
| Zheng, Y | 8 |
| Mulenga, L | 1 |
| Siika, A | 5 |
| Currier, J | 5 |
| Hosseinipour, M | 4 |
| Fehintola, FA | 1 |
| Ma, Q | 3 |
| Aweeka, FT | 5 |
| Morse, GD | 5 |
| Akinola, IT | 1 |
| Adedeji, WA | 2 |
| Lindegardh, N | 2 |
| Tarning, J | 2 |
| Ojengbede, O | 1 |
| Adewole, IF | 2 |
| Taiwo, B | 3 |
| Murphy, RL | 11 |
| Akinyinka, OO | 2 |
| Ngemu, EK | 1 |
| Khayeka-Wandabwa, C | 1 |
| Kweka, EJ | 1 |
| Choge, JK | 1 |
| Anino, E | 1 |
| Oyoo-Okoth, E | 1 |
| Goel, R | 1 |
| Rai, M | 1 |
| Chakravarty, J | 1 |
| Meena, LP | 1 |
| Tiwary, NK | 1 |
| Sundar, S | 1 |
| Bharti, A | 1 |
| Wattanakul, T | 1 |
| Avihingsanon, A | 3 |
| Martens, L | 5 |
| Meredith, S | 1 |
| Arpadi, SM | 1 |
| Kumar, AK | 3 |
| Rajesh, L | 3 |
| Chandrasekharan, C | 1 |
| Mora-Peris, B | 2 |
| Watson, V | 2 |
| Vera, JH | 1 |
| Weston, R | 1 |
| Waldman, AD | 1 |
| Kaye, S | 1 |
| Mackie, NE | 3 |
| Back, D | 11 |
| Winston, A | 5 |
| van Griensven, J | 4 |
| Phirum, L | 1 |
| Choun, K | 2 |
| Thai, S | 3 |
| De Weggheleire, A | 1 |
| Slyker, JA | 1 |
| Casper, C | 1 |
| Tapia, K | 4 |
| Richardson, B | 3 |
| Bunts, L | 1 |
| Huang, ML | 1 |
| Benki-Nugent, S | 4 |
| John-Stewart, G | 5 |
| Nyombi, B | 1 |
| Shayo, A | 1 |
| Musoke, R | 1 |
| Feng, S | 1 |
| Shaffer, D | 6 |
| Moses, A | 1 |
| Manicklal, S | 1 |
| van Niekerk, AM | 1 |
| Kroon, SM | 2 |
| Hutto, C | 1 |
| Novak, Z | 1 |
| Pati, SK | 1 |
| Chowdhury, N | 1 |
| Hsiao, NY | 1 |
| Boppana, SB | 1 |
| Tudor-Williams, G | 6 |
| Cahn, P | 10 |
| Fourie, J | 1 |
| Karatzios, C | 1 |
| Dincq, S | 1 |
| Opsomer, M | 1 |
| Kakuda, TN | 1 |
| Nijs, S | 1 |
| Tambuyzer, L | 1 |
| Tomaka, FL | 1 |
| Micek, MA | 4 |
| Dross, S | 3 |
| Blanco, AJ | 4 |
| Matunha, L | 3 |
| Seidel, K | 3 |
| Montoya, P | 4 |
| Matediana, E | 2 |
| Gantt, S | 3 |
| Gloyd, S | 4 |
| Landolt, NK | 2 |
| Ubolyam, S | 2 |
| Pinyakorn, S | 3 |
| Kerr, S | 2 |
| Ahluwalia, J | 2 |
| Thongpaeng, P | 2 |
| Thammajaruk, N | 2 |
| Cremers, S | 1 |
| Thomas, T | 2 |
| Chaithongwongwatthana, S | 3 |
| Ananworanich, J | 5 |
| Tran, DA | 1 |
| Wilson, DP | 1 |
| Shakeshaft, A | 1 |
| Ngo, AD | 1 |
| Doran, C | 1 |
| Kityo, C | 18 |
| Goodall, RL | 5 |
| Mambule, I | 3 |
| Pillay, D | 9 |
| Kasirye, R | 2 |
| Mugyenyi, P | 9 |
| Dunn, DT | 5 |
| Bhatt, NB | 2 |
| Barau, C | 1 |
| Amin, A | 1 |
| Furlan, V | 2 |
| Grinsztejn, B | 4 |
| Hickey, MD | 1 |
| Salmen, CR | 1 |
| Tessler, RA | 1 |
| Omollo, D | 1 |
| Magerenge, R | 1 |
| Mattah, B | 1 |
| Salmen, MR | 1 |
| Zoughbie, D | 1 |
| Fiorella, KJ | 1 |
| Geng, E | 1 |
| Njoroge, B | 1 |
| Jin, C | 3 |
| Baranyai, D | 1 |
| Muro, E | 2 |
| Gödtel-Armbrust, U | 1 |
| Schirmer, MA | 1 |
| Kisanga, E | 1 |
| Diczfalusy, U | 1 |
| Burger, D | 14 |
| Wojnowski, L | 1 |
| O'Brien, L | 1 |
| Shaffer, N | 7 |
| Sangrujee, N | 1 |
| Abimbola, TO | 1 |
| Andreotti, M | 8 |
| Pirillo, MF | 6 |
| Jere, H | 4 |
| Maulidi, M | 1 |
| Sagno, JB | 3 |
| Amici, R | 6 |
| Mancini, MG | 2 |
| Gennaro, E | 1 |
| Vella, S | 17 |
| Giuliano, M | 8 |
| Price, AJ | 1 |
| Kayange, M | 2 |
| Zaba, B | 1 |
| Chimbwandira, FM | 1 |
| Chirwa, Z | 2 |
| Dasgupta, AN | 1 |
| Katundu, C | 1 |
| Saul, JL | 1 |
| Glynn, JR | 2 |
| Koole, O | 2 |
| Crampin, AC | 2 |
| Kayiwa, J | 4 |
| Zangata, D | 1 |
| Nansubuga, C | 1 |
| Arach, B | 1 |
| Kenny, J | 2 |
| Wavamunno, P | 2 |
| Komunyena, J | 1 |
| Asiimwe, AR | 1 |
| Mirembe, G | 2 |
| Abongomera, G | 3 |
| Walker, SA | 1 |
| Klein, N | 2 |
| Chetty, T | 1 |
| Carter, RJ | 2 |
| Bland, RM | 3 |
| Gare, J | 1 |
| Ryan, CE | 1 |
| David, M | 1 |
| Timbi, D | 1 |
| Kaima, P | 1 |
| Kombati, Z | 1 |
| Imara, U | 1 |
| Kelly-Hanku, A | 1 |
| Siba, PM | 1 |
| Crowe, SM | 1 |
| Hearps, AC | 1 |
| Mir, F | 1 |
| Qamar, FN | 1 |
| Baig-Ansari, N | 1 |
| Abro, AG | 1 |
| Abbas, SQ | 1 |
| Kazi, MA | 1 |
| Rizvi, A | 1 |
| Zaidi, AK | 1 |
| Mukherjee, A | 1 |
| Singla, M | 1 |
| Sirohiwal, A | 1 |
| Vajpayee, M | 1 |
| Singh, R | 1 |
| Kabra, SK | 2 |
| Lodha, R | 2 |
| Muhindo, MK | 1 |
| Ikilezi, G | 1 |
| Arinaitwe, E | 1 |
| Mwangwa, F | 1 |
| Clark, TD | 1 |
| Charlebois, E | 2 |
| Rosenthal, PJ | 1 |
| Kamya, MR | 4 |
| Tappero, JW | 4 |
| Dorsey, G | 3 |
| Hamela, G | 1 |
| Kabondo, C | 1 |
| Tembo, T | 1 |
| Zimba, C | 2 |
| Kamanga, E | 1 |
| Mofolo, I | 1 |
| Bulla, B | 1 |
| Sellers, C | 1 |
| Nakanga, RC | 1 |
| Lee, C | 2 |
| Martinson, F | 4 |
| Hoffman, I | 3 |
| van der Horst, C | 9 |
| Muhe, LM | 1 |
| Tindyebwa, D | 1 |
| Abrams, E | 2 |
| Dang, N | 1 |
| Sivakumaran, H | 2 |
| Harrich, D | 2 |
| Shaw, PN | 2 |
| Coombes, AGA | 1 |
| Guo, W | 1 |
| Zhuang, D | 2 |
| Jiao, L | 1 |
| Gui, T | 1 |
| Jia, L | 1 |
| Maganda, BA | 3 |
| Kamuhabwa, AA | 3 |
| Ngasala, B | 1 |
| Sasi, PG | 1 |
| Dang, NT | 1 |
| Davis-Poynter, N | 1 |
| Coombes, AG | 1 |
| Saegusa, T | 1 |
| Di, C | 1 |
| Chen, YQ | 2 |
| Dailly, E | 8 |
| Bonnet, B | 1 |
| Pineau, S | 1 |
| Boutoille, D | 1 |
| Bouquié, R | 3 |
| Raveleau, A | 1 |
| Bouchez, S | 2 |
| Keane, NM | 1 |
| Pavlos, RK | 1 |
| McKinnon, E | 1 |
| Lucas, A | 1 |
| Rive, C | 1 |
| Blyth, CC | 1 |
| Dunn, D | 5 |
| Lucas, M | 1 |
| Mallal, S | 3 |
| Phillips, E | 5 |
| Jiang, HY | 1 |
| Zhang, MN | 1 |
| Chen, HJ | 1 |
| Deng, M | 1 |
| Ruan, B | 1 |
| Udomphanit, T | 1 |
| Rattanamanee, S | 1 |
| Harnlakorn, P | 1 |
| Sopharak, C | 1 |
| Sringam, J | 1 |
| Anutchatchaval, S | 1 |
| Tharnprisan, P | 1 |
| Kosalaraksa, P | 1 |
| Asmelash, A | 6 |
| Kaloustian, KW | 1 |
| Ogwu, A | 3 |
| Salata, R | 3 |
| de Waal, R | 2 |
| Holgate, SL | 1 |
| Horn, AR | 1 |
| Tooke, LJ | 1 |
| Blockman, M | 1 |
| McIlleron, HM | 1 |
| Cohen, K | 7 |
| Houben, RM | 1 |
| Mzembe, T | 1 |
| Van Boeckel, TP | 1 |
| Chimbwandira, F | 2 |
| McCarthy, M | 2 |
| Clumeck, N | 4 |
| Mwamba, C | 1 |
| Kabeya, K | 1 |
| Matanda, S | 1 |
| Vaira, D | 2 |
| Necsoi, C | 1 |
| Kadiebwe, D | 1 |
| Delforge, M | 1 |
| Kasamba, E | 1 |
| Milolo, C | 1 |
| Ilunga, J | 1 |
| Kapend, L | 1 |
| Crawford, KW | 1 |
| Aoudjane, S | 1 |
| González Del Castillo, AA | 1 |
| O'Connor, J | 1 |
| Noguera, M | 1 |
| Beloukas, A | 2 |
| Hopkins, M | 1 |
| Svensson, EM | 2 |
| Karlsson, MO | 3 |
| Liechty, EA | 1 |
| Busakhala, N | 1 |
| Bartelink, IH | 2 |
| Savic, RM | 2 |
| Blaschke, TF | 1 |
| Eshelman, C | 1 |
| Langat, A | 2 |
| Okinyi, HM | 1 |
| Cornejo Castro, EM | 1 |
| Jorgensen, AL | 2 |
| Dandara, C | 3 |
| Kampira, E | 2 |
| Ssali, F | 11 |
| Munderi, P | 12 |
| Sigaloff, K | 1 |
| Buzibye, A | 2 |
| Merry, C | 9 |
| Nakatudde-Katumba, L | 1 |
| Ditangco, R | 3 |
| Merati, TP | 3 |
| Pham, TT | 1 |
| Chaiwarith, R | 1 |
| Li, CK | 1 |
| Vonthanak, S | 1 |
| Van Kinh, N | 1 |
| Pujari, S | 3 |
| Wong, WW | 1 |
| Kamarulzaman, A | 4 |
| Zhang, F | 2 |
| Choi, JY | 1 |
| Ng, OT | 1 |
| Kantipong, P | 4 |
| Mustafa, M | 1 |
| Ratanasuwan, W | 3 |
| Sohn, A | 1 |
| Law, M | 2 |
| Lindsey, JC | 4 |
| Barlow-Mosha, L | 7 |
| Kamthunzi, P | 5 |
| Sambo, PM | 1 |
| Moultrie, H | 3 |
| Petzold, E | 4 |
| Palumbo, P | 7 |
| Alvarez-Uria, G | 1 |
| Pakam, R | 1 |
| Naik, PK | 1 |
| Midde, M | 1 |
| Mutsvangwa, J | 1 |
| Gwanzura, L | 1 |
| Manhanzva, MT | 1 |
| da Silva, C | 1 |
| Rokx, C | 1 |
| Blonk, M | 1 |
| Verbon, A | 1 |
| Rijnders, BJ | 1 |
| Mavura, DR | 1 |
| Masenga, EJ | 1 |
| Minja, E | 1 |
| Grossmann, H | 1 |
| Crump, JA | 2 |
| Dross, SE | 1 |
| Rossi, SS | 1 |
| Seidel, KD | 1 |
| Yang, CJ | 1 |
| Chang, SY | 3 |
| Lin, SW | 3 |
| Tsai, MS | 1 |
| Liu, WC | 2 |
| Wu, PY | 2 |
| Su, YC | 2 |
| Luo, YZ | 2 |
| Yang, SP | 2 |
| Hung, CC | 3 |
| Chang, SC | 2 |
| Bhutia, E | 1 |
| Hemal, A | 1 |
| Yadav, TP | 1 |
| Ramesh, KL | 1 |
| Gallien, S | 1 |
| Charreau, I | 1 |
| Nere, ML | 1 |
| Mahjoub, N | 1 |
| Simon, F | 1 |
| de Castro, N | 1 |
| Aboulker, JP | 4 |
| Molina, JM | 4 |
| Delaugerre, C | 4 |
| Shearer, K | 1 |
| Brennan, AT | 1 |
| Maskew, M | 1 |
| Long, L | 1 |
| Berhanu, R | 1 |
| Sanne, I | 4 |
| Fox, MP | 2 |
| Tsuchiya, N | 3 |
| Pathipvanich, P | 5 |
| Wichukchinda, N | 2 |
| Rojanawiwat, A | 4 |
| Auwanit, W | 4 |
| Ariyoshi, K | 4 |
| Sawanpanyalert, P | 4 |
| Mgelea, EM | 1 |
| Aboud, S | 1 |
| Motta, I | 1 |
| Milia, MG | 1 |
| Rostagno, R | 2 |
| Simiele, M | 2 |
| Libanore, V | 2 |
| Fontana, S | 1 |
| D'Avolio, A | 5 |
| Ghisetti, V | 1 |
| Di Perri, G | 8 |
| Čolić, A | 1 |
| Alessandrini, M | 1 |
| Baldelli, S | 1 |
| Castoldi, S | 1 |
| Charbe, N | 1 |
| Cozzi, V | 1 |
| Fucile, S | 1 |
| Mistry, N | 1 |
| Sereboe, L | 1 |
| Oakeshott, P | 1 |
| So-Ngern, A | 1 |
| Montakantikul, P | 1 |
| Olds, PK | 1 |
| Kiwanuka, JP | 1 |
| Nansera, D | 1 |
| Iveli, P | 1 |
| Noguera-Julian, A | 1 |
| Soler-Palacín, P | 1 |
| Martín-Nalda, A | 1 |
| Rovira-Girabal, N | 1 |
| Fortuny-Guasch, C | 1 |
| Figueras-Nadal, C | 1 |
| Feucht, UD | 2 |
| Meyer, A | 1 |
| Kruger, M | 1 |
| Ramana, LN | 1 |
| Sharma, S | 2 |
| Sethuraman, S | 1 |
| Ranga, U | 1 |
| Krishnan, UM | 1 |
| Sanjeeva, GN | 1 |
| Sukanya, V | 1 |
| Pavithra, HB | 1 |
| Dodderi, SK | 1 |
| Govindaraj, M | 1 |
| Shivananda, S | 1 |
| Premalatha, R | 1 |
| Cucchetto, G | 2 |
| Nicolè, S | 2 |
| Concia, E | 2 |
| Wongtrakul, J | 1 |
| Thongtan, T | 1 |
| Roytrakul, S | 1 |
| Kumrapich, B | 1 |
| Janphen, K | 1 |
| Praparattanapan, J | 1 |
| Smith, DR | 1 |
| Inui, TS | 1 |
| Gnassingbé, W | 1 |
| Akakpo, S | 2 |
| Aho, K | 1 |
| Tchangaï-Walla, K | 3 |
| Theys, K | 2 |
| Camacho, RJ | 1 |
| Gomes, P | 2 |
| Vandamme, AM | 1 |
| Sawe, FK | 2 |
| Obiero, E | 1 |
| Yegon, P | 1 |
| Langat, RC | 1 |
| Aoko, A | 1 |
| Tarus, J | 1 |
| Kiptoo, I | 1 |
| Langat, RK | 1 |
| Maswai, J | 1 |
| Bii, M | 1 |
| Khamadi, S | 1 |
| Shikuku, KP | 1 |
| Close, N | 1 |
| Sinei, S | 1 |
| Shaffer, DN | 1 |
| Gingrich, D | 1 |
| Scherpbier, HJ | 1 |
| Capparelli, E | 11 |
| Jullien, V | 1 |
| Young, SL | 1 |
| Rufini, S | 1 |
| Buonomo, E | 3 |
| Giardina, E | 1 |
| Scarcella, P | 4 |
| Marszalek, RM | 1 |
| Bae-Harboe, YS | 1 |
| Mahalingam, M | 1 |
| Masterpol, K | 1 |
| Salado-Rasmussen, K | 1 |
| Theilgaard, ZP | 1 |
| Chiduo, MG | 1 |
| Bygbjerg, IC | 1 |
| Gerstoft, J | 4 |
| Lüneborg-Nielsen, M | 1 |
| Lemnge, M | 1 |
| Katzenstein, TL | 4 |
| Chohan, BH | 2 |
| Khasimwa, B | 1 |
| Ngayo, M | 1 |
| Maleche-Obimbo, E | 1 |
| Overbaugh, J | 11 |
| Phan, CT | 1 |
| Pham, HV | 1 |
| Bi, X | 1 |
| Ishizaki, A | 1 |
| Saina, M | 1 |
| Phung, CD | 1 |
| Khu, DT | 1 |
| Ichimura, H | 2 |
| Geng, EH | 2 |
| Neilands, TB | 1 |
| Thièbaut, R | 4 |
| Bwana, MB | 2 |
| Nash, D | 2 |
| Moore, RD | 2 |
| Zannou, DM | 1 |
| Althoff, KN | 1 |
| Lim, PL | 1 |
| Easterbrook, PJ | 4 |
| Little, F | 1 |
| Nakigozi, G | 1 |
| Kiggundu, V | 1 |
| Ki Li, PC | 1 |
| Prozesky, H | 1 |
| Davies, MA | 2 |
| Reynolds, SJ | 3 |
| Egger, M | 2 |
| Vittinghoff, EV | 1 |
| Deeks, SG | 4 |
| Ciaranello, AL | 3 |
| Doherty, K | 1 |
| Harrison, L | 1 |
| Kelly, K | 1 |
| Walensky, RP | 5 |
| Losina, E | 2 |
| Muhe, L | 1 |
| Ayaya, S | 1 |
| Weinstein, MC | 1 |
| Freedberg, KA | 5 |
| Yang, W | 1 |
| Fan, P | 1 |
| Liang, Y | 1 |
| Ma, Y | 1 |
| Li, N | 1 |
| Sun, D | 1 |
| Zhu, Q | 1 |
| Sando, D | 1 |
| Spiegelman, D | 1 |
| Machumi, L | 1 |
| Mwanyika-Sando, M | 1 |
| Aris, E | 1 |
| Muya, A | 1 |
| Jackson, E | 1 |
| Baernighausen, T | 1 |
| Hertzmark, E | 1 |
| Chalamilla, G | 1 |
| Desmond, AC | 1 |
| Conolly, CA | 1 |
| Castel, SA | 1 |
| Ngaimisi, E | 2 |
| Aklillu, E | 2 |
| Abecasis, AB | 1 |
| van Laethem, K | 1 |
| Gleason, RL | 1 |
| Caulk, AW | 1 |
| Seifu, D | 1 |
| Parker, I | 1 |
| Vidakovic, B | 1 |
| Getenet, H | 1 |
| Assefa, G | 1 |
| Amogne, W | 1 |
| Aslanyan, S | 1 |
| Morrow, JS | 2 |
| Samuel, R | 2 |
| Paredes, R | 12 |
| Parboosing, R | 2 |
| Moodley, P | 3 |
| Singh, L | 2 |
| Naidoo, A | 2 |
| Gordon, M | 3 |
| Priya, MR | 1 |
| Rajendran, NN | 1 |
| Lepik, KJ | 1 |
| Yip, B | 8 |
| McGovern, RA | 1 |
| Ding, E | 1 |
| Nohpal, A | 1 |
| Watson, BE | 1 |
| Toy, J | 1 |
| Akagi, L | 1 |
| Harrigan, PR | 8 |
| Moore, DM | 1 |
| Hogg, RS | 7 |
| Montaner, JS | 22 |
| Barrios, R | 1 |
| Dominguez, K | 1 |
| Cotton, M | 4 |
| Abdissa, A | 1 |
| Olsen, MF | 1 |
| Tesfaye, M | 1 |
| Girma, T | 1 |
| Christiansen, M | 1 |
| Hagen, CM | 1 |
| Castel, S | 3 |
| Aseffa, A | 1 |
| Pedersen, C | 4 |
| Friis, H | 1 |
| Andersen, AB | 1 |
| Herce, ME | 1 |
| Kalanga, N | 1 |
| Wroe, EB | 1 |
| Keck, JW | 1 |
| Chingoli, F | 1 |
| Tengatenga, L | 1 |
| Gopal, S | 1 |
| Phiri, A | 1 |
| Mailosi, B | 1 |
| Bazile, J | 1 |
| Beste, JA | 1 |
| Elmore, SN | 1 |
| Crocker, JT | 1 |
| Rigodon, J | 1 |
| Baxi, SM | 1 |
| Greenblatt, RM | 3 |
| French, AL | 3 |
| Keller, MJ | 1 |
| Augenbraun, MH | 1 |
| Gange, SJ | 2 |
| Liu, C | 4 |
| Mack, WJ | 1 |
| Zhao, J | 1 |
| Sun, J | 3 |
| Yin, Q | 1 |
| Jiao, Y | 1 |
| Shao, Y | 1 |
| Rodrigues, M | 1 |
| Galluzzo, CM | 6 |
| Qiu, Y | 1 |
| Powis, K | 3 |
| Tih, PM | 3 |
| Woldesenbet, S | 1 |
| Puren, A | 4 |
| Sherman, G | 11 |
| Mogashoa, M | 1 |
| Bhardwaj, S | 1 |
| Chopra, M | 3 |
| Pillay, Y | 1 |
| Antunes, F | 3 |
| Zindoga, P | 1 |
| Augusto, O | 1 |
| Mahumane, I | 1 |
| Veloso, L | 1 |
| Valadas, E | 1 |
| Camacho, R | 1 |
| Nelson, JA | 2 |
| Fokar, A | 1 |
| Hudgens, MG | 4 |
| Compliment, KJ | 1 |
| Hawkins, JT | 1 |
| Tegha, G | 4 |
| Kamwendo, DD | 3 |
| Kayira, D | 5 |
| Mofolo, IA | 3 |
| Jamieson, DJ | 7 |
| Van Der Horst, CM | 2 |
| Fiscus, SA | 14 |
| Nathoo, K | 2 |
| Nahirya-Ntege, P | 1 |
| Mutasa, K | 1 |
| Williams, DE | 1 |
| Mwesigire, DM | 1 |
| Wu, AW | 2 |
| Martin, F | 1 |
| Katamba, A | 1 |
| Seeley, J | 1 |
| Pedrol, E | 8 |
| Llibre, JM | 8 |
| Tasias, M | 1 |
| Currán, A | 1 |
| Guardiola, JM | 1 |
| Deig, E | 3 |
| Guelar, A | 2 |
| Martínez-Madrid, O | 1 |
| Tikhomirova, L | 1 |
| Ramírez, R | 1 |
| Sobze, MS | 1 |
| Mayaka, GB | 1 |
| Muthoga, CW | 1 |
| Martinelli, A | 1 |
| Romano, R | 1 |
| Vullo, V | 2 |
| Knight, L | 1 |
| Todd, G | 1 |
| Muloiwa, R | 1 |
| Matjila, M | 2 |
| Lehloenya, RJ | 1 |
| Hernando, H | 1 |
| Deslandes, G | 3 |
| Jolliet, P | 7 |
| Sibanda, EL | 1 |
| Bernays, S | 1 |
| Weller, IV | 1 |
| Hakim, JG | 1 |
| Cowan, FM | 1 |
| Poongulali, S | 2 |
| Shastri, S | 1 |
| Kumar, DS | 1 |
| Arumugam, K | 1 |
| De Costa, A | 1 |
| D'Souza, G | 1 |
| Kiselinova, M | 1 |
| Malatinkova, E | 2 |
| Vervisch, K | 1 |
| Messiaen, P | 1 |
| Bonczkowski, P | 2 |
| Trypsteen, W | 1 |
| Callens, S | 1 |
| Verhofstede, C | 2 |
| De Spiegelaere, W | 2 |
| Vandekerckhove, L | 2 |
| Mhandire, D | 1 |
| Lacerda, M | 1 |
| Mhandire, K | 1 |
| Zhou, D | 1 |
| Swart, M | 1 |
| Shamu, T | 1 |
| Musingwini, T | 1 |
| Stray-Pedersen, B | 6 |
| Rougemont, M | 1 |
| Nchotu Ngang, P | 1 |
| Stoll, B | 1 |
| Delhumeau, C | 1 |
| Hill, A | 1 |
| Bonnet, F | 2 |
| Menga, G | 1 |
| Fampou, JC | 1 |
| Krogstad, P | 5 |
| Rigo, F | 1 |
| Sirirungsi, W | 2 |
| Traisathit, P | 1 |
| Mcintosh, K | 9 |
| Fehintola, F | 1 |
| Olson, A | 1 |
| Taiwo, BO | 2 |
| Conti, M | 2 |
| Mancini, R | 1 |
| Montrucchio, C | 1 |
| Capetti, A | 2 |
| Guaraldi, G | 4 |
| Cenderello, G | 1 |
| Marinaro, L | 1 |
| Tettoni, MC | 1 |
| Trentini, L | 1 |
| Kiweewa, FM | 1 |
| Bakaki, PM | 2 |
| McConnell, MS | 8 |
| Musisi, M | 1 |
| Namirembe, C | 1 |
| Nakayiwa, F | 1 |
| Kusasira, F | 1 |
| Nakintu, D | 1 |
| Mubiru, MC | 2 |
| Wiener, J | 3 |
| Chang, TS | 1 |
| Dollard, SC | 1 |
| Amin, MM | 1 |
| Ellington, S | 3 |
| Chim, B | 1 |
| Lorent, N | 1 |
| Nsagha, DS | 1 |
| Pokam, BT | 1 |
| Assob, JC | 1 |
| Njunda, AL | 1 |
| Kibu, OD | 1 |
| Tanue, EA | 1 |
| Ayima, CW | 1 |
| Weledji, PE | 1 |
| Okawa, S | 1 |
| Chirwa, M | 1 |
| Ishikawa, N | 3 |
| Kapyata, H | 1 |
| Msiska, CY | 1 |
| Syakantu, G | 1 |
| Miyano, S | 2 |
| Komada, K | 1 |
| Jimba, M | 1 |
| Yasuoka, J | 1 |
| Vogt, F | 1 |
| Ferreyra, C | 2 |
| Bernasconi, A | 1 |
| Ncube, L | 1 |
| Taziwa, F | 2 |
| Marange, W | 1 |
| Wachi, D | 1 |
| Becher, H | 1 |
| Lee, YC | 1 |
| Chen, MY | 1 |
| Kuo, CH | 1 |
| Sheng, WH | 1 |
| Hsieh, SM | 1 |
| Sun, HY | 1 |
| Chang, HY | 1 |
| Wu, MR | 1 |
| Zhang, JY | 1 |
| Cook, AD | 1 |
| Chabala, C | 2 |
| Asiimwe, A | 2 |
| Owen-Powell, E | 1 |
| Seenivasan, S | 1 |
| Vaitheeswaran, N | 1 |
| Seetha, V | 1 |
| Anbalagan, S | 1 |
| Karunaianantham, R | 2 |
| Blat, C | 1 |
| Hagey, J | 1 |
| Shade, SB | 1 |
| Vittinghoff, E | 1 |
| Newmann, SJ | 1 |
| Yogev, R | 6 |
| Pinillos, F | 2 |
| Tsai, WY | 5 |
| De Nardo, P | 1 |
| Gentilotti, E | 1 |
| Nguhuni, B | 1 |
| Vairo, F | 1 |
| Chaula, Z | 1 |
| Nicastri, E | 2 |
| Ippolito, G | 2 |
| Eisen, G | 2 |
| Meloni, ST | 1 |
| Rawizza, HE | 1 |
| Tchetgen Tchetgen, EJ | 1 |
| Agbaji, OO | 1 |
| Onwujekwe, DI | 2 |
| Gashau, W | 2 |
| Nkado, R | 1 |
| Okonkwo, P | 1 |
| Baroncelli, S | 2 |
| Holgate, S | 1 |
| Nelson, A | 1 |
| Wedderburn, C | 1 |
| Byakika-Kibwika, P | 6 |
| Else, LJ | 2 |
| Dilly Penchala, S | 1 |
| Makadzange, AT | 1 |
| Higgins-Biddle, M | 1 |
| Chimukangara, B | 1 |
| Birri, R | 1 |
| Mahlanza, T | 1 |
| McHugh, G | 1 |
| van Dijk, JH | 1 |
| Masimirembwa, C | 1 |
| Phelps, B | 1 |
| Amzel, A | 1 |
| Ojikutu, BO | 1 |
| Walker, BD | 3 |
| Ndhlovu, CE | 1 |
| Nakanga, W | 1 |
| Patel, P | 1 |
| Panjwani, S | 1 |
| Kennedy, N | 1 |
| Kawaza, K | 1 |
| Pandie, M | 3 |
| Hughes, J | 1 |
| Siwendu, S | 1 |
| Conradie, F | 3 |
| Variava, E | 1 |
| Bolaris, MA | 1 |
| Keller, MA | 1 |
| Robbins, BL | 1 |
| Likanonsakul, S | 6 |
| Suntisuklappon, B | 1 |
| Nitiyanontakij, R | 1 |
| Prasithsirikul, W | 5 |
| Nakayama, EE | 1 |
| Shioda, T | 2 |
| Sangsajja, C | 1 |
| Moodley, T | 1 |
| Sebitloane, M | 1 |
| Maharaj, N | 1 |
| Sartorius, B | 1 |
| Cha, A | 1 |
| Elsamadisi, P | 1 |
| Su, CP | 1 |
| Phipps, E | 1 |
| Birnbaum, JM | 1 |
| Mustafa, S | 2 |
| Yusuf, WN | 1 |
| Woillard, JB | 1 |
| Choon, TS | 1 |
| Hassan, NB | 2 |
| Stevens, E | 1 |
| Ferretti, F | 1 |
| Underwood, J | 1 |
| Taylor, S | 6 |
| Mendoza, Y | 1 |
| Castillo Mewa, J | 1 |
| Martínez, AA | 1 |
| Zaldívar, Y | 1 |
| Sosa, N | 1 |
| Arteaga, G | 1 |
| Armién, B | 1 |
| Bautista, CT | 1 |
| García-Morales, C | 1 |
| Tapia-Trejo, D | 1 |
| Ávila-Ríos, S | 1 |
| Reyes-Terán, G | 1 |
| Pascale, JM | 1 |
| Teeranaipong, P | 1 |
| Mekprasan, S | 1 |
| Ohata, PJ | 1 |
| Putcharoen, O | 1 |
| Aliyu, MH | 1 |
| Blevins, M | 2 |
| Audet, CM | 1 |
| Kalish, M | 1 |
| Gebi, UI | 1 |
| Onwujekwe, O | 1 |
| Lindegren, ML | 1 |
| Wester, CW | 3 |
| Dahinten, AP | 1 |
| Msuya, LJ | 1 |
| Barnett, BS | 1 |
| Chaweza, T | 1 |
| Tweya, H | 1 |
| Ngambi, W | 1 |
| Phiri, S | 1 |
| Naik, NM | 1 |
| Bacha, J | 1 |
| Gesase, AE | 1 |
| Barton, T | 2 |
| Wanless, RS | 1 |
| Minde, MM | 1 |
| Mwita, LF | 1 |
| Tolle, MA | 1 |
| Costa, S | 1 |
| Machado, M | 1 |
| Cavadas, C | 1 |
| do Céu Sousa, M | 1 |
| Capretti, MG | 1 |
| Marsico, C | 1 |
| Corvaglia, LT | 1 |
| Arcuri, S | 1 |
| Faldella, G | 1 |
| Kiragga, A | 2 |
| Julian, MN | 1 |
| Jegede, AI | 1 |
| Offor, U | 1 |
| Onanuga, IO | 1 |
| Naidu, EC | 1 |
| Azu, OO | 1 |
| Liang, B | 1 |
| Jiang, J | 1 |
| Pan, P | 1 |
| Chen, R | 1 |
| Zhao, F | 1 |
| Su, Q | 1 |
| Cao, C | 1 |
| Liang, H | 2 |
| Ye, L | 1 |
| Angelidou, K | 1 |
| Lindsey, J | 1 |
| Dittmer, S | 1 |
| Kabugho, E | 1 |
| Msuya, L | 1 |
| Sambo, P | 1 |
| Barr, E | 1 |
| Jean-Phillipe, P | 1 |
| Mofenson, L | 11 |
| Stewart, A | 1 |
| Lehloenya, R | 1 |
| Boulle, A | 6 |
| Bergmann, JN | 1 |
| Wanyenze, RK | 1 |
| Makumbi, F | 1 |
| Naigino, R | 1 |
| Kiene, SM | 1 |
| Stockman, JK | 1 |
| Moholisa, RR | 1 |
| Schomaker, M | 1 |
| Olana, T | 1 |
| Bacha, T | 1 |
| Worku, W | 1 |
| Tadesse, BT | 1 |
| de Boissieu, P | 1 |
| Dramé, M | 1 |
| Cabie, A | 1 |
| Poizot-Martin, I | 1 |
| Cotte, L | 1 |
| Garraffo, R | 2 |
| Delobel, P | 1 |
| Huleux, T | 1 |
| Rey, D | 6 |
| Birbal, S | 1 |
| Dheda, M | 1 |
| Ojewole, E | 1 |
| Oosthuizen, F | 1 |
| Wang, Q | 3 |
| Fang, L | 2 |
| Wang, A | 1 |
| Wang, F | 1 |
| Qiao, Y | 1 |
| Sullivan, SG | 1 |
| Rutherford, S | 1 |
| Abach, J | 1 |
| Thomason, M | 3 |
| Colebunders, R | 6 |
| Alioni, S | 1 |
| Kerukadho, E | 1 |
| Ndungutse, D | 1 |
| Li, YY | 1 |
| Jin, YM | 1 |
| He, LP | 1 |
| Bai, JS | 1 |
| Yu, M | 1 |
| Chen, JH | 1 |
| Kuang, YQ | 1 |
| Qin, M | 1 |
| McIntyre, J | 17 |
| Coletti, AS | 1 |
| Klingman, KL | 2 |
| Martinson, FE | 1 |
| Theron, GB | 3 |
| Mlay, P | 1 |
| Loftis, AJ | 1 |
| Purdue, L | 3 |
| Basar, M | 1 |
| L Machado, S | 1 |
| Gonçalves, GS | 1 |
| Dudley, D | 1 |
| O'Connor, D | 1 |
| Keiko Toma, H | 1 |
| Fernandes, JC | 1 |
| Tanuri, A | 2 |
| De Scheerder, MA | 1 |
| Borch, A | 1 |
| Melkova, Z | 1 |
| Koenig, R | 1 |
| Gregson, J | 1 |
| van Vuuren, C | 1 |
| Ndembi, N | 6 |
| Kanki, P | 5 |
| Hoffmann, CJ | 1 |
| Kerschberger, B | 1 |
| Raizes, E | 1 |
| Kantor, R | 3 |
| Gupta, RK | 3 |
| Gabriel, EE | 1 |
| Tauzie, J | 2 |
| Ilmet, T | 1 |
| Neal, J | 1 |
| Deygoo, N | 1 |
| Jean Philippe, P | 1 |
| Prescott, W | 1 |
| Chen, J | 5 |
| Palma, P | 1 |
| Zangari, P | 1 |
| Alteri, C | 1 |
| Tchidjou, HK | 1 |
| Manno, EC | 1 |
| Liuzzi, G | 1 |
| Perno, CF | 3 |
| Rossi, P | 1 |
| Bertoli, A | 1 |
| Bernardi, S | 1 |
| Tooke, L | 1 |
| Riemer, L | 1 |
| Harrison, M | 1 |
| Mbuagbaw, L | 1 |
| Mursleen, S | 1 |
| Irlam, JH | 2 |
| Spaulding, AB | 1 |
| Rutherford, GW | 4 |
| Siegfried, N | 4 |
| Van Tam, V | 1 |
| El-Khatib, Z | 1 |
| Santacatterina, M | 1 |
| Marrone, G | 1 |
| Chuc, NT | 1 |
| Diwan, V | 1 |
| Thorson, A | 1 |
| Le, NK | 1 |
| An, PN | 1 |
| Larsson, M | 1 |
| Brill, MJ | 1 |
| Bienczak, A | 1 |
| Bourgeois, S | 1 |
| Takeshita, LY | 1 |
| Morris, AP | 1 |
| Castro, EM | 1 |
| Alfirevic, A | 2 |
| Jones, AR | 1 |
| Rigden, DJ | 1 |
| Haldenby, S | 1 |
| Nelson, MR | 4 |
| Holden, A | 1 |
| Deloukas, P | 1 |
| Shilaih, M | 1 |
| Marzel, A | 1 |
| Braun, DL | 1 |
| Scherrer, AU | 1 |
| Kovari, H | 1 |
| Young, J | 1 |
| Darling, K | 1 |
| Hoffmann, M | 1 |
| Bernasconi, E | 3 |
| Thurnheer, MC | 1 |
| Günthard, HF | 2 |
| Kouyos, RD | 1 |
| Tan, SC | 1 |
| Ab Rahman, AK | 1 |
| Low, LL | 1 |
| Wan Yusuf, WN | 1 |
| Lau, E | 1 |
| Brophy, J | 1 |
| Samson, L | 1 |
| Kakkar, F | 1 |
| Campbell, DM | 1 |
| Yudin, MH | 1 |
| Murphy, K | 1 |
| Seto, W | 1 |
| Colantonio, D | 1 |
| Read, SE | 1 |
| Bitnun, A | 1 |
| Nkurunziza, P | 1 |
| Mugarura, L | 1 |
| Pattery, T | 1 |
| Gilks, C | 4 |
| Jindal, AB | 1 |
| Bachhav, SS | 1 |
| Devarajan, PV | 1 |
| Kimulwo, MJ | 1 |
| Okendo, J | 1 |
| Aman, RA | 1 |
| Ogutu, BR | 1 |
| Kokwaro, GO | 1 |
| Ochieng, DJ | 1 |
| Muigai, AW | 1 |
| Oloo, FA | 1 |
| Ochieng, W | 1 |
| Monera-Penduka, TG | 1 |
| Maponga, CC | 2 |
| Wolfe, AR | 2 |
| Nhachi, CF | 1 |
| Kanthula, R | 1 |
| Rossouw, TM | 1 |
| van Dyk, G | 1 |
| Silverman, R | 1 |
| Olson, S | 1 |
| Salyer, C | 1 |
| Cassol, S | 2 |
| de Beaudrap, P | 1 |
| Etard, JF | 2 |
| Guèye, FN | 1 |
| Guèye, M | 1 |
| Landman, R | 2 |
| Girard, PM | 3 |
| Turriziani, O | 1 |
| Lichtner, M | 1 |
| Stano, A | 1 |
| Tsague, G | 1 |
| Maida, P | 1 |
| Antonelli, G | 1 |
| Shear, NH | 1 |
| Milpied, B | 2 |
| Bruynzeel, DP | 1 |
| Phillips, EJ | 1 |
| Kouanfack, C | 5 |
| Laurent, C | 6 |
| Ngolle, M | 1 |
| Nkene, YM | 1 |
| Essomba, C | 1 |
| Mpoudi-Ngolé, E | 4 |
| Koulla-Shiro, S | 3 |
| Chintu, N | 8 |
| Cantrell, RA | 4 |
| Kruse, G | 3 |
| Mbewe, F | 4 |
| Sinkala, M | 26 |
| Smith, PJ | 2 |
| Stringer, EM | 10 |
| Stringer, JS | 27 |
| Kumwenda, NI | 9 |
| Hoover, DR | 17 |
| Thigpen, MC | 11 |
| Kafulafula, G | 7 |
| Li, Q | 5 |
| Mipando, L | 4 |
| Mebrahtu, T | 1 |
| Bulterys, M | 7 |
| Gray, GE | 11 |
| Saloojee, H | 1 |
| Dokekias, AE | 1 |
| Galiba, FO | 1 |
| Bokilo, AD | 1 |
| Ntsimba, P | 1 |
| Nsitou, MB | 1 |
| Malanda, F | 1 |
| Basseila, GB | 1 |
| Laureillard, D | 1 |
| Prak, N | 1 |
| Fernandez, M | 1 |
| Ngeth, C | 1 |
| Moeung, S | 1 |
| Riel, V | 1 |
| Chhneang, V | 1 |
| Song, S | 1 |
| Quillet, C | 1 |
| Piketty, C | 2 |
| Onah, HE | 1 |
| Ibeziako, N | 1 |
| Nkwo, PO | 1 |
| Obi, SN | 1 |
| Nwankwo, TO | 1 |
| Lapphra, K | 2 |
| Vanprapar, N | 4 |
| Chearskul, S | 1 |
| Phongsamart, W | 2 |
| Chearskul, P | 1 |
| Prasitsuebsai, W | 3 |
| Bain, AM | 1 |
| White, EA | 1 |
| Rutherford, WS | 1 |
| Rahman, AP | 1 |
| Busti, AJ | 1 |
| Prendergast, A | 3 |
| Mphatswe, W | 2 |
| Rakgotho, M | 1 |
| Pillay, V | 5 |
| Thobakgale, C | 2 |
| McCarthy, N | 2 |
| Morris, L | 17 |
| Goulder, P | 2 |
| Flys, TS | 4 |
| Matovu, F | 4 |
| Church, JD | 10 |
| Bagenda, D | 10 |
| Khaki, L | 1 |
| Bakaki, P | 5 |
| Eure, C | 3 |
| Moltó, J | 6 |
| Valle, M | 2 |
| Miranda, C | 2 |
| Cedeño, S | 2 |
| Miranda, J | 2 |
| Santos, JR | 2 |
| Negredo, E | 12 |
| Vilaró, J | 2 |
| Costa, J | 1 |
| Clotet, B | 25 |
| Hughes, V | 1 |
| Lehman, DA | 7 |
| Chung, MH | 6 |
| John-Stewart, GC | 10 |
| Kinuthia, J | 3 |
| Karamchand, L | 1 |
| Dawood, H | 1 |
| Chuturgoon, AA | 1 |
| Lionel, J | 1 |
| Aleyamma, TK | 1 |
| Varghese, L | 1 |
| Buck, J | 1 |
| Gopalakrishnan, G | 1 |
| Chaguturu, S | 1 |
| Cu-Uvin, S | 1 |
| Mayer, K | 2 |
| Kalemeera, F | 2 |
| Mauro, S | 1 |
| Ryan, M | 5 |
| Mayanja-Kizza, H | 3 |
| Boffito, M | 5 |
| Pornprasert, S | 2 |
| Leechanachai, P | 3 |
| Leenasirimakul, P | 2 |
| Sukunthamala, K | 1 |
| Thunjai, B | 1 |
| Phusua, A | 1 |
| Saetung, R | 1 |
| Sanguansermsri, T | 1 |
| Kitkungvan, D | 1 |
| Apisarnthanarak, A | 3 |
| Laowansiri, P | 1 |
| Mundy, LM | 3 |
| Ena, J | 2 |
| Leach, A | 1 |
| Nguyen, P | 1 |
| Naniche, D | 1 |
| Lahuerta, M | 1 |
| Bardaji, A | 1 |
| Sigauque, B | 1 |
| Romagosa, C | 1 |
| Berenguera, A | 1 |
| Mandomando, I | 1 |
| David, C | 1 |
| Sanz, S | 1 |
| Aponte, J | 1 |
| Ordi, J | 1 |
| Alonso, P | 1 |
| Puig, T | 2 |
| Ruiz, L | 10 |
| Pini, P | 1 |
| Kleinert, S | 1 |
| Phadke, MA | 1 |
| Bulakh, PM | 1 |
| Kshirsagar, NA | 2 |
| Bedri, A | 3 |
| Gudetta, B | 2 |
| Isehak, A | 2 |
| Kumbi, S | 2 |
| Lulseged, S | 2 |
| Mengistu, Y | 2 |
| Bhore, AV | 2 |
| Varadhrajan, V | 1 |
| Sastry, J | 5 |
| Mubiru, M | 9 |
| Onyango, C | 1 |
| Taylor, A | 4 |
| Abashawl, A | 2 |
| Adamu, R | 2 |
| Antelman, G | 2 |
| Bright, P | 1 |
| Chaudhary, MA | 1 |
| Coberly, J | 1 |
| Guay, L | 5 |
| Hassen, E | 2 |
| Moulton, LH | 2 |
| Nayak, U | 3 |
| Omer, SB | 8 |
| Propper, L | 1 |
| Ram, M | 2 |
| Rexroad, V | 1 |
| Ruff, AJ | 1 |
| Bae, WH | 1 |
| Wester, C | 8 |
| Smeaton, LM | 5 |
| Onyait, K | 1 |
| Thior, I | 10 |
| Sathia, L | 1 |
| Obiorah, I | 1 |
| Taylor, G | 1 |
| Kon, O | 1 |
| O'Donoghue, M | 1 |
| Gibbins, S | 1 |
| Walsh, J | 1 |
| Chuchotaworn, C | 1 |
| Moolphate, S | 1 |
| Sakornjun, W | 1 |
| Gorowara, M | 2 |
| Yamada, N | 1 |
| Yanai, H | 1 |
| Mitarai, S | 1 |
| Phanuphak, P | 8 |
| Lapadula, G | 3 |
| Calabresi, A | 2 |
| Castelnuovo, F | 2 |
| Costarelli, S | 3 |
| Quiros-Roldan, E | 4 |
| Paraninfo, G | 2 |
| Ceresoli, F | 1 |
| Gargiulo, F | 1 |
| Manca, N | 1 |
| Carosi, G | 5 |
| Torti, C | 4 |
| Van Cutsem, G | 4 |
| Hilderbrand, K | 2 |
| Mathee, S | 1 |
| Abrahams, M | 1 |
| Goemaere, E | 4 |
| Coetzee, D | 3 |
| Draper, B | 3 |
| Abdullah, F | 2 |
| Lidstrom, J | 2 |
| Brück, S | 1 |
| Witte, S | 2 |
| Brust, J | 3 |
| Schuster, D | 3 |
| Mosthaf, F | 3 |
| Procaccianti, M | 3 |
| Rump, JA | 3 |
| Petzold, D | 1 |
| Hartmann, M | 5 |
| Spensley, A | 1 |
| Turner, AN | 1 |
| Hoblitzelle, C | 1 |
| Robinson, J | 2 |
| Wilfert, C | 4 |
| van Schalkwyk, JE | 1 |
| Alimenti, A | 1 |
| Khoo, D | 1 |
| Maan, E | 1 |
| Forbes, JC | 1 |
| Burdge, DR | 1 |
| Gilgoff, S | 1 |
| Money, DM | 1 |
| Leng, K | 1 |
| Lonsdorf, A | 1 |
| Villani, P | 4 |
| Floridia, M | 4 |
| Cusato, M | 3 |
| Pinnetti, C | 2 |
| Sabbatini, F | 1 |
| Molinari, A | 2 |
| Tamburrini, E | 2 |
| Regazzi, M | 4 |
| Elsherbiny, D | 1 |
| Jansson, B | 1 |
| Simonsson, US | 1 |
| Ekouevi, DK | 18 |
| Coffie, PA | 8 |
| Becquet, R | 10 |
| Tonwe-Gold, B | 10 |
| Horo, A | 3 |
| Dabis, F | 26 |
| Stöhr, W | 2 |
| Sabin, C | 1 |
| Gilson, R | 2 |
| Hill, T | 2 |
| Ainsworth, J | 1 |
| Pozniak, A | 5 |
| Leen, C | 3 |
| Bansi, L | 1 |
| Fisher, M | 5 |
| Orkin, C | 3 |
| Anderson, J | 3 |
| Johnson, M | 5 |
| Easterbrook, P | 3 |
| Gibbons, S | 3 |
| Redfield, RR | 2 |
| Towler, WI | 3 |
| Eshleman, JR | 3 |
| Chasela, C | 4 |
| Ahmed, Y | 1 |
| Knight, R | 1 |
| Hudgens, M | 1 |
| Kazembe, P | 3 |
| Bentley, M | 1 |
| Adair, L | 2 |
| Piwoz, E | 1 |
| Duerr, A | 1 |
| Kourtis, A | 1 |
| Loeliger, AE | 1 |
| Tohill, B | 2 |
| Jamieson, D | 1 |
| Landriscina, M | 1 |
| Fabiano, A | 1 |
| Lombardi, V | 1 |
| Santodirocco, M | 1 |
| Piscazzi, A | 1 |
| Fersini, A | 1 |
| De Vis, K | 1 |
| Barone, C | 1 |
| Cignarelli, M | 1 |
| Hislop, M | 1 |
| Dowdy, DW | 1 |
| Gallant, JE | 2 |
| Regensberg, L | 1 |
| Tebruegge, M | 1 |
| Ritz, N | 1 |
| Connell, T | 1 |
| Curtis, N | 1 |
| Sumantri, S | 1 |
| Djoerban, Z | 1 |
| Kiarie, JN | 7 |
| Njiri, F | 2 |
| Tantanathip, P | 3 |
| Prasithisirikul, W | 1 |
| Chan, DJ | 2 |
| Ray, JE | 1 |
| McNally, L | 1 |
| Batterham, M | 1 |
| Smith, DE | 2 |
| L'homme, RF | 4 |
| Droste, JA | 5 |
| Wolters, LR | 1 |
| van Ewijk-Beneken Kolmer, NW | 1 |
| Gonzalez-Tome, MI | 1 |
| Amador, JT | 1 |
| Peña, MJ | 1 |
| Gomez, ML | 1 |
| Conejo, PR | 1 |
| Fontelos, PM | 1 |
| Mills, J | 1 |
| Mugenyi, K | 7 |
| Kabasinguzi, R | 4 |
| Weidenhammer, A | 1 |
| Kurowski, M | 6 |
| Read, JS | 5 |
| Sharma, U | 2 |
| Hoffman, IF | 2 |
| Pikora, C | 1 |
| Goldenberg, R | 3 |
| Rollins, NC | 2 |
| Basson, AE | 1 |
| Ntsala, M | 2 |
| Tlale, E | 1 |
| Corrigan, GE | 1 |
| Shao, X | 1 |
| Gray, G | 13 |
| Shiri, T | 1 |
| Welte, A | 1 |
| Chavanet, P | 3 |
| Schmitt, MP | 1 |
| Hoizey, G | 1 |
| Meyer, P | 1 |
| Spire, B | 2 |
| Diemer, M | 1 |
| May, T | 3 |
| Schmit, JL | 1 |
| Duong, M | 4 |
| Lang, JM | 4 |
| Darwich, L | 1 |
| Esteve, A | 1 |
| Bellido, R | 2 |
| Martinez-Picado, J | 2 |
| Metzner, KJ | 2 |
| Giulieri, SG | 1 |
| Knoepfel, SA | 1 |
| Rauch, P | 1 |
| Burgisser, P | 1 |
| Yerly, S | 2 |
| Smeaton, L | 1 |
| Rossenkhan, R | 2 |
| Stevens, L | 5 |
| Moffat, C | 5 |
| Arimi, P | 3 |
| Ndase, P | 3 |
| Leidner, J | 3 |
| Byakika-Tusiime, J | 2 |
| Oyugi, JH | 2 |
| Obua, C | 1 |
| Kiptoo, M | 1 |
| Wembe, RL | 1 |
| Ng'Ang'a, Z | 1 |
| Mueke, J | 1 |
| Kinyua, J | 1 |
| Lagat, N | 1 |
| Okoth, F | 1 |
| Songok, EM | 1 |
| Chantarangsu, S | 3 |
| Mushiroda, T | 2 |
| Mahasirimongkol, S | 4 |
| Tantisiriwat, W | 2 |
| Charoenyingwattana, A | 3 |
| Sura, T | 3 |
| Chantratita, W | 8 |
| Nakamura, Y | 2 |
| Zeh, C | 2 |
| Holland, D | 1 |
| Masaba, R | 2 |
| Odhiambo, P | 1 |
| Weidle, PJ | 6 |
| Walter, J | 2 |
| Semrau, K | 5 |
| Thea, DM | 6 |
| Aldrovandi, GM | 10 |
| Moorthy, A | 3 |
| Thakar, M | 2 |
| Kagal, A | 2 |
| Venkataramani, V | 1 |
| Balasubramaniam, U | 1 |
| Ziemniak, C | 2 |
| George, C | 1 |
| Yesoda, A | 1 |
| Jayakumar, B | 1 |
| Lal, L | 2 |
| Delvaux, T | 1 |
| Elul, B | 2 |
| Ndagije, F | 1 |
| Munyana, E | 1 |
| Roberfroid, D | 1 |
| Chow, JY | 2 |
| Meyers, T | 7 |
| Barry, G | 1 |
| Malan, E | 1 |
| Marais, B | 1 |
| Stehlau, R | 2 |
| Hammer, SM | 2 |
| Kondo, W | 2 |
| Astori, Ade A | 1 |
| Gomes, Sel-K | 1 |
| Fernandes, Rde B | 1 |
| Sasaki, Md | 2 |
| Sbalqueiro, RL | 1 |
| Patel, AK | 3 |
| Patel, KK | 2 |
| Sharma, R | 2 |
| Ranjan, RR | 1 |
| Shukla, RK | 1 |
| Patel, JA | 1 |
| Parienti, JJ | 6 |
| Aurpibul, L | 3 |
| Sirisanthana, T | 3 |
| Chigwedere, P | 1 |
| Seage, GR | 1 |
| Gruskin, S | 1 |
| Lee, TH | 2 |
| Kombat, K | 1 |
| Sundaram, M | 1 |
| Srinivas, CN | 1 |
| Shankar, EM | 1 |
| Hemanth Kumar, AK | 2 |
| Jagan, I | 1 |
| Vasantha, M | 1 |
| Rajasekaran, S | 5 |
| Mahungu, T | 2 |
| Smith, C | 1 |
| Turner, F | 1 |
| Egan, D | 3 |
| Youle, M | 3 |
| Ryan, CT | 1 |
| Jongwutiwes, U | 1 |
| Malathum, K | 2 |
| McKoy, JM | 1 |
| Bennett, CL | 2 |
| Scheetz, MH | 1 |
| Differding, V | 1 |
| Chandler, KL | 1 |
| Yarnold, PR | 1 |
| Sutton, S | 1 |
| Palella, F | 1 |
| Johnson, S | 3 |
| Obadina, E | 1 |
| Raisch, DW | 1 |
| Parada, JP | 1 |
| Harris, M | 9 |
| Côté, H | 2 |
| Ochoa, C | 2 |
| Thorne, A | 1 |
| Zala, C | 4 |
| Singer, J | 1 |
| Montaner, J | 5 |
| Maleewong, U | 1 |
| Kulsomboon, V | 1 |
| Watcharananan, S | 1 |
| Sathapatayavongs, B | 1 |
| Vogel, M | 2 |
| Bertram, N | 1 |
| Wyen, C | 3 |
| Voigt, E | 1 |
| Schwarze-Zander, C | 1 |
| Sudhop, T | 1 |
| Fätkenheuer, G | 6 |
| Rockstroh, JK | 2 |
| Reichel, C | 1 |
| Mary, JY | 2 |
| Limtrakul, A | 1 |
| Rugpao, S | 1 |
| Sirivatanapa, P | 1 |
| Gomuthbutra, V | 1 |
| Matanasaravoot, W | 1 |
| Barré-Sinoussi, F | 4 |
| Menu, E | 2 |
| Shipton, LK | 1 |
| Stock, S | 1 |
| Ndwapi, N | 1 |
| Gaolathe, T | 1 |
| Avalos, A | 1 |
| Moffat, HJ | 1 |
| Mboya, JJ | 1 |
| Widenfelt, E | 1 |
| Martinson, NA | 7 |
| Johnson, J | 1 |
| Dhlamini, P | 3 |
| Cohen, S | 2 |
| Steyn, J | 2 |
| Rutta, E | 1 |
| Gongo, R | 1 |
| Mwansasu, A | 1 |
| Mutasingwa, D | 1 |
| Rwegasira, V | 1 |
| Kishumbu, S | 1 |
| Tabayi, J | 1 |
| Masini, T | 1 |
| Ramadhani, H | 1 |
| Tebas, P | 2 |
| Hafner, R | 1 |
| Tashima, K | 1 |
| Shevitz, A | 1 |
| Yarasheski, K | 2 |
| Berzins, B | 2 |
| Owens, S | 1 |
| Forand, J | 1 |
| Evans, S | 1 |
| Murphy, R | 5 |
| Virgili, N | 3 |
| Fisac, C | 3 |
| Martínez, E | 14 |
| Ribera, E | 12 |
| Gatell, JM | 15 |
| Podzamczer, D | 14 |
| Han, J | 1 |
| Jiang, Y | 1 |
| Yao, J | 1 |
| Arrivé, E | 3 |
| Chaix, ML | 6 |
| Nerrienet, E | 3 |
| Kruy Leang, S | 1 |
| Avit, D | 2 |
| Srey, VH | 1 |
| N'Dri-Yoman, T | 2 |
| Diallo, A | 1 |
| Garcia, MV | 1 |
| Yasuda, T | 1 |
| Mukoyama, Y | 1 |
| Matsubayashi, T | 1 |
| Saeng-aroon, S | 3 |
| Matsuyama, A | 1 |
| Dahl, V | 1 |
| Palmer, S | 4 |
| Wind-Rotolo, M | 1 |
| Durand, C | 1 |
| Cranmer, L | 1 |
| Reid, A | 7 |
| Doherty, M | 1 |
| Jilek, BL | 1 |
| Kagaayi, J | 2 |
| Kizza, A | 1 |
| Laeyendecker, O | 1 |
| Lau, B | 1 |
| Ray, SC | 1 |
| Siliciano, JD | 1 |
| Quinn, TC | 2 |
| Siliciano, RF | 1 |
| Charurat, M | 1 |
| Datong, P | 1 |
| Matawal, B | 1 |
| Ajene, A | 1 |
| Blattner, W | 1 |
| Abimiku, A | 1 |
| Annan, NT | 1 |
| Nelson, M | 6 |
| Mandalia, S | 5 |
| Bower, M | 4 |
| Gazzard, BG | 6 |
| Stebbing, J | 2 |
| Ocama, P | 2 |
| Katwere, M | 1 |
| Piloya, T | 1 |
| Feld, J | 1 |
| Opio, KC | 1 |
| Katabira, E | 6 |
| Thomas, D | 1 |
| Ronald, A | 3 |
| Zaki, SA | 1 |
| Phulsunder, A | 1 |
| Shanbag, P | 1 |
| Guidozzi, F | 1 |
| Black, V | 2 |
| Benet, LZ | 1 |
| Kalinowski, A | 1 |
| Anastos, K | 3 |
| Young, M | 2 |
| Cohen, M | 2 |
| Minkoff, H | 1 |
| van Vonderen, MG | 1 |
| Lips, P | 1 |
| van Agtmael, MA | 1 |
| Hassink, EA | 1 |
| Brinkman, K | 4 |
| Geerlings, SE | 1 |
| Sutinen, J | 1 |
| Ristola, M | 1 |
| Danner, SA | 5 |
| Hauser, A | 4 |
| Bluethgen, K | 1 |
| Kuecherer, C | 4 |
| Lalloo, UG | 2 |
| Lueangniyomkul, A | 3 |
| Mankatitham, W | 4 |
| Prasithsirskul, W | 1 |
| Burapatarawong, S | 1 |
| Thongyen, S | 3 |
| Thawornwa, U | 1 |
| Prommool, V | 1 |
| Behets, F | 2 |
| Mutombo, GM | 1 |
| Edmonds, A | 1 |
| Dulli, L | 1 |
| Belting, MT | 1 |
| Kapinga, M | 1 |
| Pantazis, A | 1 |
| Tomlin, H | 1 |
| Okitolonda, E | 1 |
| Irunde, H | 1 |
| Moshiro, C | 1 |
| Foster, C | 1 |
| Lyall, H | 2 |
| Olmscheid, B | 1 |
| Pearce, G | 2 |
| Zhang, S | 1 |
| Colafigli, M | 1 |
| Di Giambenedetto, S | 4 |
| Bracciale, L | 1 |
| Fanti, I | 1 |
| Prosperi, M | 1 |
| Cauda, R | 1 |
| Martin, J | 1 |
| Kesselring, AM | 2 |
| Wit, FW | 20 |
| Sabin, CA | 4 |
| Lundgren, JD | 8 |
| Rauch, A | 1 |
| de Wolf, F | 13 |
| Mocroft, A | 5 |
| Mabuka, JM | 1 |
| Ramachandran, S | 1 |
| Scott, N | 2 |
| Kasonde, P | 7 |
| Mwiya, M | 3 |
| Decker, D | 1 |
| Elens, L | 1 |
| Haufroid, V | 1 |
| Doyen, C | 1 |
| Vandercam, B | 2 |
| Yombi, JC | 1 |
| Ammann, AJ | 1 |
| Chalermchockcharoenkit, A | 1 |
| Culnane, M | 5 |
| Chotpitayasunondh, T | 2 |
| Vanprapa, N | 1 |
| Leelawiwat, W | 1 |
| Mock, PA | 1 |
| Asavapiriyanont, S | 1 |
| Teeraratkul, A | 1 |
| McNicholl, JM | 1 |
| Agmon-Levin, N | 1 |
| Elbirt, D | 1 |
| Asher, I | 1 |
| Torten, D | 1 |
| Cohen, Y | 1 |
| Gradestein, S | 1 |
| Werner, B | 1 |
| Turner, D | 1 |
| Chowers, M | 2 |
| Gottesman, G | 1 |
| Maayan, S | 1 |
| Risenberg, K | 2 |
| Levi, I | 2 |
| Sthoeger, Z | 1 |
| Feinberg, J | 3 |
| McConnell, M | 2 |
| Megazzini, KM | 2 |
| Redden, DT | 2 |
| Krebs, DW | 2 |
| Simwenda, M | 1 |
| Tambatamba, B | 1 |
| Johnson, N | 2 |
| Palmer, P | 4 |
| Samuels, LA | 1 |
| Morgan, O | 1 |
| Onyonyor, A | 1 |
| Anderson, M | 1 |
| Moore, J | 2 |
| Billings, C | 1 |
| Harvey, KM | 2 |
| Mullings, A | 1 |
| McDonald, D | 2 |
| Alexander, G | 2 |
| Smikle, MF | 3 |
| Williams, EW | 1 |
| Davis, D | 1 |
| Christie, CD | 5 |
| White, YR | 1 |
| Pierre, RB | 1 |
| Steel-Duncan, J | 1 |
| Evans-Gilbert, T | 2 |
| Rodriguez, B | 1 |
| Ouyang, DW | 2 |
| Brogly, SB | 2 |
| Leighty, RM | 2 |
| Thompson, B | 2 |
| Tuomala, RE | 3 |
| Hershow, RC | 2 |
| Mmiro, FA | 1 |
| Mwatha, AK | 1 |
| Musoke, PM | 3 |
| Zoppini, G | 1 |
| Cammett, AM | 2 |
| Wruck, JM | 1 |
| Felizarta, F | 1 |
| Miailhes, P | 1 |
| Mallolas, J | 4 |
| Piliero, PJ | 2 |
| Parkin, N | 4 |
| Marlowe, N | 1 |
| Wilkinson, KA | 1 |
| Seldon, R | 1 |
| Meintjes, G | 1 |
| Rangaka, MX | 1 |
| Hanekom, WA | 1 |
| Sekar, V | 1 |
| Lefebvre, E | 1 |
| Mariën, K | 1 |
| De Pauw, M | 1 |
| Vangeneugden, T | 1 |
| Hoetelmans, RM | 9 |
| Miró, O | 3 |
| Rodríguez-Santiago, B | 2 |
| Garrabou, G | 1 |
| Estany, C | 1 |
| Masabeu, A | 2 |
| Force, L | 5 |
| Barrufet, P | 2 |
| Cucurull, J | 2 |
| Domingo, P | 12 |
| Alonso-Villaverde, C | 1 |
| Bonjoch, A | 7 |
| Morén, C | 1 |
| Pérez-Alvarez, N | 3 |
| Mwinga, K | 1 |
| Urassa, W | 1 |
| Carpenetti, N | 1 |
| Valentine, M | 2 |
| Goldenberg, RL | 12 |
| Franssen, R | 1 |
| Sankatsing, RR | 2 |
| Hassink, E | 2 |
| Hutten, B | 1 |
| Ackermans, MT | 1 |
| Oesterholt, R | 1 |
| Arenas-Pinto, A | 1 |
| Storfer, SP | 1 |
| Kastelein, JJ | 4 |
| Sauerwein, HP | 1 |
| Stroes, ES | 2 |
| Kurewa, EN | 1 |
| Gumbo, FZ | 5 |
| Munjoma, MW | 3 |
| Mapingure, MP | 4 |
| Chirenje, MZ | 5 |
| Rusakaniko, S | 5 |
| Galegov, GA | 1 |
| Matteelli, A | 1 |
| Saleri, N | 1 |
| Bonkoungou, V | 1 |
| Carvalho, AC | 1 |
| Kouanda, S | 2 |
| Sanou, MJ | 1 |
| Simporé, J | 4 |
| Monno, L | 1 |
| Dembele, M | 1 |
| Zachariah, R | 5 |
| Rasschaert, F | 2 |
| Mugabo, J | 1 |
| Atté, EF | 1 |
| Reid, T | 1 |
| Zhou, H | 1 |
| He, Y | 3 |
| Gong, G | 1 |
| Yin, W | 2 |
| Tozzi, V | 3 |
| Becker, S | 1 |
| Mlay, R | 1 |
| Schwandt, HM | 1 |
| Lyamuya, E | 1 |
| Ilboudo, D | 1 |
| Sanou, DS | 1 |
| Karou, D | 1 |
| Sia, DJ | 1 |
| Ouermi, D | 1 |
| Bisseye, C | 1 |
| Sagna, T | 1 |
| Odolini, S | 1 |
| Buelli, F | 1 |
| Pietra, V | 3 |
| Pignatelli, S | 2 |
| Gnoula, C | 1 |
| Nikiema, JB | 2 |
| Castelli, F | 3 |
| Namala, W | 1 |
| Kizito, H | 1 |
| Fox, ZV | 1 |
| Booth, CL | 1 |
| Smith, CJ | 1 |
| Phillips, AN | 6 |
| Li, JF | 3 |
| Shalekoff, S | 1 |
| Meddows-Taylor, S | 2 |
| Schramm, DB | 4 |
| Sim, MS | 1 |
| Cumberland, WG | 1 |
| Duan, N | 1 |
| Bryson, YJ | 2 |
| Pollock, L | 2 |
| Else, L | 1 |
| Poerksen, G | 2 |
| Molyneux, E | 3 |
| Moons, P | 2 |
| Walker, S | 1 |
| Fraser, W | 1 |
| Birbeck, GL | 1 |
| Cole, SR | 2 |
| Thigpen, M | 1 |
| Hopley, M | 1 |
| Eklund, M | 1 |
| Hall, DB | 10 |
| Robinson, P | 12 |
| Mayers, D | 5 |
| Un, P | 1 |
| Phe, T | 1 |
| Anzidei, G | 1 |
| Tibaldi, C | 1 |
| Guerra, B | 1 |
| Meloni, AM | 1 |
| Vimercati, A | 1 |
| Dalzero, S | 1 |
| Ravizza, M | 1 |
| Ellis, GM | 2 |
| Warrier, R | 1 |
| Nakamura, K | 1 |
| Nsibande, D | 1 |
| Mngoma, D | 1 |
| Narayanan, PR | 2 |
| Cheng, I | 1 |
| Vallier, N | 1 |
| Nguyen, A | 1 |
| Lima, VD | 4 |
| Hirschel, B | 5 |
| Rodríguez-Arrondo, F | 1 |
| Aguirrebengoa, K | 1 |
| Portu, J | 1 |
| Muñoz, J | 1 |
| García, MA | 1 |
| Goikoetxea, J | 1 |
| Iribarren, JA | 1 |
| Mwanza, J | 1 |
| Ivanovic, J | 1 |
| Anceschi, MM | 1 |
| Ascenzi, P | 1 |
| Signore, F | 1 |
| Pisani, G | 1 |
| Vallone, C | 1 |
| Mattia, E | 1 |
| Notari, S | 1 |
| Tempestilli, M | 1 |
| Pucillo, LP | 1 |
| Narciso, P | 4 |
| McCormick, A | 2 |
| Burke, A | 2 |
| Lyagoba, F | 3 |
| Katundu, P | 4 |
| Robertson, V | 3 |
| Yirrell, DL | 1 |
| Jaffar, S | 1 |
| Amuron, B | 2 |
| Foster, S | 3 |
| Birungi, J | 1 |
| Levin, J | 4 |
| Namara, G | 1 |
| Nabiryo, C | 1 |
| Kyomuhangi, R | 1 |
| Opio, A | 1 |
| Bunnell, R | 1 |
| Mermin, J | 3 |
| Coutinho, A | 2 |
| Grosskurth, H | 8 |
| Mudiope, P | 3 |
| Ajuna, P | 2 |
| Esimone, CO | 1 |
| Eck, G | 1 |
| Nworu, CS | 1 |
| Hoffmann, D | 1 |
| Uberla, K | 1 |
| Proksch, P | 1 |
| Toni, TA | 1 |
| Brenner, BG | 1 |
| Asahchop, EL | 1 |
| Ntemgwa, M | 1 |
| Moisi, D | 1 |
| Wainberg, MA | 5 |
| Kumwenda, N | 11 |
| Sebunya, TK | 1 |
| Hagan, JE | 1 |
| Shapiro, R | 1 |
| Moyo, SM | 1 |
| Mitchell, R | 1 |
| Kim, S | 3 |
| van Widenfelt, E | 4 |
| Darbyshire, JH | 5 |
| Bray, D | 4 |
| Babiker, AG | 3 |
| Kabuye, G | 3 |
| Nsibambi, D | 2 |
| Zalwango, E | 1 |
| Nakazibwe, M | 1 |
| Kikaire, B | 2 |
| Nassuna, G | 1 |
| Massa, R | 1 |
| Fadhiru, K | 2 |
| Namyalo, M | 1 |
| Zalwango, A | 1 |
| Generous, L | 1 |
| Khauka, P | 2 |
| Rutikarayo, N | 1 |
| Nakahima, W | 1 |
| Mugisha, A | 1 |
| Todd, J | 1 |
| Muyingo, S | 1 |
| Ruberantwari, A | 1 |
| Yirrell, D | 2 |
| Hughes, P | 1 |
| Aber, M | 1 |
| Lara, AM | 2 |
| Amurwon, J | 2 |
| Wakholi, BN | 2 |
| Whitworth, J | 1 |
| Wangati, K | 1 |
| Kajungu, D | 1 |
| Nakiyingi, J | 1 |
| Omony, W | 1 |
| Tumukunde, D | 2 |
| Otim, T | 1 |
| Musana, H | 1 |
| Akao, J | 1 |
| Kyomugisha, H | 1 |
| Byamukama, A | 1 |
| Sabiiti, J | 1 |
| Komugyena, J | 1 |
| Mukiibi, S | 1 |
| Drasiku, A | 1 |
| Byaruhanga, R | 1 |
| Labeja, O | 1 |
| Tugume, S | 2 |
| Awio, P | 1 |
| Namazzi, A | 1 |
| Bakeinyaga, GT | 1 |
| Katabira, H | 1 |
| Abaine, D | 1 |
| Tukamushaba, J | 1 |
| Anywar, W | 1 |
| Ojiambo, W | 1 |
| Angweng, E | 1 |
| Murungi, S | 2 |
| Haguma, W | 1 |
| Atwiine, S | 1 |
| Namale, L | 2 |
| Mukose, A | 1 |
| Mulindwa, G | 1 |
| Atwiine, D | 1 |
| Muhwezi, A | 1 |
| Nimwesiga, E | 1 |
| Barungi, G | 1 |
| Takubwa, J | 1 |
| Mwebesa, D | 1 |
| Kagina, G | 1 |
| Mulindwa, M | 1 |
| Ahimbisibwe, F | 1 |
| Mwesigwa, P | 1 |
| Akuma, S | 1 |
| Zawedde, C | 1 |
| Nyiraguhirwa, D | 1 |
| Tumusiime, C | 1 |
| Bagaya, L | 1 |
| Namara, W | 1 |
| Karungi, J | 1 |
| Kankunda, R | 1 |
| Enzama, R | 1 |
| Latif, A | 2 |
| Chidziva, E | 1 |
| Bulaya-Tembo, R | 1 |
| Musoro, G | 1 |
| Chimbetete, C | 1 |
| Chakonza, L | 1 |
| Mawora, A | 1 |
| Muvirimi, C | 1 |
| Tinago, G | 1 |
| Svovanapasis, P | 1 |
| Simango, M | 1 |
| Chirema, O | 1 |
| Machingura, J | 1 |
| Mutsai, S | 1 |
| Phiri, M | 1 |
| Bafana, T | 1 |
| Chirara, M | 2 |
| Muchabaiwa, L | 2 |
| Muzambi, M | 2 |
| Mutowo, J | 1 |
| Chivhunga, T | 1 |
| Chigwedere, E | 1 |
| Pascoe, M | 1 |
| Warambwa, C | 1 |
| Zengeza, E | 1 |
| Mapinge, F | 1 |
| Makota, S | 1 |
| Jamu, A | 1 |
| Ngorima, N | 1 |
| Chirairo, H | 1 |
| Chitsungo, S | 1 |
| Chimanzi, J | 1 |
| Maweni, C | 1 |
| Warara, R | 1 |
| Matongo, M | 1 |
| Mudzingwa, S | 1 |
| Jangano, M | 1 |
| Moyo, K | 1 |
| Vere, L | 1 |
| Mdege, N | 1 |
| Machingura, I | 1 |
| Kambungu, A | 1 |
| Lutwama, F | 3 |
| Nanfuka, A | 1 |
| Walusimbi, J | 1 |
| Nabankema, E | 1 |
| Nalumenya, R | 2 |
| Namuli, T | 1 |
| Kulume, R | 1 |
| Namata, I | 1 |
| Nyachwo, L | 1 |
| Florence, A | 1 |
| Kusiima, A | 1 |
| Lubwama, E | 1 |
| Nairuba, R | 1 |
| Oketta, F | 1 |
| Buluma, E | 1 |
| Waita, R | 1 |
| Ojiambo, H | 1 |
| Sadik, F | 1 |
| Wanyama, J | 1 |
| Nabongo, P | 1 |
| Oyugi, J | 1 |
| Sematala, F | 1 |
| Twijukye, C | 1 |
| Byakwaga, H | 1 |
| Ochai, R | 1 |
| Muhweezi, D | 1 |
| Etukoit, B | 1 |
| Boocock, K | 1 |
| Puddephatt, C | 1 |
| Grundy, C | 1 |
| Bohannon, J | 1 |
| Winogron, D | 1 |
| Babiker, A | 2 |
| Wilkes, H | 1 |
| Rauchenberger, M | 1 |
| Sheehan, S | 1 |
| Spencer-Drake, C | 1 |
| Taylor, K | 1 |
| Ferrier, A | 3 |
| Naidoo, B | 1 |
| Goodall, R | 2 |
| Peto, L | 1 |
| Nanfuka, R | 1 |
| Mufuka-Kapuya, C | 1 |
| Weller, I | 1 |
| Bahendeka, S | 1 |
| Bassett, M | 2 |
| Wapakhabulo, AC | 1 |
| Gazzard, B | 7 |
| Mapuchere, C | 1 |
| Burke, C | 1 |
| Jones, S | 1 |
| Newland, C | 1 |
| Rahim, S | 2 |
| Rooney, J | 2 |
| Smith, M | 1 |
| Snowden, W | 2 |
| Steens, JM | 1 |
| Breckenridge, A | 1 |
| McLaren, A | 1 |
| Hill, C | 1 |
| Matenga, J | 1 |
| Serwadda, D | 2 |
| Peto, T | 1 |
| Palfreeman, A | 1 |
| Borok, M | 1 |
| Sirianni, E | 1 |
| Altan, AM | 1 |
| Paturzo, G | 2 |
| Bramanti, P | 1 |
| Wakeham, K | 1 |
| Parkes-Ratanshi, R | 1 |
| Ggayi, AB | 1 |
| Vignoles, M | 2 |
| Barboni, G | 1 |
| Agosti, MR | 1 |
| Quarleri, J | 1 |
| García, MK | 1 |
| Ayala, SG | 1 |
| Salomón, H | 5 |
| Maria Llibre, J | 1 |
| Valero, S | 1 |
| Hudelson, SE | 7 |
| Piwowar-Manning, E | 3 |
| Nolan, ML | 1 |
| Elzi, L | 2 |
| Marzolini, C | 1 |
| Ledergerber, B | 3 |
| Weber, R | 2 |
| Ndirangu, J | 1 |
| Tanser, F | 1 |
| Herbst, AJ | 1 |
| Bland, R | 1 |
| Moses, M | 1 |
| Tayler-Smith, K | 1 |
| Misinde, D | 1 |
| Foncha, C | 1 |
| Manzi, M | 2 |
| Bauerfeind, A | 1 |
| Mwagomba, B | 1 |
| Kwanjana, J | 1 |
| Harries, AD | 2 |
| Liu, ZY | 1 |
| Guo, FP | 1 |
| Han, Y | 4 |
| Qiu, ZF | 1 |
| Zuo, LY | 1 |
| Li, YL | 1 |
| Li, TS | 1 |
| Hou, T | 1 |
| Liu, JS | 1 |
| Mlambo, M | 1 |
| Phaswana-Mafuya, N | 1 |
| Ladzani, R | 1 |
| Weberschock, T | 1 |
| Gholam, P | 1 |
| Hueter, E | 1 |
| Flux, K | 1 |
| Traisaithit, P | 1 |
| Collins, IJ | 1 |
| Sukhumanant, T | 1 |
| Achalapong, J | 2 |
| Chotivanich, N | 2 |
| Winiyakul, N | 1 |
| Ariyadej, S | 2 |
| Kanjanasing, A | 1 |
| Ratanakosol, J | 1 |
| Hemvuttiphan, J | 1 |
| Kengsakul, K | 1 |
| Wannapira, W | 1 |
| Sittipiyasakul, V | 1 |
| Pornkitprasarn, W | 1 |
| Liampongsabuddhi, P | 1 |
| Van Dyke, RB | 2 |
| Kanchana, S | 1 |
| Chaplin, B | 1 |
| Penugonda, S | 2 |
| Meloni, S | 2 |
| Akanmu, S | 1 |
| Idoko, J | 4 |
| Adewole, I | 1 |
| Corbett, AH | 4 |
| Nyirenda, J | 1 |
| Rezk, NL | 4 |
| Mkupani, P | 1 |
| Sichali, D | 1 |
| Tien, H | 1 |
| Kashuba, AD | 6 |
| Mwansambo, C | 1 |
| Weigel, R | 2 |
| Medrano, J | 1 |
| Seclen, E | 1 |
| Poveda, E | 1 |
| Rodriguez-Novoa, S | 2 |
| Morello, J | 1 |
| de Mendoza, C | 1 |
| Bolu, O | 3 |
| Anekthananon, T | 3 |
| Jariyasethpong, T | 1 |
| Potter, D | 2 |
| Mutsotso, W | 2 |
| Borkowf, CB | 2 |
| Mbori-Ngacha, D | 1 |
| Muiruri, P | 1 |
| Ong'ech, JO | 1 |
| Zulu, I | 3 |
| Njobvu, L | 1 |
| Jetsawang, B | 1 |
| Pathak, S | 1 |
| Chu, KM | 2 |
| Boulle, AM | 1 |
| Asselman, V | 1 |
| Wagner, TA | 3 |
| Kress, CM | 1 |
| Techapornroong, M | 2 |
| Wittayapraparat, P | 2 |
| Tansuphasawasdikul, S | 2 |
| Wiboonchutikul, S | 1 |
| Sukasem, C | 2 |
| Mbougua, JB | 1 |
| Bourgeois, A | 3 |
| Gwet, H | 1 |
| Ducos, J | 1 |
| Molinari, N | 2 |
| Munerato, P | 1 |
| Sucupira, MC | 1 |
| Oliveros, MP | 1 |
| Janini, LM | 1 |
| de Souza, DF | 1 |
| Pereira, AA | 1 |
| Inocencio, LA | 1 |
| Diaz, RS | 1 |
| Oliveira, I | 1 |
| Jensen-Fangel, S | 2 |
| da Silva, D | 1 |
| Ndumba, A | 1 |
| Medina, C | 1 |
| Nanadje, A | 1 |
| Rasmussen, DN | 1 |
| Rudolf, F | 1 |
| Wejse, C | 1 |
| da Silva, ZJ | 1 |
| Sodemann, M | 1 |
| Laursen, AL | 1 |
| Emmett, SD | 1 |
| Kinabo, GD | 1 |
| Swai, ME | 1 |
| Reddy, EA | 1 |
| Delva, W | 3 |
| Yard, E | 1 |
| Muigai, E | 1 |
| Oyier, V | 1 |
| Conkling, M | 1 |
| Shutes, EL | 1 |
| Karita, E | 2 |
| Chomba, E | 1 |
| Tichacek, A | 1 |
| Vwalika, B | 1 |
| Iwanowski, M | 1 |
| Allen, SA | 1 |
| Kurewa, NE | 4 |
| Kandawasvika, GQ | 2 |
| Duri, K | 3 |
| Pazvakavambwa, IE | 1 |
| Hardy, H | 1 |
| Backman, ES | 1 |
| Farber, HW | 1 |
| Rowley, CF | 3 |
| Boutwell, CL | 2 |
| Lee, EJ | 2 |
| MacLeod, IJ | 2 |
| Deshpande, A | 3 |
| Jeannot, AC | 1 |
| Schrive, MH | 2 |
| Wittkop, L | 1 |
| Pinson, P | 2 |
| Zhou, HY | 1 |
| Zheng, YH | 3 |
| Fregonese, F | 1 |
| Nantasen, I | 1 |
| Halue, G | 1 |
| Nilmanat, A | 1 |
| Chalermpolprapa, V | 1 |
| Yuthavisuthi, P | 2 |
| Ayuthaya, PI | 1 |
| Kannagi, M | 2 |
| Matediane, E | 1 |
| Jamisse, L | 3 |
| Ewings, F | 1 |
| L'homme, R | 2 |
| Potard, V | 1 |
| Chassany, O | 1 |
| Lavignon, M | 2 |
| Torpey, K | 3 |
| Dirks, R | 2 |
| Bweupe, M | 2 |
| Kabaso, M | 2 |
| Mandala, J | 2 |
| Sangiwa, G | 1 |
| Datay, MI | 1 |
| Mant, D | 1 |
| Yudkin, P | 1 |
| Giacometti, A | 1 |
| Butini, L | 1 |
| Cirioni, O | 1 |
| Costantini, A | 1 |
| Montroni, M | 1 |
| Scalise, G | 1 |
| Kuonza, LR | 1 |
| Tshuma, CD | 1 |
| Shambira, GN | 1 |
| Tshimanga, M | 1 |
| Verdon, R | 4 |
| Coquerel, A | 1 |
| Lagakos, SW | 1 |
| Gray, RJ | 1 |
| Muresan, P | 2 |
| Plipat, N | 2 |
| Hongsiriwan, S | 1 |
| Eksaengsri, A | 2 |
| Toye, M | 2 |
| Smith, ME | 3 |
| Pirillo, M | 1 |
| Palmisano, L | 1 |
| Pellegrini, M | 1 |
| Galluzzo, C | 1 |
| Weimer, L | 1 |
| Bucciardini, R | 4 |
| Fragola, V | 4 |
| Marchei, E | 1 |
| Pichini, S | 1 |
| Sax, PE | 5 |
| Reuman, EC | 1 |
| Holmes, SP | 1 |
| Ndekha, M | 1 |
| Moore, E | 1 |
| Zijlstra, EE | 3 |
| Manary, M | 1 |
| Giganti, MJ | 2 |
| Putta, NB | 1 |
| Sadoki, E | 1 |
| Butler, DM | 1 |
| Richman, DD | 6 |
| Smith, DM | 2 |
| Beldjebel, I | 1 |
| Vujcikova, J | 1 |
| Sokolova, J | 1 |
| Krcmery, V | 1 |
| Ford, D | 1 |
| Kalumbi, M | 1 |
| Grant, PR | 1 |
| Chesshyre, E | 1 |
| Weaver, MA | 1 |
| Bryan, G | 1 |
| Mukonka, V | 1 |
| Mwale, F | 1 |
| Chasela, CS | 2 |
| Knight, RJ | 2 |
| Ahmed, YI | 1 |
| Ellington, SR | 2 |
| Kacheche, Z | 2 |
| Soko, A | 2 |
| Wiener, JB | 2 |
| Chigwenembe, M | 2 |
| Sichali, DS | 2 |
| Kitch, D | 1 |
| Tumbare, E | 1 |
| Handelsman, E | 1 |
| Mburu, K | 1 |
| Jayeoba, O | 1 |
| Moko, E | 1 |
| Souda, S | 1 |
| Lubega, E | 1 |
| Akhtar, M | 1 |
| Tuomola, R | 1 |
| Martinez-Tristani, M | 1 |
| Mazhani, L | 2 |
| O'Gorman, DA | 1 |
| Nyirenda, LJ | 1 |
| Theobald, SJ | 1 |
| Tanon, AK | 1 |
| Amani-Bosse, C | 5 |
| Bédikou, G | 2 |
| Sophan, S | 1 |
| Meng, CY | 1 |
| Pean, P | 1 |
| Harwell, J | 1 |
| Hutton, E | 1 |
| Trzmielina, S | 1 |
| Somasundaran, M | 1 |
| Luzuriaga, K | 3 |
| Pugatch, D | 1 |
| Gelinck, LB | 1 |
| Emadi, SN | 1 |
| Akhavan-Mogaddam, J | 1 |
| Yousefi, M | 1 |
| Sobhani, B | 1 |
| Moshkforoush, A | 1 |
| Emadi, SE | 1 |
| Decha, P | 1 |
| Intharathep, P | 1 |
| Udommaneethanakit, T | 1 |
| Sompornpisut, P | 1 |
| Hannongbua, S | 1 |
| Parasuk, V | 1 |
| Cramer, YS | 1 |
| Rosenkranz, SL | 1 |
| Hall, SD | 1 |
| Szczech, LA | 1 |
| Amorosa, V | 1 |
| Gupta, SK | 1 |
| Lawson-Evi, K | 1 |
| Tchama, R | 1 |
| Akakpo, SA | 1 |
| Atakouma, DY | 2 |
| Beauvais, L | 1 |
| Kochar, R | 1 |
| Nevah, MI | 1 |
| Lukens, FJ | 1 |
| Fallon, MB | 1 |
| Machicao, VI | 1 |
| Okaba-Kayom, V | 2 |
| Flaherty, JP | 1 |
| Namakula, R | 3 |
| Yao, Y | 1 |
| Sun, F | 1 |
| Tougri, H | 1 |
| Doulougou, B | 1 |
| Ouedraogo, G | 1 |
| Ouedraogo, CM | 1 |
| Soudre, R | 1 |
| Sondo, B | 1 |
| Creek, TL | 1 |
| Stinson, K | 1 |
| Welty, TK | 2 |
| Wilfert, CM | 4 |
| Sturdevant, M | 1 |
| del Rio Martin, J | 1 |
| Schiano, T | 1 |
| Fiel, MI | 1 |
| Huprikar, S | 1 |
| Bersoff-Matcha, SJ | 2 |
| Rourke, D | 1 |
| Blank, J | 1 |
| Peters, PJ | 2 |
| Stringer, J | 1 |
| Intalapaporn, P | 1 |
| Brooks, JT | 2 |
| Barigye, H | 1 |
| Maher, D | 1 |
| Tindiwegi, G | 1 |
| Atuhumuza, E | 1 |
| Nakibinge, S | 1 |
| Gadhamsetty, S | 1 |
| Dixit, NM | 1 |
| Farr, SL | 1 |
| Ng'ombe, TJ | 1 |
| Tegha, GL | 1 |
| Eron, JJ | 6 |
| Banda, HN | 1 |
| Mpaso, M | 1 |
| Matiki, C | 1 |
| Kristiansen, KI | 1 |
| Muller, F | 1 |
| Kabue, MM | 1 |
| Kazembe, PN | 1 |
| Kline, MW | 1 |
| Segeral, O | 1 |
| Borand, L | 1 |
| Comets, E | 1 |
| Le Tiec, C | 1 |
| Becquemont, L | 2 |
| Ouk, V | 1 |
| Godinho, AL | 2 |
| Martins, IL | 1 |
| Oliveira, MC | 3 |
| Gomes, RA | 1 |
| Coelho, AV | 1 |
| Beland, FA | 2 |
| Sedlacek, D | 1 |
| Gatell, J | 3 |
| Hu, CC | 2 |
| Bancheno, WM | 1 |
| Mwanyumba, F | 3 |
| Mareverwa, J | 1 |
| Aaron, E | 1 |
| Kempf, MC | 1 |
| Criniti, S | 1 |
| Tedaldi, E | 1 |
| Gracely, E | 1 |
| Warriner, A | 1 |
| Kumar, R | 1 |
| Bachmann, LH | 1 |
| Manabe, Y | 1 |
| Chijoka, C | 1 |
| Kalengo, C | 1 |
| Chimsuntorn, S | 4 |
| Eampokarap, B | 1 |
| Nilkamhang, S | 1 |
| Nielsen-Saines, K | 5 |
| Haswell, J | 2 |
| Doro Altan, AM | 1 |
| Bachani, D | 1 |
| Chan, PL | 1 |
| Srikantiah, P | 1 |
| Graham, SM | 1 |
| Gitau, R | 1 |
| Jalalian-Lechak, Z | 1 |
| Peshu, N | 1 |
| Mandaliya, K | 4 |
| Jaoko, W | 1 |
| Ndinya-Achola, J | 1 |
| Spaulding, A | 2 |
| Sonderup, M | 1 |
| Meissner, P | 1 |
| Mendelson, M | 1 |
| Stringer, E | 4 |
| Mngqibisa, R | 1 |
| Atwine, D | 1 |
| Salata, RA | 1 |
| Alston-Smith, B | 2 |
| Walawander, A | 1 |
| Purcelle-Smith, E | 1 |
| Eshleman, S | 1 |
| Millar, L | 2 |
| Lurie, MN | 1 |
| Triche, EW | 1 |
| De Bruyn, G | 1 |
| Harwell, JI | 1 |
| McGarvey, ST | 1 |
| Benaboud, S | 2 |
| Rey, E | 2 |
| Sim, KL | 1 |
| Cournil, A | 1 |
| Coudray, M | 1 |
| Essomba, CN | 1 |
| Tonfack, CA | 1 |
| Biwolé-Sida, M | 1 |
| Bork, K | 1 |
| Coakley, P | 1 |
| Tattevin, P | 3 |
| Arvieux, C | 6 |
| Courpotin, C | 1 |
| Ouattara, E | 1 |
| Moh, R | 2 |
| Messou, E | 1 |
| Sissoko, M | 1 |
| Anglaret, X | 3 |
| Eholié, SP | 1 |
| Danel, C | 2 |
| Tchatchueng Mbougua, JB | 1 |
| Ngom Guèye, NF | 2 |
| Snowden, WB | 1 |
| Mosteller, M | 1 |
| Thoofer, NK | 1 |
| Hughes, AR | 1 |
| Kayma, S | 1 |
| Salmond, W | 1 |
| Maganda, A | 1 |
| Galla, M | 1 |
| Byamugisha, J | 1 |
| Eley, B | 2 |
| Giddy, J | 1 |
| Technau, K | 1 |
| Keiser, O | 2 |
| Tsague, L | 1 |
| Tsiouris, FO | 1 |
| Mugisha, V | 1 |
| Tene, G | 2 |
| Nyankesha, E | 1 |
| Koblavi-Deme, S | 1 |
| Mugwaneza, P | 1 |
| Kayirangwa, E | 1 |
| Sahabo, R | 1 |
| Huang, S | 3 |
| Kaiser, KA | 1 |
| Scheuerle, A | 1 |
| Stanley, K | 4 |
| Delfraissy, JF | 4 |
| Ravich, VL | 1 |
| Masso, M | 1 |
| Vaisman, II | 1 |
| Hanna, LE | 1 |
| Mbuagbaw, LC | 1 |
| Haïm-Boukobza, S | 1 |
| Flandre, P | 3 |
| Valin, N | 1 |
| Fourati, S | 1 |
| Sayon, S | 1 |
| Simon, A | 4 |
| van Luin, M | 1 |
| Smit, C | 2 |
| Rigter, IM | 1 |
| Franssen, EJ | 1 |
| Richter, C | 2 |
| Kroon, F | 1 |
| Dorton, BJ | 1 |
| Mulindwa, J | 1 |
| Li, MS | 1 |
| Chintu, NT | 1 |
| Chibwesha, CJ | 1 |
| Joshi, S | 1 |
| Khandekar, M | 1 |
| Karmarkar, A | 1 |
| Paranjape, R | 1 |
| Jamkar, A | 1 |
| de Vincenzi, I | 1 |
| Ashworth, R | 1 |
| Ruff, A | 2 |
| Van Dyke, R | 1 |
| Cababasay, MP | 1 |
| Louw, J | 1 |
| Smith, E | 2 |
| Maupin, R | 2 |
| Sreenivasan, S | 1 |
| Dasegowda, V | 1 |
| Auephanwiriyakul, S | 1 |
| Sumonphan, E | 1 |
| Theera-Umpon, N | 1 |
| Tayapiwatana, C | 2 |
| Lipscomb, JT | 1 |
| Chen, YH | 1 |
| Jeena, PM | 1 |
| Reichert, K | 1 |
| Adhikari, M | 2 |
| Popat, M | 1 |
| Carlin, JB | 1 |
| Weber, MW | 1 |
| Hamer, DH | 1 |
| Basu, S | 1 |
| Kumar, A | 1 |
| Das, BK | 1 |
| Dlamini, JN | 1 |
| Hu, Z | 1 |
| Somaroo, H | 1 |
| Highbarger, HC | 1 |
| Follmann, DA | 1 |
| Dewar, RL | 1 |
| Pau, AK | 1 |
| Hughes, M | 3 |
| Chu, J | 3 |
| Holmes, CB | 2 |
| Pillay, S | 1 |
| Pilger, D | 1 |
| Somogyi, S | 1 |
| Wensing, AM | 1 |
| Back, NK | 1 |
| Arcilla, MS | 1 |
| Frissen, JP | 1 |
| Taylor, BS | 1 |
| Azcoaga-Lorenzo, A | 1 |
| Alvarez, A | 1 |
| Palma, PP | 1 |
| Velilla, E | 1 |
| del Amo, J | 1 |
| Bolhaar, MG | 1 |
| Karstaedt, AS | 1 |
| Sikwane, E | 1 |
| Majaja, M | 1 |
| Neveu, D | 1 |
| Viljoen, J | 1 |
| Nagot, N | 1 |
| Danaviah, S | 1 |
| Van de Perre, P | 1 |
| Lengruber, RB | 1 |
| Delviks-Frankenberry, KA | 1 |
| Nikolenko, GN | 1 |
| Baumann, J | 1 |
| Santos, AF | 1 |
| Pathak, VK | 1 |
| Soares, MA | 1 |
| Agibothu Kupparam, HK | 1 |
| Mahalingam, V | 1 |
| Soundararajan, L | 1 |
| Perumal Kannabiran, B | 1 |
| Navaneethapandian, PG | 1 |
| Shah, I | 2 |
| Karunaianandham, R | 1 |
| Sikhamani, R | 1 |
| Ukwe, CV | 1 |
| Ekwunife, OI | 1 |
| Udeogaranya, OP | 1 |
| Iwuamadi, UI | 1 |
| Welz, T | 1 |
| Childs, K | 1 |
| Post, FA | 1 |
| Parham, L | 1 |
| de Rivera, IL | 1 |
| Murillo, W | 1 |
| Naver, L | 1 |
| Largaespada, N | 1 |
| Albert, J | 2 |
| Karlsson, AC | 1 |
| Kieffer, MP | 1 |
| Nhlabatsi, B | 1 |
| Mahdi, M | 1 |
| Hoffman, HJ | 1 |
| Kudiabor, K | 1 |
| Schipani, A | 1 |
| Hendra, H | 2 |
| Davies, G | 1 |
| Rockstroh, J | 3 |
| Johnson, MA | 3 |
| Maserati, R | 2 |
| Brandolini, M | 1 |
| Cattelan, A | 1 |
| Orani, A | 2 |
| Sighinolfi, L | 1 |
| Uglietti, A | 1 |
| Sotgiu, G | 2 |
| Manga, NM | 2 |
| Poda, A | 1 |
| Bazolo, N | 1 |
| Sané, O | 1 |
| Batista, G | 1 |
| Guèye, NF | 1 |
| Badiane, CI | 1 |
| Dolgin, E | 1 |
| Fogel, J | 1 |
| Taylor, AW | 1 |
| Paintsil, E | 1 |
| Østergaard, LR | 1 |
| Bula, A | 1 |
| Mossdorf, E | 2 |
| Stoeckle, M | 1 |
| Mwaigomole, EG | 1 |
| Chiweka, E | 1 |
| Kibatala, PL | 1 |
| Geubbels, E | 1 |
| Urassa, H | 1 |
| Abdulla, S | 1 |
| Yuan, J | 1 |
| Guo, S | 1 |
| Hall, D | 11 |
| Jayadev, S | 1 |
| Distel, M | 1 |
| Storfer, S | 4 |
| Huang, Z | 1 |
| Mootsikapun, P | 2 |
| Maruszak, H | 1 |
| Jeganathan, S | 1 |
| Andrade-Villanueva, J | 3 |
| Gellermann, HJ | 1 |
| de Rossi, L | 2 |
| Cairns, V | 1 |
| Gómez Q, CH | 1 |
| Vesga G, JF | 1 |
| Lowenstein De M, E | 1 |
| Suárez R, JO | 1 |
| Gil L, FA | 1 |
| Valderrama B, SL | 1 |
| Tamara, JR | 1 |
| Castro P, NA | 1 |
| Alvarez M, CA | 1 |
| Ciampa, PJ | 1 |
| Burlison, JR | 1 |
| Moon, TD | 1 |
| Rothman, RL | 1 |
| Goray, A | 1 |
| Chaddha, U | 1 |
| Tayal, S | 1 |
| Lala, M | 1 |
| Arastéh, K | 4 |
| Migrone, H | 1 |
| Lutz, T | 1 |
| Opravil, M | 1 |
| Gellermann, H | 1 |
| Stitelman, OM | 1 |
| De Gruttola, V | 1 |
| van der Laan, MJ | 1 |
| Górgolas, M | 4 |
| Hidalgo, C | 1 |
| Williams, F | 2 |
| Guerrero, MF | 1 |
| Chibowa, MC | 1 |
| Nair, A | 1 |
| Owino-Ong'or, W | 1 |
| Hunt, GM | 1 |
| Bommenel, T | 1 |
| Launay, O | 5 |
| Meynard, JL | 1 |
| Gilquin, J | 1 |
| Lascaux, AS | 1 |
| Mahamat, A | 1 |
| Martinez, V | 2 |
| Pradier, C | 1 |
| Rouveix, E | 1 |
| Perez, F | 2 |
| Maruva, M | 1 |
| Engelsmann, B | 1 |
| Keatinge, J | 1 |
| Mugwagwa, R | 1 |
| Gras, A | 1 |
| Schneider, S | 2 |
| Karasi, JC | 1 |
| Ternes, AM | 1 |
| Sauvageot, N | 1 |
| Karasi-Omes, C | 1 |
| Henry, AP | 1 |
| Schmit, JC | 2 |
| Tudor Car, L | 1 |
| van-Velthoven, MH | 1 |
| Brusamento, S | 1 |
| Elmoniry, H | 1 |
| Car, J | 1 |
| Majeed, A | 1 |
| Atun, R | 2 |
| Mankhatitham, W | 2 |
| Joseph, O | 1 |
| Biodun, O | 1 |
| Michael, E | 1 |
| van der Merwe, L | 3 |
| Brocklehurst, P | 4 |
| Sint, TT | 2 |
| Schrijvers, R | 1 |
| Desimmie, BA | 1 |
| Debyser, Z | 1 |
| Schouten, EJ | 1 |
| Midiani, D | 1 |
| Makombe, SD | 1 |
| Mnthambala, A | 1 |
| Meguid, T | 1 |
| Ben-Smith, A | 1 |
| Van Damme, W | 1 |
| Shawa, M | 1 |
| Ranopa, M | 1 |
| Bacheler, L | 2 |
| Van Houtte, M | 1 |
| Takahashi, A | 1 |
| Kubo, M | 1 |
| Kamatani, N | 1 |
| Chen, S | 11 |
| Gathe, J | 1 |
| Santiago, S | 1 |
| Horban, A | 8 |
| Bogner, J | 2 |
| Spencer, D | 1 |
| Zhang, W | 2 |
| Drulak, M | 1 |
| Gozalo, C | 1 |
| Gérard, L | 4 |
| Loiseau, P | 1 |
| Dellamonica, P | 4 |
| Wigzell, H | 1 |
| Falksveden, L | 1 |
| Wahren, B | 2 |
| Bambara, RA | 1 |
| Wu, H | 2 |
| Smith, HM | 1 |
| Lowe, NR | 1 |
| Demeter, LM | 1 |
| Dykes, C | 1 |
| Claassen, M | 2 |
| Zeier, M | 1 |
| Preiser, W | 2 |
| Puertas, MC | 1 |
| Bannister, W | 1 |
| Kisic, M | 1 |
| Cozzi-Lepri, A | 3 |
| Pou, C | 1 |
| Betancor, G | 1 |
| Gargalianos, P | 1 |
| Bánhegyi, D | 2 |
| Lundgren, J | 1 |
| Menéndez-Arias, L | 1 |
| Yoon, K | 1 |
| Lei, Y | 1 |
| Shi, R | 1 |
| Gee, W | 1 |
| Lin, ET | 1 |
| Kjaer, J | 1 |
| Von Wyl, V | 1 |
| Kronborg, G | 1 |
| Castagna, A | 3 |
| Bogner, JR | 4 |
| Kanhon, SK | 1 |
| Touré, H | 2 |
| Ettiegne-Traoré, V | 1 |
| Martins, AN | 1 |
| Arruda, MB | 1 |
| Aleixo, AW | 1 |
| Pires, AF | 1 |
| Greco, DB | 1 |
| de M Brindeiro, R | 1 |
| Calis, JC | 1 |
| Geelen, SP | 1 |
| van Vugt, M | 1 |
| Plettenberg, A | 2 |
| Livrozet, JM | 3 |
| Witt, MD | 1 |
| Macha, S | 1 |
| Berger, F | 1 |
| Stern, J | 1 |
| Venkatesan, P | 1 |
| Ramesh Kumar, S | 1 |
| Iliayas, S | 1 |
| Menon, PA | 1 |
| Selvaraju, S | 1 |
| Pooranagangadevi, NP | 1 |
| Dilip, M | 1 |
| Ramachandran, R | 1 |
| Lim, HC | 1 |
| Curlin, ME | 1 |
| Mittler, JE | 1 |
| Kim, HN | 1 |
| Scott, J | 1 |
| Cent, A | 1 |
| Cook, L | 1 |
| Morrow, RA | 1 |
| Jerome, KR | 1 |
| Lule, G | 1 |
| Zona, S | 1 |
| Orlando, G | 1 |
| Carli, F | 1 |
| Stentarelli, C | 1 |
| Luzi, K | 1 |
| Garlassi, E | 1 |
| Menozzi, M | 1 |
| Bagni, P | 1 |
| Adorni, F | 3 |
| Kay, J | 1 |
| Wanzira, H | 1 |
| Sandison, T | 1 |
| Bigira, V | 1 |
| Homsy, J | 2 |
| Shah, SK | 1 |
| Dawson, L | 1 |
| Dixon, DO | 1 |
| Lie, RK | 1 |
| von Kleist, M | 1 |
| Schütte, C | 1 |
| Kredo, T | 2 |
| Mauff, K | 1 |
| Barnes, KI | 2 |
| Diero, LO | 1 |
| Somi, GR | 1 |
| Okong, P | 3 |
| Otieno, JA | 2 |
| Wabwire, D | 2 |
| Braitstein, P | 1 |
| Musick, BS | 1 |
| Novais, DA | 1 |
| da Silva, JL | 1 |
| Santos, PP | 1 |
| Dejesus, E | 2 |
| Mills, A | 1 |
| Bhatti, L | 1 |
| Conner, C | 1 |
| Cabello Úbeda, A | 1 |
| Sanz Moreno, J | 1 |
| Meesters, R | 1 |
| Hooff, G | 1 |
| van Huizen, N | 1 |
| Gruters, R | 1 |
| Luider, T | 1 |
| Anwikar, SR | 1 |
| Bandekar, MS | 1 |
| Smrati, B | 1 |
| Pazare, AP | 1 |
| Tatke, PA | 1 |
| Chetchotisakd, P | 1 |
| Jirajariyavej, S | 1 |
| Munsakul, W | 1 |
| Bowonwattanuwong, C | 1 |
| Petoumenos, K | 1 |
| Bhakeecheep, S | 1 |
| Hoffmann, C | 2 |
| Schewe, CK | 1 |
| Weitner, L | 1 |
| Stellbrink, HJ | 2 |
| Heil, EL | 1 |
| Lau, TC | 1 |
| Tsui, SK | 1 |
| Kang, Y | 1 |
| Zheng, B | 1 |
| Cecchini, D | 1 |
| Urueña, A | 1 |
| Trinidad, P | 1 |
| Vesperoni, F | 1 |
| Mecikovsky, D | 1 |
| Kou, H | 2 |
| Fu, Q | 2 |
| Qiu, Z | 3 |
| Zuo, L | 1 |
| Ye, M | 2 |
| López-Martínez, A | 1 |
| O'Brien, NM | 1 |
| Caro-Vega, Y | 1 |
| Crabtree-Ramírez, B | 1 |
| Sierra-Madero, J | 1 |
| Brown, KC | 1 |
| Hoskins, JM | 1 |
| Thirumaran, RK | 1 |
| Tien, HC | 1 |
| Shumba, I | 1 |
| Lamba, JK | 1 |
| Schuetz, EG | 1 |
| McLeod, HL | 1 |
| Rosso, R | 1 |
| Rossotti, R | 1 |
| Di Biagio, A | 1 |
| Nicolini, L | 1 |
| Viscoli, C | 1 |
| Porter, KA | 2 |
| Poole, C | 1 |
| Skinner-Adams, TS | 2 |
| D'Amico, R | 2 |
| McCarthy, JS | 2 |
| Meshnick, SR | 2 |
| Ribaudo, H | 1 |
| Parekh, N | 1 |
| Sang-a-gad, P | 1 |
| Lertkoonalak, R | 1 |
| Eiamsirikit, N | 1 |
| Buranawanitchakorn, Y | 1 |
| Yutthakasemsunt, N | 1 |
| Mekviwattanawong, S | 1 |
| Aitken, SC | 1 |
| Mariki, G | 1 |
| Van der Ven, AJ | 2 |
| Ward, D | 1 |
| Cordes, C | 2 |
| Wang, E | 1 |
| Quinson, A | 1 |
| Britto, P | 2 |
| Roongpisuthipong, A | 1 |
| Prommas, S | 1 |
| Rasri, W | 1 |
| Drake, AL | 2 |
| Roxby, AC | 2 |
| Ongecha-Owuor, F | 2 |
| Wald, A | 2 |
| Emery, S | 3 |
| Hongsiriwon, S | 1 |
| Ngampiyaskul, C | 1 |
| Limwongse, C | 1 |
| Wittawatmongkol, O | 1 |
| Kabat, B | 1 |
| Tisserand, P | 1 |
| Matta, M | 1 |
| Péré, H | 1 |
| Fournier, J | 1 |
| Mbitikon, O | 1 |
| Uriel, A | 1 |
| Lewthwaite, P | 1 |
| Lynn, DJ | 1 |
| Schmidt, NC | 1 |
| Roman-Pouriet, J | 1 |
| Fernandez, AD | 2 |
| Beck-Sagué, CM | 1 |
| Leonardo-Guerrero, J | 1 |
| Nicholas, SW | 1 |
| Elbireer, A | 2 |
| Nolan, M | 1 |
| Janoff, EN | 1 |
| Snijdewind, IJ | 1 |
| Godfried, MH | 5 |
| Nellen, JF | 2 |
| Boer, K | 5 |
| van der Ende, ME | 13 |
| Wongsawat, J | 1 |
| Bentley, ME | 1 |
| Mkhomawanthu, C | 1 |
| King, CC | 2 |
| Chitsulo, P | 1 |
| Tembo, M | 1 |
| Piwoz, EG | 1 |
| Mapingure, PM | 1 |
| Tamalet, C | 1 |
| Cottalorda, J | 1 |
| Izopet, J | 1 |
| Trabaud, MA | 1 |
| Rogez, S | 1 |
| Ruffault, A | 1 |
| Henquell, C | 1 |
| Signori-Schmuck, A | 1 |
| Bouvier-Alias, M | 1 |
| Vallet, S | 1 |
| Wann, SR | 1 |
| Hopley, MJ | 1 |
| Maldarelli, F | 2 |
| Karmacharya, BM | 1 |
| Tansuphaswadikul, S | 3 |
| Sahassananda, D | 1 |
| Dhitavat, J | 2 |
| Maek-a-nantawat, W | 1 |
| Svensson, E | 1 |
| Huitema, A | 1 |
| Dong, BJ | 1 |
| Frymoyer, A | 1 |
| Verotta, D | 1 |
| Lizak, P | 1 |
| Kromdijk, W | 1 |
| Mulder, JW | 11 |
| Rosing, H | 2 |
| Smit, PM | 1 |
| Huitema, AD | 10 |
| Vanpouille, C | 1 |
| Lisco, A | 1 |
| Introini, A | 1 |
| Grivel, JC | 1 |
| Munawwar, A | 1 |
| Merbah, M | 1 |
| Schinazi, RF | 1 |
| Derudas, M | 1 |
| McGuigan, C | 1 |
| Margolis, L | 1 |
| Amoroso, A | 1 |
| Etienne-Mesubi, M | 1 |
| Edozien, A | 1 |
| Ojoo, S | 1 |
| Sheneberger, R | 1 |
| Obiefune, M | 1 |
| Hossain, MB | 1 |
| Stafford, K | 1 |
| Heil, SG | 1 |
| Schenk, PW | 1 |
| van der Heiden, I | 1 |
| Lindemans, J | 1 |
| van Schaik, RH | 1 |
| Kemal, KS | 1 |
| Ramirez, CM | 1 |
| Burger, H | 1 |
| Foley, B | 1 |
| Hamy, F | 1 |
| Petrovic, K | 1 |
| Minin, VN | 1 |
| Suchard, MA | 1 |
| Weiser, B | 1 |
| Eluwa, GI | 1 |
| Badru, T | 1 |
| Agu, KA | 1 |
| Akpoigbe, KJ | 1 |
| Chabikuli, O | 1 |
| Hamelmann, C | 1 |
| Sewangi, J | 1 |
| Mbezi, P | 2 |
| Dugange, F | 1 |
| Lau, I | 1 |
| Ziske, J | 1 |
| Theuring, S | 1 |
| Wamalwa, DC | 1 |
| McCoy, CO | 1 |
| Matsen, FA | 1 |
| Custers-Allen, R | 1 |
| Bushman, FD | 1 |
| Ouattara, EN | 1 |
| Wong, AY | 1 |
| Hsu, HE | 1 |
| Eholié, S | 1 |
| Gabillard, D | 1 |
| Uthman, O | 1 |
| Hougardy, JM | 1 |
| Husson, C | 1 |
| Van Vooren, JP | 1 |
| Gastaldello, K | 1 |
| Nortier, JL | 1 |
| Goffard, JC | 1 |
| van Hoog, S | 1 |
| Nellen, J | 2 |
| Scherpbier, H | 1 |
| Nachman, S | 8 |
| Luaengniyomkul, A | 1 |
| Carlsson, J | 1 |
| Butterworth, AS | 1 |
| Anquetil, D | 1 |
| Zongo, D | 1 |
| Le Bihan, L | 1 |
| Pinson, PR | 1 |
| Adair, LS | 1 |
| Oudijk, JM | 1 |
| Qiu, M | 1 |
| Chu, Y | 1 |
| Yuan, Z | 1 |
| Song, H | 1 |
| Wu, Z | 1 |
| Sikazwe, I | 1 |
| Balamane, M | 1 |
| Melikian, GL | 1 |
| Katzenstein, DA | 2 |
| Moyo, T | 1 |
| Weaver, M | 1 |
| Suzuki, C | 1 |
| Hayashi, C | 1 |
| Cusato, J | 1 |
| Baietto, L | 1 |
| Pennings, PS | 1 |
| Mayito, J | 1 |
| Nabukeera, L | 1 |
| Ntale, M | 1 |
| Pakker, N | 2 |
| Hanpithakpong, W | 1 |
| de Vries, PJ | 1 |
| Matemo, DN | 1 |
| Mujuru, HA | 1 |
| Veloso, VG | 2 |
| Joao, EC | 2 |
| Pilotto, JH | 2 |
| Santos, B | 1 |
| Fonseca, R | 1 |
| Kreitchmann, R | 1 |
| Pinto, J | 2 |
| Mussi-Pinhata, MM | 1 |
| Ceriotto, M | 1 |
| Machado, D | 1 |
| Bethel, J | 3 |
| Morgado, MG | 1 |
| Dickover, R | 1 |
| Camarca, M | 2 |
| Siberry, G | 1 |
| Moreira, RI | 1 |
| Bastos, FI | 1 |
| Xu, J | 2 |
| Rassool, M | 1 |
| Chibowa, M | 1 |
| Amod, F | 1 |
| Halvas, E | 1 |
| Smith, L | 1 |
| Schooley, R | 1 |
| Mellors, J | 2 |
| Yap, SH | 2 |
| Herman, BD | 1 |
| Radzio, J | 1 |
| Sluis-Cremer, N | 2 |
| Nugroho, AW | 1 |
| Wiria, MS | 1 |
| Grilo, NM | 1 |
| Okomo, U | 1 |
| Togun, T | 1 |
| Oko, F | 1 |
| Peterson, K | 1 |
| Townend, J | 1 |
| Peterson, I | 1 |
| Jaye, A | 1 |
| Minniear, TD | 1 |
| Polle, N | 1 |
| Oyaro, B | 1 |
| Akoth, B | 1 |
| Ndivo, R | 1 |
| Angira, F | 1 |
| Mills, LA | 1 |
| Thomas, TK | 1 |
| Tierney, J | 1 |
| Gibb, D | 1 |
| Ha, TT | 1 |
| Anh, NM | 1 |
| Bao, NH | 1 |
| Tuan, PL | 1 |
| Caridha, R | 1 |
| Hien, NT | 1 |
| Cam, PD | 1 |
| Ehrnst, A | 1 |
| Zuniga, I | 1 |
| Biot, M | 1 |
| Ford, NP | 1 |
| Katile, D | 1 |
| Diallo, F | 1 |
| Fofana, DB | 1 |
| Maiga, MY | 1 |
| Sylla, A | 1 |
| Traore, HA | 1 |
| Bellosillo, N | 1 |
| Guidi, M | 1 |
| Arab-Alameddine, M | 1 |
| Rotger, M | 2 |
| Aouri, M | 1 |
| Telenti, A | 2 |
| Decosterd, LA | 1 |
| Buclin, T | 2 |
| Csajka, C | 1 |
| Sarmati, L | 1 |
| Montano, M | 1 |
| Andreis, S | 1 |
| Scaggiante, R | 1 |
| Galgani, A | 1 |
| Viscione, M | 1 |
| Ricciardi, A | 1 |
| Andreoni, C | 1 |
| Boros, S | 1 |
| Palù, G | 1 |
| Zhang, HJ | 1 |
| Zhang, XM | 1 |
| Xu, HF | 1 |
| Huang, JD | 1 |
| Zheng, BJ | 1 |
| Galli, L | 1 |
| Bocchiola, B | 1 |
| Cahua, T | 1 |
| Panzini, P | 1 |
| Zandonà, D | 1 |
| Salpietro, S | 1 |
| Maillard, M | 2 |
| Danise, A | 1 |
| Pazzi, A | 1 |
| Lazzarin, A | 2 |
| Lee, H | 1 |
| Rath, BA | 1 |
| Olshen, RA | 1 |
| Halpern, J | 1 |
| Merigan, TC | 2 |
| Htun, WL | 1 |
| Bowonwatanuwong, C | 3 |
| Phonrat, B | 1 |
| Uttayamakul, S | 2 |
| Khusmith, S | 1 |
| Richardson, DM | 1 |
| Leger, PD | 1 |
| Kinikar, AA | 1 |
| Khandave, M | 1 |
| Shankar, AV | 1 |
| Nyesigire Ruhinda, E | 1 |
| Kiwanuka, J | 1 |
| Bera, E | 1 |
| Mia, R | 1 |
| Rossi, S | 1 |
| Moss, M | 1 |
| Kriengsinyot, R | 2 |
| Schoenenberger, JA | 1 |
| Aragones, AM | 1 |
| Cano, SM | 1 |
| Castello, A | 1 |
| Gomez-Arbones, X | 1 |
| Porcel, JM | 1 |
| Agbaji, O | 1 |
| Graham, C | 1 |
| Muazu, M | 1 |
| Nimzing, L | 1 |
| Sankalé, JL | 3 |
| Ekong, E | 1 |
| Hawkins, C | 1 |
| Arpadi, S | 1 |
| Teeratakulpisarn, N | 1 |
| Jadwattanakul, T | 2 |
| Kerr, SJ | 1 |
| Chomchey, N | 1 |
| Hongchookiat, P | 1 |
| Mathajittiphun, P | 1 |
| Rungrojrat, P | 1 |
| Praihirunyakit, P | 1 |
| Valcour, V | 1 |
| Kim, JH | 1 |
| Shikuma, C | 1 |
| Fogel, JM | 1 |
| Alexandre, M | 1 |
| Kozal, MJ | 1 |
| Svarovskaia, ES | 1 |
| Jakobsen, MR | 2 |
| Hullsiek, KH | 1 |
| Ostergaard, L | 2 |
| Miller, MD | 1 |
| Mudzviti, T | 1 |
| Sibanda, M | 1 |
| Gavi, S | 1 |
| Foissac, F | 1 |
| Bouazza, N | 1 |
| Lachassinne, E | 2 |
| Zhang, C | 1 |
| Zhou, M | 1 |
| Xie, J | 2 |
| Guo, F | 1 |
| Ghanem, KG | 1 |
| Mudiope, PK | 2 |
| Nyende, L | 1 |
| Mulira, R | 1 |
| Elbireer, S | 1 |
| McMahon, DK | 1 |
| Zheng, L | 1 |
| Bonhomme, J | 1 |
| Lederman, MM | 3 |
| Hinkle, J | 3 |
| Rousseau, F | 3 |
| Pavlos, R | 1 |
| James, I | 1 |
| Mallal, SA | 1 |
| Andrieux-Meyer, I | 2 |
| Vitoria, M | 1 |
| Renaud-Théry, F | 1 |
| Hargreaves, S | 1 |
| Mills, EJ | 1 |
| Neubert, J | 1 |
| Pfeffer, M | 1 |
| Borkhardt, A | 1 |
| Niehues, T | 2 |
| Adams, O | 1 |
| Bolten, M | 1 |
| Reuter, S | 1 |
| Stannigel, H | 1 |
| Laws, HJ | 1 |
| Du, X | 1 |
| Castro, EC | 1 |
| Barlow-Mosha, LN | 1 |
| Bagenda, DS | 1 |
| Butler, LM | 1 |
| Sharma, AM | 1 |
| Klarskov, K | 1 |
| Mukherjee, S | 1 |
| Ghosh, S | 1 |
| Goswami, DN | 1 |
| Samanta, A | 1 |
| Siu, V | 1 |
| Teque, F | 1 |
| Levy, JA | 1 |
| Chan, J | 1 |
| Ribalta, J | 2 |
| Ferré, R | 1 |
| Sirera, G | 3 |
| Salazar, J | 2 |
| Masana, L | 1 |
| Achmat, Z | 1 |
| Baleta, A | 10 |
| Woods, D | 1 |
| Das, P | 2 |
| Casado, JL | 5 |
| Moreno, A | 4 |
| Hertogs, K | 5 |
| Dronda, F | 5 |
| Moreno, S | 5 |
| Anderson, JR | 2 |
| Cingolani, A | 3 |
| Forbici, F | 1 |
| Rizzo, MG | 2 |
| Trotta, MP | 1 |
| Ammassari, A | 3 |
| Girardi, E | 2 |
| Ferrer, E | 6 |
| Consiglio, E | 1 |
| Perez, P | 1 |
| Perez, JL | 2 |
| Luna, E | 1 |
| González, A | 6 |
| Lozano, L | 2 |
| Ocaña, I | 3 |
| Casiró, A | 1 |
| Aranda, M | 3 |
| Martínez-Lacasa, J | 1 |
| Miró, JM | 5 |
| Badía, X | 1 |
| Casado, A | 1 |
| Lupo, S | 1 |
| Maños, M | 1 |
| Estela, J | 1 |
| Morlese, JF | 1 |
| Qazi, NA | 1 |
| De Maat, MM | 6 |
| Mathôt, RA | 1 |
| Veldkamp, AI | 5 |
| Huitma, AD | 1 |
| Meenhorst, PL | 6 |
| Van Gorp, EC | 5 |
| Carlier, H | 3 |
| Volmink, J | 7 |
| Nachega, J | 1 |
| Mandel, L | 1 |
| Surattanont, F | 1 |
| Guiramand-Hugon, S | 2 |
| Joly, V | 2 |
| Certain, A | 1 |
| Lévy, C | 1 |
| Rivet, S | 1 |
| Jacomet, C | 1 |
| Yéni, P | 2 |
| Lawson-Ayayi, S | 1 |
| Ramanampamonjy, R | 1 |
| Lacoste, D | 1 |
| Bernard, N | 1 |
| Malvy, D | 1 |
| Bonarek, M | 1 |
| Djossou, F | 1 |
| Beylot, J | 1 |
| Morlat, P | 1 |
| Arribas, JR | 2 |
| Pulido, F | 2 |
| Fleming, T | 8 |
| Mracna, M | 5 |
| Becker-Pergola, G | 4 |
| Hoggard, PG | 2 |
| Kewn, S | 1 |
| Maherbe, A | 1 |
| Almond, LM | 3 |
| Sales, SD | 1 |
| Gould, J | 1 |
| Lou, Y | 2 |
| De Vries, C | 2 |
| Kreiss, JK | 1 |
| James, JS | 8 |
| Klosinski, L | 1 |
| Hashimoto, H | 1 |
| Kapiga, SH | 1 |
| Murata, Y | 1 |
| Bateman, C | 5 |
| Annas, GJ | 1 |
| Barnett, S | 1 |
| Apuzzo, L | 1 |
| Raines, C | 1 |
| Hendrix, C | 1 |
| Hamzeh, F | 1 |
| Gallant, J | 1 |
| Oliva, J | 1 |
| Sanz, J | 4 |
| Molina, JA | 1 |
| Rubio, R | 1 |
| Casas, E | 2 |
| Mariño, A | 1 |
| Moodley, J | 4 |
| Hofmyer, J | 1 |
| Nikodem, C | 1 |
| Gigliotti, M | 3 |
| Boshoff, L | 1 |
| Sullivan, JL | 11 |
| Arnedo, M | 2 |
| Fumero, E | 5 |
| McKenna, P | 1 |
| Rinehart, A | 1 |
| Barberá, MJ | 2 |
| Pumarola, T | 3 |
| Gudiol, F | 1 |
| Bell, C | 1 |
| Matthews, GV | 3 |
| Stout, JP | 4 |
| Chapman, V | 2 |
| Kumwenda-Phiri, R | 1 |
| Núñez, M | 3 |
| González-Requena, D | 1 |
| González-Lahoz, J | 9 |
| van Leeuwen, R | 4 |
| Squires, K | 2 |
| Staszewski, S | 7 |
| van Eeden, A | 1 |
| Moroni, M | 1 |
| Pavia, AT | 1 |
| Schmidt, RE | 3 |
| Gulick, R | 1 |
| van der Valk, M | 2 |
| van Weert, L | 2 |
| Johnson, VA | 3 |
| Sommadossi, JP | 5 |
| Chiesa, E | 1 |
| Bini, T | 1 |
| Rizzardini, G | 1 |
| Faggion, I | 1 |
| Mussini, C | 1 |
| Sollima, S | 1 |
| Melzi, S | 1 |
| Bongiovanni, M | 1 |
| Tordato, F | 1 |
| Cicconi, P | 1 |
| d'Arminio Monforte, A | 1 |
| Marseille, E | 3 |
| Torralba, M | 1 |
| Laurence, J | 4 |
| Boyle, BA | 4 |
| Knudtson, E | 1 |
| Para, M | 1 |
| Boswell, H | 1 |
| Sullivan, JR | 1 |
| Rachlis, A | 1 |
| Verweij-Van Wissen, CP | 1 |
| Schneider, L | 2 |
| Paris, L | 1 |
| Legrand, M | 3 |
| Herson, S | 1 |
| Casssetti, LI | 1 |
| Losso, M | 1 |
| Wruck, J | 1 |
| McDonough, M | 2 |
| Robinson, PA | 4 |
| de Vries-Sluijs, TE | 1 |
| Dieleman, JP | 5 |
| Arts, D | 1 |
| Schutten, M | 1 |
| Dorenbaum, A | 4 |
| Blanchard, S | 1 |
| Gelber, RD | 3 |
| Mzyece, E | 1 |
| Makuka, I | 1 |
| Kwape, P | 1 |
| Chilufya, M | 1 |
| Pérez-Elías, MJ | 2 |
| Antela, A | 3 |
| Gutiérrez, C | 1 |
| Kontorinis, N | 1 |
| Dieterich, DT | 2 |
| Quaghebeur, A | 2 |
| Matsuoka-Aizawa, S | 1 |
| Tsuchiya, K | 1 |
| Kimura, S | 2 |
| Tatsumi, M | 1 |
| Meldrum, J | 1 |
| Verweel, G | 1 |
| Sharland, M | 1 |
| Novelli, V | 1 |
| Dumont, G | 1 |
| Ball, C | 1 |
| Wilkins, E | 3 |
| Walters, S | 1 |
| Mudenda, V | 2 |
| Kumwenda, R | 2 |
| Pillay, C | 2 |
| Chezzi, C | 1 |
| Lupondwana, P | 1 |
| Levin, L | 1 |
| Venter, F | 1 |
| Kappelhoff, BS | 5 |
| Kironde, S | 1 |
| Lukwago, J | 1 |
| Ssenyonga, R | 1 |
| Rely, K | 1 |
| Bertozzi, SM | 1 |
| Avila-Figueroa, C | 1 |
| Guijarro, MT | 1 |
| ter Heine, R | 2 |
| Mairuhu, AT | 3 |
| Bruun, JN | 1 |
| Lackmann, GM | 1 |
| Schmidt, B | 1 |
| Vermund, S | 1 |
| Acosta, E | 2 |
| Moyle, GJ | 3 |
| Arnaiz, JA | 4 |
| Dalmau, D | 6 |
| Knobel, H | 8 |
| Riera, M | 2 |
| Segura, F | 2 |
| Richart, C | 1 |
| Cortés, C | 1 |
| Javaloyas, M | 1 |
| Cruceta, A | 3 |
| de Lazzari, E | 3 |
| Beckerman, KP | 2 |
| Sherman, J | 2 |
| Ducar, C | 2 |
| Deseyve, M | 4 |
| Duefield, C | 1 |
| Miotti, P | 2 |
| Kirk, O | 4 |
| Obel, N | 5 |
| Mathiesen, L | 1 |
| Nielsen, H | 2 |
| Bertolli, J | 1 |
| Hu, DJ | 1 |
| Nieburg, P | 1 |
| Macalalad, A | 1 |
| Simonds, RJ | 2 |
| Caumes, E | 2 |
| Bossi, P | 1 |
| Bricaire, F | 1 |
| Leen, CL | 1 |
| Law, WP | 1 |
| Dore, GJ | 1 |
| Duncombe, CJ | 1 |
| Mahanontharit, A | 2 |
| Chaguturu, SK | 1 |
| Mahajan, AP | 1 |
| Flanigan, TP | 3 |
| Mayer, KH | 4 |
| Stern, JO | 2 |
| Love, J | 2 |
| Lanes, S | 1 |
| Imperiale, MS | 1 |
| Mayers, DL | 1 |
| Gibbons, A | 2 |
| Broadhead, RL | 3 |
| Lema, V | 2 |
| Liomba, G | 3 |
| Nkhoma, C | 4 |
| Miotti, PG | 3 |
| Seminari, E | 1 |
| Ravasi, G | 1 |
| Marubbi, F | 1 |
| Meneghetti, G | 1 |
| Kapiriri, L | 1 |
| Robberstad, B | 1 |
| Robbestad, B | 1 |
| Frithjof Norheim, O | 1 |
| Ayouba, A | 1 |
| Cunin, P | 1 |
| Foupouapouognigni, Y | 1 |
| Kfutwah, A | 1 |
| Thonnon, J | 1 |
| Scarlatti, G | 1 |
| Monny-Lobé, M | 1 |
| Eteki, N | 2 |
| Tardy, M | 1 |
| Leke, R | 1 |
| Nkam, M | 2 |
| Nlend, AE | 1 |
| Martin, PM | 1 |
| Wood, E | 2 |
| O'Shaughnessy, MV | 3 |
| Moorman, A | 1 |
| Tong, TC | 1 |
| Holmberg, S | 1 |
| Greenberg, AE | 2 |
| Vilarasau, C | 1 |
| Amador, C | 1 |
| Benito, C | 1 |
| Fenoll, V | 1 |
| Pasquau, F | 2 |
| Verbiest, W | 1 |
| Larder, B | 3 |
| Brumme, ZL | 1 |
| Alexander, C | 1 |
| Tilley, J | 1 |
| Weissbrich, B | 1 |
| Langmann, P | 3 |
| Schubert, J | 1 |
| Jassoy, C | 1 |
| Yang, X | 1 |
| Chang, WH | 1 |
| Rouse, DJ | 3 |
| Marseille, EA | 1 |
| Perez-Then, E | 1 |
| Peña, R | 1 |
| Tavarez-Rojas, M | 1 |
| Peña, C | 1 |
| Quiñonez, S | 1 |
| Buttler, M | 1 |
| Ammann, A | 1 |
| Hernández, W | 1 |
| Goyanes, M | 1 |
| Miguez, MJ | 1 |
| Shor-Posner, G | 2 |
| Lambert, JS | 1 |
| Harris, DR | 1 |
| Stiehm, ER | 1 |
| Meyer, WA | 1 |
| Sankatsing, SU | 2 |
| Weverling, GJ | 4 |
| van't Klooster, G | 1 |
| Gruzdev, B | 1 |
| Rakhmanova, A | 2 |
| Jurriaans, S | 5 |
| Prins, JM | 5 |
| Heath, KV | 1 |
| de la Rosa, R | 1 |
| Lee, N | 1 |
| Azoulay, S | 1 |
| Nevers, MC | 1 |
| Créminon, C | 1 |
| Heripret, L | 1 |
| Durant, J | 1 |
| Grassi, J | 1 |
| Guedj, R | 1 |
| Duval, D | 1 |
| Jordan, WC | 1 |
| Jefferson, R | 1 |
| Yemofio, F | 1 |
| Tolbert, L | 1 |
| Conlon, V | 1 |
| Carroll, H | 1 |
| Green, DC | 1 |
| Green, A | 1 |
| Green, R | 1 |
| Dubuisson, JG | 1 |
| King, JR | 3 |
| Turner, ML | 1 |
| Bennetto, C | 1 |
| Hudson, CP | 5 |
| Cooper, E | 1 |
| Jackson, B | 2 |
| Yoakim, C | 1 |
| Bonneau, PR | 1 |
| Déziel, R | 1 |
| Doyon, L | 1 |
| Guse, I | 1 |
| Landry, S | 2 |
| Malenfant, E | 1 |
| Naud, J | 1 |
| Ogilvie, WW | 1 |
| O'Meara, JA | 1 |
| Plante, R | 1 |
| Simoneau, B | 1 |
| Thavonekham, B | 1 |
| Bös, M | 1 |
| Cordingley, MG | 1 |
| Mathiesen, LR | 2 |
| Gerntholtz, L | 1 |
| Balasubramanian, R | 1 |
| Maupin, RT | 1 |
| Delke, I | 1 |
| Fiore, S | 1 |
| Ngwena, C | 1 |
| Schattenkerk, JK | 1 |
| Schneider, MM | 1 |
| Frissen, PH | 1 |
| Vibhagool, A | 2 |
| Rattanasiri, S | 3 |
| Thakkinstian, A | 2 |
| Arranz-Caso, JA | 1 |
| Estrada, V | 5 |
| García-Diaz, JD | 1 |
| Manfredi, R | 6 |
| Chiodo, F | 4 |
| Baylor, MS | 1 |
| Johann-Liang, R | 1 |
| Rodríguez Guardado, A | 1 |
| Maradona Hidalgo, JA | 1 |
| Asensi Alvarez, V | 1 |
| Cartón Sánchez, JA | 1 |
| López, S | 2 |
| Milinkovic, A | 3 |
| Soler, A | 2 |
| García-Viejo, MA | 2 |
| Nunes, V | 1 |
| Casademont, J | 1 |
| Cardellach, F | 1 |
| Jaspan, HB | 1 |
| Garry, RF | 1 |
| Grossman, Z | 1 |
| Istomin, V | 1 |
| Averbuch, D | 1 |
| Lorber, M | 1 |
| Bar Yaacov, N | 1 |
| Macías, J | 1 |
| Castellano, V | 1 |
| Merchante, N | 1 |
| Palacios, RB | 1 |
| Mira, JA | 1 |
| Sáez, C | 1 |
| García-García, JA | 1 |
| Lozano, F | 1 |
| Gómez-Mateos, JM | 1 |
| Pineda, JA | 1 |
| Blanckenberg, DH | 1 |
| Beniowski, M | 2 |
| Boron-Kaczmarska, A | 2 |
| Trocha, H | 1 |
| Halota, W | 1 |
| Jessen, H | 2 |
| Smith, N | 1 |
| Fletcher, C | 1 |
| Parmar, D | 1 |
| Carr, A | 4 |
| Baraldi, E | 2 |
| Miller, S | 1 |
| van der Westhuizen, IP | 1 |
| Malan, DR | 1 |
| Santos, BR | 1 |
| Mulcahy, F | 5 |
| Levi, GC | 1 |
| Reboredo, G | 1 |
| Cassetti, I | 1 |
| Petit, D | 1 |
| Dam, JP | 1 |
| Roudière, L | 1 |
| Boukli, N | 1 |
| Dupont, B | 1 |
| Prévoteau du Clary, F | 1 |
| Patey, O | 1 |
| David, F | 1 |
| Lortholary, O | 1 |
| Devidas, A | 1 |
| Urbinelli, R | 1 |
| Allaert, FA | 1 |
| Skowron, G | 3 |
| Leoung, G | 1 |
| Lewis, R | 1 |
| Grosso, R | 1 |
| Jacobs, M | 1 |
| Kerr, B | 1 |
| MacGregor, T | 1 |
| Fisher, A | 1 |
| Odgen, R | 1 |
| Yen-Lieberman, B | 1 |
| Smart, T | 1 |
| Fleck, F | 1 |
| Servais, J | 1 |
| Lambert, C | 1 |
| Vanhove, D | 1 |
| Fischer, A | 1 |
| Baurith, T | 1 |
| Schneider, F | 1 |
| Hemmer, R | 1 |
| Thompson, CA | 1 |
| Massari, V | 3 |
| Vabret, A | 2 |
| Bouvet, E | 1 |
| Larouzé, B | 1 |
| Fidler, S | 1 |
| Tamm, N | 1 |
| Clarke, JR | 1 |
| Weber, JN | 1 |
| Taylor, GP | 4 |
| Jones, SA | 2 |
| Coovadia, AH | 2 |
| Urban, MF | 2 |
| Bolton, KD | 1 |
| Breurec, S | 1 |
| Léautez, S | 1 |
| Bourin, M | 1 |
| Rouet, F | 6 |
| Inwoley, A | 1 |
| Viho, I | 9 |
| Bequet, L | 5 |
| Kravchenko, AV | 2 |
| Miroshnichenko, AV | 1 |
| Beliaeva, VV | 1 |
| Serebrovskaia, LV | 1 |
| Bogoslovskaia, EV | 1 |
| Sitdykova, IuR | 1 |
| Waters, L | 1 |
| Jones, R | 1 |
| Michailidis, C | 1 |
| Sawleshwarkar, S | 1 |
| Chama, CM | 1 |
| Audu, BM | 1 |
| Kyari, O | 1 |
| Urban, M | 3 |
| Chersich, M | 2 |
| Stek, AM | 1 |
| Nachman, SA | 1 |
| Baker, D | 2 |
| Gonzalez-Garcia, A | 1 |
| Provisor, A | 1 |
| Thorpe, EM | 2 |
| Paul, ME | 1 |
| Foca, M | 2 |
| Gandia, J | 1 |
| Wei, LJ | 2 |
| Stevens, LM | 1 |
| McNamara, J | 3 |
| Mukotekwa, T | 1 |
| Miller, A | 1 |
| Orne-Gliemann, J | 1 |
| Glenshaw, M | 1 |
| Chitsike, I | 2 |
| Meyer-Kleinmann, J | 1 |
| Cunningham, SP | 1 |
| Henry, K | 2 |
| Claxton, S | 1 |
| Kane, E | 1 |
| Bordenave, B | 1 |
| Klebert, M | 1 |
| Powderly, WG | 2 |
| Kanshana, S | 1 |
| Thaineua, V | 1 |
| Hammer, S | 2 |
| Nour, S | 1 |
| Muñoz-Moreno, JA | 2 |
| Viciana, P | 1 |
| Galindos, MJ | 1 |
| Miralles, C | 2 |
| Rodriguez Fumaz, C | 1 |
| Puig, J | 3 |
| Gel, S | 4 |
| Rodríguez, E | 1 |
| Videla, S | 2 |
| Hamatake, R | 1 |
| Check, E | 1 |
| Fleming, TR | 1 |
| Sweat, MD | 1 |
| O'Reilly, KR | 1 |
| Schmid, GP | 1 |
| Denison, J | 1 |
| de Zoysa, I | 1 |
| Santamariña, E | 1 |
| Lopez, JC | 3 |
| Barrios, A | 1 |
| LaFraniere, S | 1 |
| Petit, JM | 1 |
| Masson, D | 1 |
| Buisson, M | 3 |
| Duvillard, L | 1 |
| Bour, JB | 1 |
| Brindisi, MC | 1 |
| Galland, F | 1 |
| Guiguet, M | 1 |
| Gambert, P | 1 |
| Portier, H | 3 |
| Vergès, B | 1 |
| Raiteri, R | 2 |
| Reynolds, HE | 2 |
| Garazzino, S | 2 |
| Sinicco, A | 2 |
| Chiesi, A | 1 |
| Mulchany, F | 1 |
| Machala, L | 1 |
| Mutunga, L | 1 |
| Sienz, M | 1 |
| Zilly, M | 2 |
| Ebigbo, A | 1 |
| Knipper, A | 1 |
| Winzer, R | 1 |
| Kodama, E | 1 |
| Ikeuchi, M | 1 |
| Matsuoka, M | 2 |
| Harada, S | 1 |
| Mitsuya, H | 1 |
| Mahillo, B | 1 |
| Rivero, A | 1 |
| Gonzalez, J | 1 |
| Blanco, JL | 4 |
| Boix, V | 1 |
| Arroyo, JA | 2 |
| Rodriguez, D | 1 |
| Montes, ML | 1 |
| Arranz, A | 2 |
| Sarasa, M | 1 |
| Gil, P | 1 |
| de Górgolas, M | 1 |
| Rivas, P | 2 |
| Yera, C | 1 |
| García, R | 1 |
| Granizo, JJ | 1 |
| Fernández-Guerrero, M | 1 |
| Burke, J | 1 |
| Stocker, H | 2 |
| Kreckel, P | 1 |
| Herzmann, C | 2 |
| Claus, J | 1 |
| Hintsche, B | 1 |
| Schlote, F | 1 |
| Shahar, E | 1 |
| Krivoy, N | 1 |
| Weltfriend, S | 1 |
| Pollack, S | 1 |
| Techasathit, W | 1 |
| Sonjai, A | 1 |
| Suwanagool, S | 1 |
| Karcher, H | 4 |
| Stroes, E | 1 |
| Bloch, M | 1 |
| Schechter, M | 1 |
| Goulder, PJ | 1 |
| Blanckenberg, N | 2 |
| Dong, K | 1 |
| Laplumé, H | 1 |
| Martin, D | 2 |
| Jelaska, A | 1 |
| Tempelman, C | 2 |
| Timmermans, S | 2 |
| Pujari, SN | 1 |
| Naik, E | 1 |
| Dravid, A | 1 |
| Patel, JK | 1 |
| Mane, AA | 1 |
| Bhagat, S | 1 |
| Kabura, MN | 1 |
| John, FN | 1 |
| Nduati, RW | 1 |
| Mbori-Ngacha, DA | 2 |
| González de Requena, D | 3 |
| Gallego, O | 1 |
| Corral, A | 1 |
| Jiménez-Nácher, I | 6 |
| Mbu, RE | 1 |
| Mbopi-Keou, FX | 1 |
| Alemnji, G | 1 |
| Alemdji, G | 1 |
| Nkengasong, JN | 2 |
| Meli, C | 1 |
| Nana, PN | 1 |
| Ako, SN | 1 |
| Tonye, RN | 1 |
| Leke, RJ | 1 |
| Partisani, M | 2 |
| Hess-Kempf, G | 1 |
| Krantz, V | 2 |
| Priester, M | 2 |
| Cheneau, C | 1 |
| Bernard-Henry, C | 2 |
| de Mautort, E | 2 |
| Decroix, L | 1 |
| Lecossier, D | 1 |
| Shulman, NS | 1 |
| Zolopa, AR | 1 |
| Clavel, F | 1 |
| Hance, AJ | 1 |
| Rey-Joly, C | 1 |
| Wyles, DL | 1 |
| Gerber, JG | 2 |
| Lyons, FE | 1 |
| Coughlan, S | 1 |
| Byrne, CM | 1 |
| Hopkins, SM | 1 |
| Hall, WW | 1 |
| Mulcahy, FM | 3 |
| Singer, E | 1 |
| Roehr, B | 1 |
| Boeri, E | 1 |
| Serra, G | 1 |
| Ratti, D | 1 |
| Gallotta, G | 1 |
| Vacchini, D | 1 |
| Tremolada, Y | 1 |
| León, A | 2 |
| Laguno, M | 1 |
| Mullings, AA | 1 |
| Williams, E | 1 |
| Whorms, S | 2 |
| Figueroa, JP | 2 |
| Steel-Duncan, JC | 2 |
| Pierre, R | 2 |
| Rodriquez, B | 1 |
| Hambleton, I | 1 |
| Gabay, L | 1 |
| Massaquoi, I | 1 |
| Asiimwe, S | 1 |
| Arts, EJ | 3 |
| Whalen, CC | 2 |
| Ahmad, K | 1 |
| Aranzabal, L | 1 |
| Moya, J | 1 |
| Quereda, C | 1 |
| Diz, S | 1 |
| Moreno, L | 1 |
| Marín, A | 1 |
| Hernandez-Ranz, F | 1 |
| Kohli, E | 2 |
| Piroth, L | 2 |
| Martha, B | 1 |
| Grappin, M | 2 |
| Mommeja-Marin, H | 1 |
| Wakeford, C | 1 |
| Shaw, A | 2 |
| Quinn, J | 1 |
| Gish, RG | 1 |
| Sakarovitch, C | 3 |
| Fassinou, P | 2 |
| Dequae-Merchadou, L | 2 |
| Welffens-Ekra, C | 1 |
| Chitale, R | 1 |
| Mukiibi, J | 2 |
| Hoover, D | 2 |
| Broadhead, R | 2 |
| Petzoldt, D | 2 |
| Marcellin, F | 1 |
| Lallemant, MJ | 1 |
| Kunkeaw, S | 1 |
| Huisamen, CB | 1 |
| Badaro, R | 1 |
| de Wet, J | 1 |
| Lane, HC | 2 |
| Folkers, GK | 1 |
| Fauci, AS | 1 |
| Lange, J | 5 |
| Turner, VF | 1 |
| Andrews, S | 1 |
| Lazanas, MK | 1 |
| Schellens, JH | 2 |
| Maclean, CC | 2 |
| Nolan, D | 2 |
| Thorne, C | 2 |
| Poirier, JM | 1 |
| Robidou, P | 1 |
| Jaillon, P | 1 |
| Kamenga, C | 1 |
| de Zoysa, IF | 1 |
| Vwalika, C | 2 |
| Shutes, E | 1 |
| Aldrovandi, G | 2 |
| Montero, M | 2 |
| García-Gibert, L | 1 |
| Giménez-Arnau, AM | 1 |
| Lee, J | 1 |
| Leith, J | 3 |
| Hinzmann, R | 2 |
| Couzin, J | 1 |
| Dreyfuss, ML | 2 |
| Kigozi, G | 1 |
| Chen, MZ | 1 |
| Wabwire-Mangen, F | 1 |
| Wawer, MJ | 1 |
| Nalugoda, F | 1 |
| Kiwanuka, N | 1 |
| Kiddugavu, M | 1 |
| Gray, RH | 2 |
| Bodasing, N | 1 |
| Nyirenda, C | 1 |
| Mallewa, J | 1 |
| Cleary, PR | 1 |
| de Baar, MP | 1 |
| Colombo, S | 1 |
| Bleiber, G | 1 |
| Lee, BL | 1 |
| Biollaz, J | 1 |
| Décosterd, L | 1 |
| Mougnutou, R | 2 |
| Nkoué, N | 2 |
| Lactuock, B | 1 |
| Liégeois, F | 1 |
| Zekeng, L | 2 |
| Winters, MA | 1 |
| Kovari, L | 1 |
| Heseltine, PN | 1 |
| Dieleman, J | 1 |
| Sprenger, H | 1 |
| Schneider, ME | 1 |
| Stephenson, J | 2 |
| Crespo, M | 3 |
| Roson, B | 2 |
| Crommentuyn, KM | 1 |
| Tin, EE | 1 |
| Wilairatana, P | 1 |
| Krudsood, S | 1 |
| Oberdorfer, A | 1 |
| Akarathum, N | 1 |
| Kanjanavanit, S | 1 |
| Wannarit, P | 1 |
| Flys, T | 1 |
| Nissley, DV | 1 |
| Claassen, CW | 1 |
| Jones, D | 2 |
| Shi, C | 1 |
| Strathern, JN | 1 |
| Taha, T | 2 |
| Han, XX | 1 |
| Cui, WG | 1 |
| Liu, BG | 1 |
| Wang, Yn | 1 |
| Zhang, ZN | 1 |
| Geng, WQ | 1 |
| Diao, YY | 1 |
| Dai, D | 1 |
| Jiang, YJ | 1 |
| Shang, H | 1 |
| Tampellini, L | 1 |
| Sebastiani, T | 1 |
| Pocaterra, D | 1 |
| Morini, JP | 1 |
| Deleuze, J | 1 |
| Krivine, A | 1 |
| Gorin, I | 1 |
| Perrin, L | 1 |
| Dupin, N | 1 |
| Galvez, J | 1 |
| Prieto, A | 1 |
| Vilades, C | 1 |
| De Requena, DG | 2 |
| Weinberg, WG | 1 |
| Piliero, P | 1 |
| Hofstede, HT | 1 |
| Bosch, M | 1 |
| Tuldrà, A | 2 |
| Fumaz, CR | 3 |
| Garcés, B | 1 |
| Johnston, S | 3 |
| Arnó, A | 3 |
| Balagué, M | 3 |
| Jou, A | 2 |
| Tural, C | 2 |
| Romeu, J | 4 |
| Cruz, L | 2 |
| Francia, E | 2 |
| Arrizabalaga, J | 2 |
| Ruiz, I | 2 |
| Hascoet, C | 3 |
| Besnier, JM | 3 |
| Bellein, V | 3 |
| Breux, JP | 3 |
| Zucman, D | 2 |
| Rozenbaum, W | 3 |
| Montella, F | 1 |
| Uip, DE | 1 |
| Thompson, MA | 2 |
| Russell, DB | 1 |
| Koopmans, PP | 3 |
| Hekster, YA | 3 |
| Lemmer, P | 1 |
| Schuman, M | 1 |
| Omes, C | 1 |
| Tayari, JC | 1 |
| Fundira, L | 1 |
| Wennig, R | 1 |
| Bolton, C | 1 |
| van Niekerk, R | 1 |
| Levy, J | 2 |
| Degroot, A | 1 |
| Edirisinghe, D | 1 |
| Dalton, M | 1 |
| Bonington, A | 1 |
| Holland, DT | 1 |
| Peter, T | 2 |
| Connor, JD | 1 |
| Ochoa de Echagüen, A | 1 |
| Xercavins, M | 1 |
| Chumpathat, N | 4 |
| Chaovavanich, A | 5 |
| Urassa, P | 1 |
| Gosling, R | 1 |
| Pool, R | 1 |
| Reyburn, H | 1 |
| Idigbe, EO | 2 |
| Adewole, TA | 1 |
| Odunukwe, NN | 1 |
| Audu, RA | 2 |
| Araoyinbo, ID | 1 |
| Onyewuche, JI | 1 |
| Salu, OB | 2 |
| Adedoyin, JA | 1 |
| Musa, AZ | 2 |
| Sciandra, M | 1 |
| Marrone, R | 1 |
| De Rosa, FG | 1 |
| Mahlat, U | 1 |
| Kolladarungkri, T | 1 |
| Zijenah, L | 2 |
| Sheldon, W | 1 |
| Mateta, P | 2 |
| Johnston, E | 2 |
| Wells, J | 1 |
| Shetty, AK | 1 |
| Contag, CH | 1 |
| Upadhyay, A | 1 |
| Rodríguez-Pardo, D | 1 |
| Rubio, M | 1 |
| Falcó, V | 2 |
| Pahissa, A | 2 |
| Arranz Caso, JA | 1 |
| Santos, I | 1 |
| Castilla, V | 1 |
| Molina, JP | 1 |
| Fernández Guerrero, M | 1 |
| Hodge, J | 1 |
| Wiznia, A | 6 |
| Damle, B | 1 |
| Sheriff, M | 1 |
| van't Hoog, AH | 1 |
| Marum, LH | 1 |
| Misore, AO | 1 |
| Nganga, LW | 1 |
| Decock, KM | 1 |
| Joy, S | 1 |
| Poi, M | 1 |
| Hughes, L | 1 |
| Brady, MT | 1 |
| Koletar, SL | 1 |
| Para, MF | 1 |
| Cuzin, L | 1 |
| Pugliese, P | 1 |
| Bugnon, F | 1 |
| Delpierre, C | 1 |
| Cua, E | 1 |
| Massip, P | 1 |
| Friedland, GH | 2 |
| Welty, ER | 1 |
| Ndikintum, G | 1 |
| Nkuoh, G | 1 |
| Nkfusai, J | 1 |
| Sutthent, R | 1 |
| Arworn, D | 1 |
| Kaoriangudom, S | 1 |
| Chokphaibulkit, K | 1 |
| Chaisilwatana, P | 1 |
| Wirachsilp, P | 1 |
| Thiamchai, V | 1 |
| Sirapraphasiri, T | 1 |
| Tanprasertsuk, S | 1 |
| Clark, R | 1 |
| Girault, V | 1 |
| Kearney, BP | 1 |
| Vallabhaneni, S | 1 |
| Cecelia, AJ | 4 |
| Yepthomi, T | 3 |
| Saghayam, S | 3 |
| Carpenter, CC | 1 |
| Quian, J | 1 |
| Visconti, A | 1 |
| Gutiérrez, S | 3 |
| Galli, A | 1 |
| Maturo, M | 1 |
| Galeano, V | 1 |
| Serra, M | 1 |
| Lioni, M | 1 |
| Jooste, JP | 1 |
| Van Zyl, AJ | 1 |
| Baker, A | 1 |
| Crawford, W | 1 |
| Jassen, A | 1 |
| Savadogo, A | 1 |
| Nadembega, WM | 1 |
| Yara, J | 1 |
| Zoungrana, N | 1 |
| Bakouan, D | 1 |
| Musumeci, S | 1 |
| Lazaro, E | 1 |
| Dore-Mbami, M | 1 |
| Ba-Gomis, FO | 1 |
| Téa-Diop, Y | 1 |
| Kouakou, K | 1 |
| Diby, J | 1 |
| Sia, E | 1 |
| Soppi, S | 1 |
| Essien, S | 1 |
| Chenal, H | 1 |
| Calvet, GA | 1 |
| Menezes, JA | 1 |
| D'Ippolito, MM | 1 |
| Cruz, ML | 1 |
| Salgado, LA | 1 |
| Matos, HJ | 1 |
| Vezina, HE | 1 |
| Ravindran, GD | 1 |
| Kurpad, AV | 1 |
| Raj, TD | 1 |
| Fox, K | 1 |
| Weller, D | 1 |
| Cavert, W | 1 |
| Balfour, HH | 1 |
| Mohey, R | 2 |
| Tolstrup, M | 2 |
| Jørgensen, LB | 2 |
| Møller, BK | 1 |
| Black, FT | 2 |
| Kjems, J | 1 |
| Daniel, OJ | 1 |
| Krain, AB | 1 |
| Ogun, SA | 1 |
| Odusoga, OL | 1 |
| Kumar, PN | 1 |
| Rodriguez-French, A | 1 |
| Tashima, KT | 1 |
| Averitt, D | 1 |
| Wannamaker, PG | 1 |
| Williams, VC | 1 |
| Shaefer, MS | 1 |
| Pakes, GE | 1 |
| Pappa, KA | 1 |
| Menan, H | 2 |
| Autar, RS | 1 |
| Sankote, J | 1 |
| Sujaikaew, K | 1 |
| Drobacheff-Thiebaut, C | 1 |
| Gavignet, B | 1 |
| Mercier, M | 1 |
| Laurent, R | 2 |
| Greiner, T | 1 |
| Janowitz, B | 1 |
| Homan, R | 1 |
| Johnson, L | 1 |
| Schmitz, T | 1 |
| Kleinkauf, N | 1 |
| Klempa, B | 1 |
| Ringe, H | 1 |
| Varnholt, V | 1 |
| Grosch-Wörner, I | 1 |
| Parsons, T | 2 |
| Leth, FV | 1 |
| Johnson, D | 1 |
| Losso, MH | 2 |
| Koh, MT | 1 |
| Loubser, S | 1 |
| Balfe, P | 1 |
| Oleske, JM | 1 |
| Talbot, M | 2 |
| Cervantes, M | 1 |
| Mascaró, J | 1 |
| Cinquegrana, D | 1 |
| Siegfried, NL | 2 |
| Van Deventer, PJ | 1 |
| Mahomed, FA | 1 |
| Lyons, F | 1 |
| Hopkins, S | 2 |
| Kelleher, B | 1 |
| McGeary, A | 1 |
| Sheehan, G | 1 |
| Geoghegan, J | 1 |
| Bergin, C | 1 |
| McCormick, PA | 1 |
| Hemanthkumar, AK | 2 |
| Sukumar, B | 1 |
| Sathishnarayan, S | 1 |
| Raja, K | 1 |
| Kumaraswami, V | 2 |
| Soorapanth, S | 1 |
| Sansom, S | 1 |
| Besser, M | 1 |
| Boltz, V | 1 |
| Coffin, J | 1 |
| Kouam, L | 1 |
| Nsangou, I | 1 |
| Mbanya, D | 1 |
| Kongnyuy, EJ | 1 |
| Ngassa, P | 1 |
| Tebeu, PM | 1 |
| Elobe, N | 1 |
| Kamgaing, NG | 1 |
| Doh, AS | 1 |
| Maida, I | 1 |
| Ríos, MJ | 1 |
| Martín-Carbonero, L | 2 |
| Toro, C | 1 |
| Mura, MS | 1 |
| Babudieri, S | 1 |
| Garcia-Samaniego, J | 1 |
| Pinoges, L | 1 |
| Szumilin, E | 1 |
| Ferradini, L | 1 |
| Zheng, H | 1 |
| Geffen, N | 1 |
| Nattrass, N | 2 |
| Kalamya, JN | 1 |
| Obonyo, J | 1 |
| Ojwang, J | 1 |
| Mugumya, R | 1 |
| Opio, C | 1 |
| Kankasa, MP | 1 |
| Germinario, EA | 1 |
| Bassani, L | 1 |
| Dehò, L | 1 |
| Vyankandondera, J | 2 |
| Tribut, O | 1 |
| Jones, DC | 1 |
| Saradha, B | 1 |
| Gilbert, PB | 2 |
| Heymann, SJ | 2 |
| Lagakos, S | 3 |
| Mouly, S | 1 |
| Rizzo-Padoin, N | 1 |
| Simoneau, G | 1 |
| Aymard, G | 3 |
| Salvat, C | 1 |
| Mahé, I | 1 |
| Bergmann, JF | 1 |
| Littera, R | 1 |
| Carcassi, C | 1 |
| Masala, A | 1 |
| Piano, P | 1 |
| Serra, P | 1 |
| Ortu, F | 1 |
| Corso, N | 1 |
| Casula, B | 1 |
| La Nasa, G | 1 |
| Contu, L | 1 |
| Manconi, PE | 1 |
| Nightingale, S | 1 |
| Ward, DJ | 1 |
| Curtin, JM | 1 |
| Olawumi, HO | 1 |
| Olatunji, PO | 1 |
| Muangchana, K | 1 |
| Kebaabetswe, P | 1 |
| Mazonde, P | 1 |
| Ritchie, MD | 1 |
| Motsinger, AA | 1 |
| Donahue, JP | 1 |
| Erdem, H | 1 |
| Raffanti, S | 1 |
| Rebeiro, P | 1 |
| George, AL | 1 |
| Kim, RB | 2 |
| Haines, JL | 1 |
| Andersen, JW | 1 |
| Wilkinson, GR | 1 |
| Ingram, CD | 1 |
| François-Brunet, C | 1 |
| Garré, M | 3 |
| Souala, F | 1 |
| Poggensee, G | 1 |
| Gingelmaier, A | 1 |
| Kästner, R | 1 |
| Eberle, J | 1 |
| Mylonas, I | 1 |
| Belohradsky, BH | 1 |
| Friese, K | 1 |
| Grubert, TA | 1 |
| Summers, K | 1 |
| Wire, MB | 1 |
| Stein, DS | 2 |
| Masterman, A | 1 |
| Min, SS | 1 |
| Shelton, MJ | 1 |
| Germano, P | 2 |
| Guidotti, G | 2 |
| Loureiro, S | 2 |
| da Cruz Gomes, A | 1 |
| Valls Blazquez, MC | 1 |
| Sagay, AS | 1 |
| Musa, J | 1 |
| Adewole, AS | 1 |
| Imade, GE | 1 |
| Ekwempu, CC | 1 |
| Kapiga, S | 1 |
| Rexroad, VE | 1 |
| Hamzeh, FM | 1 |
| Stamper, PD | 1 |
| Yeni, PG | 2 |
| Bouchaud, O | 2 |
| von Hentig, N | 1 |
| Carlebach, A | 3 |
| Gute, P | 3 |
| Knecht, G | 1 |
| Klauke, S | 1 |
| Rohrbacher, M | 1 |
| Harder, S | 1 |
| Haberl, A | 3 |
| Dijkema, T | 1 |
| Warris, A | 1 |
| Phanupak, P | 1 |
| Pujary, S | 1 |
| Getahun, A | 1 |
| Tansuphasawadikul, S | 1 |
| Cooper, CL | 2 |
| Bhayroo, S | 1 |
| Buyse, S | 1 |
| Vibert, E | 1 |
| Sebagh, M | 1 |
| Antonini, T | 1 |
| Ichai, P | 1 |
| Castaing, D | 1 |
| Samuel, D | 1 |
| Duclos-Vallée, JC | 1 |
| Thistle, P | 1 |
| Spitzer, RF | 1 |
| Glazier, RH | 1 |
| Pilon, R | 1 |
| Arbess, G | 1 |
| Simor, A | 1 |
| Boyle, E | 1 |
| Gottesman, M | 1 |
| Silverman, M | 1 |
| Inthong, Y | 2 |
| Phoorisri, T | 2 |
| Gu, SM | 1 |
| Mshali, I | 1 |
| Phakati, S | 1 |
| Rampon, O | 1 |
| De Rossi, A | 1 |
| Park, JG | 2 |
| Stek, A | 3 |
| Clax, PA | 2 |
| Yu, S | 2 |
| Lertora, JJ | 2 |
| Mayer, A | 1 |
| Simo, S | 1 |
| Ali, M | 1 |
| Yazaki, H | 1 |
| Honda, M | 1 |
| Genka, I | 2 |
| Teruya, K | 2 |
| Tachikawa, N | 2 |
| Kikuchi, Y | 2 |
| Piyavong, B | 1 |
| Onyewuche, J | 1 |
| Funso-Adebayo, EO | 1 |
| Iroha, EO | 1 |
| Ezeaka, VC | 1 |
| Adetifa, IM | 1 |
| Okoeguale, B | 1 |
| Chand, F | 1 |
| Timite-Konan, M | 2 |
| Dahri, K | 1 |
| Ensom, MH | 1 |
| Arici, C | 1 |
| Airoldi, M | 2 |
| Ripamonti, D | 1 |
| Quinzan, G | 1 |
| Gregis, G | 1 |
| Ravasio, V | 1 |
| Bombana, E | 1 |
| Suter, F | 1 |
| Leyes, M | 1 |
| Balkus, J | 1 |
| Manuel, R | 1 |
| Djedje, M | 1 |
| Seoighe, C | 1 |
| Ketwaroo, F | 1 |
| Scheffler, K | 1 |
| Wood, N | 1 |
| Duffet, R | 1 |
| Zvelebil, M | 1 |
| Hide, W | 2 |
| Forna, F | 1 |
| Liechty, CA | 1 |
| Solberg, P | 1 |
| Asiimwe, F | 1 |
| Were, W | 1 |
| Behumbiize, P | 1 |
| Tong, T | 1 |
| Westreich, D | 1 |
| Eron, J | 1 |
| Horst, Cv | 1 |
| Van Rie, A | 1 |
| Rakhmanina, NY | 1 |
| van den Anker, JN | 1 |
| Williams, K | 1 |
| Sever, JL | 1 |
| Spiegel, HM | 1 |
| Soldin, SJ | 1 |
| van Heeswijk, RP | 4 |
| Paton, NI | 1 |
| Chen, YM | 1 |
| Lee, CK | 1 |
| Li, PC | 1 |
| Chuah, J | 2 |
| Frost, KR | 1 |
| Law, MG | 2 |
| Natarajan, U | 1 |
| Pym, A | 1 |
| McDonald, C | 1 |
| Velisetty, P | 1 |
| Edwards, SG | 2 |
| Hay, P | 4 |
| Welch, J | 2 |
| de Ruiter, A | 2 |
| Erhabor, O | 1 |
| Ejele, OA | 1 |
| Nwauche, CA | 1 |
| Ruiz, A | 1 |
| Patel, J | 1 |
| Shah, N | 1 |
| Patel, B | 1 |
| Maniar, JK | 1 |
| Shah, SR | 1 |
| Verma, R | 1 |
| Kamath, R | 1 |
| Gupte, P | 1 |
| Maniar, A | 1 |
| Mbamanya, F | 1 |
| Natarajan, V | 1 |
| Alfaro, RM | 1 |
| Formentini, E | 1 |
| Masur, H | 1 |
| Athichathanabadi, C | 1 |
| Khongnorasat, S | 1 |
| Niamba, P | 1 |
| Traoré, A | 1 |
| Taïeb, A | 1 |
| Lupodwana, P | 1 |
| Steyn, JG | 1 |
| Mtonga, V | 1 |
| Lee, A | 1 |
| Lu, D | 1 |
| Shi, Q | 1 |
| Tien, PC | 1 |
| Kaplan, RC | 1 |
| Hessol, NA | 1 |
| Cole, S | 1 |
| Vigen, C | 1 |
| Justman, J | 1 |
| Arroyo, E | 1 |
| Valenzuela, B | 1 |
| Portilla, J | 1 |
| Climent-Grana, E | 1 |
| Pérez-Ruixo, JJ | 1 |
| Merino, E | 1 |
| Suksomboon, N | 1 |
| Poolsup, N | 1 |
| Ket-Aim, S | 1 |
| Ellis, JC | 1 |
| Ewings, FM | 2 |
| Bell, F | 1 |
| Chileshe, R | 1 |
| Abernethy, J | 1 |
| Asboe, D | 1 |
| Williams, IG | 2 |
| Hooker, MH | 1 |
| Kasenga, F | 1 |
| Hurtig, AK | 1 |
| Emmelin, M | 1 |
| Patel, D | 1 |
| Cortina-Borja, M | 1 |
| Alcorn, K | 1 |
| Haddow, LJ | 1 |
| Wood, CW | 1 |
| Ainsworth, JG | 1 |
| Kurle, SN | 1 |
| Sen, S | 1 |
| Hayatnagarkar, SS | 1 |
| Tripathy, SP | 1 |
| Paranjape, RS | 1 |
| Perre, PV | 1 |
| Natu, SA | 1 |
| Daga, SR | 1 |
| Hahn, JA | 1 |
| Maier, M | 1 |
| Samuel, NM | 3 |
| Parameshwari, S | 1 |
| Dharmarajan, S | 1 |
| Van Hook, HM | 1 |
| Jacob, SM | 1 |
| Junankar, V | 1 |
| Stoszek, SK | 1 |
| Piwowar, E | 1 |
| Bertelsen, L | 1 |
| Laursen, A | 1 |
| Mkhwanazi, N | 1 |
| Kiepiela, P | 1 |
| Rollins, N | 2 |
| Little, K | 1 |
| Mzolo, S | 1 |
| Horwood, C | 1 |
| Tam, LW | 1 |
| Brumme, CJ | 1 |
| Lalonde, MS | 2 |
| Troyer, RM | 2 |
| Syed, AR | 1 |
| Bulime, S | 1 |
| Demers, K | 1 |
| Poubeau, P | 1 |
| Sandrine, PF | 1 |
| Sylvie, A | 1 |
| André, E | 1 |
| Abdoulaye, D | 1 |
| Bernard, L | 1 |
| André, C | 1 |
| Gasiorowski, J | 1 |
| Panos, G | 1 |
| Monforte, Ad | 2 |
| Mahajan, A | 1 |
| Sharma, H | 1 |
| Bhagat, A | 1 |
| Tandon, VR | 1 |
| Bennetto-Hood, C | 1 |
| Woodman, K | 1 |
| Ashouri, N | 1 |
| Igumbor, OJ | 1 |
| Pengpid, S | 1 |
| Obi, CL | 1 |
| Brasme, JF | 1 |
| Mille, F | 1 |
| Benhayoun, M | 1 |
| Bavoux, F | 1 |
| Teissier, N | 1 |
| Dauger, S | 1 |
| Nangola, S | 1 |
| Pattarawarapan, M | 1 |
| Yue, J | 1 |
| Wu, S | 1 |
| Yan, Y | 1 |
| Jahnke, N | 2 |
| Faye, MM | 1 |
| Sow, AI | 1 |
| Songa, PM | 1 |
| Mugasha, EB | 1 |
| Colvin, M | 1 |
| Willumsen, J | 1 |
| Apornpong, T | 1 |
| Teeratakulpisarn, S | 1 |
| Taweepolcharoen, C | 1 |
| Mangclaviraj, S | 1 |
| Limpongsanurak, S | 1 |
| Eiamapichart, P | 1 |
| Luesomboon, W | 1 |
| Kamudhamas, A | 1 |
| Tangsathapornpong, A | 1 |
| Vitavasiri, C | 1 |
| Singhakowinta, N | 1 |
| Attakornwattana, V | 1 |
| Methajittiphun, P | 1 |
| Chunloy, K | 1 |
| Preetiyathorn, W | 1 |
| Aumchantr, T | 1 |
| Toro, P | 1 |
| El-Sadr, W | 1 |
| Abdel-Megeed, MF | 1 |
| Beadsworth, M | 1 |
| Mateyu, G | 1 |
| Longwe, T | 1 |
| Pensi, T | 1 |
| Donninger, S | 1 |
| Semitala, F | 1 |
| Mwebaze-Songa, P | 1 |
| Schaefer, P | 1 |
| Spacek, LA | 1 |
| Gasasira, AF | 1 |
| Thomas, DL | 2 |
| Devaleenal, B | 2 |
| Palanivel, V | 1 |
| Muthu, S | 1 |
| Flanigan, T | 1 |
| Toure, S | 2 |
| El-Sadr, WM | 1 |
| Schouten, WE | 1 |
| Ramírez-Hernández, M | 1 |
| Sánchez-Sierra, B | 1 |
| Martínez-Escribano, JA | 1 |
| Kassaye, S | 1 |
| Lee, E | 1 |
| Winters, M | 1 |
| Pandey, N | 1 |
| Chandrakar, AK | 1 |
| Adile, SL | 1 |
| Garg, ML | 1 |
| Patel, S | 1 |
| Dao, H | 1 |
| Ekpini, R | 1 |
| Barnhart, M | 1 |
| Song, R | 1 |
| Jelagat, J | 1 |
| Dzombo, D | 1 |
| Mwalimu, M | 1 |
| Shikely, K | 1 |
| D'costa, GF | 1 |
| Khadke, K | 1 |
| Patil, YV | 1 |
| Kumar, P | 1 |
| Anitha, S | 2 |
| Bharucha, KE | 1 |
| Kulkarni, P | 1 |
| Phadke, M | 1 |
| Chantratitra, W | 1 |
| Leng, LK | 1 |
| Thisyakorn, U | 1 |
| Trinavarat, P | 1 |
| Sosothikul, D | 1 |
| Mehta, U | 1 |
| Marier, JF | 1 |
| Dimarco, M | 1 |
| Guilbaud, R | 1 |
| Dodard, C | 1 |
| Morelli, G | 1 |
| Tippabhotla, SK | 1 |
| Singla, AK | 1 |
| Thudi, NR | 1 |
| Monif, T | 1 |
| Djadou, KE | 1 |
| Ocloo, A | 1 |
| Dokounor, D | 1 |
| Agbodjan-Djossou, O | 1 |
| Akakpossa, A | 1 |
| Santos, RP | 1 |
| Ramilo, O | 1 |
| Safrit, JT | 1 |
| Chottanapund, S | 2 |
| Sittibusaya, C | 2 |
| Moolasart, V | 2 |
| Termvises, P | 1 |
| De Silvestri, A | 1 |
| Cologni, G | 1 |
| Puoti, M | 1 |
| Sheen, CW | 1 |
| Fahey, J | 1 |
| Zanin, M | 1 |
| Tyssen, D | 1 |
| Wynhoven, B | 1 |
| Kuiper, M | 1 |
| Götte, M | 1 |
| Mahajan, VK | 1 |
| Sharma, NL | 1 |
| Sarin, S | 1 |
| Bansal, A | 1 |
| Sud, N | 1 |
| Nagdeo, N | 1 |
| Thombare, VR | 1 |
| Shekelle, P | 1 |
| Maglione, M | 1 |
| Geotz, MB | 1 |
| Wagner, G | 1 |
| Hilton, L | 1 |
| Carter, J | 1 |
| Tringle, C | 1 |
| Mojica, W | 1 |
| Newberry, S | 1 |
| Saitoh, A | 1 |
| Sarles, E | 1 |
| Kovacs, A | 2 |
| Burchett, SK | 2 |
| Chaillot, F | 1 |
| Le Moal, G | 1 |
| Jarrousse, B | 1 |
| Ba, M | 1 |
| Dakouo, ML | 1 |
| Doumbia, A | 1 |
| Haidara, I | 1 |
| Maïga, A | 1 |
| Carcelain, G | 1 |
| Van Rompaey, SE | 1 |
| Kitahata, MM | 1 |
| Yoshida, LM | 1 |
| Taguchi, M | 1 |
| Matsuda, M | 1 |
| Ly, N | 1 |
| Phoung, V | 1 |
| Min, DC | 2 |
| Srey, C | 1 |
| Kruy, LS | 2 |
| Koum, K | 1 |
| Chhum, V | 1 |
| Glaziou, P | 2 |
| Reynes, JM | 1 |
| Ojesina, AI | 1 |
| Mullins, C | 1 |
| Imade, G | 1 |
| Samuels, J | 1 |
| Pam, S | 1 |
| Sagay, S | 1 |
| Downing, R | 1 |
| Berenguer, J | 1 |
| Bellón, JM | 1 |
| Miralles, P | 1 |
| Alvarez, E | 1 |
| Castillo, I | 1 |
| Cosín, J | 1 |
| Sánchez Conde, M | 1 |
| Padilla, B | 1 |
| Resino, S | 1 |
| Kigonya, C | 1 |
| Moura, MD | 1 |
| Senna, MI | 1 |
| Madureira, DF | 1 |
| Fonseca, LM | 1 |
| Mesquita, RA | 1 |
| Bannister, WP | 1 |
| Loveday, C | 1 |
| Karlsson, A | 1 |
| Lewden, C | 1 |
| Chêne, G | 2 |
| Clarisse, AB | 1 |
| Carmona, A | 1 |
| Luque, S | 1 |
| Berenguer, N | 1 |
| Matthias, R | 1 |
| Scullard, G | 1 |
| Schwenk, A | 1 |
| Meyssonnier, V | 1 |
| Caumes, PE | 1 |
| Kodama, EN | 1 |
| Sarafianos, SG | 1 |
| Schuckmann, MM | 1 |
| Sakagami, Y | 1 |
| Takiguchi, M | 1 |
| Subramanyam, S | 1 |
| Muderspach, L | 1 |
| Dandona, L | 1 |
| Kumar, SG | 1 |
| Ramesh, YK | 1 |
| Rao, MC | 1 |
| Dandona, R | 1 |
| Lee, B | 1 |
| Mangklabruks, A | 1 |
| Biron, C | 1 |
| Ou, QY | 1 |
| Huang, ZL | 1 |
| Gras, L | 1 |
| Knechten, H | 1 |
| Esser, S | 1 |
| Jaeger, H | 1 |
| Harrer, T | 1 |
| Mauss, S | 1 |
| van Lunzen, J | 1 |
| Skoetz, N | 1 |
| Jetter, A | 1 |
| Groneuer, C | 1 |
| Fraundorf, E | 1 |
| Demers, KR | 1 |
| Kyeyune, F | 1 |
| Syed, A | 1 |
| Vitezica, ZG | 1 |
| Lonjou, C | 1 |
| Borot, N | 1 |
| Ledger, TN | 1 |
| Lefebvre, A | 1 |
| Hovnanian, A | 1 |
| Hayden, A | 1 |
| Wright, E | 1 |
| Brew, BJ | 2 |
| Ali, ST | 1 |
| Arayawichanont, A | 1 |
| Imran, D | 1 |
| Kongsaengdao, S | 1 |
| Kruy, L | 1 |
| Samintharapanya, K | 1 |
| Sarim, C | 1 |
| Tau, G | 1 |
| Thangsing, C | 1 |
| Vin-Samnang, C | 1 |
| Wesselingh, SL | 1 |
| Eyakuze, C | 1 |
| Jones, DA | 1 |
| Starrs, AM | 1 |
| Sorkin, N | 1 |
| Saekang, N | 1 |
| Pairoj, W | 1 |
| Dube, S | 1 |
| Boily, MC | 1 |
| Mahomva, A | 1 |
| Chikhata, F | 1 |
| Gregson, S | 1 |
| Carraro, EA | 1 |
| Prandel, E | 1 |
| Dias, JM | 1 |
| Perini, J | 1 |
| Macedo, RL | 1 |
| Cornelsen, TC | 1 |
| Sbalquiero, R | 1 |
| Rees, H | 1 |
| Madden, E | 1 |
| Lee, G | 1 |
| Kotler, DP | 1 |
| Lewis, CE | 1 |
| Tracy, R | 1 |
| Heymsfield, S | 1 |
| Shlipak, MG | 1 |
| Scherzer, R | 1 |
| Grunfeld, C | 1 |
| Kirere Mathe, M | 1 |
| Sondag-Thull, D | 1 |
| Lepage, P | 1 |
| Lybaek, D | 1 |
| Larsen, CS | 1 |
| Hu, C | 1 |
| Best, B | 1 |
| Watts, H | 1 |
| Jimenez, E | 4 |
| Shearer, WT | 1 |
| Asenjo, MA | 1 |
| Damming, M | 1 |
| Pérez, H | 2 |
| Laufer, N | 1 |
| Gómez, A | 1 |
| Coll, P | 1 |
| Lottner, J | 1 |
| Rolón, M | 1 |
| Gomutbutra, V | 1 |
| Ghosh, M | 1 |
| Bii, SC | 1 |
| Otieno-Nyunya, B | 1 |
| Rotich, JK | 1 |
| Green, H | 1 |
| Compagnucci, A | 1 |
| Saidi, Y | 1 |
| Lai, AR | 1 |
| Kouadio, B | 1 |
| Seyler, C | 1 |
| Traore, M | 1 |
| Dakoury-Dogbo, N | 1 |
| Duvignac, J | 1 |
| Diakite, N | 1 |
| Karcher, S | 1 |
| Grundmann, C | 1 |
| Engelbrecht, S | 1 |
| Laten, JD | 1 |
| Millogo, A | 1 |
| Lankoandé, D | 1 |
| Yaméogo, I | 1 |
| Yaméogo, AA | 1 |
| Sawadogo, AB | 1 |
| Izzo, I | 1 |
| Oberdorfer, P | 1 |
| Washington, CH | 1 |
| Jittamala, P | 1 |
| Gozlan, M | 1 |
| Corbeil, J | 1 |
| Looney, D | 1 |
| Ignacio, C | 1 |
| Sullivan, J | 1 |
| Cheeseman, S | 1 |
| Barringer, K | 1 |
| Pauletti, D | 1 |
| Emini, EA | 1 |
| Byrnes, VW | 1 |
| Condra, JH | 1 |
| Schleif, WA | 1 |
| Sardana, VV | 1 |
| Cheeseman, SH | 3 |
| McLaughlin, MM | 2 |
| Greenough, TC | 2 |
| Hattox, SE | 2 |
| Myers, M | 9 |
| McLaughlin, M | 1 |
| Erice, A | 1 |
| de Jong, MD | 4 |
| Loewenthal, M | 1 |
| Boucher, CA | 5 |
| van der Ende, I | 1 |
| Schipper, P | 1 |
| Imrie, A | 3 |
| Weigel, HM | 2 |
| Kauffmann, RH | 2 |
| Koster, R | 1 |
| Koup, RA | 1 |
| Andrews, C | 1 |
| Bova, CA | 1 |
| Pav, JW | 3 |
| Roy, T | 1 |
| Keirns, JJ | 1 |
| Dornadula, G | 2 |
| Pomerantz, RJ | 2 |
| Nowak, MA | 2 |
| D'Aquila, RT | 3 |
| Fischl, MA | 2 |
| Liou, SH | 1 |
| Timpone, J | 1 |
| Basgoz, N | 1 |
| Niu, M | 1 |
| Hirsch, MS | 3 |
| Zhu, QY | 1 |
| Scarborough, A | 1 |
| Polsky, B | 1 |
| Chou, TC | 2 |
| Voelker, R | 1 |
| Sorice, F | 1 |
| Mueller, BU | 2 |
| Sei, S | 1 |
| Anderson, B | 1 |
| Farley, M | 1 |
| Venzon, DJ | 1 |
| Schwartzentruber, DJ | 1 |
| Fox, C | 1 |
| Pizzo, PA | 1 |
| Kilby, JM | 1 |
| Rabin, L | 1 |
| Hincenbergs, M | 1 |
| Moreno, MB | 1 |
| Warren, S | 1 |
| Linquist, V | 1 |
| Datema, R | 1 |
| Charpiot, B | 1 |
| Seifert, J | 1 |
| Kaneshima, H | 1 |
| McCune, JM | 1 |
| Havlir, DV | 1 |
| Eastman, S | 1 |
| Gamst, A | 1 |
| Tucker, TJ | 1 |
| Lumma, WC | 1 |
| Culberson, JC | 1 |
| Bonhoeffer, S | 1 |
| May, RM | 1 |
| Rutschmann, O | 1 |
| Stechenberg, B | 1 |
| Lamson, M | 3 |
| Cort, S | 1 |
| Grob, PM | 1 |
| Muchmore, E | 1 |
| Ho, DD | 1 |
| Norris, S | 1 |
| Shih, CK | 1 |
| Adams, J | 1 |
| Beveridge, A | 1 |
| Genn, W | 1 |
| Vizzard, J | 1 |
| Collins, DO | 1 |
| Sakamoto, A | 1 |
| de Boer, RJ | 1 |
| Foudraine, NA | 2 |
| Goudsmit, J | 3 |
| Miller, V | 3 |
| Phair, JP | 1 |
| Max, B | 1 |
| Mourikes, N | 1 |
| Alaeus, A | 1 |
| Cox, S | 1 |
| Holtzer, CD | 1 |
| Coleman, RL | 1 |
| Warren, KJ | 1 |
| Boxwell, DE | 1 |
| Kim, NY | 1 |
| Drolet, BA | 1 |
| Cooper, D | 5 |
| Durakovic, C | 1 |
| Rae, S | 4 |
| Shillington, A | 1 |
| Montaner, JG | 1 |
| Dohnanyi, C | 1 |
| Leitze, Z | 1 |
| Nadeem, A | 1 |
| Saul, Z | 1 |
| Roberts, I | 1 |
| Manthous, CA | 1 |
| Barry, MG | 2 |
| Tjia, JF | 1 |
| Halifax, KL | 1 |
| Breckenridge, AM | 1 |
| Gagnier, P | 1 |
| Pav, J | 1 |
| Gwynne, M | 1 |
| Siminski, S | 2 |
| Beckerman, K | 1 |
| Lukashov, VV | 2 |
| Notermans, DW | 1 |
| Roos, M | 1 |
| Schuitemaker, H | 1 |
| Mo, T | 1 |
| Raboud, JM | 3 |
| Ho, TT | 1 |
| Wong, KH | 1 |
| Chan, KC | 1 |
| Bourezane, Y | 1 |
| Salard, D | 1 |
| Vandel, S | 1 |
| Drobacheff, C | 1 |
| Markus, R | 1 |
| Zhou, XJ | 1 |
| Sheiner, LB | 1 |
| Everall, IP | 1 |
| Clay, PG | 1 |
| Rathbun, RC | 1 |
| Slater, LN | 1 |
| Haubrich, R | 1 |
| Richman, D | 1 |
| Hillebrand-Haverkort, ME | 1 |
| Sturkenboom, MC | 2 |
| Stricker, BH | 2 |
| Dusek, A | 2 |
| Elliott, T | 1 |
| Horton, S | 1 |
| Dransfield, K | 2 |
| Murarka, A | 1 |
| Hom, D | 1 |
| Antón, P | 1 |
| Rodriguez-Rosado, R | 1 |
| Dona, MC | 1 |
| Barreiro, PM | 1 |
| Pakker, NG | 1 |
| Kroon, ED | 1 |
| Roos, MT | 1 |
| Otto, SA | 1 |
| Hamann, D | 1 |
| Claessen, FA | 1 |
| Kroon, FP | 1 |
| ten Napel, CH | 1 |
| Sprenger, HG | 1 |
| Schellekens, PT | 1 |
| Miedema, F | 1 |
| de Jong, JJ | 1 |
| Hillebrand, ME | 1 |
| Baan, E | 1 |
| Huismans, R | 1 |
| ten Veen, JH | 2 |
| Heelon, MW | 1 |
| Meade, LB | 1 |
| Hellmann, NS | 1 |
| Grant, RM | 1 |
| Parkin, NT | 1 |
| Becker, M | 1 |
| Symonds, W | 1 |
| Chesney, M | 1 |
| Volberding, PA | 1 |
| De Wit, S | 1 |
| Sternon, J | 1 |
| Conget, I | 1 |
| Casamitjana, R | 1 |
| Aldeen, T | 1 |
| Wells, C | 1 |
| Davidson, F | 1 |
| Lau, R | 1 |
| Descamps, V | 1 |
| L'Heriteau, F | 1 |
| Schortgen, F | 1 |
| Regnier, B | 1 |
| Altice, FL | 1 |
| Cooney, EL | 1 |
| Otero, MJ | 1 |
| Fuertes, A | 1 |
| Sánchez, R | 1 |
| Luna, G | 1 |
| Shaw, AJ | 1 |
| McLean, KA | 1 |
| François, C | 2 |
| Michau, C | 1 |
| Gyssens, IC | 1 |
| Sturkenboom, MJ | 1 |
| Niesters, HG | 1 |
| Demoly, P | 1 |
| Messaad, D | 1 |
| Fabre, J | 1 |
| Reynes, J | 1 |
| Bousquet, J | 1 |
| Cattelan, AM | 2 |
| Erne, E | 1 |
| Salatino, A | 1 |
| Trevenzoli, M | 3 |
| Carretta, G | 1 |
| Meneghetti, F | 2 |
| Cadrobbi, P | 1 |
| Vázquez-Rosales, G | 1 |
| García Lerma, JG | 1 |
| Yamamoto, S | 1 |
| Switzer, WM | 1 |
| Folks, TM | 1 |
| Renault, B | 1 |
| Birmingham, K | 2 |
| Pilcher, CD | 1 |
| Ngo, L | 1 |
| Sista, P | 1 |
| Gleavy, J | 1 |
| Brooks, D | 1 |
| Venetta, T | 1 |
| DiMassimo, E | 1 |
| Crowe, S | 1 |
| Kempf, G | 1 |
| Nicolle, M | 1 |
| Lurie, P | 1 |
| Wolfe, SM | 1 |
| Campa, AM | 1 |
| Baum, MK | 1 |
| Temesgen, Z | 1 |
| Wright, AJ | 1 |
| Simon-Meyer, J | 1 |
| Nkoghe, D | 1 |
| Léonard, P | 1 |
| Demonty, J | 1 |
| Van Cauwenberge, A | 1 |
| Garcia-Arata, I | 1 |
| Bloor, S | 1 |
| Blazquez, J | 1 |
| Magenta, L | 1 |
| Piffaretti, JC | 1 |
| Carota, A | 1 |
| Moccetti, T | 1 |
| Baño Rodrigo, MD | 1 |
| Agujetas Rodríguez, M | 1 |
| López García, ML | 1 |
| Guillén Llera, JL | 1 |
| Nisius, G | 1 |
| Auger, S | 1 |
| Sidley, P | 2 |
| Ricciardulli, D | 3 |
| Clarke, SM | 2 |
| Healy, CM | 1 |
| Condon, S | 1 |
| Butler, KM | 1 |
| Little, J | 1 |
| Halifax, K | 1 |
| Drake, S | 1 |
| Belloso, WH | 1 |
| Benetucci, JA | 1 |
| Cahn, PE | 1 |
| Lasala, MC | 1 |
| Lopardo, G | 1 |
| Saracco, M | 1 |
| Nelson, E | 1 |
| Davey, RT | 1 |
| Allende, MC | 1 |
| Clarke, S | 2 |
| Harrington, P | 2 |
| Condon, C | 1 |
| Kelleher, D | 1 |
| Smith, OP | 1 |
| Blanco, F | 1 |
| Casimiro, C | 1 |
| de la Cruz, JJ | 1 |
| Berthelot, JM | 1 |
| Kwakkelstein, MO | 3 |
| Briones, C | 1 |
| Dona, C | 2 |
| Lyall, EG | 1 |
| Ward, C | 1 |
| Pinzani, V | 1 |
| Faucherre, V | 1 |
| Peyriere, H | 1 |
| Blayac, JP | 1 |
| Cheesbrough, A | 1 |
| Reynolds, B | 1 |
| Goldfarb-Rumyantzev, AS | 1 |
| Jeyakumar, A | 1 |
| Gumpeni, R | 1 |
| Rubin, D | 1 |
| Taylor, DL | 1 |
| Ahmed, PS | 1 |
| Tyms, AS | 1 |
| Wood, LJ | 1 |
| Kelly, LA | 1 |
| Chambers, P | 1 |
| Clarke, J | 1 |
| Bedard, J | 1 |
| Bowlin, TL | 1 |
| Rando, RF | 1 |
| Johnson, G | 3 |
| Lee, S | 4 |
| Mendez, H | 2 |
| Aguayo, R | 2 |
| Dieudonne, A | 2 |
| Bamji, M | 1 |
| Rana, S | 1 |
| Sever, J | 1 |
| Galluzzo, MC | 1 |
| Giannini, G | 2 |
| Tomino, C | 2 |
| Binelli, A | 1 |
| Weimer, LE | 2 |
| Baldini, F | 2 |
| Murri, R | 2 |
| Cooper, PA | 1 |
| Jivkov, BI | 1 |
| Schorn, MC | 1 |
| Hollanders, RM | 1 |
| van Ewijk-Beneken Kolmer, EW | 1 |
| Wuis, EW | 1 |
| Workman, J | 1 |
| Drake, SM | 1 |
| White, DJ | 1 |
| Stinnett, AA | 1 |
| Barry, M | 1 |
| Téllez, MJ | 1 |
| Hoetelmans, R | 1 |
| Clarke, DF | 1 |
| Nielsen, C | 1 |
| O'Farrell, N | 1 |
| Escolano, C | 1 |
| Mora, A | 1 |
| Gregori, J | 1 |
| Nogueira, E | 1 |
| García, F | 1 |
| Sambeat, MA | 2 |
| Gomez-Sirvent, JL | 1 |
| Gallart, T | 1 |
| Mirra, M | 1 |
| Marzi, M | 1 |
| Massella, M | 1 |
| Baraboutis, JG | 1 |
| Sha, BE | 1 |
| Proia, LA | 1 |
| Kessler, HA | 2 |
| Akue, JP | 1 |
| Babaki, P | 2 |
| Charpak, N | 2 |
| de Thé, G | 2 |
| Rea, MF | 1 |
| Huraux, C | 2 |
| Ndiaye, B | 2 |
| Pratomo, H | 2 |
| Zetterström, R | 2 |
| Miller, WC | 1 |
| Aberg, JA | 1 |
| Hamrick, HJ | 1 |
| Resch, W | 1 |
| Stuelke, EL | 1 |
| Watkins, T | 1 |
| Swanstrom, R | 1 |
| Morris, K | 1 |
| Lhotska, L | 1 |
| Armstrong, H | 1 |
| McNeeley, DF | 1 |
| Raguin, G | 1 |
| Metry, DW | 1 |
| Lahart, CJ | 1 |
| Farmer, KL | 1 |
| Hebert, AA | 1 |
| Sabido, R | 1 |
| Martí-Belda, P | 1 |
| Dehertogh, P | 1 |
| Haehl, M | 1 |
| Gulick, RM | 2 |
| Tung, R | 1 |
| Snyder, S | 1 |
| Palacios Muñoz, R | 1 |
| Santos González, J | 1 |
| Bosch García, R | 1 |
| Márquez Solero, M | 1 |
| Izzedine, H | 1 |
| Launay-Vacher, V | 1 |
| Deray, G | 1 |
| Dionisio, D | 1 |
| Mininni, S | 1 |
| Bartolozzi, D | 1 |
| Esperti, F | 1 |
| Vivarelli, A | 1 |
| Leoncini, F | 1 |
| Moyle, G | 3 |
| Yamamoto, Y | 1 |
| Yasuoka, A | 1 |
| Yasuoka, C | 1 |
| Dovie Akue, JP | 1 |
| Ferreira Rea, M | 1 |
| Benn, PD | 1 |
| Mercey, DE | 1 |
| Brink, N | 1 |
| Scott, G | 1 |
| Larger, E | 1 |
| Longuet, P | 1 |
| Vilde, JL | 1 |
| Math t, RA | 1 |
| de Villar, N | 1 |
| Serrano-Ríos, M | 1 |
| Jeffrey, S | 1 |
| Hanna, G | 1 |
| D'Aquila, R | 1 |
| Wallace, L | 1 |
| Logue, K | 1 |
| Cordova, B | 1 |
| Buckery, R | 1 |
| Gallagher, K | 1 |
| Scarnati, H | 1 |
| Tritch, R | 1 |
| Rizzo, C | 1 |
| Gilden, D | 1 |
| Benson, M | 1 |
| Shannon, M | 1 |
| Bowers, M | 1 |
| Mascolini, M | 1 |
| Link, D | 1 |
| Bowersox, J | 1 |
| Doepel, L | 1 |
| Folkers, G | 1 |
| MacDougall, DS | 2 |
| Wool, M | 1 |
| Bartlett, JG | 1 |
| Cadman, J | 1 |
| Kasper, T | 1 |
| Fornataro, K | 2 |
| Lindsay, MK | 1 |
| Bartnof, HS | 1 |
| Shalit, P | 1 |
| Farrell, P | 1 |
| Lindgren, P | 1 |
| Wang, YG | 1 |
| Cunningham, S | 4 |
| Wantman, M | 1 |
| Prakash, M | 1 |
| Poreddy, V | 1 |
| Tiyyagura, L | 1 |
| Bonacini, M | 1 |
| Zuber, B | 1 |
| Böttiger, D | 1 |
| Benthin, R | 1 |
| ten Haaft, P | 1 |
| Heeney, J | 1 |
| Oberg, B | 1 |
| Churchill, D | 1 |
| Williams, I | 1 |
| Thomsen, HF | 1 |
| Larsen, L | 1 |
| Hankins, C | 1 |
| Curry, R | 1 |
| Pérez-Cuevas, JB | 1 |
| Marcos, MA | 1 |
| Carné, X | 1 |
| Rovere, P | 1 |
| De Checchi, G | 1 |
| Turazzini, M | 1 |
| Parrinello, A | 1 |
| Newson, R | 1 |
| Ives, N | 1 |
| Pereira, S | 1 |
| Kollmann, C | 1 |
| Tremblay, C | 1 |
| Giguel, F | 1 |
| Barracchini, A | 1 |
| De Longis, P | 1 |
| Goldschmidt, RH | 1 |
| Bangsberg, D | 1 |
| Das, S | 1 |
| Allan, PS | 1 |
| Wade, AA | 1 |
| van Praag, RM | 2 |
| Repping, S | 1 |
| de Vries, JW | 1 |
| Suzuki, K | 1 |
| Kaufmann, GR | 1 |
| Mukaide, M | 1 |
| Cunningham, P | 1 |
| Harris, C | 1 |
| Leas, L | 1 |
| Kondo, M | 1 |
| Imai, M | 1 |
| Pett, SL | 1 |
| Finlayson, R | 1 |
| Zaunders, J | 1 |
| Kelleher, A | 1 |
| Tjia, J | 1 |
| Gibbons, SE | 1 |
| Hudson, J | 1 |
| Hoy, J | 1 |
| Doong, N | 1 |
| French, M | 1 |
| Fagot, JP | 1 |
| Mockenhaupt, M | 1 |
| Bouwes-Bavinck, JN | 1 |
| Naldi, L | 1 |
| Viboud, C | 1 |
| Roujeau, JC | 1 |
| Smith, AN | 2 |
| Arribas, J | 1 |
| Lafeuillade, A | 2 |
| Rohban, R | 1 |
| Mouroux, M | 1 |
| Tricot, C | 1 |
| Agher, R | 1 |
| Huraux, JM | 1 |
| Matías-Guiu, X | 1 |
| Pujol, RM | 1 |
| Domingo, JC | 1 |
| Vázquez, G | 1 |
| Glenn Fowler, M | 1 |
| Römer, K | 1 |
| Kamps, R | 1 |
| Salzberger, B | 1 |
| Neau, D | 1 |
| Larbère, J | 1 |
| Birac, V | 1 |
| Ragnaud, JM | 1 |
| Street, JC | 1 |
| Obee, EM | 1 |
| Dileanis, J | 1 |
| Lugo, M | 1 |
| Smith, PF | 1 |
| DiCenzo, R | 1 |
| Rottmann, C | 1 |
| Larbalestier, N | 1 |
| Glesby, M | 1 |
| Behrens, G | 1 |
| Stellato, RK | 1 |
| Molhuizen, HO | 1 |
| Paes, D | 1 |
| Lampe, F | 1 |
| Lamson, MJ | 1 |
| Leitz, G | 1 |
| Pou, L | 1 |
| Lopez, RM | 1 |
| L'Héritier, A | 1 |
| Florence, KJ | 1 |
| Sulkowski, MS | 1 |
| Mehta, SH | 1 |
| Bundow, D | 1 |
| Rosoff, L | 1 |
| Aboulafia, DM | 1 |
| Seifert, LL | 1 |
| Yozviak, JL | 1 |
| Doerfler, RE | 1 |
| Woodward, WC | 1 |
| Bonard, D | 1 |
| Faure, M | 1 |
| Huët, C | 1 |
| Caumont, A | 1 |
| Roques, P | 1 |
| Salamon, R | 1 |
| Fleury, H | 1 |
| Pelton, S | 1 |
| Rathore, MH | 1 |
| Song, LY | 1 |
| Ashraf, H | 1 |
| Schirmer, D | 1 |
| Väth, T | 1 |
| Desch, S | 1 |
| Brun, SC | 1 |
| Hicks, C | 1 |
| King, M | 1 |
| Wheeler, D | 1 |
| Stryker, R | 1 |
| Riddler, S | 1 |
| Thompson, M | 1 |
| Real, K | 1 |
| Hsu, A | 1 |
| Kempf, D | 1 |
| Japour, AJ | 1 |
| Sun, E | 1 |
| Sasset, L | 1 |
| Sgarabotto, D | 1 |
| Olivieri, J | 1 |
| Khoury, M | 1 |
| Jones, TT | 1 |
| van Rossum, AM | 1 |
| Fraaij, PL | 1 |
| de Groot, R | 1 |
| von Giesen, HJ | 1 |
| Köller, H | 1 |
| Theisen, A | 1 |
| Arendt, G | 1 |
| Kijak, G | 1 |
| Federico, A | 1 |
| Saman, M | 1 |
| Rekacewicz, C | 2 |
| Leng, C | 1 |
| Abdool Karim, S | 1 |
| Abdool Karim, Q | 1 |
| Cooper, P | 1 |
| Hussey, G | 1 |
| Madhi, S | 1 |
| Pettifor, JM | 1 |
| Thula, S | 1 |
| Williamson, C | 1 |
| Moretti, F | 1 |
| Fausti, C | 1 |
| Pan, A | 1 |
| Casari, S | 1 |
| Mildvan, D | 1 |
| Yarrish, R | 1 |
| Marshak, A | 1 |
| Hutman, HW | 1 |
| Jambroes, M | 1 |
| Juttmann, J | 1 |
| Dodi, F | 1 |
| Alessandrini, A | 1 |
| Camera, M | 1 |
| Gaffuri, L | 1 |
| Morandi, N | 1 |
| Pagano, G | 1 |
| Huff, B | 1 |
| Titier, K | 1 |
| Lagrange, F | 1 |
| Péhourcq, F | 1 |
| Edno-Mcheik, L | 1 |
| Moore, N | 1 |
| Molimard, M | 1 |
| Skordis, J | 1 |
| Tidwell, RR | 1 |
| Gebbie, KM | 1 |
| Imperiale, M | 1 |
| Cullinan, K | 2 |
| Weel, J | 1 |
| Cunningham-Schrader, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase 3 Trial to Evaluate Two Simplified Antiretroviral Treatment Strategies in HIV Infected Children, Treated by Antiretroviral Triple Therapy Before One Year of Age, in Virological Success in Africa (Burkina Faso, Côte d'Ivoire, Rwanda)[NCT01127204] | Phase 2/Phase 3 | 161 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| "Observational Study on Tolerability and Observance of Post-exposure Prophylaxis With Doravirine in HIV Viral Risk"[NCT05761509] | 200 participants (Anticipated) | Observational | 2023-06-08 | Recruiting | |||
| Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection[NCT01404312] | Phase 3 | 3,000 participants (Actual) | Interventional | 2012-05-23 | Completed | ||
| BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana[NCT02369406] | Phase 2/Phase 3 | 67 participants (Actual) | Interventional | 2015-05-04 | Active, not recruiting | ||
| Optimal Combination Therapy After Nevirapine Exposure[NCT00089505] | Phase 3 | 745 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| PHPT-5 Second Phase: Perinatal Antiretroviral Intensification for the Prevention of Mother-to-child Transmission of HIV in Thai Women Having Received Less Than 8 Weeks of HAART During Pregnancy[NCT01511237] | Phase 3 | 379 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Phase III Trial to Determine the Efficacy and Safety of an Extended Regimen of Nevirapine in Infants Born to HIV-Infected Women to Prevent Vertical HIV Transmission During Breastfeeding[NCT00074412] | Phase 3 | 2,026 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study[NCT02140255] | Phase 1/Phase 2 | 905 participants (Anticipated) | Interventional | 2015-01-23 | Recruiting | ||
| Short Duration Exclusive Breastfeeding With Abrupt Weaning to Reduce the Risk of Mother-to-Child HIV Transmission[NCT00310726] | 1,435 participants (Actual) | Interventional | 2001-05-31 | Completed | |||
| Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)[NCT01061151] | Phase 3 | 3,747 participants (Actual) | Interventional | 2011-03-01 | Completed | ||
| Treatment Options for Protease Inhibitor-exposed Children[NCT01146873] | Phase 3 | 300 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women[NCT02082652] | Phase 4 | 60 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.[NCT01805258] | Phase 3 | 135 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Novel Approaches to Monitoring and Utilizing Adherence to HIV Therapy in Uganda[NCT01596322] | 750 participants (Actual) | Observational | 2004-09-30 | Completed | |||
| Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria[NCT02447159] | 554 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| Adaptive Evaluation of mHealth and Conventional Adherence Support Interventions to Optimize Outcome With New Treatment Regimens for Drug-resistant Tuberculosis and HIV in South Africa[NCT05633056] | 360 participants (Anticipated) | Interventional | 2023-02-28 | Not yet recruiting | |||
| Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326] | Phase 2/Phase 3 | 570 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Observational Cohort of HIV Infected Adults and Children in the PHPT Network Hospitals in Thailand[NCT00433030] | 2,816 participants (Actual) | Observational | 2007-01-31 | Completed | |||
| EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV[NCT02699736] | 23,000 participants (Actual) | Observational [Patient Registry] | 1994-01-31 | Enrolling by invitation | |||
| Predictors of Antiretroviral Pharmacokinetics in HIV-infected Women With Virologic Suppression on Combination Antiretroviral Therapy[NCT00433979] | 88 participants (Actual) | Observational | 2007-02-28 | Completed | |||
| The Effect of Phenytoin on the Pharmacokinetics of Nevirapine and the Development of Nevirapine Resistance After a Single Dose Nevirapine (VIramune®), Which is Part of ARV Prophylaxis for PMTCT in Moshi, TAnzania, and in Lusaka, Zambia (VITA2 Trial)[NCT01187719] | Phase 2 | 66 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women[NCT00993031] | Phase 3 | 389 participants (Actual) | Interventional | 2009-12-15 | Completed | ||
| Solid Organ Transplantation in HIV: Multi-Site Study[NCT00074386] | 275 participants (Actual) | Observational | 2003-10-31 | Completed | |||
| Interactions Between Antiretrovirals and Combined Oral Contraceptive Pills[NCT00829114] | Phase 4 | 370 participants (Anticipated) | Interventional | 2009-03-31 | Completed | ||
| PROMISE EBF: Promoting Infant Health and Nutrition in Sub-Saharan Africa: Safety and Efficacy of Exclusive Breastfeeding Promotion in the Era of HIV[NCT00397150] | 2,579 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| A Long-term Follow-up Study for HIV-infected Individuals Who Have Participated in HIV-NAT Study Protocols[NCT00411983] | 10,000 participants (Anticipated) | Observational | 2002-11-30 | Recruiting | |||
| Clinical Relevance of Nevirapine Resistance[NCT00117728] | Phase 3 | 250 participants (Anticipated) | Interventional | 2005-04-30 | Recruiting | ||
| Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)[NCT00428116] | 140 participants (Actual) | Interventional | 2007-09-30 | Terminated (stopped due to DSMB recommended termination because TI was safe but not durable.) | |||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children[NCT00978068] | Phase 3 | 176 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study[NCT01772940] | Phase 4 | 425 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| A Phase I, Open-label, Randomized Crossover Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Lopinavir/Ritonavir and Single-dose TMC207 in Healthy Subjects.[NCT00828529] | Phase 1 | 16 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| A Phase I, Open-label, Single-sequence Drug-drug Interaction Trial to Investigate the Pharmacokinetic Interaction Between Steady-state Nevirapine and Single-dose TMC207 in HIV-1 Infected Subjects.[NCT00910806] | Phase 1 | 16 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Phase II, Parallel, Randomized, Clinical Trials Comparing the Responses to Initiation of NNRTI-Based Versus PI-Based Antiretroviral Therapy in HIV Infected Infants Who Have and Have Not Previously Received Single Dose Nevirapine for Prevention of Mother-t[NCT00307151] | Phase 2 | 452 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Vicente Ferrer HIV Cohort Study[NCT02454569] | 30,000 participants (Anticipated) | Observational [Patient Registry] | 2009-09-30 | Recruiting | |||
| The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients[NCT03789968] | 411 participants (Actual) | Observational | 2019-09-01 | Completed | |||
| Clinic-based ART Diagnostic Evaluation[NCT01791556] | 820 participants (Actual) | Interventional | 2010-01-26 | Completed | |||
| Therapeutic Drug Monitoring of Corticosteroids/β2-agonists in Hair in Asthmatic Patients: an Open-label Feasibility Study[NCT03691961] | 24 participants (Actual) | Interventional | 2018-09-20 | Active, not recruiting | |||
| Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)[NCT05333679] | 200 participants (Anticipated) | Interventional | 2022-03-02 | Recruiting | |||
| Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults[NCT02067767] | Phase 2 | 53 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Maternal and Infant Peripartum Nevirapine, Versus Infant Only Peripartum Nevirapine, or Maternal Lopinavir/Ritonavir in Addition to Standard Zidovudine Prophylaxis for the Prevention of Perinatal HIV in Thailand.[NCT00409591] | Phase 3 | 435 participants (Actual) | Interventional | 2008-07-31 | Terminated (stopped due to Change in National PMTCT guidelines in Thailand) | ||
| A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women[NCT01789879] | Phase 2 | 60 participants (Actual) | Interventional | 2014-03-04 | Completed | ||
| Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial[NCT01805752] | 369 participants (Actual) | Interventional | 2013-03-31 | Completed | |||
| P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART[NCT00719602] | Early Phase 1 | 105 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomised Controlled Trial to Assess Antiretroviral Treatment Strategies in Relation to Adherence, Resistance and Virological Treatment Failure[NCT01433601] | 640 participants (Actual) | Interventional | 2007-08-31 | Active, not recruiting | |||
| Effect of Moringa Oleifera (Moringa, Drumstick/Horseradish Tree) on The Pharmacokinetics of Efavirenz and Nevirapine In-vivo.[NCT01410058] | 19 participants (Actual) | Observational | 2013-01-31 | Completed | |||
| Addition of Single-dose, Maternal Tenofovir and Emtricitabine to Reduce Non-nucleoside Reverse Transcriptase Inhibitor Resistance Mutations in the Setting of Zidovudine and Nevirapine for Prevention of Mother-to-child HIV Transmission[NCT00204308] | Phase 2 | 400 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission[NCT00115648] | Phase 3 | 3,300 participants (Anticipated) | Interventional | 2004-04-30 | Completed | ||
| Presumptive and Definitive Virologic HIV Diagnosis in Hospitalized Malawian Infants[NCT01388452] | 300 participants (Actual) | Interventional | 2011-06-30 | Completed | |||
| ARVs to Prevent Breastmilk HIV:Viral and Immune Responses[NCT00167674] | Phase 2 | 58 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women[NCT00209781] | 1,028 participants | Interventional | 2003-08-31 | Active, not recruiting | |||
| Prevention of Maternal to Infant HIV Transmission in India[NCT00061321] | Phase 3 | 770 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant[NCT00074399] | Phase 3 | 775 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| A Phase III Randomized Clinical Trial of the Standard Two Dose Nevirapine (NVP) Regimen With the Addition of HIV Immune Globulin(HIVIGLOB) or Extended Infant NVP Dosing Compared With the Standard NVP Regimen Alone for the Prevention of Maternal-Infant HIV[NCT00639938] | Phase 3 | 722 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Anti[NCT00476853] | Phase 2 | 42 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study[NCT00703898] | Phase 4 | 140 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Cohort Study To Assess The Impact Of A Breastfeeding Counselling And Support Strategy To Promote Exclusive Breastfeeding On Post-Natal Transmission Of HIV In African Women[NCT01948557] | 3,465 participants (Actual) | Interventional | 2001-10-31 | Completed | |||
| Botswana Diarrheal Diseases Study[NCT00197652] | 1,350 participants (Actual) | Observational | 2001-03-31 | Completed | |||
| Botswana Pediatric Respiratory Disease and Bloodstream Infection[NCT00197691] | 0 participants | Observational | 2001-03-31 | Completed | |||
| Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-infected Ugandan Adults[NCT01025830] | Phase 4 | 20 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting[NCT00028314] | 150 participants | Interventional | 2002-03-31 | Completed | |||
| Phase II Trial, Multicentre, Opened Label Evaluating the Pharmacokinetics and the Safety and Toxicity of the Tenofovir-Emtricitabine Combination in Pregnant Women and Infants in Africa and Asia[NCT00334256] | Phase 2 | 72 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)[NCT00122226] | Phase 4 | 50 participants | Interventional | 2003-01-31 | Active, not recruiting | ||
| Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin[NCT00483054] | Phase 3 | 142 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)[NCT01066858] | 1,765 participants (Actual) | Observational | 2011-03-22 | Completed | |||
| Randomised, Prospective Multicentre Clinical Study on the Effect of the Combination of Lopinavir/Rtv + Nevirapine as Maintenance Bitherapy (Without Nucleoside Analogues) in Comparison With a Triple Therapy Including Lopinavir/Rtv + Nucleoside Analogues in[NCT00335686] | Phase 4 | 67 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission[NCT00021671] | Phase 3 | 3,720 participants | Interventional | Completed | |||
| HIV Exposure, Disease Acquisition and Progression Among Children: Role of Maternal Immunogenetics, Viral Genetic Diversity, HAART Exposure, Co-morbidities and Psycho-Social Status: (UZ-CHS Birth Cohort)[NCT04087239] | 1,200 participants (Actual) | Observational | 2016-01-26 | Active, not recruiting | |||
| Efavirenz Pharmacokinetics and Pharmacogenomics in Older HIV-infected Patients[NCT01886404] | 30 participants (Actual) | Observational [Patient Registry] | 2013-12-01 | Completed | |||
| An Open-label Study Evaluating the Resistance Profile of Single Dose Nevirapine(NVP) When Combined With a 4 or 7 Day Course of Combivir® (ZDV/3TC) Compared to Single Dose Nevirapine for the Prevention of Mother to Child Transmission (pMTCT) of HIV - Treat[NCT00144183] | Phase 3 | 407 participants | Interventional | 2003-01-31 | Completed | ||
| Optimizing the Delivery of Maternal and Child Health Services to Strengthen the Primary Health Care System in Rural South Africa[NCT02626351] | 3,172 participants (Actual) | Interventional | 2015-07-15 | Completed | |||
| Short-term Effectiveness of a Community Health Worker Intervention for HIV-infected Pregnant Women in Tanzania to Improve Treatment Adherence and Retention in Care: A Cluster-Randomized Trial[NCT03058484] | 1,830 participants (Actual) | Interventional | 2015-05-01 | Completed | |||
| Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models[NCT02776254] | 3,100 participants (Actual) | Interventional | 2016-03-31 | Completed | |||
| A Phase 2, One Arm, Open Label, Feasibility Study Assessing One Month Zidovudine/Didanosine Postpartum Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine to Prevent Mother to Child Transmission of HIV[NCT00142337] | Phase 2 | 244 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| Efavirenz to Nevirapine Switch in HIV-1 Infected Patients With Severe Dyslipidemia: A Randomized Controlled Study[NCT00405171] | Phase 4 | 40 participants | Interventional | 2003-06-30 | Completed | ||
| A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months[NCT00312091] | Phase 1/Phase 2 | 44 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| HIV Infection and Breastfeeding: Interventions for Maternal and Infant Health[NCT00164736] | Phase 3 | 2,369 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Pharmacokinetics and Safety of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants[NCT04862975] | 200 participants (Anticipated) | Observational | 2024-01-08 | Not yet recruiting | |||
| Lopinavir/Ritonavir/Combivir vs. Abacavir/Zidovudine/Lamivudine for Virologic Efficacy and the Prevention of Mother-to-Child HIV Transmission Among Breastfeeding Women With CD4 Counts Greater Than or Equal to 200 Cells/mm3 in Botswana[NCT00270296] | Phase 2 | 730 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children[NCT02682810] | 4,000 participants (Actual) | Interventional | 2016-02-29 | Completed | |||
| Nevirapine Pharmacodynamics and Resistance Among HIV-Infected Mothers in Lilongwe, Malawi[NCT00164762] | 126 participants (Actual) | Observational | 2005-06-30 | Completed | |||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Etravirine (ETR) in Antiretroviral (ARV) Treatment-Experienced HIV-1 Infected Infants and Children, Aged ≥ 2 Months to < 6 Years[NCT01504841] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | 2013-03-14 | Completed | ||
| Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy[NCT00617643] | Phase 4 | 18 participants (Anticipated) | Interventional | 2008-05-31 | Completed | ||
| Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.[NCT00389207] | Phase 3 | 576 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomised, Double Blind, Double Dummy, Parallel Group, Active Controlled Trial to Evaluate the Antiviral Efficacy of 400 mg QD neVirapine Extended Release Formulation in Comparison to 200 mg BID neVirapinE Immediate Release in Combination With Truvada®[NCT00561925] | Phase 3 | 1,068 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Evaluation of Safety and Efficacy of Two Different Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment in Patients With HIV-1 and Tuberculosis[NCT00332306] | Phase 3 | 180 participants (Anticipated) | Interventional | 2006-06-30 | Active, not recruiting | ||
| Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults[NCT00790881] | Phase 4 | 36 participants (Anticipated) | Interventional | 2008-10-31 | Completed | ||
| The HIV Second-line Therapy AntiRetroviral Study in Patients Who Failed NNRTI-based Regimens[NCT00627055] | Phase 4 | 200 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| The Effect of Single Dose Carbamazepine on the Pharmacokinetics of Single Dose Nevirapine (Viramune, NVP) and Development of NVP Resistance, PMTCT Program of Moshi, Tanzania (VITA1)[NCT00294892] | Phase 2 | 144 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| [NCT00398684] | Phase 3 | 1,792 participants | Interventional | 2001-01-31 | Completed | ||
| Phase II Study of the Pharmacokinetics of Nevirapine and the Incidence of Nevirapine Resistance Mutations in HIV-Infected Women Receiving a Single Intrapartum Dose of Nevirapine With the Concomitant Administration of Zidovudine/Didanosine or Zidovudine/Di[NCT00109590] | Phase 2 | 175 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding[NCT00530777] | Phase 2 | 148 participants (Actual) | Interventional | 2008-04-30 | Completed | ||
| Phase III Randomized Trial of the Safety and Efficacy of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV-1 Transmission[NCT00099359] | Phase 3 | 1,735 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection[NCT01780831] | Phase 1 | 52 participants (Actual) | Interventional | 2014-01-28 | Completed | ||
| Maintaining Options for Mothers Study (MOMS): A Phase II Randomized Comparison of Three Antiretroviral Strategies Administered for 7 or 21 Days to Reduce the Emergence of Nevirapine Resistant HIV-1 Following a Single Intrapartum Dose of Nevirapine[NCT00099632] | Phase 2 | 484 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Research on the Antiretroviral Therapy and Immune Reconstitution on Chinese HIV/AIDS Patients[NCT00872417] | Phase 4 | 750 participants (Anticipated) | Interventional | 2009-03-31 | Not yet recruiting | ||
| A Phase III Placebo-Controlled Trial to Determine the Efficacy of Oral AZT and the Efficacy of Oral Nevirapine for the Prevention of Vertical Transmission of HIV-1 Infection in Pregnant Ugandan Women and Their Neonates[NCT00006396] | Phase 3 | 1,500 participants | Interventional | Completed | |||
| A Phase III Randomized, Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000869] | Phase 3 | 2,009 participants | Interventional | Completed | |||
| A Phase III Randomized Trial of the Safety and Antiretroviral Effects of Zidovudine/Lamivudine/Abacavir Versus Zidovudine/Lamivudine/Lopinavir/Ritonavir in the Prevention of Perinatal Transmission of HIV[NCT00086359] | Phase 3 | 19 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Assessment of Safety and Toxicity Among Infants Born to HIV-1-Infected Women Enrolled in Antiretroviral Treatment Protocols in Diverse Areas of the World[NCT00100867] | 236 participants (Actual) | Observational | 2006-06-30 | Completed | |||
| Pharmacokinetic Properties of Antiretroviral and Related Drugs During Pregnancy and Postpartum[NCT00042289] | 1,578 participants (Actual) | Observational | 2003-06-09 | Completed | |||
| A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00001135] | Phase 3 | 2,009 participants | Interventional | Completed | |||
| A Phase III Randomized, Double-Blinded Study of Nevirapine for the Prevention of Maternal-Fetal Transmission in Pregnant HIV-Infected Women[NCT00000942] | Phase 3 | 1,244 participants | Interventional | Completed | |||
| Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.[NCT01908660] | 192 participants (Actual) | Observational [Patient Registry] | 2007-01-31 | Completed | |||
| Tenofovir, Emtricitabine, and Nevirapine for Recently HIV-Infected Subjects: Can Short-Course, Once Daily Therapy Reduce the Viral Load at 12 Months From Estimated Date of Infection?[NCT00087464] | 0 participants (Actual) | Interventional | Withdrawn (stopped due to study was withdrawn before any participants were recruited and enrolled) | ||||
| Randomized Trial of Protease Inhibitor-Including vs. Protease Inhibitor-Sparing Regimens for Women Who Initiate Therapy of HIV Infection During Pregnancy[NCT00017719] | Phase 3 | 440 participants | Interventional | 2002-05-31 | Completed | ||
| An Open-Label, Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Pre-menopausal Women[NCT00961272] | 6 participants (Actual) | Observational | 2009-07-31 | Completed | |||
| A Phase IV, Open-Label, Single-Sequence Pilot Study to Characterize the Pharmacokinetics of a 400mg Oral Dose of Raltegravir in the Cervicovaginal Fluids of HIV-Infected Women[NCT00774683] | 1 participants (Actual) | Observational | 2008-08-31 | Completed | |||
| A Phase IV, Open-Label Study to Characterize the First-Dose and Multiple-Dose Pharmacokinetics of Raltegravir in the Gastrointestinal Tract of Healthy Male Volunteers[NCT01325051] | Phase 1 | 15 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| A Cohort Observational Study to Assess the Virologic Response to Standard HIV Treatment in Bamako, Mali[NCT00703404] | 76 participants (Actual) | Observational | 2008-06-18 | Completed | |||
| A Phase I Study of the Safety, Tolerance, and Pharmacokinetics of Tenofovir Disoproxil Fumarate (TDF) and the Combination of TDF Plus Emtricitabine in HIV-1 Infected Pregnant Women and Their Infants[NCT00076791] | Phase 1 | 66 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| Phase I/II Study to Assess the Safety and Plasma Concentrations of Nevirapine Given Daily, Twice a Week or Weekly as Prophylaxis in Breastfeeding Infants From Birth to 6 Months[NCT00006279] | Phase 1 | 75 participants | Interventional | Completed | |||
| A Randomized, Open-Label Study of the Long-Term Effectiveness of Three Initial Highly Active Antiretroviral Therapy (HAART) Strategies in HAART-Niave, HIV-Infected Persons[NCT00000922] | 1,710 participants | Interventional | Completed | ||||
| A Phase II Randomized, Multicenter Protocol Evaluating Two Antiretroviral Regimens Containing Combinations of Protease Inhibitors, NRTIs, and an NNRTI[NCT00000924] | Phase 2 | 120 participants | Interventional | Completed | |||
| "Prevention of Milk-Borne Transmission of HIV-1C in Botswana (Mashi)"[NCT00197587] | 1,200 participants (Actual) | Interventional | 2002-08-31 | Completed | |||
| A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Zidovudine (ZDV), Lamivudine (3TC), and Nevirapine (NVP) as GPO-Vir Z30 Pediatric Tablets Versus the Individual Liquid Formulations in HIV-Infected Children Greater Than[NCT00672412] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Phase I Three-way Crossover Bioequivalence Study of Pediatric Formulations of Lamivudine/Zidovudine/Nevirapine Using Healthy Adult Volunteers[NCT01469520] | Phase 1 | 24 participants (Actual) | Interventional | 2010-10-31 | Active, not recruiting | ||
| ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial[NCT02459678] | 454 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| RAD-1: A Phase I/II Antiretroviral Management Algorithm for Pediatric Subjects of Four-Drug Combination Therapies Based on Prior Antiretroviral Experience[NCT00000902] | Phase 1 | 217 participants | Interventional | Completed | |||
| A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV-Infected Children. PRAM-2: A Phase I/II Randomized, Multicenter Protocol Comparing Four Antiretroviral Regimens Containing Combinations of Protease Inh[NCT00001091] | Phase 1 | 200 participants | Interventional | Completed | |||
| [NCT00466180] | Phase 4 | 62 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Between Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) and Selected Protease Inhibitor (PI) and Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapies Among HIV-Infected W[NCT00016601] | 76 participants | Interventional | 2001-06-30 | Completed | |||
| An Open Label, Staggered Rising Dose Cohort Study Assessing Safety, Tolerance, and Activity of BI-RG-587 in Patients With HIV Infection (CD4+ Cell Count < 400 Cells/mm3)[NCT00000962] | Phase 1 | 30 participants | Interventional | Completed | |||
| An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)[NCT00000649] | Phase 1 | 30 participants | Interventional | Completed | |||
| A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine[NCT00000770] | Phase 2 | 400 participants | Interventional | Completed | |||
| Pharmacokinetics, Safety, Tolerance, and Activity of Nevirapine (BI-RG-587) Alone and in Combination With AZT in Mildly to Moderately Symptomatic HIV-1 Infected Children[NCT00001111] | 35 participants | Interventional | Completed | ||||
| Global Initiative to Characterize Differences in Antiretroviral Pharmacokinetics in HIV-Infected Populations[NCT00054743] | Phase 4 | 24 participants (Actual) | Interventional | 2003-02-06 | Completed | ||
| A Phase I Study of Safety and Pharmacokinetics of Nevirapine in HIV-1 Infected Pregnant Women and Neonates Born to HIV-1 Infected Mothers[NCT00000808] | Phase 1 | 49 participants | Interventional | Completed | |||
| A Phase I Study of Tenofovir Disoproxil Fumarate (PMPA Prodrug), A Novel Nucleotide Analog Reverse Transcriptase Inhibitor in Children With HIV Infection[NCT00024986] | Phase 1 | 30 participants | Interventional | 2001-10-31 | Completed | ||
| A 48-Weeks National Multicenter Randomized Open Clinical Trial Evaluating Tolerance and Efficacy of a Treatment Simplification by Lopinavir/Ritonavir Versus Continuation of Current Treatment in HIV-Infected Patients With a Viral Load Inferior to 50 Copies[NCT00140751] | Phase 3 | 186 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Mother-Infant Rapid Intervention at Delivery (MIRIAD)[NCT00046436] | 7,500 participants | Observational | Terminated | ||||
| A Phase II Study of 1) Amprenavir (141W94/VX478) Plus 3TC Plus ZDV (or d4T) or 2) IDV Plus NVP Plus 3TC Plus d4T in Subjects Previously Treated With Amprenavir and 3) Other Treatment Regimens (Observational ARM) in Subjects Previously Treated With Amprena[NCT00001095] | Phase 2 | 94 participants | Interventional | Completed | |||
| A Pilot Study to Evaluate the Immunologic Consequences of a Highly Active Antiretroviral Therapy Regimen (HAART) Consisting of Ritonavir (ABT-538), Zidovudine (AZT), and Lamivudine (3TC) in Moderately Advanced HIV-1 Disease[NCT00001075] | 55 participants | Interventional | Completed | ||||
| Antiretroviral Activity and Tolerability of Once Daily Etravirine in Treatment-Naïve Adults With HIV-1 Infection[NCT00959894] | Phase 2 | 80 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| Multicenter, Pilot Study of Telbivudine (LdT) Anti-HBV Treatment Prior to the Initiation of Highly Active Antiretroviral Therapy Containing Lamivudine in Subjects Coinfected With HBV and HIV[NCT00051090] | 0 participants (Actual) | Interventional | Withdrawn | ||||
| A Phase II Rolling Arm Master Protocol (PRAM) of Novel Antiretroviral Therapy in Stable Experienced HIV- Infected Children; PRAM-1: ZDV+3TC vs. d4T+Ritonavir vs. ZDV+3TC+Ritonavir; PRAM-1, Step 2: d4T+Nevirapine+Ritonavir; PRAM-1, Step 3: d4T+Indinavir vs[NCT00001083] | Phase 2 | 240 participants | Interventional | Completed | |||
| A Phase II Pharmacokinetic Study of the Transdermal Contraceptive System and Oral Contraceptive in HIV-1 Infected Women on Lopinavir/Ritonavir[NCT00125983] | Phase 2 | 32 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Incidence rate (events per 100 person-years) was estimated, and 95.1% confidence interval used to account for interim analysis of primary efficacy outcome. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | Events per 100 person-years (Number) |
|---|---|
| RPT Plus INH Regimen (Arm A) | 0.6506 |
| INH Regimen (Arm B) | 0.6736 |
Cumulative incidence function estimated nonparametrically, treating TB-related deaths as competing risks. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| Cumulative incidence by 1 year post-randomization | Cumulative incidence by 2 years post-randomization | Cumulative incidence by 3 years post-randomization | Cumulative incidence by 4 years post-randomization | |
| INH Regimen (Arm B) | 0.5 | 1.0 | 1.5 | 2.0 |
| RPT Plus INH Regimen (Arm A) | 0.3 | 0.4 | 0.9 | 1.6 |
Data table estimates for percentage who died by each time point were estimated using Kaplan-Meier at 1, 2, 3, and 4 years post-entry. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| 1 year post-entry | 2 years post-entry | 3 years post-entry | 4 years post-entry | |
| INH Regimen (Arm B) | 0.63 | 1.15 | 1.62 | 2.29 |
| RPT Plus INH Regimen (Arm A) | 0.35 | 0.49 | 1.05 | 2.00 |
"Mean and standard deviation.~Week 16 samples have not yet been analyzed because the metabolite assay is being validated, and requires submission for approval by the Clinical Pharmacology Quality Assurance Program. Analysis of week 16 samples are anticipated to be available in September 2019." (NCT01404312)
Timeframe: Measured at Weeks 0, 2, 4, and 16
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week 0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 3787 | 3870 | 4082 |
Mean and standard deviation (NCT01404312)
Timeframe: Measured at Weeks 0, 2, and 4
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 7573 | 6234 | 5797 |
Among MTB-diagnosed participants who underwent drug-susceptibility testing, the number who had any resistance to a particular drug. (NCT01404312)
Timeframe: After TB diagnosis
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifampin72268104 | Rifampin72268105 | Isoniazid72268104 | Isoniazid72268105 | Ethambutol72268104 | Ethambutol72268105 | Pyrazinamide72268104 | Pyrazinamide72268105 | |||||||||
| Developed Resistance | Did not Develop Resistance | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 1 | |||||||||||||||
| INH Regimen (Arm B) | 1 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 14 | |||||||||||||||
| INH Regimen (Arm B) | 11 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 2 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 12 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 6 | |||||||||||||||
| INH Regimen (Arm B) | 6 | |||||||||||||||
Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 6 |
| NVP/LPV_r | 4 |
| NoNVP/NVP | 19 |
| NoNVP/LPV_r | 26 |
The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 15 |
| NVP/LPV_r | 0 |
| NoNVP/NVP | 35 |
| NoNVP/LPV_r | 0 |
Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 32 |
| NVP/LPV_r | 10 |
| NoNVP/NVP | 42 |
| NoNVP/LPV_r | 50 |
Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.
| Intervention | participants (Number) |
|---|---|
| NVP/NVP | 20 |
| NoNVP/NVP | 51 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.
| Intervention | cells/mm^3 (Median) | |
|---|---|---|
| Week 48 CD4 count change from randomization | Week 96 CD4 count change from randomization | |
| NoNVP/LPV_r | 172 | 256 |
| NoNVP/NVP | 172 | 223 |
| NVP/LPV_r | 201 | 278 |
| NVP/NVP | 191 | 291 |
Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
| Intervention | Percent of participants (Number) | |
|---|---|---|
| week 48 percent of virologic failure or death | week 96 percent of virologic failure or death | |
| NoNVP/LPV_r | 14 | 20 |
| NoNVP/NVP | 14 | 17 |
| NVP/LPV_r | 4 | 12 |
| NVP/NVP | 23 | 31 |
Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
| Intervention | percent of participants (Number) | |
|---|---|---|
| week 48 percent of full adherence in past month | week 96 percent of full adherence in past month | |
| NoNVP/LPV_r | 86 | 87 |
| NoNVP/NVP | 90 | 93 |
| NVP/LPV_r | 88 | 95 |
| NVP/NVP | 89 | 94 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
| Intervention | weeks (Number) | ||
|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | |
| NVP/LPV_r | 60 | 84 | NA |
| NVP/NVP | 12 | 12 | 60 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
| Intervention | weeks (Number) | ||
|---|---|---|---|
| 5th percentile | 10th percentile | 25th percentile | |
| NoNVP/LPV_r | 12 | 36 | 132 |
| NoNVP/NVP | 24 | 36 | NA |
For those infants who were randomized at 6 weeks and who initiated study drug we looked at the frequency and severity of adverse reactions through 18 months of study. The severity of all AEs was graded according to the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. The term severity is described as the intensity grade or level for specific event (i.e. mild, moderate, severe, or life-threatening). Severity is not the same as seriousness. (NCT00074412)
Timeframe: 6 weeks through 18 months
| Intervention | Number of Adverse Events (Number) | ||||
|---|---|---|---|---|---|
| Death | Life-Threatening | Severe | Moderate | Mild | |
| Nevirapine | 26 | 87 | 375 | 694 | 832 |
| Placebo | 30 | 87 | 332 | 677 | 838 |
(NCT00074412)
Timeframe: At Month 6
| Intervention | participants (Number) | |
|---|---|---|
| # of HIV infections at 6 months | # of Infants at risk for HIV infection at 6 months | |
| Nevirapine | 8 | 700 |
| Placebo | 18 | 699 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # Infant Deaths at 18 months | # Infants at risk of death at 18 months | |
| Nevirapine | 26 | 678 |
| Placebo | 30 | 684 |
(NCT00074412)
Timeframe: At Months 6 and 18
| Intervention | participants (Number) | |
|---|---|---|
| Number of Infants Alive and HIV-free at 6 months | Number of Infants Alive and HIV-free at 18 months | |
| Nevirapine | 689 | 629 |
| Placebo | 683 | 616 |
(NCT00074412)
Timeframe: At Month 18
| Intervention | participants (Number) | |
|---|---|---|
| # of infants with HIV infection at 18 months | # of infants @ risk for HIV infection at 18 months | |
| Nevirapine | 16 | 664 |
| Placebo | 23 | 663 |
Defined as HIV nucleic acid test (NAT) positivity of the specimen drawn at either the birth (Day 0-5) or Week 1 (Day 6-14) visit, confirmed by HIV NAT positivity of a second specimen collected at a different time point (NCT01061151)
Timeframe: Measured at birth or Week 1 study visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Antepartum Arm A | 25 |
| Antepartum Arm B | 7 |
| Antepartum Arm C | 2 |
Detected by HIV NAT positivity (NCT01061151)
Timeframe: Measured at the birth (<= 3 days postpartum) visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Antepartum Arm A | 22 |
| Antepartum Arm B | 4 |
| Antepartum Arm C | 2 |
"AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses listed in Appendix IV. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 0.08 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 0.25 |
Number of women who died during the maternal health component; that is, who had been randomized to either continue or discontinue ART after risk of HIV vertical transmission through breastfeeding was over. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 0.24 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 0.43 |
"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 1.30 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 1.43 |
"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 3.47 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 5.61 |
"HIV/AIDS-related event refers to the WHO Clinical Stage 4 illnesses, pulmonary tuberculosis, and other serious bacterial infections listed in Appendix IV of the protocol. Stage 4 illnesses were reviewed and confirmed by an Endpoint review group." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 1.14 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 1.24 |
AIDS-defining illness refers to the WHO Clinical Stage 4 illnesses in Appendix IV of the protocol. These events were reviewed and confirmed by an Endpoint review group. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 0.24 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 0.49 |
Incidence of tuberculosis. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 0.40 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 0.31 |
"Cardiovascular or metabolic events of particular concern were included in this analysis. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates.~Metabolic events considered were diabetes mellitus, lipodystrophy, or dyslipidemia. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | events per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 2.9 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 5.7 |
Particular events were targeted as those of particular concern. This outcome considered all such events: death, events defining WHO stages II, III, or IV, targeted cardiovascular adverse events, other targeted adverse events, or cancers which were not AIDS-defining. A complete list can be found in Appendix IV of the Protocol. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | events per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 9.0 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 14.0 |
"This outcome included AIDS-defining illnesses or cardiovascular, hepatic, or renal adverse events of particular concern which were evaluated as serious. Serious outcomes were both those defined as serious according to the International Conference on Harmonization (ICH) definition, or outcomes with grades equal to or worse than 3 (Severe). A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Cardiovascular events considered were hypertension, congestive heart failure, stroke, Transient Ischemia Event (TIA), pulmonary embolism, myocardial infarction (whether acute symptomatic or silent), coronary artery disease, deep vein thrombosis, peripheral vascular disease, or symptomatic HIV-associated cardiomyopathy. Hepatic events considered were cirrhosis and idiopathic sclerosing cholangitis. Renal events considered were renal insufficiency, acute or chronic." (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | events per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 0.5 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 0.9 |
Other (non-cardiologic) medical conditions of particular concern were included in this outcome. A Poisson model with time to first event as an offset and an over-dispersion parameter was used to estimate incidence rates. Events included were metabolic events, hepatic events, renal events, infections such as pulmonary tuberculosis, malaria, or other serious bacterial infections, and others. (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | events per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 4.0 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 4.6 |
The maternal safety endpoints summarized include grade 2, 3 or 4 hematologies (hemoglobin (Hb), White Blood Cells (WBC), Absolute Neutrophil Count (ANC), platelet count), chemistries (Alanine Aminotransferase (ALT or SGPT), serum creatinine), and grade 3 or 4 signs and symptoms that occurred post-randomization. These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: From study entry until July 7, 2015, an average of 94 weeks of follow-up.
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Maternal Health Arm A (Continue Triple ARVs) | 15.3 |
| Maternal Health Arm B (Discontinue Triple ARVs) | 13.9 |
Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit (i.e., any visit after the Week 1 [Day 6-14] visit), confirmed by HIV NAT positivity of a second specimen drawn at a different time point. Analyses were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Postpartum Arm A (Maternal Prophylaxis) | 0.56 |
| Postpartum Arm B (Infant Prophylaxis) | 0.55 |
These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
| Intervention | New cases per 100 person-years (Number) |
|---|---|
| Postpartum Arm A (Maternal Prophylaxis) | 14.4 |
| Postpartum Arm B (Infant Prophylaxis) | 14.1 |
Defined as infant HIV NAT positivity of a specimen drawn at any post-randomization visit, confirmed by HIV NAT positivity of a second specimen drawn at a different time point, or infant death. Analyses (Kaplan-Meier probabilities) were conducted at the Mother-Infant (M-I) pair level, hence the worst outcome for multiple births was counted as a single event. (NCT01061151)
Timeframe: Measured through 24 months post-delivery
| Intervention | Probability (Number) |
|---|---|
| Postpartum Arm A (Maternal Prophylaxis) | 0.971 |
| Postpartum Arm B (Infant Prophylaxis) | 0.977 |
Composite outcome (NCT01061151)
Timeframe: Measured at birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Period 2 | |
| Antepartum Arm C | 111 |
Composite outcome (NCT01061151)
Timeframe: Measured at birth
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Periods 1 and 2 | Period 2 | |
| Antepartum Arm A | 389 | 91 |
| Antepartum Arm B | 563 | 123 |
These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Period 2 | |
| Antepartum Arm C | 60 |
These events were graded using the Division of AIDS (DAIDS) AE Grading Table, Version 1.0, December 2004, Clarification August 2009, which is available on the RSC website (http://rsc.tech-res.com). (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Periods 1 and 2 | Period 2 | |
| Antepartum Arm A | 261 | 59 |
| Antepartum Arm B | 318 | 61 |
"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Period 2 | |
| Antepartum Arm C | 23 |
"Complications included deaths, diagnoses, signs/symptoms, chemistry lab tests, or hematological lab tests, with grades of 3 (Severe) or worse. Obstetrical complications were those classified by the MedDra coding system as Pregnancy, puerperium and perinatal conditions, except if the condition was the death of the fetus: Abortions not specified as induced or spontaneous, Abortions spontaneous, or Stillbirth and foetal death." (NCT01061151)
Timeframe: Measured through the Week 1 postpartum study visit
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Periods 1 and 2 | Period 2 | |
| Antepartum Arm A | 89 | 20 |
| Antepartum Arm B | 75 | 12 |
For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age
| Intervention | Proportional probability (Number) | |
|---|---|---|
| Overall survival, period 2 group | HIV-free survival, period 2 group | |
| Antepartum Arm C | 0.942 | 0.921 |
For overall survival, failure was defined to be death. For HIV-free survival, failure was defined to be either death or developing HIV. The probability of living, or living without HIV infection, at 104 weeks was calculated by Kaplan-Meier estimation of the survival function. (NCT01061151)
Timeframe: Measured from birth through 104 weeks of age
| Intervention | Proportional probability (Number) | |||
|---|---|---|---|---|
| Overall survival, Periods 1 & 2 group (arms A & B only) | Overall survival, period 2 group | HIV-free survival, Periods 1&2 group (arms A&B only) | HIV-free survival, period 2 group | |
| Antepartum Arm A | 0.959 | 0.951 | 0.937 | 0.936 |
| Antepartum Arm B | 0.967 | 0.982 | 0.947 | 0.940 |
Analyses (Kaplan-Meier probabilities) conducted for all individual infants (rather than M-I pair) (NCT01061151)
Timeframe: Measured at 12 and 24 months post-delivery
| Intervention | Probability (Number) | |
|---|---|---|
| 12 months post delivery | 24 months post delivery | |
| Postpartum Arm A (Maternal Prophylaxis) | 0.988 | 0.978 |
| Postpartum Arm B (Infant Prophylaxis) | 0.989 | 0.987 |
Analysis used the principle of intent to treat. (NCT01061151)
Timeframe: Measured at the time of delivery
| Intervention | Participants (Count of Participants) | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Periods 1 and 272329519 | Periods 1 and 272329520 | Period 272329520 | Period 272329519 | Period 272329521 | ||||||
| HIV RNA < 400 copies/mL | HIV RNA >= 400 copies/mL | |||||||||
| Antepartum Arm A | 415 | |||||||||
| Antepartum Arm B | 1092 | |||||||||
| Antepartum Arm A | 929 | |||||||||
| Antepartum Arm B | 275 | |||||||||
| Antepartum Arm A | 102 | |||||||||
| Antepartum Arm B | 259 | |||||||||
| Antepartum Arm C | 225 | |||||||||
| Antepartum Arm A | 210 | |||||||||
| Antepartum Arm B | 62 | |||||||||
| Antepartum Arm C | 79 | |||||||||
"Adherence is by maternal report; adherence through hair analysis is not included here.~The protocol did not distinguish between outcomes essential to the primary publication and outcomes for subsequent publications of lesser priority. This outcome measure was listed as secondary in the protocol but the intention was as an exploratory outcome since adherence was not a focus of the study." (NCT01061151)
Timeframe: Week 6 visit (14 days - 9 weeks postpartum); Week 14 visit (10-19 weeks postpartum); Week 26 visit (20 to 31 weeks postpartum); Week 50 visit (44 to 55 weeks postpartum); and Week 74 visit (68 to 80 weeks postpartum).
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 6 visit72329524 | Week 6 visit72329525 | Week 14 visit72329524 | Week 14 visit72329525 | Week 26 visit72329524 | Week 26 visit72329525 | Week 50 visit72329524 | Week 50 visit72329525 | Week 74 visit72329524 | Week 74 visit72329525 | |||||||||||||||||||||||||||||||
| Missed dose over 1 month ago | Never missed a dose | Missed dose 2-4 weeks ago | Missed dose within last 2 weeks | |||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 1003 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 1104 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 12 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 17 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 4 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 140 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 74 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 956 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 1081 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 20 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 0 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 35 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 112 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 50 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 888 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 1035 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 48 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 31 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 8 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 103 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 47 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 716 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 841 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 37 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 34 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 7 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 64 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 30 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 311 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 377 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm A (Maternal Prophylaxis) | 15 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 2 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 1 | |||||||||||||||||||||||||||||||||||||||
| Postpartum Arm B (Infant Prophylaxis) | 9 | |||||||||||||||||||||||||||||||||||||||
CD4 Cell Percentage at 48 Weeks After Randomization (NCT01146873)
Timeframe: 48 weeks
| Intervention | percentage of cells (Mean) |
|---|---|
| Group 1: Lopinavir/Ritonavir (LPV/r) | 34.7 |
| Group 2: Efavirenz (EFV) | 37.5 |
Probability of viral failure defined as >= 2 HIV RNA measurements >1000 copies/ml using survival analysis by 48 weeks post-randomization. (NCT01146873)
Timeframe: 48 weeks
| Intervention | probability of viral failure (Mean) |
|---|---|
| Group 1: Lopinavir/Ritonavir (LPV/r) | 0.020 |
| Group 2: Efavirenz (EFV) | 0.027 |
Probability of viral rebound defined as >=1 HIV RNA measurements >50 copies/ml using survival analysis by 48 weeks post-randomization. (NCT01146873)
Timeframe: 48 weeks
| Intervention | probability of viral rebound (Mean) |
|---|---|
| Group 1: Lopinavir/Ritonavir (LPV/r) | 0.284 |
| Group 2: Efavirenz (EFV) | 0.176 |
Highest grade ALT after randomization. Grading was determined based on the Division of AIDS (2004) Toxicity Tables to grade adverse reactions. Grading scale: 0 (none), 1 (mild), 2 (moderate), 3 (severe), 4 (potentially life-threatening). (NCT01146873)
Timeframe: through 48 weeks post randomization
| Intervention | number of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 0 | Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Group 1: Lopinavir/Ritonavir (LPV/r) | 139 | 8 | 0 | 1 | 0 |
| Group 2: Efavirenz (EFV) | 120 | 16 | 10 | 3 | 1 |
Percentage of participants with elevated total cholesterol, elevated LDL, abnormal HDL, or abnormal triglycerides at 40 weeks after randomization (NCT01146873)
Timeframe: 40 weeks
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Elevated total cholesterol | Elevated LDL | Abnormal HDL | Abnormal triglycerides | |
| Group 1: Lopinavir/Ritonavir (LPV/r) | 24.8 | 18.6 | 4.8 | 22.8 |
| Group 2: Efavirenz (EFV) | 13.3 | 9.8 | 4.2 | 10.5 |
antiretroviral hair concentrations (per doubling) (NCT00993031)
Timeframe: delivery
| Intervention | antiretroviral hair concentration(ng/mg) (Mean) |
|---|---|
| Without Protease Inhibitor | 5.7 |
| With Protease Inhibitor | 6.6 |
CD4 cell count recovery efavirenz at delivery (NCT00993031)
Timeframe: Time of randomization to delivery, an average of 20 weeks
| Intervention | CD4 cell count (Median) |
|---|---|
| Without Protease Inhibitor | -7 |
| With Protease Inhibitor | 57 |
Pre-eclampsia Defined by Hypertension > 140/90 on Two Occasions Measured > 6 Hours Apart With ≥1+ Proteinuria on Clean Catch Urine Dipstick (NCT00993031)
Timeframe: Time from randomization until delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 0 |
| With Protease Inhibitor | 0 |
(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from delivery until 24 months after delivery or cessation of breastfeeding
| Intervention | treatments (Number) |
|---|---|
| Group A | 21 |
| Group B | 13 |
(NCT00993031)
Timeframe: Number of treatments given for clinical malaria based on postive blood smear from time from randomization until 24 months after delivery or cessation of breastfeeding
| Intervention | treatments (Number) |
|---|---|
| With Protease Inhibitor | 17 |
| Without Protease Inhibitor | 17 |
(NCT00993031)
Timeframe: Randomization to one month postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 12 |
| With Protease Inhibitor | 8 |
Virologic suppression was defined as plasma HIV-1 RNA 400 copies/ml or less based on the lower limit of detection of the available test. (NCT00993031)
Timeframe: Time from randomization until delivery, an average of 20 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 166 |
| With Protease Inhibitor | 153 |
HIV tested by DNA PCR (NCT00993031)
Timeframe: Delivery to 48 weeks postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 0 |
| With Protease Inhibitor | 2 |
Proportion of women with severe maternal Anemia (hemoglobin < 8g/dl by hemacue or CBC) at any point during the trial in Each Treatment Group (NCT00993031)
Timeframe: Time from randomization until one year follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Without Protease Inhibitor | 11 |
| With Protease Inhibitor | 11 |
Number of participants with positive placental RDT for malaria. Malaria rapid diagnostic tests (RDTs) assist in the diagnosis of malaria by detecting evidence of malaria parasites (antigens) in human blood. RDTs permit a reliable detection of malaria infections particularly in remote areas with limited access to good quality microscopy services. (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 6 |
| Without Protease Inhibitor | 7 |
Number of participants with positive placental histopathology slide for malaria (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 62 |
| Without Protease Inhibitor | 47 |
Percent of evaluated participants with composite clinical outcome defined by LBW, stillbirth (intrauterine fetal demise >20wks GA), late spontaneous abortion(miscarriage 12-20wks GA), preterm delivery(<37wks gestation), neonatal death(death of live-born infant within first 28 days) (NCT00993031)
Timeframe: Time from randomization until 24 months postpartum or cessation of breastfeeding
| Intervention | % of evaluated participants with outcome (Number) |
|---|---|
| With Protease Inhibitor | 33.9 |
| Without Protease Inhibitor | 27.8 |
Number of participants with positive placental blood PCR for malaria (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 6 |
| Without Protease Inhibitor | 7 |
Number of participants with positive placental blood smear for malaria (NCT00993031)
Timeframe: Delivery
| Intervention | participants (Number) |
|---|---|
| With Protease Inhibitor | 5 |
| Without Protease Inhibitor | 6 |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 310 |
| No Intervention | 161 |
The EBF prevalences based on 24-h recall at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 56 |
| No Intervention | 30 |
The EBF prevalences (24-h recall) at 12 weeks in the intervention and control clusters. (NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 323 |
| No Intervention | 161 |
(NCT00397150)
Timeframe: at 3 months of age
| Intervention | participants (Number) |
|---|---|
| Intervention | 104 |
| No Intervention | 101 |
Weight and height will be transformed to the weight-for-age Z-score (i.e., WAZ) and height-for-age Z-score (i.e., HAZ) using World Health Organization Child Growth Standards, taking into account the infant's age and gender. (NCT00428116)
Timeframe: 18 months of post-randomization follow-up
| Intervention | z-score (Median) | |
|---|---|---|
| WAZ (z-score) | HAZ (z-score) | |
| Continued HAART | -0.57 | -1.04 |
| Interrupted HAART | -0.17 | -0.78 |
severe adverse events including death, pneumonia, diarrhea, and other adverse events (NCT00428116)
Timeframe: 18 months post-randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Severe adverse events | Pneumonia | Diarrhea | Death | |
| Continue HAART | 2 | 4 | 7 | 1 |
| Interrupted HAART | 1 | 3 | 12 | 0 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent parasitemia at 28 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy
| Intervention | Cummulative Risk Percentage (Number) |
|---|---|
| LPV/r + 2 NRTIs | 14.0 |
| NVP or EFV + 2 NRTIs | 40.8 |
To assess the effect of potential interactions between ART and artemether-lumefantrine, the risks of recurrent malaria at 63 days were compared between the two groups. (NCT00978068)
Timeframe: 28 days after antimalarial therapy
| Intervention | Cumulative Risk Percentage (Number) |
|---|---|
| LPV/r + 2 NRTIs | 28.1 |
| NVP or EFV + 2 NRTIs | 54.2 |
To assess the effect of ART independently of potential interactions with antimalarial therapy after treatment for malaria, we compared the two groups with respect to the time to the first episode of malaria. Cumulative risk was estimated using the Kaplan-Meier product-limit formula. (NCT00978068)
Timeframe: Enrollment to 6 months follow up
| Intervention | Cumulative Risk Percentage (Number) |
|---|---|
| LPV/r + 2 NRTIs | 40.7 |
| NVP or EFV + 2 NRTIs | 52.5 |
(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study
| Intervention | Episodes/ Person-Yr at Risk (Number) |
|---|---|
| Group 1 | 0.024 |
| Group 2 | 0.026 |
(NCT00978068)
Timeframe: Time from randomization to at least 24 months of follow up or until end of the study
| Intervention | Episodes/ Person-Yr at Risk (Number) |
|---|---|
| Group 1: LPV/r + 2 NRTIs | 1.32 |
| Group 2: Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTIs | 2.25 |
The rates of adverse events, defined as severity grade 2 or higher that are possibly, probably or definitely related to study drugs over the course of the 28-day period after antimalarial therapy with artemether-lumefantrine (AL). (NCT00978068)
Timeframe: 28 days after antimalarial therapy
| Intervention | % uncomplicated malaria episodes w/ AEs (Number) |
|---|---|
| LPV/r + 2 NRTIs | 71.0 |
| NVP or EFV + 2 NRTIs | 79.3 |
Change was calculated as CD4 percent at week 48 minus entry CD4 percent (last CD4 percent before randomization date). Only subjects who reached 48 weeks of follow-up before DSMB decisions to unblind each Cohort were included in summary. (NCT00307151)
Timeframe: 48 weeks if before date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
| Intervention | Percent of CD4 (Mean) |
|---|---|
| Coh I: NVP | 13.9 |
| Coh I: LPV/r | 12.0 |
| Coh II: NVP | 15.2 |
| Coh II: LPV/r | 14.3 |
Numbers of participants developing new NRTI, NNRTI or PI-resistant virus after reaching a virologic failure endpoint (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
| Intervention | participants (Number) |
|---|---|
| Coh I: NVP | 16 |
| Coh I: LPV/r | 1 |
| Coh II: NVP | 10 |
| Coh II: LPV/r | 4 |
Virologic failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR death on or before 24 weeks. Results report percent of participants reaching a virologic failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
| Intervention | Percent of participants (Number) |
|---|---|
| Coh I: NVP | 27.4 |
| Coh I: LPV/r | 10.4 |
| Coh II: NVP | 28.6 |
| Coh II: LPV/r | 12.9 |
Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR permanent discontinuation of the randomized NNRTI or PI component of study treatment at or prior to 24 weeks of treatment for any reason including death. Results report percent of participants reaching a treatment failure endpoint by week 24 calculated using the Kaplan-Meier method. (NCT00307151)
Timeframe: Earlier of 24 weeks or date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
| Intervention | Percent of participants (Number) |
|---|---|
| Coh I: NVP | 39.6 |
| Coh I: LPV/r | 21.7 |
| Coh II: NVP | 40.8 |
| Coh II: LPV/r | 19.3 |
Results report 2nd percentile of time from randomization to death (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
| Intervention | Weeks (Number) |
|---|---|
| Coh I: NVP | 11 |
| Coh I: LPV/r | 3 |
| Coh II: NVP | 2 |
| Coh II: LPV/r | 83 |
HIV-related disease progression was defined as progression in WHO clinical stage from stage at entry or death. For subjects in WHO Stage IV at entry, disease progression was defined as death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
| Intervention | Weeks (Number) | |
|---|---|---|
| 5th percentile | 10th percentile | |
| Coh I: LPV/r | 2 | 4 |
| Coh I: NVP | 11 | 17 |
| Coh II: LPV/r | 35 | 132 |
| Coh II: NVP | 8 | 35 |
Treatment failure is defined as a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR permanent discontinuation of the randomized NNRTI or PI component of study treatment for any reason including death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
| Intervention | Weeks (Number) | |
|---|---|---|
| 10th percentile | 25th percentile | |
| Coh I: LPV/r | 4 | 36 |
| Coh I: NVP | 12 | 16 |
| Coh II: LPV/r | 14 | 36 |
| Coh II: NVP | 4 | 16 |
Virologic failure is defined as the earlier of a confirmed plasma HIV-1 RNA level that is <1 log10 copies/mL below the study entry value at 12 to 24 weeks after treatment is initiated OR a confirmed plasma HIV-1 RNA level >400 copies/mL at 24 weeks OR a confirmed viral rebound >4000 copies/mL after week 24 OR death. (NCT00307151)
Timeframe: Until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009 - median follow-up 48 weeks and range 0 - 125 weeks; Coh II: October 27, 2010 - median follow-up 72 weeks and range from 0 to 204 weeks)
| Intervention | Weeks (Number) | |
|---|---|---|
| 5th percentile | 10th percentile | |
| Coh I: LPV/r | 16 | 24 |
| Coh I: NVP | 12 | 12 |
| Coh II: LPV/r | 16 | 24 |
| Coh II: NVP | 12 | 16 |
Safety events include lab abnormalities, signs or symptoms of grade 3 or higher. Events were graded according to the Division of AIDS Table for Grading Severity of Adult and Pediatric Adverse Events, Version 1.0. Events defined as new if first occurrence was after initiation of study treatment or if severity increased from entry and while on the NNRTI or PI component of study treatment. (NCT00307151)
Timeframe: On randomized NNRTI or PI component of study treatment and until date of DSMB decision to unblind Cohort results (Coh I: April 20, 2009; Coh II: October 27, 2010)
| Intervention | Weeks (Number) | |
|---|---|---|
| 10th percentile | 25th percentile | |
| Coh I: LPV/r | 8 | 36 |
| Coh I: NVP | 4 | 24 |
| Coh II: LPV/r | 4 | 12 |
| Coh II: NVP | 3 | 4 |
Area under the plasma concentration time curve, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h (NCT01410058)
Timeframe: Baseline (day 22), Post-moringa (day 35)
| Intervention | h*microgram/mL (Geometric Mean) | |
|---|---|---|
| Baseline (Day 22) | Post-moringa (Day 35) | |
| Efavirenz | 34.67 | 32.58 |
| Nevirapine | 94.17 | 100.44 |
plasma concentration 12h post dose, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h (NCT01410058)
Timeframe: Baseline (Day 22); Post-moringa (Day 35)
| Intervention | microgram/mL (Geometric Mean) | |
|---|---|---|
| Baseline (Day 22) | Post-moringa (Day 35) | |
| Efavirenz | 2.96 | 2.53 |
| Nevirapine | 7.30 | 7.55 |
Maximum plasma concentration post does, determined using a non-compartmental approach by means of the Phoenix WinNonlin software application. Time points for sample collection were 0.5, 1, 1.5, 2, 3, 4, 6, 8 and 12 h (NCT01410058)
Timeframe: Baseline (day 22), Post-moringa (day 35)
| Intervention | microgram/mL (Geometric Mean) | |
|---|---|---|
| Baseline (Day 22) | Post-moringa (Day 35) | |
| Efavirenz | 5.08 | 5.51 |
| Nevirapine | 9.92 | 10.57 |
Mean Area Under the Plasma Concentration-Time Curve for each drug, log transformed (NCT01025830)
Timeframe: Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing
| Intervention | hour*milligram/liter (Geometric Mean) |
|---|---|
| Generic Stavudine | 3.6 |
| Brand Stavudine | 3.4 |
| Generic Nevirapine | 85.8 |
| Brand Nevirapine | 79.2 |
| Generic Lamivudine | 5.2 |
| Brand Lamivudine | 6.4 |
Maximum concentration of drug in plasma that was attained post dosing (NCT01025830)
Timeframe: Assessed at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 10 and 12 hr post-dosing
| Intervention | milligram/liter (Geometric Mean) |
|---|---|
| Generic Stavudine | 1.6 |
| Brand Stavudine | 1.3 |
| Generic Nevirapine | 8.8 |
| Brand Nevirapine | 8.4 |
| Generic Lamivudine | 1.0 |
| Brand Lamivudine | 1.3 |
Number of infants with HIV-positive status (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months
| Intervention | Infants (Number) |
|---|---|
| TZV Arm | 6 |
| Kaletra Arm | 1 |
| NVP Arm | 1 |
Suppression of the plasma HIV-1 RNA level to less than 400 copies per milliliter (NCT00270296)
Timeframe: Throughout study, including breastfeeding, assessed up to 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| TZV Arm | 274 |
| Kaletra Arm | 256 |
| NVP Arm | 160 |
Geometric Mean (Standard Deviation) of the area under the plasma concentration-time curve over 12 hours (AUC12h) of ETR. (NCT01504841)
Timeframe: Pre-dose, 1, 2, 4, 6, 9, and 12 hours post-dose measured at intensive PK visit (within 7-10 days after last dose of study drug administration)
| Intervention | ng*h/mL (Geometric Mean) |
|---|---|
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 5512.85 |
| Cohort II: Treatment Experienced, 1 to 2 Years of Age | 4821.76 |
Number (%) of participants with a >5% decline in absolute CD4 percent from baseline at weeks 12, 24, and 48, by Cohort, including Clopper-Pearson confidence intervals. (NCT01504841)
Timeframe: Measured at baseline and at Weeks 12, 24, and 48
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1272045667 | Week 1272045668 | Week 2472045667 | Week 2472045668 | Week 4872045667 | Week 4872045668 | |||||||
| >5% decline in CD4 % from baseline | Increase or <5% decline in CD4 % from baseline | |||||||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 1 | |||||||||||
| Cohort II: Treatment Experienced, 1 to 2 Years of Age | 2 | |||||||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 10 | |||||||||||
| Cohort II: Treatment Experienced, 1 to 2 Years of Age | 1 | |||||||||||
| Cohort II: Treatment Experienced, 1 to 2 Years of Age | 3 | |||||||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 2 | |||||||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 9 | |||||||||||
Number (%) of participants with confirmed Virologic Failure, defined as: failure to suppress plasma HIV-1 RNA to fewer than 400 copies/ml and failure to achieve at least a 2-log10 reduction (from baseline) in HIV-1 RNA at Weeks 24 or 48, by Cohort, with Clopper-Pearson confidence intervals. The initial HIV-1 RNA results that met the Virologic Failure definition were each confirmed by a second result obtained within 1 to 4 weeks of the initial result obtained at Week 24 and/or 48. (NCT01504841)
Timeframe: Baseline, Week 24, and Week 48
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Week 2472045667 | Week 2472045668 | Week 4872045667 | Week 4872045668 | |||||
| Virologic Failure | No Virologic Failure | |||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 2 | |||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 9 | |||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 3 | |||||||
| Cohort II: Treatment Experienced, 1 to 2 Years of Age | 3 | |||||||
| Cohort I: Treatment Experienced, 2 to 6 Years of Age | 8 | |||||||
| Cohort II: Treatment Experienced, 1 to 2 Years of Age | 1 | |||||||
Proportion of Patients reporting CNS (central nervous system) side effects of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 41 |
| Nevirapine BID | 41 |
| Atazanvir/Ritonavir | 37 |
Proportion of Patients reporting hepatic events of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 26 |
| Nevirapine BID | 24 |
| Atazanvir/Ritonavir | 92 |
Proportion of Patients reporting rash of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 75 |
| Nevirapine BID | 64 |
| Atazanvir/Ritonavir | 74 |
Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response. (NCT00389207)
Timeframe: Baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 143.86 |
| Nevirapine BID | 143.21 |
| Nevirapine QD+BID | 143.71 |
| Atazanvir/Ritonavir | 143.00 |
Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count < 50 copies/mL up to Visit 10 (week 48) or loss of virologic response (NCT00389207)
Timeframe: baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 143.86 |
| Nevirapine BID | 143.21 |
| Nevirapine QD+BID | 143.71 |
| Atazanvir/Ritonavir | 143.00 |
Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response (NCT00389207)
Timeframe: baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 12.00 |
| Nevirapine BID | 12.14 |
| Nevirapine QD+BID | 12.00 |
| Atazanvir/Ritonavir | 23.71 |
Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | cells/mm^3 (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in CD4+ count to Week 4 | Change in CD4+ count to Week 8 | Change in CD4+ count to Week 12 | Change in CD4+ count to Week 24 | Change in CD4+ count to Week 36 | Change in CD4+ count to Week 48 | Change in CD4+ count to Week 60 | Change in CD4+ count to Week 72 | Change in CD4+ count to Week 84 | Change in CD4+ count to Week 96 | Change in CD4+ count to Week 108 | Change in CD4+ count to Week 120 | Change in CD4+ count to Week 132 | Change in CD4+ count to Week 144/EOT | |
| Atazanvir/Ritonavir | 86.1 | 98.0 | 110.9 | 133.8 | 163.4 | 183.6 | 208.2 | 231.9 | 246.4 | 251.6 | 267.2 | 269.2 | 281.3 | 285.8 |
| Nevirapine QD+BID | 77.2 | 105.6 | 120.3 | 134.4 | 160.1 | 168.2 | 184.8 | 213.7 | 223.0 | 217.7 | 231.2 | 231.3 | 243.4 | 251.0 |
Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in Framingham score to Week 48 | Change in Framingham score to Week 96 | Change in Framingham score to Week 144/EOT | |
| Atazanvir/Ritonavir | 0.66 | 1.19 | 0.82 |
| Nevirapine QD+BID | 0.50 | 0.93 | 1.14 |
Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in MHS score to Week 48 | Change in MHS score to Week 96 | Change in MHS score to Week 144/EOT | |
| Atazanvir/Ritonavir | 4.52 | 4.89 | 4.70 |
| Nevirapine QD+BID | 6.09 | 6.10 | 4.76 |
QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in PHS score to Week 48 | Change in PHS score to Week 96 | Change in PHS score to Week 144/EOT | |
| Atazanvir/Ritonavir | 3.35 | 3.00 | 3.35 |
| Nevirapine QD+BID | 3.34 | 3.19 | 2.22 |
Calculations based on the MDRD algorithm. (NCT00389207)
Timeframe: From baseline to Week 48, 96, 144
| Intervention | mL/min/1.73 m^2 (Mean) | ||
|---|---|---|---|
| change baseline to week 48 (N=143, 128, 271, 173) | change baseline to week 96 (N=130, 122, 252, 157) | change baseline to week 144 (N=163, 168, 331, 174) | |
| Atazanvir/Ritonavir | -7.18 | -11.53 | -9.56 |
| Nevirapine BID | -5.92 | -10.02 | -6.33 |
| Nevirapine QD | -3.91 | -6.93 | -3.27 |
| Nevirapine QD+BID | -4.86 | -8.42 | -4.82 |
Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/dL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| total cholesterol, week 48 (N=138,122,164) | total cholesterol, week 96 (N=124,114,147) | total cholesterol, week 144 (N=154,155,160) | LDL-c, week 48 (N=136,117,159) | LDL-c, week 96 (N=119,110,145) | LDL-c, week 144 (N=151,150,157) | HDL, week 48(N=138,122,164) | HDL, week 96 (N=124,114,147) | HDL, week 144(N=154,155,160) | |
| Atazanvir/Ritonavir | 20.84 | 29.99 | 28.13 | 10.58 | 19.19 | 17.61 | 3.49 | 4.74 | 5.73 |
| Nevirapine BID | 29.54 | 36.87 | 30.66 | 17.70 | 21.66 | 17.95 | 11.59 | 13.33 | 10.47 |
| Nevirapine QD | 29.28 | 39.17 | 33.12 | 16.54 | 21.93 | 21.42 | 12.06 | 13.86 | 12.61 |
Change of hsCRP from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/L (Mean) | ||
|---|---|---|---|
| hsCRP, week 48 (N=142,126,173) | hsCRP, week 96 (N=128,120,157) | hsCRP, week 144 (N=160,164,174) | |
| Atazanvir/Ritonavir | -0.70 | 0.35 | 0.04 |
| Nevirapine BID | -0.67 | -0.79 | -0.02 |
| Nevirapine QD | -1.01 | -1.54 | -0.09 |
Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| total triglycerides, week 48 (N=138,122,164) | total triglycerides, week 96 (N=124,114,147) | total triglycerides, week 144 (N=154,155,160) | |
| Atazanvir/Ritonavir | 0.20 | 0.28 | 0.17 |
| Nevirapine BID | -0.33 | -0.25 | -0.07 |
| Nevirapine QD | -0.37 | -0.22 | -0.24 |
Change of total triglycerides from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| total triglycerides, week 48 (N=138,120,164) | total triglycerides, week 96 (N=124,113,147) | total triglycerides, week 144 (N=153,153,159) | |
| Atazanvir/Ritonavir | 36.28 | 30.45 | 27.11 |
| Nevirapine BID | 1.67 | 5.35 | 6.11 |
| Nevirapine QD | 0.08 | 9.34 | -3.46 |
Changes frombaseline apolipoprotein A1 & B (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | g/L (Mean) | |||||
|---|---|---|---|---|---|---|
| apolipoprotein A1, week 48 (N=134,121,156) | apolipoprotein A1, week 96 (N=115,106,141) | apolipoprotein A1, week 144 (N=144,140,148) | apolipoprotein B, week 48 (N=134,120,156) | apolipoprotein B, week 96 (N=115,106,141) | apolipoprotein B, week 144 (N=144,139,148) | |
| Atazanvir/Ritonavir | 0.08 | 0.07 | 0.06 | 0.03 | 0.03 | 0.03 |
| Nevirapine BID | 0.23 | 0.23 | 0.14 | 0.03 | -0.00 | 0.05 |
| Nevirapine QD | 0.23 | 0.23 | 0.16 | 0.00 | 0.00 | 0.01 |
Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Number of substitutions (Number) | ||
|---|---|---|---|
| Emtricitabine-associated substitutions at Week 48 | Tenofovir-associated substitutions at Week 48 | Nevirapine-associated substitutions at Week 48 | |
| Atazanvir/Ritonavir | 0 | 0 | 0 |
| Nevirapine QD+BID | 21 | 11 | 34 |
Number of patients with AE elevated serum glucose (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with glycaemic abnormalities | Number without glycaemic abnormalities | |
| Atazanvir/Ritonavir | 3 | 190 |
| Nevirapine QD+BID | 0 | 376 |
Number of patients with AE lipodystrophy (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with lipodystrophy | Number without lipodystrophy | |
| Atazanvir/Ritonavir | 1 | 192 |
| Nevirapine QD+BID | 1 | 375 |
Cost effectiveness assessment by number of patients with non-scheduled physician visits (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
| Intervention | patients (Number) | |||
|---|---|---|---|---|
| Number between baseline and Week 24 | Number between Week 24 and Week 48 | Number between Week 48 and Week 96 | Number between Week 96 and Wk 144/EOT | |
| Atazanvir/Ritonavir | 35 | 35 | 28 | 35 |
| Nevirapine QD+BID | 74 | 45 | 58 | 58 |
Cost effectiveness assessment by number of patients hospitalized (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
| Intervention | Patients (Number) | |||
|---|---|---|---|---|
| Number hospitalized between baseline and Week 24 | Number hospitalized between Week 24 and Week 48 | Number hospitalized between Week 48 and Week 96 | Number hospitalized between Week 96 and Wk 144/EOT | |
| Atazanvir/Ritonavir | 2 | 5 | 5 | 1 |
| Nevirapine QD+BID | 8 | 6 | 5 | 9 |
(NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) | ||
|---|---|---|---|
| DAIDS 2 moderate | DAIDS 3 severe | DAIDS 4 potential lifethreatening | |
| Atazanvir/Ritonavir | 72 | 39 | 9 |
| Nevirapine BID | 84 | 28 | 15 |
| Nevirapine QD | 74 | 30 | 9 |
(NCT00389207)
Timeframe: at Week 48, 96, 144
| Intervention | participants (Number) | ||
|---|---|---|---|
| virologic failure at Week 48 | virologic failure at Week 96 | virologic failure at Week 144 | |
| Atazanvir/Ritonavir | 25 | 13 | 17 |
| Nevirapine BID | 25 | 25 | 28 |
| Nevirapine QD | 20 | 15 | 19 |
| Nevirapine QD+BID | 45 | 40 | 47 |
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| virologic rebound after CVR at Week 24 | virologic rebound after CVR at Week 48 | virologic rebound after CVR at Week 96 | virologic rebound after CVR at Week 144 | |
| Atazanvir/Ritonavir | 2 | 2 | 2 | 5 |
| Nevirapine BID | 2 | 3 | 6 | 6 |
| Nevirapine QD | 2 | 3 | 3 | 4 |
| Nevirapine QD+BID | 4 | 6 | 9 | 10 |
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| virologic rebound after CVR at Week 24 | virologic rebound after CVR at Week 48 | virologic rebound after CVR at Week 96 | virologic rebound after CVR at Week 144 | |
| Atazanvir/Ritonavir | 5 | 12 | 10 | 15 |
| Nevirapine BID | 2 | 5 | 6 | 9 |
| Nevirapine QD | 3 | 4 | 4 | 8 |
| Nevirapine QD+BID | 5 | 9 | 10 | 17 |
VL <400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | Proportion of patients (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion with VL<400 copies /mL at Week 4 | Proportion with VL<400 copies /mL at Week 8 | Proportion with VL<400 copies /mL at Week 12 | Proportion with VL<400 copies /mL at Week 24 | Proportion with VL<400 copies /mL at Week 36 | Proportion with VL<400 copies /mL at Week 48 | Proportion with VL<400 copies /mL at Week 60 | Proportion with VL<400 copies /mL at Week 72 | Proportion with VL<400 copies /mL at Week 84 | Proportion with VL<400 copies /mL at Week 96 | Proportion with VL<400 copies /mL at Week 108 | Proportion with VL<400 copies /mL at Week 120 | Proportion with VL<400 copies /mL at Week 132 | Proportion with VL<400 copies /mL at Week 144/EOT | |
| Atazanvir/Ritonavir | 0.287 | 0.679 | 0.834 | 0.956 | 0.966 | 0.977 | 0.988 | 0.988 | 0.994 | 0.987 | 1.000 | 0.994 | 0.993 | 0.986 |
| Nevirapine QD+BID | 0.365 | 0.714 | 0.856 | 0.924 | 0.968 | 0.985 | 0.993 | 0.996 | 0.988 | 1.000 | 0.996 | 1.000 | 0.996 | 0.991 |
VL <50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | Proportion of patients (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion with VL<50 copies /mL at Week 4 | Proportion with VL<50 copies /mL at Week 8 | Proportion with VL<50 copies /mL at Week 12 | Proportion with VL<50 copies /mL at Week 24 | Proportion with VL<50 copies /mL at Week 36 | Proportion with VL<50 copies /mL at Week 48 | Proportion with VL<50 copies /mL at Week 60 | Proportion with VL<50 copies /mL at Week 72 | Proportion with VL<50 copies /mL at Week 84 | Proportion with VL<50 copies /mL at Week 96 | Proportion with VL<50 copies /mL at Week 108 | Proportion with VL<50 copies /mL at Week 120 | Proportion with VL<50 copies /mL at Week 132 | Proportion with VL<50 copies /mL at Week 144/EOT | |
| Atazanvir/Ritonavir | 0.09 | 0.25 | 0.412 | 0.779 | 0.83 | 0.886 | 0.901 | 0.915 | 0.896 | 0.924 | 0.968 | 0.955 | 0.947 | 0.929 |
| Nevirapine QD+BID | 0.107 | 0.304 | 0.515 | 0.842 | 0.907 | 0.931 | 0.959 | 0.965 | 0.972 | 0.98 | 0.964 | 0.976 | 0.971 | 0.952 |
Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia) (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | patients (Number) | |
|---|---|---|
| Number with serum lipid abnormalities | Number without serum lipid abnormalities | |
| Atazanvir/Ritonavir | 4 | 189 |
| Nevirapine QD+BID | 9 | 367 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144. (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | participants (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 143 | 50 |
| Nevirapine BID | 113 | 75 |
| Nevirapine QD | 121 | 67 |
| Nevirapine QD+BID | 234 | 142 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Patients (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 126 | 67 |
| Nevirapine BID | 124 | 64 |
| Nevirapine QD | 126 | 62 |
| Nevirapine QD+BID | 250 | 126 |
Treatment response is defined as a VL <50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Patients (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 142 | 51 |
| Nevirapine QD+BID | 261 | 115 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96. (NCT00389207)
Timeframe: From baseline to Week 96
| Intervention | participants (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 149 | 44 |
| Nevirapine BID | 122 | 66 |
| Nevirapine QD | 131 | 57 |
| Nevirapine QD+BID | 253 | 123 |
Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with tr.-emerg. AIDS-def.illness | Number without tr.-emerg. AIDS-def.illness | |
| Atazanvir/Ritonavir | 7 | 186 |
| Nevirapine QD+BID | 26 | 350 |
Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness. (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with AIDS-def. illness leading to death | Number without AIDS-def. illness leading to death | |
| Atazanvir/Ritonavir | 0 | 193 |
| Nevirapine QD+BID | 3 | 373 |
(NCT00561925)
Timeframe: baseline, week 144
| Intervention | cells/cubic millimeter (Mean) |
|---|---|
| NVP IR 200mg BID | 239.3 |
| NVP XR 400mg QD | 270.7 |
(NCT00561925)
Timeframe: baseline, week 144
| Intervention | log10 copies/mL (Mean) |
|---|---|
| NVP IR 200mg BID | -2.7 |
| NVP XR 400mg QD | -2.8 |
Frequency of patients with hepatitis symptoms (NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)
| Intervention | participants (Number) |
|---|---|
| NVP IR | 10 |
| NVP XR | 8 |
| IR-IR/XR | 2 |
| XR-IR/XR | 0 |
Relative bioavailability measured of trough concentrations. Analysis based on adjusted by-treatment geometric means, the adjusted geometric mean ratio of NVP XR : NVP IR and it's 90% confidence interval with p-value and the inter-individual geometric coefficient of variation. (NCT00561925)
Timeframe: week 132
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| NVP IR | 4567.03 |
| NVP XR | 3634.26 |
Primary endpoint was the number of patients with a sustained virologic response through week 48 using LLOQ = 50 copies/mL (NCT00561925)
Timeframe: week 48
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Non responder | |
| NVP IR 200mg BID | 384 | 122 |
| NVP XR 400mg QD | 409 | 96 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.012 | 0.022 | 0.024 | 0.026 | 0.026 | 0.026 | 0.026 | 0.029 | 0.029 | 0.032 | 0.038 |
| NVP XR | 0.000 | 0.002 | 0.010 | 0.016 | 0.018 | 0.018 | 0.018 | 0.020 | 0.022 | 0.022 | 0.022 | 0.022 | 0.026 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.012 | 0.049 | 0.059 | 0.063 | 0.063 | 0.067 | 0.070 | 0.076 | 0.076 | 0.076 | 0.076 |
| NVP XR | 0.000 | 0.002 | 0.014 | 0.026 | 0.034 | 0.036 | 0.036 | 0.043 | 0.049 | 0.056 | 0.058 | 0.058 | 0.070 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.006 | 0.027 | 0.033 | 0.039 | 0.039 | 0.042 | 0.044 | 0.053 | 0.053 | 0.053 | 0.053 |
| NVP XR | 0.000 | 0.000 | 0.002 | 0.006 | 0.008 | 0.008 | 0.008 | 0.015 | 0.019 | 0.028 | 0.031 | 0.033 | 0.033 |
(NCT00561925)
Timeframe: week 0 to 72
| Intervention | cumulative probability (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week >=72 | |
| NVP IR | 0.000 | 0.000 | 0.002 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 | 0.004 |
| NVP XR | 0.000 | 0.000 | 0.006 | 0.008 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 | 0.010 |
(NCT00561925)
Timeframe: week 0 to 144
| Intervention | cumulative probability (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week 72 to <84 | Interval Week 84 to <96 | Interval Week 96 to <108 | Interval Week 108 to <120 | Interval Week 120 to <132 | Interval Week 132 to <144 | |
| NVP IR | 0.000 | 0.000 | 0.034 | 0.067 | 0.081 | 0.093 | 0.113 | 0.130 | 0.156 | 0.172 | 0.192 | 0.202 | 0.213 | 0.229 | 0.243 | 0.267 | 0.275 | 0.289 |
| NVP XR | 0.000 | 0.000 | 0.026 | 0.046 | 0.059 | 0.067 | 0.083 | 0.115 | 0.139 | 0.156 | 0.162 | 0.176 | 0.188 | 0.206 | 0.218 | 0.232 | 0.236 | 0.244 |
(NCT00561925)
Timeframe: week 0 to 144
| Intervention | proportion of participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week 72 to <84 | Interval Week 84 to <96 | Interval Week 96 to <108 | Interval Week 108 to <120 | Interval Week 120 to <132 | Interval Week 132 to <144 | Interval Week 144 to <168 | |
| NVP IR 200mg BID | 0 | 0.006 | 0.006 | 0.023 | 0.029 | 0.029 | 0.031 | 0.04 | 0.042 | 0.047 | 0.047 | 0.052 | 0.054 | 0.054 | 0.057 | 0.057 | 0.06 | 0.06 | 0.062 |
| NVP XR 400mg QD | 0 | 0.002 | 0.006 | 0.008 | 0.01 | 0.019 | 0.021 | 0.025 | 0.025 | 0.027 | 0.027 | 0.032 | 0.035 | 0.04 | 0.04 | 0.045 | 0.047 | 0.047 | 0.047 |
(NCT00561925)
Timeframe: week 0 to 144
| Intervention | proportion of participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interval Week 0 to <2 | Interval Week 2 to <4 | Interval Week 4 to <6 | Interval Week 6 to <8 | Interval Week 8 to <12 | Interval Week 12 to <16 | Interval Week 16 to <24 | Interval Week 24 to <32 | Interval Week 32 to <40 | Interval Week 40 to <48 | Interval Week 48 to <60 | Interval Week 60 to <72 | Interval Week 72 to <84 | Interval Week 84 to <96 | Interval Week 96 to <108 | Interval Week 108 to <120 | Interval Week 120 to <132 | Interval Week 132 to <144 | Interval Week 144 to <168 | |
| NVP IR 200mg BID | 1 | 0.84 | 0.838 | 0.834 | 0.834 | 0.832 | 0.83 | 0.822 | 0.806 | 0.792 | 0.777 | 0.759 | 0.733 | 0.713 | 0.686 | 0.662 | 0.65 | 0.63 | 0.61 |
| NVP XR 400mg QD | 1 | 0.865 | 0.865 | 0.865 | 0.863 | 0.861 | 0.859 | 0.848 | 0.832 | 0.816 | 0.808 | 0.788 | 0.766 | 0.745 | 0.719 | 0.697 | 0.681 | 0.671 | 0.66 |
(NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)
| Intervention | participants (Number) | |
|---|---|---|
| DAIDS grade 3 or 4 AEs | DAIDS grade 4 AEs | |
| IR-IR/XR | 71 | 11 |
| NVP IR | 53 | 17 |
| NVP XR | 111 | 25 |
| XR-IR/XR | 8 | 3 |
Frequency of patients with drug related rash events by functional grouping (NCT00561925)
Timeframe: until last patient completed 144 weeks (up to 193 weeks)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| rash group I | rash group II | rash group IIA | rash group III | rash group IV | |
| IR-IR/XR | 6 | 3 | 1 | 0 | 0 |
| NVP IR | 9 | 6 | 4 | 3 | 0 |
| NVP XR | 11 | 13 | 5 | 5 | 0 |
| XR-IR/XR | 0 | 0 | 0 | 0 | 0 |
Endpoint was the number of patients with a sustained virologic response through week 144 using LLOQ = 50 copies/mL (NCT00561925)
Timeframe: week 144
| Intervention | participants (Number) | |
|---|---|---|
| Responder | Non responder | |
| NVP IR 200mg BID | 296 | 210 |
| NVP XR 400mg QD | 321 | 184 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug*hr/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 99.7 |
| At Day 30 Ppm | NA |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 10.78 |
| At Day 30 Ppm | 12.96 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 11.2 |
| At Day 30 Ppm | NA |
(NCT00109590)
Timeframe: at 24 weeks postpartum
| Intervention | log10 copies/mL (Median) |
|---|---|
| Arm A : LPV/r x 7d | 4.3 |
| Arm B : no LPV/r | 3.9 |
| Arm C: LPV/r x 30d | 4.0 |
Adverse events were graded using the Division of AIDS (DAIDS) Table for Grading > the Severity of Adult and Pediatric Adverse Events (December 2004). All grade 3 and higher signs, symptoms, and laboratory toxicities (and events of any grade that led to a change in study treatment) were included. (NCT00109590)
Timeframe: After start of study Treatment (postpartum)
| Intervention | participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 2 |
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 2 |
Data was analyzed with WinNonLin (Version 5.2, Pharsight, USA) using non-compartmental methods. The pharmacokinetic parameters were calculated using the linear-trapezoidal rule. Cpredose and C4hour at the two measurement times were compared within-subject using the Wilcoxon signed-rank test. (NCT00109590)
Timeframe: Within 72 hours postpartum and during the first 30 days postpartum
| Intervention | ug/mL (Median) |
|---|---|
| Within 72 Hrs Ppm | 6.08 |
| At Day 30 Ppm | 9.17 |
Resistance mutations as identified by consensus sequencing or OLA (NCT00109590)
Timeframe: 24 weeks postpartum
| Intervention | participants (Number) |
|---|---|
| Arm B : no LPV/r | 0 |
| Arm C: LPV/r x 30d | 0 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 3.6 |
| Arm B : no LPV/r | 7.1 |
| Arm C : LPV/r x 30d | 5.3 |
The incidence of new NVP resistance mutations at day 10 or week 6 postpartum in each randomized arm. Samples with viral load <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: at Day 10 or Week 6 postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A: LPV/r x 7d | 4.9 |
| Arm B: no LPV/r | 9.5 |
| Arm C : LPV/r x 30d | 7.0 |
The incidence of new NVP resistance mutation in plasma HIV within 8 weeks postpartum in each randomized arm was estimated using an exact binomial confidence interval. If a resistance mutation was detected at any of the timepoints then an endpoint was met. Samples with VL <500 copies/mL were considered free of mutations. If a resistance result was missing for reasons other than VL <500 copies/ml (e.g.missed visit), it was conservatively imputed as resistant in the primary analysis. (NCT00109590)
Timeframe: within 8 weeks postpartum.
| Intervention | percent of participants (Number) |
|---|---|
| Arm A : LPV/r x 7d | 7.1 |
| Arm B : no LPV/r | 12.5 |
| Arm C: LPV/r x 30d | 5.3 |
Resistance mutations as identified by OLA in plasma samples or PBMC at 72 weeks postpartum amongst women who had new NVP resistance mutations within 8 weeks postpatrum. These results were based on the 13 women who developed a new NVP resistance mutation in the first 8 weeks postpartum. For the primary outcome measure 1, one particpant in arm A was unavailable for follow-up after week 5 and was conservatively imputed to have developed resistance mutation. (NCT00109590)
Timeframe: within 72 weeks postpartum
| Intervention | participants (Number) | |
|---|---|---|
| OLA in plasma samples | OLA in PBMC | |
| Arm A : LPV/r x 7d | 0 | 0 |
| Arm B : no LPV/r | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 1 |
(NCT00109590)
Timeframe: At Week 5 postpartum (ZDV) and at the first timepoint with viral load >=500 copies/ml after treatment discontinuation (ddI and LPV/r).
| Intervention | percent of participants (Number) | ||
|---|---|---|---|
| The proportion of women with new ZDV resistance | The proportion of women with new ddI resistance | The proportion of women with new LPV/r resistance | |
| Arm A : LPV/r x 7d | 0 | 0 | 0 |
| Arm B : no LPV/r | 1.78 | 0 | 0 |
| Arm C: LPV/r x 30d | 0 | 0 | 0 |
Calculated as log10 plasma viral load at 34 weeks gestation - log10 plasma viral load at 38 weeks gestation (NCT00530777)
Timeframe: 4 weeks
| Intervention | log10 copies/mL (Mean) |
|---|---|
| Valacyclovir | -0.53 |
| Placebo | 0.03 |
Mother-to-child HIV transmission (NCT00530777)
Timeframe: 1 year postpartum
| Intervention | Participants (Number) |
|---|---|
| Valacyclovir | 6 |
| Placebo | 4 |
Intrapartum HIV infection at 3 Months (NCT00099359)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| ARM A (ZDV - Standard of Care) | 24 |
| ARM B (ZDV + NVP) | 11 |
| ARM C (ZDV +3TC+NFV) | 12 |
In utero HIV-1 infection rate (NCT00099359)
Timeframe: birth
| Intervention | participants (Number) |
|---|---|
| Arm A (ZDV Only) | 37 |
| ARM B (ZDV + NVP) | 28 |
| ARM C (ZDV + 3TC + NFV) | 28 |
(NCT00099359)
Timeframe: through age 6 months
| Intervention | participants (Number) |
|---|---|
| Arm A (ZDV Only) | 11 |
| ARM B (ZDV + NVP) | 15 |
| ARM C (ZDV + 3TC + NFV) | 17 |
Serious Adverse Events by System Organ Class=Blood and lymphatic system disorders (NCT00099359)
Timeframe: through age 6 months.
| Intervention | participants (Number) |
|---|---|
| ARM A (ZDV Only) | 86 |
| ARM B (ZDV + NVP) | 59 |
| ARM C (ZDV + 3TC/NFV) | 110 |
Descriptive study of 3TC and NFV pharmacokinetics during first two weeks of life using weight band dosing regimen in a subset of enrolled infants. (NCT00099359)
Timeframe: through age 14 days
| Intervention | ug*h/mL (Median) | |||
|---|---|---|---|---|
| (NFV-AUC-12h) 4-7 day | (NFV-AUC-12h) 10-14 day | (3TC-AUC-12 h) 4-7 day | (3TC-AUC-12h) 10-14 day | |
| ARM C (ZDV + 3TC/NFV) | 20.7 | 25.5 | 4.0 | 7.9 |
Descriptive study of NVP pharmacokinetics during first two weeks of life using weight band dosing in a subset of enrolled infants. (NCT00099359)
Timeframe: 14 days
| Intervention | ng/mL (Median) | |||
|---|---|---|---|---|
| NVP conc prior to 3rd dose | NVP peak conc (Cmax) post 3rd dose | NVP conc 3-5 day post 3rd dose | NVP conc 7 day post 3rd dose | |
| ARM B (ZDV + NVP) | 362 | 2286 | 459 | 76 |
Risk factors to be assessed include maternal HIV-1 RNA levels at delivery, maternal syphilis and other infections, obstetrical factors such as duration of membrane rupture, and adherence to neonatal medication. (NCT00099359)
Timeframe: through age 3 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Treatment Arm C (ZDV+3TC/NFV) | Treatment Arm B (ZDV+NFV) | Treatment Arm A (ZDV only) | Illegal Substance Abuse during pregnancy | |
| Infected | 12 | 11 | 24 | 7 |
| Uninfected | 516 | 523 | 505 | 130 |
Area Under the Concentration-time Curve at 24-hour interval (AUC24) based on intensive PK sampling around Cohort 1 RAL dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 RAL dose #1 (within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.
| Intervention | mg*h/L (Geometric Mean) |
|---|---|
| Cohort 1 RAL-naive: 3 mg/kg for First Dose | 53.88 |
| Cohort 1 RAL-naive: 2 mg/kg for First Dose | 44.26 |
| Cohort 1 RAL-exposed 1.5 mg/kg | 37.42 |
Area Under the Concentration-time Curve at the 24-hour interval (AUC24) for Cohort 2 initial RAL dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.
| Intervention | mg*h/L (Geometric Mean) |
|---|---|
| Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life | 38.2 |
| Cohort 2 RAL-exposed: 1.5mg/kg Once Daily on Days 1-7 of Life | 42.89 |
Last concentration of the drug (Clast) at 24 hour interval post dosing for the Cohort 2 initial RAL dose (within 48 and at 12-60 hours of birth for RAL-naive and RAL-exposed, respectively). This is the plasma RAL concentration from a sample collected at or close to 24 hours post dose. (NCT01780831)
Timeframe: Cohort 2 initial dose (within 48 and between 12-60 hours of birth for RAL-naive and RAL-exposed groups, respectively) intensive PK sampling: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Cohort 2 RAL-naive: 1.5 mg/kg Once Daily on Days 1-7 of Life | 947.90 |
| Cohort 2 RAL-exposed: 1.5 mg/kg Once Daily on Days 1-7 of Life | 946.24 |
Maximum concentration (Cmax) for Cohort 1 dose #1 (within 48 hours of birth) (NCT01780831)
Timeframe: Cohort 1 dose #1(within 48 hours of birth) intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12 (±1), 24 (±1) hours post-dose.
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| Cohort 1 RAL-naive: 3 mg/kg for First Dose | 3360.89 |
| Cohort 1 RAL-naive: 2 mg/kg for First Dose | 3405.24 |
| Cohort 1 RAL-exposed: 1.5 mg/kg for First Dose | 2188.82 |
Cohort 1 Dose #1 neonatal RAL elimination was represented by Clearance (CL/F), which is the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Cohort 1 Dose #1 Intensive PK sampling: within 30 min pre-dose; and 1-2, 4-8, 12, 24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.
| Intervention | L/hr (Median) |
|---|---|
| (TA)6(TA)6 | 0.11 |
| (TA)6(TA)7 | 0.06 |
Cohort 2 initial dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians (i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 initial dose: within 1 hour pre-dose; and 1-2, 6-10, 20-24 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.
| Intervention | L/hr (Median) |
|---|---|
| (TA)6(TA)6 Wildtype | 0.1 |
| Mutation | 0.1 |
Cohort 2 15-18 days of life dose neonatal RAL elimination was represented by Clearance (CL/F), which is defined as the volume of plasma cleared of the drug per unit time at 15-18 days of life when RAL dosing would have been 3 mg/kg twice daily. Genotyping for polymorphisms of UGT1A1 were performed on infants who were eligible for PK sampling and were consented by their mothers/guardians(i.e. genotyping was optional) . (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2 hours post-dose, 4-6, 8-12 hours post-dose. Samples for UGT1A1 genotype testing were collected at study entry.
| Intervention | L/hr (Median) |
|---|---|
| (TA)6(TA)6 Wildtype | 0.5 |
| Mutation | 0.5 |
Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 RAL-naive | 2 |
| Cohort 1 RAL-exposed | 2 |
| Cohort 1 Total | 4 |
| Cohort 2 RAL-naive | 11 |
| Cohort 2 RAL-exposed | 4 |
| Cohort 2 Total | 15 |
Number of infants who died or had adverse events (AEs) of Grade 3 or 4 as defined in DAIDS AE Grading Table. Events with onset dates prior to first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. (NCT01780831)
Timeframe: From first dosing of RAL through 6 weeks of life
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 RAL-naive | 2 |
| Cohort 1 RAL-exposed | 2 |
| Cohort 1 Total | 4 |
| Cohort 2 RAL-naive | 7 |
| Cohort 2 RAL-exposed | 4 |
| Cohort 2 Total | 11 |
"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 24 weeks of life
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 RAL-naive | 1 |
| Cohort 1 RAL-exposed | 0 |
| Cohort 1 Total | 1 |
| Cohort 2 RAL-naive | 0 |
| Cohort 2 RAL-exposed | 0 |
| Cohort 2 Total | 0 |
"Number of infants who died or had Suspected Adverse Drug Reaction (SADR) of Grade 3 or 4 as defined in DAIDS AE Grading Table.~Events with onset dates prior to the first RAL dosing and congenital anomalies assessed as baseline by the study team were considered baseline events and not AEs. SADRs are AEs assessed as definitely related, probably related or possibly related to RAL." (NCT01780831)
Timeframe: From first RAL dose through 6 weeks of life
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 RAL-naive | 1 |
| Cohort 1 RAL-exposed | 0 |
| Cohort 1 Total | 1 |
| Cohort 2 RAL-naive | 0 |
| Cohort 2 RAL-exposed | 0 |
| Cohort 2 Total | 0 |
Area Under the Concentration-time Curve at 12-hour interval (AUC12) of RAL for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.
| Intervention | mg*h/L (Geometric Mean) |
|---|---|
| Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-18 of Life | 14.3 |
| Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life | 18.25 |
RAL concentration at 12 hours (C12) for Cohort 2 at 15-18 days of life. (NCT01780831)
Timeframe: Intensive PK sampling for Cohort 2 at 15-18 days of life: within 1 hour pre-dose; and 1-2, 4-6, 8-12 hours post-dose.
| Intervention | mg*h/L (Geometric Mean) |
|---|---|
| Cohort 2 RAL-naive: 3 mg/kg Twice Daily on Days 8-28 of Life | 176.11 |
| Cohort 2 RAL-exposed: 3 mg/kg Twice Daily on Days 8-28 of Life | 273.59 |
participants assigned to 7-day treatment arm and 21-day treatment arm were supposed to stay in study treatment for 7 days and 21 days respectively. (NCT00099632)
Timeframe: From first day of study treatment to last day of study treatment (up to 21 days)
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 2 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 0 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 5 |
"For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed to the primary endpoint; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed to primary endpoint.~10 participants who did not have resistance samples available were excluded from the primary endpoint analysis." (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 3 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 1 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 1 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 0 |
For the 7-day treatment duration group, only the genotype results from weeks 3 and 7 contributed; For the 21-day treatment duration groups, only the genotype results from weeks 5 and 9 contributed. (NCT00099632)
Timeframe: 2 and 6 weeks after completion of treatment
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 0 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 0 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 0 |
"Grade 3 or higher signs and symptoms, laboratory abnormalities, events that are reported through the EAE system, and any grade event that leads to a treatment change from first day of study treatment to week 12.~Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death" (NCT00099632)
Timeframe: From first day of study treatment to week 12
| Intervention | participants (Number) |
|---|---|
| 7-day Lamivudine/Zidovudine (3TC/ZDV) | 5 |
| 21-day Lamivudine/Zidovudine (3TC/ZDV) | 1 |
| 7-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 1 |
| 21-day Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) | 0 |
| 7-day Lopinavir/Ritonavir (LPV/r) | 2 |
| 21-day Lopinavir/Ritonavir (LPV/r) | 2 |
Infant plasma concentrations were collected and measured during the first 9 days of life. Half-life is defined as 0.693/k, where k, the elimination rate constant, is the slope of the decline in concentrations. (NCT00042289)
Timeframe: Infant plasma samples at 2-10, 18-28, 36-72 hours and 5-9 days after birth.
| Intervention | hour (Median) |
|---|---|
| DTG 50mg q.d. | 32.8 |
| EVG/COBI 150/150mg q.d. | 7.6 |
| DRV/COBI 800/150 mg q.d. | NA |
| EFV 600 mg q.d. (Outside THA) | 65.6 |
Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.
| Intervention | unitless (Median) |
|---|---|
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 0.15 |
| DTG 50mg q.d. | 1.25 |
| EVG/COBI 150/150mg q.d. | 0.91 |
| DRV/COBI 800/150 mg q.d. | 0.07 |
| ATV/COBI 300/150 mg q.d. | 0.07 |
| TFV 300mg q.d. | 0.88 |
Cord blood and maternal plasma concentrations were collected and measured at delivery, and compared as a ratio. For arms with zero overall participants analyzed, samples were below the limit of quantification and ratios could not be calculated. (NCT00042289)
Timeframe: Measured at time of delivery with single cord blood and single maternal plasma sample.
| Intervention | unitless (Median) |
|---|---|
| TAF 10mg q.d. w/COBI | 0.97 |
| EFV 600 mg q.d. (Outside THA) | 0.67 |
| EFV 600mg q.d. | 0.49 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 0.2 |
| RAL 400mg b.i.d. | 1.5 |
| ETR 200mg b.i.d. | 0.52 |
| MVC 150 or 300mg b.i.d. | 0.33 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 0.14 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 0.16 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | 0.19 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 0.12 |
| RPV 25mg q.d. | 0.55 |
| ATV/RTV 300/100mg q.d. or TFV/ATV/RTV 300/300/100mg q.d. | 0.18 |
| DRV/RTV 800/100mg q.d. or DRV/RTV 600/100mg b.i.d. | 0.18 |
Serum concentrations of the contraceptives. Note that no historical controls were provided by team pharmacologists and thus no comparisons were done for contraceptive concentrations in women using hormonal contraceptives and selected ARV drugs as compared to historical controls not using those ARV drugs. (NCT00042289)
Timeframe: Measured at 6-7 weeks after contraceptive initiation postpartum
| Intervention | pg/mL (Median) |
|---|---|
| ATV/RTV/TFV 300/100/300mg q.d. With ENG | 604 |
| LPV/RTV 400/100 b.i.d. With ENG | 428 |
| EFV 600mg q.d. With ENG | 125 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12h (area-under-the-curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8 and 12 hours post dosing.
| Intervention | mcg*hr/mL (Median) | |
|---|---|---|
| Before contraceptive initiation | After contraceptive initiation | |
| LPV/RTV 400/100 b.i.d. With ENG | 115.97 | 100.20 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2-12 wks postpartum before contraceptive initiation and 6-7 wks after contraceptive initiation. Blood samples were drawn pre-dose and at 0, 1, 2, 6, 8, 12, and 24 hours post dosing.
| Intervention | mcg*hr/mL (Median) | |
|---|---|---|
| Before contraceptive initiation | After contraceptive initiation | |
| ATV/RTV/TFV 300/100/300mg q.d. With ENG | 53.96 | 55.25 |
| EFV 600mg q.d. With ENG | 53.64 | 56.65 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 20 | 21 |
| MVC 150 or 300mg b.i.d. | 8 | 7 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC (area under the curve) were determined using the linear trapezoidal rule. See PK target in the Protocol Appendix V. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 (and 24) hours post dosing.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/RTV Arm 1: 300/100mg q.d. | 1 | 12 | 12 |
| DRV/COBI 800/150 mg q.d. | 3 | 4 | 14 |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 7 | 16 | 22 |
| DRV/RTV 600/100mg b.i.d. | 7 | 19 | 22 |
| DRV/RTV 800/100mg q.d. | 9 | 19 | 22 |
| DTG 50mg q.d. | 9 | 20 | 23 |
| EFV 600 mg q.d. (Outside THA) | 12 | 33 | 34 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 8 | 29 | 27 |
| ETR 200mg b.i.d. | 5 | 13 | 7 |
| EVG/COBI 150/150mg q.d. | 8 | 10 | 18 |
| FPV/RTV 700/100mg b.i.d. | 8 | 26 | 22 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 10 | 19 | 26 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 9 | 30 | 27 |
| ATV/COBI 300/150 mg q.d. | 1 | 2 | 5 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 15 | 14 |
| RAL 400mg b.i.d. | 11 | 33 | 30 |
| RPV 25mg q.d. | 14 | 26 | 25 |
| TAF 10mg q.d. w/COBI | 15 | 23 | 22 |
| TAF 25mg q.d. | 13 | 23 | 24 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 10 | 24 | 18 |
| TFV 300mg q.d. | 2 | 27 | 27 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 1 | 11 | 12 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 7 | 23 | 32 |
Infant plasma concentrations were collected and measured during the first 9 days of life. (NCT00042289)
Timeframe: Blood samples were collected at 2-10, 18-28, 36-72 hours and 5-9 days after birth.
| Intervention | mcg/mL (Median) | |||
|---|---|---|---|---|
| 2-10 hours after birth | 18-28 hours after birth | 36-72 hours after birth | 5-9 days after birth | |
| DRV/COBI 800/150 mg q.d. | 0.35 | 1.43 | 1.87 | 1.72 |
| DTG 50mg q.d. | 1.73 | 1.53 | 1.00 | 0.06 |
| EFV 600 mg q.d. (Outside THA) | 1.1 | 1.0 | 0.9 | 0.4 |
| EVG/COBI 150/150mg q.d. | 0.132 | 0.032 | 0.005 | 0.005 |
Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
| Intervention | ng*hour/mL (Geometric Mean) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| MVC 150 or 300mg b.i.d. | NA | 2717 | 3645 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 55.1 | 51.8 | 79.6 |
| DRV/RTV 600/100mg b.i.d. | 45.8 | 45.9 | 61.7 |
| FPV/RTV 700/100mg b.i.d. | 43.50 | 32.15 | 51.60 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 34.2 | 33.5 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC12 (area under the curve from 0 to 12 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured in 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hrs post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ETR 200mg b.i.d. | 4.5 | 8.3 | 5.3 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 14.9 | 16.1 | 27.1 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 72 | 96 | 133 |
| RAL 400mg b.i.d. | 6.6 | 5.4 | 11.6 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24 (area under the curve from 0 to 24 hours) were determined using the linear trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/COBI 300/150 mg q.d. | 25.33 | 18.85 | 36.20 |
| ATV/RTV Arm 1: 300/100mg q.d. | 88.2 | 41.9 | 57.9 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 30.6 | 45.7 | 48.8 |
| DRV/COBI 800/150 mg q.d. | 50.00 | 42.05 | 95.55 |
| DRV/RTV 800/100mg q.d. | 64.6 | 63.5 | 103.9 |
| DTG 50mg q.d. | 47.6 | 49.2 | 65.0 |
| EFV 600 mg q.d. (Outside THA) | 47.30 | 60.02 | 62.70 |
| EVG/COBI 150/150mg q.d. | 15.3 | 14.0 | 21.0 |
| TAF 10mg q.d. w/COBI | 0.197 | 0.206 | 0.216 |
| TAF 25mg q.d. | 0.171 | 0.212 | 0.271 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 0.181 | 0.257 | 0.283 |
| TFV 300mg q.d. | 1.9 | 2.4 | 3.0 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 14.5 | 28.8 | 39.6 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 26.2 | 37.7 | 58.7 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
| Intervention | mg*hour/L (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 55.4 | 58.3 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. AUC24h (area-under-the-curve from 0 to 24 hours) were determined using the trapezoidal rule. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, 12 and 24 hours post dosing.
| Intervention | mg*hour/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| RPV 25mg q.d. | 1.969 | 1.669 | 2.387 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | mg/L (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 5.44 | 5.10 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/COBI 300/150 mg q.d. | 2.82 | 2.20 | 3.90 |
| ATV/RTV Arm 1: 300/100mg q.d. | NA | 3.6 | 4.1 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 3.11 | 4.51 | 4.52 |
| DRV/COBI 800/150 mg q.d. | 4.59 | 3.67 | 7.04 |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 6.22 | 6.55 | 8.96 |
| DRV/RTV 600/100mg b.i.d. | 5.64 | 5.53 | 7.78 |
| DRV/RTV 800/100mg q.d. | 6.77 | 5.78 | 8.11 |
| DTG 50mg q.d. | 3.62 | 3.54 | 4.85 |
| EFV 600 mg q.d. (Outside THA) | 3.87 | 5.13 | 4.41 |
| FPV/RTV 700/100mg b.i.d. | 5.61 | 5.12 | 6.75 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 3.89 | 3.62 | 5.37 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 5.1 | 5.0 |
| TFV 300mg q.d. | 0.250 | 0.245 | 0.298 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 1.2 | 2.5 | 4.1 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 2.73 | 3.56 | 5.43 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ETR 200mg b.i.d. | 0.70 | 1.01 | 0.63 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 8.4 | 10.7 | 14.6 |
| RAL 400mg b.i.d. | 2.250 | 1.770 | 3.035 |
| RPV 25mg q.d. | 0.145 | 0.134 | 0.134 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | ng/mL (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| MVC 150 or 300mg b.i.d. | 448 | 647 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Cmax was the maximum observed concentration after a dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm; Blood samples were drawn pre-dose and at 1, 2, 4, 6, 8,12 (and 24) hours post dosing.
| Intervention | ng/mL (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| EVG/COBI 150/150mg q.d. | 1447.1 | 1432.8 | 1713.1 |
| TAF 10mg q.d. w/COBI | 80.4 | 91.2 | 98.2 |
| TAF 25mg q.d. | 69.7 | 96 | 133 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 87.8 | 107 | 141 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
| Intervention | ng/mL (Geometric Mean) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| MVC 150 or 300mg b.i.d. | 108 | 128 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| DRV/RTV 600 or 800 or 900/100mg b.i.d. Then 800 or 900/100mg b.i.d. Then 600/100mg b.i.d. | 2.84 | 2.52 | 4.51 |
| DRV/RTV 600/100mg b.i.d. | 2.12 | 2.22 | 2.51 |
| FPV/RTV 700/100mg b.i.d. | 2.12 | 1.64 | 2.87 |
| NFV Arm 2: 1250mg b.i.d. Then 1875mg b.i.d. Then 1250mg b.i.d. | NA | 0.47 | 0.52 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 12h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation); 3rd trimester (30-38 gestation); and either 2-3 wks, 2-8 wks, or 6-12 wks postpartum, depending on study arm. Trough concentration was measured 12 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ETR 200mg b.i.d. | 0.36 | 0.48 | 0.38 |
| IDV/RTV Arm 2: 400/100mg q.d. (Only THA) | 0.13 | 0.13 | 0.28 |
| LPV/RTV Arm 3: 400/100mg b.i.d. Then 600/150mg b.i.d. Then 400/100mg b.i.d. | 3.7 | 5.1 | 7.2 |
| RAL 400mg b.i.d. | 0.0621 | 0.064 | 0.0797 |
"Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose.~For the TAF 25 mg q.d., 10 mg q.d. w/COBI, and 25 mg q.d. w/COBI or RTV boosting arms, samples were all below the limit of quantification and statistical analyses were not conducted." (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| ATV/COBI 300/150 mg q.d. | 0.21 | 0.21 | 0.61 |
| ATV/RTV Arm 1: 300/100mg q.d. | 2.0 | 0.7 | 1.2 |
| ATV/RTV Arm 2: 300/100mg q.d. Then 400/100mg q.d. Then 300/100mg q.d. | 0.49 | 0.71 | 0.90 |
| DRV/COBI 800/150 mg q.d. | 0.33 | 0.27 | 1.43 |
| DRV/RTV 800/100mg q.d. | 0.99 | 1.17 | 2.78 |
| DTG 50mg q.d. | 0.73 | 0.93 | 1.28 |
| EFV 600 mg q.d. (Outside THA) | 1.49 | 1.48 | 1.94 |
| EVG/COBI 150/150mg q.d. | 0.0258 | 0.0487 | 0.3771 |
| TAF 10mg q.d. w/COBI | 0.00195 | 0.00195 | 0.00195 |
| TAF 25mg q.d. | 0.00195 | 0.00195 | 0.00195 |
| TAF 25mg q.d. w/COBI or RTV Boosting | 0.00195 | 0.00195 | 0.00195 |
| TFV 300mg q.d. | 0.039 | 0.054 | 0.061 |
| TFV/ATV/RTV Arm 1: 300/300/100mg q.d. | 0.3 | 0.5 | 0.8 |
| TFV/ATV/RTV Arm 2: 300/300/100mg q.d. Then 300/400/100mg q.d Then 300/300/100mg q.d. | 0.44 | 0.57 | 1.26 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
| Intervention | mg/L (Median) | |
|---|---|---|
| 3rd Trimester | Postpartum | |
| EFV 600mg q.d. | 1.60 | 2.05 |
Pharmacokinetic parameters were determined from plasma concentration-time profiles using noncompartmental methods. Trough concentration was the measured concentration from the 24h post-dose sample after an observed dose. (NCT00042289)
Timeframe: Measured at 2nd trimester (20-26 wks gestation), 3rd trimester (30-38 wks gestation), and either 2-3 wks, 2-8 wks or 6-12 wks postpartum depending on study arm. Trough concentration was measured 24 hrs after an observed dose.
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| 2nd Trimester | 3rd Trimester | Postpartum | |
| RPV 25mg q.d. | 0.063 | 0.056 | 0.081 |
The per-protocol analysis of change in CD4+ cell count from baseline to Week 24 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% confidence interval (CI). (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | cells/uL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 156 |
The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 48 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 48 weeks
| Intervention | cells/uL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 163 |
The per-protocol intention-to-treat analysis of change in CD4+ cell count from baseline to Week 96 was calculated using the measurement closest to schedule and within the analysis window, and quantified with an estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | cells/uL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 224 |
Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | ratio of trunk fat % : lower limb fat % (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.02 |
Change from baseline to follow-up in fat mass ratio was calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Fat mass ratio was calculated as the ratio of trunk fat percentage and lower limb fat percentage (% trunk fat mass / % lower limb fat mass). Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | ratio of trunk fat % : lower limb fat % (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.06 |
Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | µU/ml*mmol/L (Median) |
|---|---|
| Etravirine 400 mg Once Daily | -0.08 |
Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 48 weeks
| Intervention | µU/ml*mmol/L (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.71 |
Metabolic data analyses were conducted as-treated. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. Changes from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | µU/ml*mmol/L (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.23 |
This secondary outcome measure assessed the ratio of semen:plasma concentration of etravirine in paired semen and plasma samples collected from 14 male participants at Week 4 of treatment with etravirine and fixed dose tenofovir/emtricitabine. (NCT00959894)
Timeframe: 4 weeks
| Intervention | ratio of semen:plasma drug concentration (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 0.192 |
Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks
| Intervention | ng*hr/mL (Median) |
|---|---|
| Etravirine 400 mg Once Daily | 8024.40 |
The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring). (NCT00959894)
Timeframe: 96 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.69 |
The primary study endpoint was the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 24 of study participation. The per-protocol primary analysis was conducted intention-to-treat, with missing evaluations counted as failures. Achievement of HIV-1 viral load below 50 copies/ml was defined as having HIV-1 RNA <50 copies/ml during the Week 24 analysis window (>18 and <30 weeks post-entry). (NCT00959894)
Timeframe: 24 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.87 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 24 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 24 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.89 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <200 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.82 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA 200 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.77 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 48 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 48 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.77 |
This secondary outcome assessed the proportion of participants who achieved HIV-1 RNA <50 copies/ml at Week 96 of study treatment. The per-protocol analysis was conducted intention-to-treat, with missing evaluations counted as failures. (NCT00959894)
Timeframe: 96 weeks
| Intervention | proportion of participants (Number) |
|---|---|
| Etravirine 400 mg Once Daily | 0.71 |
Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | percentage of body fat (Median) | ||
|---|---|---|---|
| Total body fat | Limb fat | Trunk fat | |
| Etravirine 400 mg Once Daily | 0.43 | 0.48 | 0.32 |
Changes from baseline to follow-up in limb fat, trunk fat, total body fat, and lean mass were calculated. Whole body Dual X-ray Absorptiometry (DEXA) scans (Hologic Discovery W, Hologic Inc., Bedford, MA) were conducted at baseline, Week 24, and Week 96 to assess body fat distribution. Calculations of change from baseline to follow-up used the value closest to schedule and within the analysis window, and were quantified with the estimated median and distribution-free 95% CI. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | percentage of body fat (Median) | ||
|---|---|---|---|
| Total body fat | Limb fat | Trunk fat | |
| Etravirine 400 mg Once Daily | 1.44 | 0.82 | 1.93 |
Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 24 weeks
| Intervention | mg/dL (Median) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Fasting glucose | |
| Etravirine 400 mg Once Daily | -7 | 1 | -9 | -16 | 1 |
Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. (NCT00959894)
Timeframe: Baseline to 48 weeks
| Intervention | mg/dL (Median) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Fasting glucose | |
| Etravirine 400 mg Once Daily | 6 | 5 | -1 | -10 | 2 |
Metabolic data analyses were conducted as-treated. Changes in total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose from baseline to follow-up were calculated using the value closest to schedule and within the analysis window, and were quantified with the median and inter-quartile range. Insulin resistance was estimated by the homeostasis model assessment of insulin resistance (HOMA-IR), and was calculated as [fasting insulin (µU/mL) × fasting glucose (mmol/L)]/22.5. (NCT00959894)
Timeframe: Baseline to 96 weeks
| Intervention | mg/dL (Median) | ||||
|---|---|---|---|---|---|
| Total cholesterol | HDL-cholesterol | LDL-cholesterol | Triglycerides | Fasting glucose | |
| Etravirine 400 mg Once Daily | 6 | 4 | -5 | 3 | 2 |
Population pharmacokinetics were calculated using sparse sampling. Plasma concentrations of etravirine measured in samples from participants who provided blood samples at multiple study visits, with variation in sampling times relative to dosing of etravirine used to cover the spectrum of the dosing schedule. Model simulations and fitting were performed with NONMEM ® 7.3. (ICON, plc) and model exploration was performed with Berkeley Madonna (Berkeley, CA, USA) (NCT00959894)
Timeframe: At or after 4 weeks
| Intervention | ng/mL (Median) | |
|---|---|---|
| Etravirine trough plasma concentration | Etravirine peak plasma concentration | |
| Etravirine 400 mg Once Daily | 217.47 | 480.99 |
Per-protocol, genotype testing was conducted at confirmation of virologic failure if the confirmatory HIV-1 RNA was above the laboratory-specified threshold of 500 copies/mL. HIV-1 genotype was determined using the TRUGENE® HIV-1 assay (Siemens Healthcare Diagnostics, Tarrytown, NY) (NCT00959894)
Timeframe: 96 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Y181C | E138K | E138K, Y181C, M230L, M184I, K219E, V75I | No resistance-associated mutations detected | |
| Etravirine 400 mg Once Daily | 1 | 1 | 1 | 3 |
"The safety/tolerability endpoint was defined as the first grade 3 or higher sign, symptom or laboratory abnormality that was at least one grade higher than baseline among participants ever exposed to etravirine (regardless of treatment status), or permanent discontinuation of etravirine due to any toxicity (regardless of grade). Modification of tenofovir/emtricitabine was not a safety/tolerability event.~The Kaplan-Meier method was used to estimate the proportion of participants ever exposed to etravirine who remained event-free through Week 96, with a 95% CI using Greenwood's variance estimate and a log-log transformation. Time was handled as continuous (weeks from treatment start to event or censoring)." (NCT00959894)
Timeframe: 96 weeks
| Intervention | participants (Number) | ||
|---|---|---|---|
| At least one safety/tolerability event | Signs or Symptoms | Laboratory Abnormalities | |
| Etravirine 400 mg Once Daily | 23 | 13 | 10 |
132 reviews available for nevirapine and HIV Coinfection
| Article | Year |
|---|---|
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; | 2005 |
Pyrroloaryls and pyrroloheteroaryls: Inhibitors of the HIV fusion/attachment, reverse transcriptase and integrase.
Topics: Anti-HIV Agents; Drug Discovery; HIV; HIV Fusion Inhibitors; HIV Infections; HIV Integrase; HIV Inte | 2015 |
Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.
Topics: Adult; Anti-HIV Agents; Ghana; HIV Infections; Humans; Lamivudine; Nevirapine; Retrospective Studies | 2022 |
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Ben | 2020 |
Effects of CYP2B6 polymorphisms on plasma nevirapine concentrations: a systematic review and meta-analysis.
Topics: Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Polymorphism, Genetic; Reverse Transcri | 2020 |
Influence of Malnutrition on the Pharmacokinetics of Drugs Used in the Treatment of Poverty-Related Diseases: A Systematic Review.
Topics: HIV Infections; Humans; Malaria; Malnutrition; Nevirapine; Pharmaceutical Preparations; Poverty | 2021 |
Concomitant contraceptive implant and efavirenz use in women living with HIV: perspectives on current evidence and policy implications for family planning and HIV treatment guidelines.
Topics: Adult; Alkynes; Benzoxazines; Contraception; Contraceptive Agents; Counseling; Cyclopropanes; Drug I | 2017 |
Developments in early diagnosis and therapy of HIV infection in newborns.
Topics: Anti-HIV Agents; Early Diagnosis; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm | 2018 |
Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Com | 2017 |
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities | 2018 |
Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; HLA Antigens; Hu | 2019 |
HIV drug resistance in mothers and infants following use of antiretrovirals to prevent mother-to-child transmission.
Topics: Alkynes; Anti-HIV Agents; Aptamers, Nucleotide; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; D | 2013 |
HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV- | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynuc | 2013 |
Prevention of perinatal HIV I transmission by protease inhibitor based triple drug antiretroviral therapy versus nevirapine as single dose at the time of delivery.
Topics: Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV Proteas | 2012 |
Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Treatment Outcome; | 2013 |
Nevirapine-based regimens in HIV-infected antiretroviral-naive patients: systematic review and meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI | 2013 |
Antiretroviral treatment in HIV-infected infants and young children: novel issues raised by the Mississippi baby.
Topics: Age Factors; Anti-HIV Agents; Clinical Protocols; Female; HIV Infections; Humans; Infant; Infant, Ne | 2014 |
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi | 2014 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines | 2014 |
Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Black People; Cyclopropanes; Cytochrome P-450 CYP2A6; Cytoch | 2015 |
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Fem | 2015 |
Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents; Cyclopropanes; Drug | 2015 |
Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?
Topics: Adult; Africa South of the Sahara; Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; D | 2016 |
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infecti | 2016 |
A review of drug patch testing and implications for HIV clinicians.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Hypersensitivity; HIV Infections; Humans; Nevirapine; Patc | 2008 |
A multimodal, evidence-based approach to achieve lipid targets in the treatment of antiretroviral-associated dyslipidemia: case report and review of the literature.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dyslip | 2008 |
Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.
Topics: Adult; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infec | 2008 |
Hepatotoxicity associated with long- versus short-course HIV-prophylactic nevirapine use: a systematic review and meta-analysis from the Research on Adverse Drug events And Reports (RADAR) project.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2009 |
[A fixed dose anti-HIV combination for the poor? Triomune].
Topics: Africa; Anti-HIV Agents; Developing Countries; Drug Administration Schedule; Drug Combinations; HIV | 2009 |
Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?
Topics: Adenine; Adult; Africa South of the Sahara; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2009 |
Optimal versus suboptimal treatment for HIV-infected pregnant women and HIV-exposed infants in clinical research studies.
Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV | 2009 |
[Highly efficient chemoprophylaxis of perinatal transmission of HIV 1 infection in HIV-infected pregnant women].
Topics: Animals; Anti-HIV Agents; Azides; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, | 2009 |
Pharmacogenetics of antiretrovirals.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Cycloprop | 2010 |
Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Child; Cyclopropanes; Drug Interactions; HIV In | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Th | 2010 |
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infecti | 2010 |
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; D | 2011 |
Integrating prevention of mother-to-child HIV transmission (PMTCT) programmes with other health services for preventing HIV infection and improving HIV outcomes in developing countries.
Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infectious Disease Transmissi | 2011 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudi | 2011 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sec | 2011 |
Guidelines for the use of extended-release nevirapine in HIV-infected patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Delayed-Action Preparations; HIV Infections; Humans; Nevirapi | 2011 |
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch | 2011 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fet | 2011 |
Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
Topics: Aged, 80 and over; Antiretroviral Therapy, Highly Active; Ascites; Chemical and Drug Induced Liver I | 2012 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; | 2012 |
NNRTIs: future prospects.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Forecasting; HIV Infections; Humans; Nevirapine; Reverse Trans | 2012 |
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Combi | 2012 |
Safety of nevirapine in HIV-infected pregnant women initiating antiretroviral therapy at higher CD4 counts: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Contraindications; Female; HIV Infections; Humans; Nevirapine | 2012 |
Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; HIV Infections; Humans; Nevirap | 2013 |
Mother to child transmission of HIV.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections | 2002 |
Mother to child transmission of HIV.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Combined Modality Therapy; Female; HIV Infections | 2002 |
Non-nucleoside reverse transcriptase inhibitors--an overview.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1 | 2003 |
NNRTI hepatotoxicity: efavirenz versus nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Hepat | 2002 |
Toxicity of non-nucleoside analogue reverse transcriptase inhibitors.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind | 2003 |
Protease inhibitor-sparing regimens: new evidence strengthens position.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Clinical Trials as | 2003 |
HIV: mother to child transmission.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections | 2003 |
[Antiretroviral-induced toxiderma in HIV-infected patients].
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; | 2003 |
Perspectives on HAART: switch maintenance therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV | 2003 |
Efficacy and durability of nevirapine in antiretroviral-experienced patients.
Topics: HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; Salvage Therapy | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Prevention of mother-to-child transmission of HIV--what next?
Topics: Breast Feeding; Developed Countries; Developing Countries; Drug Resistance, Viral; Female; HIV Infec | 2003 |
Issues in antiretroviral toxicity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Exanthema; Female; HIV | 2003 |
Nevirapine to prevent mother-to-child transmission of HIV-1 among women of unknown serostatus.
Topics: Africa; AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disea | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzox | 2003 |
Hepatotoxicity associated with nevirapine use.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Female; HIV Infec | 2004 |
Preventing neonatal HIV: a review.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious | 2003 |
Clinical utility of current NNRTIs and perspectives of new agents in this class under development.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis | 2004 |
Nevirapine in the treatment of HIV.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV I | 2004 |
[Combined antiretroviral therapy with nevirapine of HIV-infected adults].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Reverse | 2004 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
The safety of antiretroviral drugs in pregnancy.
Topics: Abnormalities, Drug-Induced; Acidosis, Lactic; Anemia; Animals; Anti-Retroviral Agents; Chemical and | 2005 |
Nevirapine toxicity--implications for management of South African patients.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV-1; Humans; Infectious Disease | 2005 |
Preventing mother-to-child transmission of HIV: successes and challenges.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Drug Resistance, Viral; Fema | 2005 |
HIV: mother to child transmission.
Topics: Administration, Intravaginal; Anti-HIV Agents; Breast Feeding; Cesarean Section; Female; HIV Infecti | 2005 |
Do non-nucleoside reverse transcriptase inhibitors contribute to lipodystrophy?
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Cardiovascular Diseases; Cyclopropanes; HIV Infection | 2005 |
Sex differences in antiretroviral therapy-associated intolerance and adverse events.
Topics: Acidosis, Lactic; Anti-Retroviral Agents; Didanosine; Exanthema; Female; HIV Infections; Humans; Liv | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials | 2005 |
Controversies in the use of nevirapine for prevention of mother-to-child transmission of HIV.
Topics: Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Dis | 2006 |
HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Early Diagnosis; H | 2005 |
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV I | 2006 |
Nevirapine toxicity.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Liver; Nevirapine; Pregnancy; Pregnancy Complicatio | 2006 |
Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV?
Topics: Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; I | 2006 |
[The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R | 2006 |
HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug T | 2006 |
Evaluation of nevirapine-switch strategies for HIV treatment.
Topics: Adult; Australia; CD4 Lymphocyte Count; Drug Administration Schedule; Europe; Female; HIV Infections | 2006 |
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2006 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2007 |
Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?
Topics: Algorithms; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopro | 2007 |
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Tolerance; Exanthema; HIV Infections; | 2007 |
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infectio | 2007 |
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1 | 2007 |
International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Clinical Trials as Topic; Drug Administrati | 2007 |
Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Female; HIV Infections; Humans; Infectious | 2007 |
Is it safe to switch between efavirenz and nevirapine in the event of toxicity?
Topics: Alkynes; Benzoxazines; Chemical and Drug Induced Liver Injury; Cross Reactions; Cyclopropanes; Drug | 2007 |
Antiretroviral (ARV) drug resistance in the developing world.
Topics: Africa; Anti-HIV Agents; Asia; Child; Developing Countries; Drug Resistance, Viral; Female; HIV; HIV | 2007 |
Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Therapy, | 2008 |
The genetic and functional basis of HIV-1 resistance to nonnucleoside reverse transcriptase inhibitors.
Topics: Antiviral Agents; Benzodiazepines; Benzoxazoles; Clinical Trials as Topic; Drug Resistance, Microbia | 1994 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
AIDS pathogenesis: from models to viral dynamics in patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; HIV; HIV Infection | 1995 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors: L-697,661 and nevirapine.
Topics: Benzoxazoles; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyridines; Pyrid | 1996 |
Current clinical experience with nevirapine for HIV infection.
Topics: Antiviral Agents; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Nevirapine; Pyridines | 1996 |
Development of nonnucleoside HIV reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; Drug Design; HIV Infections; HIV Reverse Transcriptase; H | 1996 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Ther | 1997 |
Antiviral chemotherapy.
Topics: Adult; Antiviral Agents; Child; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Protease | 1997 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N | 1997 |
Use of nonnucleoside reverse-transcriptase inhibitors.
Topics: Anti-HIV Agents; Delavirdine; Drug Interactions; HIV Infections; Humans; Nevirapine; Reverse Transcr | 1998 |
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV I | 1998 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; | 1998 |
Natural endogenous reverse transcription of HIV-1.
Topics: Animals; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nevirapine; Reverse Transcriptase Inhibitor | 1998 |
[Nevirapine (Viramune): a new HIV inhibitor].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhib | 1999 |
New reverse transcriptase inhibitors.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Dideoxynucleosides; HIV Infections; HIV | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; D | 1999 |
Efavirenz: resistance and cross-resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Microbial; Geno | 1999 |
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Mul | 1999 |
Nevirapine: pharmacokinetic considerations in children and pregnant women.
Topics: Adult; Area Under Curve; Child; Drug Administration Schedule; Drug Interactions; Female; Half-Life; | 2000 |
Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV In | 2000 |
The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Clinical Trials as Topic; Cyclopropane | 2001 |
International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug R | 2001 |
The role of NNRTIs in antiretroviral combination therapy: an introduction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox | 2001 |
Comparison of NNRTIs in antiretroviral-naïve patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropane | 2001 |
Comparison of NNRTIs in antiretroviral-experienced patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV In | 2001 |
Factors affecting adherence and convenience in antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; | 2001 |
Other issues: penetration into sanctuary sites, immune reconstitution and NNRTI sequencing.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; | 2001 |
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combinat | 2001 |
Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors.
Topics: Alkynes; Benzoxazines; Biological Availability; Cyclopropanes; Delavirdine; Drug Interactions; Femal | 2001 |
Prevention of mother-to-child transmission of HIV: challenges for the current decade.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Drug Resistance, Microbial; Female; Health Resour | 2001 |
The role of nevirapine in the treatment of HIV-1 disease.
Topics: Anti-HIV Agents; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Interac | 2001 |
Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature.
Topics: Adult; Anti-HIV Agents; Communication Barriers; Female; HIV Infections; Humans; Nevirapine; Patient | 2001 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
HIV-1 drug resistance and mother-to-child transmission.
Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans | 2001 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Clinical Trial | 2002 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
426 trials available for nevirapine and HIV Coinfection
| Article | Year |
|---|---|
Lower Insulin Sensitivity in Newborns With In Utero HIV and Antiretroviral Exposure Who Are Uninfected in Botswana.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; Female; HIV Infections; Humans; Infant; Infant, N | 2022 |
Brief Report: Long-Term Clinical, Immunologic, and Virologic Outcomes Among Early-Treated Children With HIV in Botswana: A Nonrandomized Controlled Clinical Trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Botswana; CD4 Lymphocyte Count; HIV Infections; HIV-1; Huma | 2023 |
Bone and Renal Health in Infants With or Without Breastmilk Exposure to Tenofovir-Based Maternal Antiretroviral Treatment in the PROMISE Randomized Trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Bone Density; Female; HIV Infections; Humans; Kidney; Lumba | 2023 |
Linked dual-class HIV resistance mutations are associated with treatment failure.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Emtricitabi | 2019 |
Maternal Humoral Immune Responses Do Not Predict Postnatal HIV-1 Transmission Risk in Antiretroviral-Treated Mothers from the IMPAACT PROMISE Study.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibody-Dependent Cell Cytotoxicity; Breast Feeding; Coh | 2019 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; | 2019 |
A mobile health-facilitated behavioural intervention for community health workers improves exclusive breastfeeding and early infant HIV diagnosis in India: a cluster randomized trial.
Topics: Adult; Anti-HIV Agents; Behavior Therapy; Breast Feeding; Cluster Analysis; Community Health Workers | 2020 |
Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Arylamine N-Acetyltransferase; Benzoxazines; Cyclopropa | 2021 |
Maternal HBV Viremia and Association With Adverse Infant Outcomes in Women Living With HIV and HBV.
Topics: Anti-HIV Agents; Birth Weight; Coinfection; Double-Blind Method; Female; Hepatitis B; Hepatitis B vi | 2021 |
Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Iso | 2021 |
Pharmacokinetics and safety of early nevirapine-based antiretroviral therapy for neonates at high risk for perinatal HIV infection: a phase 1/2 proof of concept study.
Topics: Anti-HIV Agents; Female; Gestational Age; HIV Infections; Humans; Infant; Infant, Newborn; Infectiou | 2021 |
Efficacy of Mobile phone use on adherence to Nevirapine prophylaxis and retention in care among the HIV-exposed infants in prevention of mother to child transmission of HIV: a randomized controlled trial.
Topics: Anti-HIV Agents; Cell Phone Use; Child; Female; HIV Infections; Humans; Infant; Infectious Disease T | 2021 |
Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component.
Topics: Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV Seropositivity; H | 2021 |
Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial.
Topics: Adult; Anti-Retroviral Agents; Child Development; Female; HIV Infections; Humans; Infant; Male; Milk | 2021 |
Switching to Efavirenz Versus Remaining on Ritonavir-boosted Lopinavir in Human Immunodeficiency Virus-infected Children Exposed to Nevirapine: Long-term Outcomes of a Randomized Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child, Preschool; Cyclopropanes; Femal | 2017 |
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Clinical Protocols; Dose-Response Relationship, Dr | 2017 |
Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.
Topics: Adult; Anti-HIV Agents; Asian People; Cambodia; Cytochrome P-450 CYP2B6; Female; HIV Infections; Hum | 2017 |
Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI | 2017 |
Pharmacogenetics of artemether-lumefantrine influence on nevirapine disposition: Clinically significant drug-drug interaction?
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Cross-Over Studies; Cytochrome P-45 | 2019 |
Conditional cash transfers to prevent mother-to-child transmission in low facility-delivery settings: evidence from a randomised controlled trial in Nigeria.
Topics: Adult; Delivery, Obstetric; Female; HIV Infections; Hospitals, Public; Humans; Infant, Newborn; Infa | 2019 |
Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel; | 2019 |
The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Biotransformation; Cytochrome P-450 | 2013 |
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzo | 2013 |
Population pharmacokinetic analysis of a nevirapine-based HIV-1 prevention of mother-to-child transmission program in Uganda to assess the impact of different dosing regimens for newborns.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dise | 2013 |
Cluster randomised trial of the uptake of a take-home infant dose of nevirapine in Kenya.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, | 2010 |
Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Asian People; Biotransforma | 2013 |
Short communication: effect of short-course antenatal zidovudine and single-dose nevirapine on the BED capture enzyme immunoassay levels in HIV type 1 subtype C infection.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Antibodies; HIV Infections; HIV-1; | 2013 |
Is nevirapine dose-escalation appropriate in young, African, HIV-infected children?
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Exanthema; Female; HIV; HIV Infections; Humans | 2013 |
Livolin ameliorates elevations in alanine transaminase in HIV infected patients commencing highly active antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly A | 2012 |
Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Chemoprevention; Cytochrome P-450 CYP2B6; Fem | 2013 |
HIV disease progression in the first year after delivery among African women followed in the HPTN 046 clinical trial.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Disease Progression; Doubl | 2013 |
Effect of 7 days of phenytoin on the pharmacokinetics of and the development of resistance to single-dose nevirapine for perinatal HIV prevention: a randomized pilot trial.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Drug Interactions; Drug Resistance, Viral; Female; Half-Lif | 2013 |
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte Count; Cohort S | 2013 |
Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyc | 2013 |
Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin | 2013 |
Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; | 2013 |
Nevirapine-based antiretroviral therapy does not reduce oral contraceptive effectiveness.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Contraceptives, Oral; Dru | 2013 |
Early changes in hepatic function among HIV-tuberculosis patients treated with nevirapine or efavirenz along with rifampin-based anti-tuberculosis therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; CD4 Lymp | 2013 |
Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.
Topics: Anthropometry; Anti-HIV Agents; Body Height; Body Weight; Chemoprevention; Child, Preschool; Female; | 2013 |
Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropa | 2013 |
Efficacy and safety of an extended nevirapine regimen in infants of breastfeeding mothers with HIV-1 infection for prevention of HIV-1 transmission (HPTN 046): 18-month results of a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Africa; Anti-HIV Agents; Breast Feeding; Chemoprevention; Double-Blind Method; Fe | 2014 |
Maternal anaemia and duration of zidovudine in antiretroviral regimens for preventing mother-to-child transmission: a randomized trial in three African countries.
Topics: Adult; Africa South of the Sahara; Anemia; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; I | 2013 |
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Over Studies; Dela | 2014 |
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HI | 2014 |
Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.
Topics: Adenine; Adult; Antiviral Agents; Creatinine; Deoxycytidine; Drug Therapy, Combination; Emtricitabin | 2014 |
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 | 2014 |
Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant | 2014 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2014 |
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
Topics: Adolescent; Area Under Curve; Child; Drug Eruptions; Drug Resistance, Viral; Female; HIV Infections; | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; D | 2014 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; | 2014 |
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides | 2014 |
Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children.
Topics: Antimalarials; Artemisinins; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; HI | 2014 |
Hypothesis testing for an extended cox model with time-varying coefficients.
Topics: Algorithms; Biometry; Computer Simulation; Data Interpretation, Statistical; Female; HIV Infections; | 2014 |
Predictors of suboptimal CD4 response among women achieving virologic suppression in a randomized antiretroviral treatment trial, Africa.
Topics: Adenine; Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Deoxycyti | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combinati | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Dru | 2014 |
Correlates of age at attainment of developmental milestones in HIV-infected infants receiving early antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child Development; Female; Follow-Up | 2015 |
Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
Topics: Africa South of the Sahara; Anti-HIV Agents; Child, Preschool; Female; HIV Infections; HIV-1; Humans | 2014 |
The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
Topics: HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Prospective Studies; Pyrimidines; Reverse Trans | 2015 |
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resis | 2015 |
Kericho CLinic-based ART Diagnostic Evaluation (CLADE): design, accrual, and baseline characteristics of a randomized controlled trial conducted in predominately rural, district-level, HIV clinics of Kenya.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; HIV-1; Humans; Kenya; Male; M | 2015 |
Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genot | 2015 |
Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infant, | 2015 |
Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Delayed-Action Preparations; Drug-Related Side | 2015 |
Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cyclopropanes; Cy | 2015 |
Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1.
Topics: Adult; Aged; Anti-HIV Agents; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infecti | 2015 |
Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2016 |
Randomized noninferiority trial of two maternal single-dose nevirapine-sparing regimens to prevent perinatal HIV in Thailand.
Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA, Viral; Double-Blind Method; Female; HIV Infections; Hu | 2015 |
Cytomegalovirus IgG Level and Avidity in Breastfeeding Infants of HIV-Infected Mothers in Malawi.
Topics: Anti-HIV Agents; Antibodies, Viral; Antibody Affinity; Breast Feeding; Cytomegalovirus; Cytomegalovi | 2015 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Prescho | 2016 |
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Therapy, | 2015 |
Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Co | 2016 |
Population pharmacokinetics of nevirapine in Malaysian HIV patients: a non-parametric approach.
Topics: Adult; Aged; Anti-HIV Agents; Area Under Curve; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infec | 2016 |
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cognition; Cognition Disorders; Emtricitabine, Tenofovir | 2016 |
Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delive | 2016 |
Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Female; Follow-Up Stu | 2016 |
Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention.
Topics: Adult; Anti-Retroviral Agents; Black or African American; CD4 Lymphocyte Count; Drug Therapy, Combin | 2016 |
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination | 2016 |
Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cluster Analysis; Counseling; Female; HIV Infections; | 2016 |
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or Nevirapine.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Constitutive Androstane Receptor; Contraceptive Agen | 2017 |
Addition of single-dose tenofovir and emtricitabine to intrapartum nevirapine to reduce perinatal HIV transmission.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Drug Administration Schedule; Drug Therapy, C | 2008 |
Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; C | 2008 |
Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2008 |
HIV-1 persists in breast milk cells despite antiretroviral treatment to prevent mother-to-child transmission.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cell-Free Syste | 2008 |
Lymphocyte mitochondrial depolarization and apoptosis in HIV-1-infected HAART patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Apoptosis; Benzoxazines; CD4-Positive T-Lymphocytes; | 2008 |
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Drugs, Generic; Female; HIV Infections | 2008 |
Mother-to-child transmission of HIV-1: association with malaria prevention, anaemia and placental malaria.
Topics: Adult; Anemia; Anti-HIV Agents; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; HIV | 2008 |
Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.
Topics: Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active | 2008 |
Concomitant use of nonnucleoside analogue reverse transcriptase inhibitors and rifampicin in TB/HIV type 1-coinfected patients.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Ch | 2008 |
Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Hu | 2008 |
Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Computer Simulation; Cross-Sectional Studi | 2009 |
Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) protocol in Lilongwe, Malawi.
Topics: Anti-Retroviral Agents; Breast Feeding; Clinical Protocols; Female; HIV Infections; Humans; Infant, | 2009 |
Nevirapine toxicity in non-HIV cancer patients.
Topics: Aged; HIV Infections; Humans; Middle Aged; Neoplasm Staging; Nevirapine; Thyroid Neoplasms | 2008 |
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Seroposit | 2008 |
Determining an optimal testing strategy for infants at risk for mother-to-child transmission of HIV-1 during the late postnatal period.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; H | 2008 |
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Vir | 2009 |
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf | 2009 |
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf | 2009 |
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf | 2009 |
Risk factors for early and late transmission of HIV via breast-feeding among infants born to HIV-infected women in a randomized clinical trial in Botswana.
Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf | 2009 |
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drugs, Generic; Drugs, Investigational; Female; HIV Infe | 2008 |
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Huma | 2009 |
Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infec | 2009 |
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibit | 2009 |
Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Li | 2009 |
Resistance mutations in HIV-1 infected pregnant women and their infants receiving antiretrovirals to prevent HIV-1 vertical transmission in China.
Topics: Adult; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combinatio | 2009 |
Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1.
Topics: Adenine; Adult; Anti-HIV Agents; Cambodia; Cote d'Ivoire; Deoxycytidine; Drug Administration Schedul | 2009 |
Timing and determinants of mother-to-child transmission of HIV in Nigeria.
Topics: Adult; Anti-HIV Agents; Birth Weight; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hum | 2009 |
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV I | 2009 |
A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2009 |
Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Base Sequence; DNA | 2009 |
Predictors of rapid HIV testing acceptance and successful nevirapine administration in Zambian labor wards.
Topics: Anti-HIV Agents; Chemoprevention; Clinical Laboratory Techniques; Female; HIV Infections; Humans; In | 2009 |
Predictors of early and late mother-to-child transmission of HIV in a breastfeeding population: HIV Network for Prevention Trials 012 experience, Kampala, Uganda.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious | 2009 |
Pharmacokinetic assessment of nevirapine and metabolites in human immunodeficiency virus type 1-infected patients with hepatic fibrosis.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle A | 2009 |
Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients.
Topics: Adult; Cross-Over Studies; Darunavir; Drug Interactions; Drug Therapy, Combination; Female; HIV Infe | 2009 |
Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composit | 2009 |
Selected hematologic and biochemical measurements in African HIV-infected and uninfected pregnant women and their infants: the HIV Prevention Trials Network 024 protocol.
Topics: Adult; Anti-HIV Agents; Blood Cell Count; Double-Blind Method; Female; Follow-Up Studies; Gestationa | 2009 |
Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apolipoprotein A-I; Cholesterol, HDL; | 2009 |
[Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Didanosi | 2009 |
Comparing couples' and individual voluntary counseling and testing for HIV at antenatal clinics in Tanzania: a randomized trial.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Counseling; Family Characteristics; Female; HIV Infectio | 2010 |
Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressu | 2009 |
Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte | 2009 |
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2009 |
Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Sched | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Dru | 2009 |
A cluster-randomized trial of enhanced labor ward-based PMTCT services to increase nevirapine coverage in Lusaka, Zambia.
Topics: Adult; Anti-HIV Agents; Female; Fetal Blood; Health Services Accessibility; HIV Infections; Humans; | 2010 |
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Dru | 2010 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV I | 2009 |
Temporal reduction of HIV type 1 viral load in breast milk by single-dose nevirapine during prevention of MTCT.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Crea | 2010 |
Co-administration of fluconazole increases nevirapine concentrations in HIV-infected Ugandans.
Topics: Adult; Anti-HIV Agents; Antifungal Agents; Cryptococcosis; Drug Interactions; Female; Fluconazole; H | 2010 |
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; | 2010 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Meth | 2010 |
Long-term efficacy and safety of once-daily nevirapine in combination with tenofovir and emtricitabine in the treatment of HIV-infected patients: a 72-week prospective multicenter study (TENOR-trial).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Fema | 2009 |
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms; | 2010 |
Is single-dose NVP relevant in the era of more efficacious PMTCT regimens? Lessons from Zambia.
Topics: Anti-HIV Agents; Clinical Protocols; Developing Countries; Disease Transmission, Infectious; Drug Re | 2010 |
Pharmacokinetics of lopinavir-ritonavir with and without nonnucleoside reverse transcriptase inhibitors in Ugandan HIV-infected adults.
Topics: Adult; Aged; Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Female; HIV | 2010 |
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
Topics: Administration, Oral; Anti-HIV Agents; Child; Child, Preschool; Cross-Over Studies; Female; HIV Infe | 2010 |
Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Administration Schedu | 2010 |
Nonnucleoside reverse transcriptase inhibitor concentrations during treatment interruptions and the emergence of resistance: a substudy of the ISS-PART Trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Dr | 2010 |
Eighteen-month follow-up of HIV-1-infected mothers and their children enrolled in the Kesho Bora study observational cohorts.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Burkina Faso; CD4 Lym | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug The | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Antiretroviral regimens in pregnancy and breast-feeding in Botswana.
Topics: Adult; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female; Follow-U | 2010 |
Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 2010 |
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, P | 2011 |
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransfe | 2010 |
Antiretroviral therapies in women after single-dose nevirapine exposure.
Topics: Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug T | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Antiretroviral treatment for children with peripartum nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV In | 2010 |
Growth of infants born to HIV-infected women in South Africa according to maternal and infant characteristics.
Topics: Adult; Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Epidemiologic Methods; Femal | 2010 |
Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Infan | 2011 |
Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; HIV-1; Hum | 2011 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2011 |
Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Hypersensitivity; Gene Frequen | 2011 |
Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Congenital Abnormalities; Double-Blind Method; Female; Heart | 2011 |
"Forgiving" a missed daily dose.
Topics: Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; HIV Infections; Humans; Medicatio | 2011 |
CD4+ cell count and risk for antiretroviral drug resistance among women using peripartum nevirapine for perinatal HIV prevention.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Seroposit | 2011 |
Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2011 |
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Thera | 2011 |
Slower clearance of nevirapine resistant virus in infants failing extended nevirapine prophylaxis for prevention of mother-to-child HIV transmission.
Topics: Base Sequence; Breast Feeding; Child; Drug Administration Schedule; Drug Resistance, Viral; Ethiopia | 2011 |
Rapid intrapartum or postpartum HIV testing at a midwife obstetric unit and a district hospital in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Cluster Analysis; Feasibility Studies; Female; HIV Infections; H | 2011 |
Twelve-month follow-up of Six Week Extended Dose Nevirapine randomized controlled trials: differential impact of extended-dose nevirapine on mother-to-child transmission and infant death by maternal CD4 cell count.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Female | 2011 |
Postexposure prophylaxis of breastfeeding HIV-exposed infants with antiretroviral drugs to age 14 weeks: updated efficacy results of the PEPI-Malawi trial.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease Transmis | 2011 |
Improved detection of incident HIV infection and uptake of PMTCT services in labor and delivery in a high HIV prevalence setting.
Topics: Anti-HIV Agents; Eswatini; Female; Fetal Blood; HIV Antibodies; HIV Infections; Humans; Incidence; I | 2011 |
Once-a-day (QD) vs. twice-daily (BID) nevirapine as simplification in PI-treated patients after 2 mos. of BID induction.
Topics: Adolescent; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fem | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemia | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtrici | 2011 |
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.
Topics: Alleles; Anti-HIV Agents; Antiviral Agents; Drug Administration Schedule; Drug Resistance, Viral; Fe | 2011 |
Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies | 2011 |
Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
Topics: Adult; Alkynes; Antibiotics, Antitubercular; Benzoxazines; Chemical and Drug Induced Liver Injury; C | 2011 |
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HI | 2011 |
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Adminis | 2011 |
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Bi | 2011 |
Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY).
Topics: Adolescent; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Immunoglobulins, Intravenous; In | 2011 |
Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Biological Availability; Delayed-Action Pr | 2011 |
Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo | 2011 |
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Resistance, Viral; F | 2011 |
Interaction between artemether-lumefantrine and nevirapine-based antiretroviral therapy in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug | 2011 |
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Drug Therapy, Combinat | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Did | 2011 |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2011 |
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease | 2012 |
Intrapartum single-dose carbamazepine reduces nevirapine levels faster and may decrease resistance after a single dose of nevirapine for perinatal HIV prevention.
Topics: Adolescent; Adult; Carbamazepine; CD4 Lymphocyte Count; Chi-Square Distribution; Drug Interactions; | 2012 |
Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Delayed-Action Preparations; Drug Substitution; Female | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HI | 2012 |
Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.
Topics: Acyclovir; Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Female; HIV Infections; HIV-1; H | 2012 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig | 2011 |
Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Hi | 2012 |
A lipid-based nutrient supplement mitigates weight loss among HIV-infected women in a factorial randomized trial to prevent mother-to-child transmission during exclusive breastfeeding.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Dietary Supplements; Female; HIV Infections; HIV-1; H | 2012 |
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; HIV Infections; Humans | 2012 |
Nevirapine pharmacokinetics and risk of rash and hepatitis among HIV-infected sub-Saharan African women.
Topics: Adult; Africa South of the Sahara; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Dru | 2012 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycy | 2012 |
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Body Height; Body Weight; Chi-Square Distribution; Child, Pre | 2012 |
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV | 2012 |
The frequency of malaria is similar among women receiving either lopinavir/ritonavir or nevirapine-based antiretroviral treatment.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Malaria; Nevirapine; Ritonavir | 2012 |
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Hum | 2012 |
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; F | 2012 |
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisin | 2012 |
Effects of valacyclovir on markers of disease progression in postpartum women co-infected with HIV-1 and herpes simplex virus-2.
Topics: Acyclovir; Antiviral Agents; Biomarkers; CD4 Antigens; Disease Progression; Female; Herpes Genitalis | 2012 |
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2012 |
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
Topics: Adult; Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Death; Drug Resistance, Viral; Endpoint Determ | 2012 |
Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity.
Topics: Adult; Aged; Anti-HIV Agents; Biomarkers; Case-Control Studies; Chromatography, Liquid; Female; Hapt | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch | 2012 |
Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional | 2012 |
Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission.
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infa | 2013 |
Influence of ABCB-1 C3435T polymorphisms on plasma nevirapine and efavirenz levels and their effects on virologic and immunological outcomes in HIV/TB co-infected Thai adults under anti-retroviral therapy.
Topics: Adult; Alkynes; Analysis of Variance; Antiretroviral Therapy, Highly Active; Antitubercular Agents; | 2012 |
Growth patterns among HIV-exposed infants receiving nevirapine prophylaxis in Pune, India.
Topics: Adult; Anthropometry; Female; HIV Infections; HIV Seropositivity; Humans; India; Infant; Infant, New | 2012 |
Anaemia in HIV-infected children: severity, types and effect on response to HAART.
Topics: Adolescent; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; | 2012 |
Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2013 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucl | 2013 |
Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when coadministered with combined oral contraceptives.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptives, Oral, Synthetic; Cyclopro | 2013 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, C | 2013 |
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administrati | 2012 |
Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants.
Topics: Anti-Retroviral Agents; Breast Feeding; Chemoprevention; Drug Resistance, Viral; Female; Genotype; H | 2013 |
The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; CD4 Lymphocyte Count; Chemical | 2013 |
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; | 2013 |
Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Aspartate Aminotransfer | 2013 |
Comparison of nevirapine plasma concentrations between lead-in and steady-state periods in Chinese HIV-infected patients.
Topics: Adolescent; Aged; Anti-HIV Agents; China; Female; HIV Infections; Humans; Male; Middle Aged; Nevirap | 2013 |
Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
Topics: Adult; Anti-HIV Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; HIV Infections; HIV | 2002 |
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combina | 2002 |
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivu | 2002 |
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Male; Nevirapine | 2002 |
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions | 2002 |
Compliance with antiretroviral regimens to prevent perinatal HIV-1 transmission in Kenya.
Topics: Adult; Anti-HIV Agents; Female; Focus Groups; Follow-Up Studies; Health Knowledge, Attitudes, Practi | 2003 |
A phase I/II study of nevirapine for pre-exposure prophylaxis of HIV-1 transmission in uninfected subjects at high risk.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Follow-Up Studies; Hepatitis C; HIV Infection | 2003 |
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV- | 2003 |
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug | 2003 |
Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N | 2003 |
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV In | 2003 |
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans; | 2003 |
Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose.
Topics: Adult; Anti-HIV Agents; Bahamas; Brazil; Double-Blind Method; Europe; Female; Fetal Blood; HIV Infec | 2003 |
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine.
Topics: Adolescent; Adult; Breast Feeding; Drug Administration Schedule; Female; HIV Infections; HIV Seropos | 2003 |
Feeding risk cut for HIV-infected women.
Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; | 2003 |
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Disease Progression; Drug The | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Disease Transmission, Infectious; Drug Administration Schedule; Female; Foll | 2003 |
Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosin | 2003 |
Short postexposure prophylaxis in newborn babies to reduce mother-to-child transmission of HIV-1: NVAZ randomised clinical trial.
Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infan | 2003 |
Low rate of mother-to-child transmission of HIV-1 after nevirapine intervention in a pilot public health program in Yaoundé, Cameroon.
Topics: Anti-HIV Agents; Cameroon; Female; HIV Infections; HIV-1; Humans; Immunoenzyme Techniques; Infant; I | 2003 |
A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study.
Topics: Adult; Anti-HIV Agents; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination | 2003 |
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2003 |
Performance characteristics of HIV-1 culture and HIV-1 DNA and RNA amplification assays for early diagnosis of perinatal HIV-1 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; DNA, Viral; HIV Infections; HIV-1; Humans; Infa | 2003 |
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosi | 2003 |
A randomized trial comparing initial HAART regimens of nelfinavir/nevirapine and ritonavir/saquinavir in combination with two nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Ther | 2003 |
Treatment of HIV-infected patients with a combination of efavirenz, nevirapine and nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Huma | 2004 |
Efavirenz versus nevirapine in current clinical practice: a prospective, open-label observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Diseases | 2004 |
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; H | 2004 |
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2004 |
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The | 2004 |
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The | 2004 |
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The | 2004 |
Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The | 2004 |
Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Cetirizine; Double-Blind Method; Exanthema; Female; Histamine H1 Antagonists | 2004 |
A comparison of the CD4 response to antiretroviral regimens in patients commencing therapy with low CD4 counts.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop | 2004 |
Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Inf | 2004 |
Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; | 2004 |
Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Blood Glucose; Body Composition; Bone Density; C-Peptide; Cy | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-B | 2004 |
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; | 2004 |
Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Chemical and Drug Induced Live | 2004 |
Follow-up measurements of Nevirapine plasma levels over a prolonged period.
Topics: Anti-HIV Agents; Body Weight; Drug Monitoring; Female; Follow-Up Studies; HIV; HIV Infections; Human | 2004 |
Failure of cetirizine to prevent nevirapine-associated rash: a double-blind placebo-controlled trial for the GESIDA 26/01 Study.
Topics: Cetirizine; Double-Blind Method; Exanthema; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged | 2004 |
Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; H | 2004 |
Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients.
Topics: Adult; Aged; Analgesics, Opioid; Anti-HIV Agents; Area Under Curve; Dose-Response Relationship, Drug | 2004 |
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol, HDL; Cyclopropanes; Female; HIV Infectio | 2004 |
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV | 2004 |
Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Generic; Fem | 2004 |
Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Base Sequence; Benzoxazines; Cyclopropanes | 2005 |
Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol, HDL; Cholesterol, LDL; D | 2005 |
Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Drug Therapy, Combination | 2005 |
Haematological changes in African children who received short-term prophylaxis with nevirapine and zidovudine at birth.
Topics: Agranulocytosis; Anemia; Anti-HIV Agents; Blood Cell Count; Drug Therapy, Combination; Female; Hemat | 2004 |
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Comorbidity; Cyclopropanes; Exanthema; Female; Germany; HIV | 2005 |
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, | 2005 |
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV | 2005 |
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzox | 2005 |
A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients.
Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; | 2005 |
The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2005 |
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug | 2005 |
Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine.
Topics: Adult; Alkynes; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; | 2005 |
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
Topics: Adult; Aged; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; | 2005 |
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antire | 2005 |
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bezafibrate; C | 2005 |
Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort).
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Huma | 2005 |
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resista | 2005 |
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Topics: Adult; Anthropometry; Anti-HIV Agents; Body Size; Drug Administration Schedule; Drug Therapy, Combin | 1999 |
Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.
Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections | 1999 |
A randomized trial of two postexposure prophylaxis regimens to reduce mother-to-child HIV-1 transmission in infants of untreated mothers.
Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infa | 2005 |
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals.
Topics: Adult; Anti-HIV Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; Female; HIV | 2005 |
Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.
Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Inf | 2005 |
Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro | 2005 |
Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant | 2005 |
Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
Topics: Academies and Institutes; Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort | 2005 |
Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease T | 2005 |
Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resista | 2005 |
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow- | 2005 |
Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; | 2005 |
Timing of maternal and neonatal dosing of nevirapine and the risk of mother-to-child transmission of HIV-1: HIVNET 024.
Topics: Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; | 2005 |
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newb | 2005 |
Reduction of mother-to-child transmission of HIV at Saint Camille Medical Centre in Burkina Faso.
Topics: Adolescent; Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Burkina Faso; Drug Administratio | 2006 |
Acute and chronic chorioamnionitis and the risk of perinatal human immunodeficiency virus-1 transmission.
Topics: Acute Disease; Adult; Anti-HIV Agents; Chorioamnionitis; Chronic Disease; Female; Fetal Blood; HIV I | 2006 |
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Cohort Studies; Confidence Intervals; Cross-Over Studi | 2006 |
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Co | 2006 |
Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; HIV Infections; HIV-1; Hu | 2006 |
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
Topics: Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Infant, Newborn | 2006 |
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration | 2006 |
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration | 2006 |
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration | 2006 |
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration | 2006 |
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
Topics: Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudin | 2006 |
Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Disease-Free Survi | 2006 |
Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Female; Fo | 2006 |
Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Interactions; Female; Furans; HIV; HIV Infections; HIV Prot | 2006 |
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Topics: Adult; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Gene | 2007 |
Highly active antiretroviral treatment containing efavirenz or nevirapine and related toxicity in the TREAT Asia HIV Observational Database.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Ind | 2006 |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinatio | 2006 |
A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV- | 2007 |
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infectio | 2007 |
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Coun | 2007 |
Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human | 2007 |
Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Area Under Curve; Benzoxazines; CD4 Lymphocyt | 2007 |
Intrapartum transmission after mucosal exposure to HIV was not observed with single-dose nevirapine for mother and child.
Topics: Adult; Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn | 2007 |
Response to antiretroviral therapy after a single, peripartum dose of nevirapine.
Topics: Adult; Anti-Retroviral Agents; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combinatio | 2007 |
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cohort Studies; Cote d'Ivoir | 2007 |
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Dis | 2007 |
Antiretroviral-associated toxicity among HIV-1-seropositive pregnant women in Mozambique receiving nevirapine-based regimens.
Topics: Adult; Alanine Transaminase; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparta | 2007 |
Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV | 2007 |
Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Child; Data Interpretation, Statistical; Drug Monitoring; Female; HIV Infections; H | 2007 |
Safety of nevirapine in pregnancy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Exanthema | 2007 |
Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV- | 2007 |
Transmission rates in consecutive pregnancies exposed to single-dose nevirapine in Soweto, South Africa and Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Drug Administration Schedule; Female; HIV Infections; Humans; | 2007 |
A virological benefit from an induction/maintenance strategy: the Forte trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Disease Progression; | 2007 |
Late postnatal transmission of HIV-1 and associated factors.
Topics: Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Incidence; Infant; Infant, | 2007 |
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
Topics: Adult; Africa; Anti-HIV Agents; Apolipoproteins; Blood Chemical Analysis; Breast Feeding; Cholestero | 2007 |
High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Thera | 2007 |
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.
Topics: Alkynes; Benzoxazines; Cholesterol, LDL; Coronary Disease; Cross-Over Studies; Cyclopropanes; Dose-R | 2007 |
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Argentina; CD | 2007 |
HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
Topics: Africa; Anti-HIV Agents; Black People; DNA Mutational Analysis; Drug Administration Schedule; Drug R | 2007 |
Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Combinations; Follow-Up Studies | 2007 |
Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical | 2007 |
Data shows long-term nevirapine efficacy and increases in good cholesterol.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cholesterol, HDL; Cyclopropanes; Drug | 2007 |
Pathology of placenta in HIV infection.
Topics: Anti-HIV Agents; Chorioamnionitis; Female; Fetal Death; HIV Infections; Humans; Hyperplasia; Infant, | 2007 |
Mother-to-child transmission of HIV among women who chose not to exclusively breastfeed their infants in Pune, India.
Topics: Adult; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cohort Studies; Drug Administration Schedule | 2007 |
Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
Topics: Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combination; Female; HI | 2007 |
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV | 2007 |
Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transm | 2007 |
Effect of twice-daily nevirapine on adherence in HIV-1-infected patients: a randomized controlled study.
Topics: Adult; Aged; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Linear Models; Logistic Mo | 2007 |
High uptake of exclusive breastfeeding and reduced early post-natal HIV transmission.
Topics: Breast Feeding; Female; HIV Infections; Humans; Infant; Infant Food; Infant, Newborn; Infectious Dis | 2007 |
Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2008 |
[Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Topics: Acquired Immunodeficiency Syndrome; Adult; Amylases; Anti-HIV Agents; Antiretroviral Therapy, Highly | 2007 |
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cohort Studies | 2008 |
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Com | 2008 |
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Area Under Curve; Body Weight; Child; Child, Pres | 2008 |
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combin | 2008 |
Trial studies extended release Viramune.
Topics: Anti-HIV Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; HIV | 2008 |
Temporal and lateral dynamics of HIV shedding and elevated sodium in breast milk among HIV-positive mothers during the first 4 months of breast-feeding.
Topics: Breast Feeding; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn | 2008 |
Nevirapine concentrations in newborns receiving an extended prophylactic regimen.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; HIV | 2008 |
Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.
Topics: Adolescent; Alkynes; Benzoxazines; CD4 Lymphocyte Count; CD4-CD8 Ratio; Child; Child, Preschool; Cyc | 2008 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; | 2008 |
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi | 1995 |
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi | 1995 |
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi | 1995 |
Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Therapy, Combi | 1995 |
High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection.
Topics: Adult; Antiviral Agents; HIV Core Protein p24; HIV Infections; Humans; Middle Aged; Nevirapine; Pyri | 1995 |
Resistance, drug failure, and disease progression.
Topics: Antiviral Agents; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; H | 1994 |
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protoco
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Com | 1996 |
A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV | 1996 |
Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection.
Topics: Administration, Oral; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; | 1997 |
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; | 1998 |
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
Topics: Anti-HIV Agents; Consumer Product Safety; Drug Therapy, Combination; Female; HIV Infections; HIV Pro | 1998 |
Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; In | 1998 |
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
Topics: Anti-HIV Agents; Australia; Canada; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Ther | 1998 |
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Didanosine; Double-Blind Met | 1999 |
Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions; | 1999 |
A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006).
Topics: Anti-HIV Agents; Consumer Product Safety; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Inf | 1999 |
Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Topics: Adult; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infect | 1999 |
[Experience with nevirapine taken once daily in 93 HIV-infected patients].
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infect | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; H | 1999 |
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; H | 1998 |
Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; Humans; Male; Nevi | 1998 |
dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Nelfinavir | 1998 |
[Encouraging study results. HIV from birth on--virostatic drugs can decrease the risk].
Topics: Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Infectious Dise | 1999 |
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Topics: Adult; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Mul | 1999 |
South Africa's Medicines Control Council contradicts Health Minister.
Topics: Adverse Drug Reaction Reporting Systems; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Inf | 2000 |
Nevirapine and perinatal transmission.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe | 2000 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response | 2000 |
Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV | 2000 |
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; | 2000 |
Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clin
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethnicity; Female; HIV Infectio | 2000 |
Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combina | 2000 |
Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone | 2000 |
Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combina | 2000 |
Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infe | 2000 |
The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans | 2000 |
Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combinati | 2001 |
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relation | 2001 |
Viramune triple combo reduces viral load below limit of detection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans | 1997 |
Viramune cleared for use in combination with protease inhibitors.
Topics: Adult; Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; Female; HIV Infections; HIV Protea | 1998 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Human | 1995 |
Maintaining a low viral load with Nevirapine?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combina | 1998 |
Major advance in protecting newborns: one Nevirapine dose cuts infection in half.
Topics: Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Dis | 1999 |
Virus sidesteps convergent therapy.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Human | 1995 |
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
Topics: Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; | 2001 |
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort | 2001 |
Long-term follow-up of antiretroviral-naive HIV-positive patients treated with nevirapine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; HIV-1; Huma | 2001 |
Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infe | 2001 |
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug The | 2001 |
The effect of nevirapine in combination with nelfinavir in heavily pretreated HIV-1-infected patients: a prospective, open-label, controlled, randomized study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV | 2001 |
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; | 2001 |
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
Topics: Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combinat | 2001 |
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Topics: Adult; Anthropometry; Anti-HIV Agents; Body Composition; CD4 Lymphocyte Count; Cholesterol; Drug The | 2001 |
Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV-1; Humans; Infant; Infectio | 2001 |
Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Indinavir; Male; Nevirapine; Semen | 2001 |
Spanish study looks at the effect of nevirapine on the liver.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Live | 2001 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox | 2001 |
Switching to nevirapine--results after one year.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Fema | 2001 |
Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy.
Topics: Adipocytes; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Blood Glucose; | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2001 |
Mechanism of virologic failure after substitution of a protease inhibitor by nevirapine in patients with suppressed plasma HIV-1 RNA.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combin | 2001 |
Baseline CD4(+) cell count, not viral load, correlates with virologic suppression induced by potent antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Therapy, Combinat | 2001 |
Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.
Topics: Anti-HIV Agents; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Diseas | 2001 |
Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T | 2001 |
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
Topics: Adult; Anti-HIV Agents; Coronary Artery Disease; Drug Therapy, Combination; Female; HIV Infections; | 2001 |
Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
Topics: Adult; Anti-HIV Agents; Anti-Inflammatory Agents; Dideoxynucleosides; Drug Hypersensitivity; Female; | 2001 |
Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Administrat | 2002 |
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
Topics: Adult; Age Factors; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Inf | 2000 |
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HI | 2002 |
Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Co | 2002 |
Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female | 2002 |
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Fem | 2002 |
Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Viral Diseases; Cyclopropanes; | 2002 |
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Inf | 2002 |
Effect of HIV-1 antiretroviral prophylaxis on hepatic and hematological parameters of African infants.
Topics: Alanine Transaminase; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newb | 2002 |
Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Contraceptives, Oral, Combined; Drug Interactions; Drug Th | 2002 |
Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Drug | 2002 |
1437 other studies available for nevirapine and HIV Coinfection
| Article | Year |
|---|---|
Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Computer-Aided Design; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; | 2006 |
Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Topics: Amines; Drug Resistance, Multiple, Viral; Heterocyclic Compounds; HIV Infections; HIV Reverse Transc | 2006 |
A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.
Topics: Administration, Oral; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cell Line; Cyclopropanes; Dog | 2007 |
1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Biological Assay; Cell Line; Chemistry, Pharmaceutical; Drug Design; Drug Evaluatio | 2008 |
Inhibition of the CRM1-mediated nucleocytoplasmic transport by N-azolylacrylates: structure-activity relationship and mechanism of action.
Topics: Acrylates; Active Transport, Cell Nucleus; Binding Sites; Exportin 1 Protein; HeLa Cells; HIV Infect | 2008 |
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor.
Topics: Anti-HIV Agents; Cells, Cultured; Cervix Uteri; Dose-Response Relationship, Drug; Female; HIV Infect | 2009 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse | 2009 |
Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum | 2009 |
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance, | 2010 |
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation; Nitriles | 2010 |
Highly suppressing wild-type HIV-1 and Y181C mutant HIV-1 strains by 10-chloromethyl-11-demethyl-12-oxo-calanolide A with druggable profile.
Topics: Animals; Anti-HIV Agents; Biological Availability; Brain; Cell Line; Cell Survival; HIV Infections; | 2010 |
Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Vir | 2010 |
Biomimetic synthesis and anti-HIV activity of dimeric phloroglucinols.
Topics: Anti-HIV Agents; Biomimetic Materials; Dimerization; HIV Infections; HIV Reverse Transcriptase; Huma | 2010 |
Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reve | 2010 |
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
Topics: Aniline Compounds; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Hydrogen Bonding; Magne | 2010 |
Hybrid diarylbenzopyrimidine non-nucleoside reverse transcriptase inhibitors as promising new leads for improved anti-HIV-1 chemotherapy.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; | 2010 |
Anti-HIV and antiplasmodial activity of original flavonoid derivatives.
Topics: Anti-HIV Agents; Antimalarials; Cell Line; Cell Survival; Flavonoids; HIV; HIV Infections; Humans; M | 2010 |
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-oxopyrimidines (S-DACOs) as high active anti-HIV agents.
Topics: Anti-HIV Agents; Cell Line; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Nevirapine; Pyri | 2011 |
Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylacetamides as potent HIV-1 inhibitors.
Topics: Acetamides; Anti-HIV Agents; Cell Line; HIV Infections; HIV Reverse Transcriptase; HIV-1; HIV-2; Hum | 2011 |
Discovery of 3,4-dihydropyrimidin-2(1H)-ones with inhibitory activity against HIV-1 replication.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV-1; Humans; Pyrimidinones; Stereoisomerism; Structu | 2012 |
Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Mole | 2012 |
Synthesis and biological evaluation of phosphonate analogues of nevirapine.
Topics: HIV Infections; HIV-1; Humans; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Str | 2013 |
Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs.
Topics: Cell Line; Delavirdine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nevirapine; Pyrida | 2013 |
Design, synthesis and biological evaluation of 3-benzyloxy-linked pyrimidinylphenylamine derivatives as potent HIV-1 NNRTIs.
Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; M | 2013 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HI | 2014 |
Design, Synthesis, and Biological Evaluation of Novel Benzoyl Diarylamine/ether Derivatives as Potential Anti-HIV-1 Agents.
Topics: Aniline Compounds; Anti-HIV Agents; Cell Line; Drug Design; Ether; HIV Infections; HIV-1; Humans; Mo | 2015 |
Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
Topics: Anti-HIV Agents; Binding Sites; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Human | 2016 |
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Isatin; Mole | 2017 |
Synthesis, Antiviral Potency, in Vitro ADMET, and X-ray Structure of Potent CD4 Mimics as Entry Inhibitors That Target the Phe43 Cavity of HIV-1 gp120.
Topics: Anti-HIV Agents; Biomimetic Materials; CD4 Antigens; Cell Line; Crystallography, X-Ray; HIV Envelope | 2017 |
Design and synthesis of hybrids of diarylpyrimidines and diketo acids as HIV-1 inhibitors.
Topics: Anti-HIV Agents; Cell Line; Drug Design; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HI | 2017 |
Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
Topics: Animals; Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV Infections; HIV Reverse Transcri | 2017 |
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Do | 2018 |
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; R | 2019 |
Ligand-Based Design of Nondimethylphenyl-Diarylpyrimidines with Improved Metabolic Stability, Safety, and Oral Pharmacokinetic Profiles.
Topics: Administration, Oral; Animals; Anti-HIV Agents; Apoptosis; Drug Design; Female; HIV Infections; HIV- | 2019 |
Rational design and Structure-Activity relationship of coumarin derivatives effective on HIV-1 protease and partially on HIV-1 reverse transcriptase.
Topics: Anti-HIV Agents; Cell Line; Coumarins; Dose-Response Relationship, Drug; Drug Design; HIV Infections | 2020 |
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reve | 2022 |
Maternal Human Immunodeficiency Virus (HIV) Drug Resistance Is Associated With Vertical Transmission and Is Prevalent in Infected Infants.
Topics: Anti-HIV Agents; Breast Feeding; Case-Control Studies; Drug Resistance; Female; HIV; HIV Infections; | 2022 |
Effect of HIV, antiretrovirals, and genetics on methadone pharmacokinetics: Results from the methadone antiretroviral pharmacokinetics study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Constitutive Androstane Receptor; HIV Infecti | 2021 |
Could pharmacogenetics aid the prediction of nevirapine pharmacokinetics and allow individualized treatment?
Topics: Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Pharmacogenetics; Prec | 2021 |
High nevirapine levels in breast milk and consequences in HIV-infected child when initiated on antiretroviral therapy.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; M | 2021 |
Association between social psychological status and efavirenz and nevirapine plasma concentration among HIV patients in Kenya.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; HIV I | 2021 |
HIV Encephalopathy in ART-Naïve, Hospitalized Infants in Mozambique.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Di | 2021 |
Improved Hematologic Outcomes in HIV1-Exposed Infants Receiving Nevirapine Compared With Zidovudine for Postnatal Prophylaxis in a High Resource Setting.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; | 2022 |
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Hair; HI | 2022 |
Trough plasma nevirapine levels, immunologic and virologic responses in composite CYP2B6*6/*18 HIV-infected adult Nigerian patients.
Topics: Adult; Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Nigeria; Retros | 2022 |
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
Topics: Agammaglobulinemia; Anti-HIV Agents; Drug Resistance, Viral; Genetic Diseases, X-Linked; HIV Infecti | 2021 |
The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes: Lessons from Botswana.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; Cyclopropanes; Cytochrome P-450 CYP2B6; Genotype; | 2022 |
Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infection | 2022 |
Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based Dosing.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; | 2022 |
Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Infant; Infant, Newborn; Maravi | 2022 |
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral T | 2022 |
Contraceptive implant use duration is not associated with breakthrough pregnancy among women living with HIV and using efavirenz: a retrospective, longitudinal analysis.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Contraceptive Agents; Cyclopropanes; Female; HIV Infection | 2022 |
Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1.
Topics: Animals; Arylsulfotransferase; Cytosol; Exanthema; HIV Infections; Humans; Isoenzymes; Nevirapine; P | 2022 |
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Case-Control Studies; CD4 Lymphocyte Count; Child; HIV Infection | 2023 |
Antiretroviral therapy resistance mutations among HIV infected people in Kazakhstan.
Topics: Anti-HIV Agents; Darunavir; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Ka | 2022 |
Impact of Drug Exposure on Resistance Selection Following Artemether-Lumefantrine Treatment for Malaria in Children With and Without HIV in Uganda.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Drug Comb | 2023 |
Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon.
Topics: Adolescent; Anti-HIV Agents; Cameroon; Drug Resistance, Viral; Follow-Up Studies; Health Facilities; | 2022 |
Twenty years of Prevention of Mother to Child HIV Transmission: research to implementation at a national referral hospital in Uganda.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; Hospitals; Humans; Infant, Newborn; Infectious Disea | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Findings from a pilot study of buprenorphine population pharmacokinetics: A potential effect of HIV on buprenorphine bioavailability.
Topics: Biological Availability; Buprenorphine; HIV Infections; Humans; Nevirapine; Opioid-Related Disorders | 2022 |
Nevirapine plasma concentration is associated with virologic failure and the emergence of drug-resistant mutations among HIV patients in Kenya: A cross sectional study.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; HIV Infections; HIV-1; Huma | 2022 |
Case study on antiretroviral drugs uptake from soil irrigated with contaminated water: Bio-accumulation and bio-translocation to roots, stem, leaves, and fruits.
Topics: Bioaccumulation; Fruit; HIV Infections; Humans; Nevirapine; Soil; Soil Pollutants; Vegetables; Water | 2023 |
Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Lopinav | 2023 |
Antiretroviral postnatal prophylaxis to prevent HIV vertical transmission: present and future strategies.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Inf | 2023 |
The quality of antiretroviral medicines: an uncertain problem.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; HIV Infections; Humans; Nevirapine | 2023 |
Methods optimization and application: Solid phase extraction, ultrasonic extraction and Soxhlet extraction for the determination of antiretroviral drugs in river water, wastewater, sludge, soil and sediment.
Topics: Ecosystem; HIV Infections; Humans; Nevirapine; Rivers; Sewage; Soil; Solid Phase Extraction; Ultraso | 2023 |
Prevalence of pretreatment drug resistance in persons initiating and reinitiating antiretroviral therapy in Sri Lanka: results from a national representative survey.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Fem | 2023 |
A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine.
Topics: Anti-HIV Agents; Canada; HIV Infections; Humans; Lamivudine; Nevirapine; Oxazines; Patient Acceptanc | 2023 |
Uptake of selected antiretrovirals by pepper (Capsicum annum), radish (Raphanus sativus), and ryegrass (Lolium perenne) grown on two contrasting soils and fertilized with human urine-derived fertilizers.
Topics: Animals; Capsicum; Crops, Agricultural; Fertilizers; HIV Infections; Humans; Lolium; Nevirapine; Rap | 2023 |
Optimizing antiretroviral therapy for children living with HIV: Experience from an observational cohort in Lesotho.
Topics: Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lesotho; Lopinavir | 2023 |
Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
Topics: Animals; Anti-HIV Agents; Cat Diseases; Cats; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma | 2023 |
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2019 |
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glo | 2020 |
Longitudinal adherence to maternal antiretroviral therapy and infant Nevirapine prophylaxis from 6 weeks to 18 months postpartum amongst a cohort of mothers and infants in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; Follow-Up Studi | 2019 |
Extended Prophylaxis With Nevirapine Does Not Affect Growth in HIV-Exposed Infants.
Topics: Anti-HIV Agents; Child Development; Female; Growth; HIV Infections; Humans; Infant; Infectious Disea | 2019 |
Pediatric Antiretroviral Therapeutic Drug Monitoring: A Five and a Half Year Experience from a South African Tertiary Hospital.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Ch | 2020 |
'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, V | 2020 |
Nevirapine Use Is Associated with Higher Bone Mineral Density in HIV-1 Positive Subjects on Long-Term Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adult; Bone Density; Cross-Sectional Studies; Female; Follow-Up Studies; HIV | 2020 |
Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.
Topics: Anti-HIV Agents; Botswana; Child; Child, Preschool; HIV Infections; Humans; Infant; Infant, Newborn; | 2021 |
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia; Anti-HIV Agents; Anti-Retroviral Agent | 2019 |
Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling.
Topics: Adolescent; Adult; Ambulatory Care; Anti-Retroviral Agents; Drug Therapy, Combination; Female; Follo | 2020 |
Incidence and predictors of nevirapine and efavirenz-associated rash among Indonesian HIV patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Exanthema; | 2022 |
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Combinations; Female; HIV Infections; Humans; Infant, Ne | 2020 |
Anti-HIV drugs promote β-amyloid deposition and impair learning and memory in BALB/c mice.
Topics: Administration, Oral; AIDS Dementia Complex; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; | 2020 |
Correlates of loss to follow-up and missed diagnosis among HIV-exposed infants throughout the breastfeeding period in southern Mozambique.
Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease T | 2020 |
Effect of nevirapine, efavirenz and lopinavir/ritonavir on the therapeutic concentration and toxicity of lumefantrine in people living with HIV at Lagos University Teaching Hospital, Nigeria.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Be | 2020 |
Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; P | 2020 |
Barriers and enablers of adherence to infant nevirapine prophylaxis against HIV 1 transmission among 6-week-old HIV exposed infants: A prospective cohort study in Northern Uganda.
Topics: Adult; Age Factors; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disea | 2020 |
Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; | 2020 |
Magnitude of first line antiretroviral therapy treatment failure and associated factors among adult patients on ART in South West Shoa, Central Ethiopia.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Ethiopia; Female; HIV | 2020 |
Prevalence of nonsuppressed viral load and associated factors among HIV-positive adults receiving antiretroviral therapy in Eswatini, Lesotho, Malawi, Zambia and Zimbabwe (2015 to 2017): results from population-based nationally representative surveys.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Eswatini; Female; | 2020 |
Human Immunodeficiency Virus-1 Subtype-C Genetically Diversify to Acquire Higher Replication Competence in Human Host with Comorbidities.
Topics: Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine | 2021 |
Advancing knowledge in perinatal HIV treatment.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2021 |
Association of SNPs in HLA-C and ZNRD1 Genes With HIV-1 Mother-to-Child Transmission in Zambia Population.
Topics: Adult; Anti-HIV Agents; DNA-Binding Proteins; Female; Genetic Predisposition to Disease; Genotype; H | 2021 |
LC-MS/MS Quantification of Nevirapine and Its Metabolites in Hair for Assessing Long-Term Adherence.
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Female; Hair; HIV; HIV Infections; Humans; Mal | 2020 |
Mother-to-Child HIV Transmission among Pregnant Women in a City with the Highest Rates of HIV in Brazil.
Topics: Brazil; Child; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmiss | 2022 |
The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies.
Topics: Adult; Aged; Animals; Anti-HIV Agents; Apolipoprotein A-I; Cells, Cultured; Cholesterol, HDL; Cross- | 2021 |
HIV-free survival among breastfed infants born to HIV-positive women in northern Uganda: a facility-based retrospective study.
Topics: Anti-HIV Agents; Breast Feeding; Cohort Studies; Female; HIV Infections; Humans; Infant; Infant, New | 2020 |
Effects of the Pratt pouch model of dispensing nevirapine prophylaxis on HIV exposed infant completion of 6 weeks of prophylaxis in Uganda.
Topics: Adult; Anti-HIV Agents; Drug Implants; Drug Packaging; Female; HIV Infections; Humans; Infant; Infan | 2021 |
Nevirapine Pharmacokinetics in Neonates Between 25 and 32 Weeks Gestational Age for the Prevention of Mother-to-Child Transmission of HIV.
Topics: Administration, Oral; Anti-HIV Agents; Female; Gestational Age; HIV Infections; HIV-1; Humans; Infan | 2021 |
Adverse Reactions to Antiretrovirals in Cuban Patients Living with HIV/AIDS.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Cuba; Female; HIV Infections; Humans; I | 2021 |
Histopathological changes in Oreochromis mossambicus (Peters, 1852) ovaries after a chronic exposure to a mixture of the HIV drug nevirapine and the antibiotics sulfamethoxazole and trimethoprim.
Topics: Africa; Animals; Anti-Bacterial Agents; COVID-19; Female; HIV Infections; Humans; Nevirapine; Ovary; | 2021 |
HIV virological non-suppression and its associated factors in children on antiretroviral therapy at a major treatment centre in Southern Ghana: a cross-sectional study.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; | 2021 |
Topics: Adolescent; Adult; Aged; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under | 2022 |
Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; | 2017 |
Efficacy and safety of switching from nevirapine immediate-release twice daily to nevirapine extended-release once daily in virologically suppressed HIV-infected patients: a retrospective cohort study in Taiwan.
Topics: Adult; Anti-HIV Agents; Delayed-Action Preparations; Drug Administration Schedule; Drug Monitoring; | 2017 |
Uptake and performance of prevention of mother-to-child transmission and early infant diagnosis in pregnant HIV-infected women and their exposed infants at seven health centres in Addis Ababa, Ethiopia.
Topics: Adolescent; Adult; Anti-HIV Agents; Ethiopia; Female; Follow-Up Studies; Guideline Adherence; Health | 2017 |
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C | 2017 |
Maternal Syphilis: An Independent Risk Factor for Mother to Infant Human Immunodeficiency Virus Transmission.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cost-Benefit Anal | 2017 |
Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; F | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxaz | 2017 |
Pharmacokinetics-based adherence measures for antiretroviral therapy in HIV-infected Kenyan children.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Kenya; | 2017 |
[Obesity, high blood pressure, hypercholesterolaemia, and untreated diabetes in HIV-infected and HIV-uninfected Adults in Mbuji-Mayi (Democratic republic of congo)].
Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cross-Sectional Studies; Delayed | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Co | 2017 |
Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
Topics: Adult; Anti-HIV Agents; Anticholesteremic Agents; Antiretroviral Therapy, Highly Active; Cholesterol | 2017 |
Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraception; Contraceptive Agent | 2017 |
HIV Resistance and Prevention of Mother-to-Child Transmission Regimen in HIV-Infected Infants in Northern Tanzania.
Topics: Anti-HIV Agents; Blood; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infec | 2017 |
Sub-therapeutic nevirapine concentration during antiretroviral treatment initiation among children living with HIV: Implications for therapeutic drug monitoring.
Topics: Child; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Fema | 2017 |
Mother-to-child transmission of HIV in Kenya: A cross-sectional analysis of the national database over nine years.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Databases, Factual; | 2017 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop | 2017 |
Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in Cameroon.
Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Carnitine; DNA, Mitochondrial; Energy | 2017 |
Factors affecting high-density lipoprotein cholesterol in HIV-infected patients on nevirapine-based antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Apolipoprotein C-III; Cholesterol Ester Transfer Prote | 2017 |
HIV status and hearing loss among children between 6 and 12 years of age at a large urban health facility in south western Uganda.
Topics: Anti-Retroviral Agents; Audiometry, Pure-Tone; Child; Cross-Sectional Studies; Female; Hearing Loss; | 2017 |
Towards a universal second-line fixed-dose combination ART.
Topics: Anti-HIV Agents; HIV Infections; Humans; Nevirapine | 2018 |
HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induce | 2018 |
Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; Cohort Studies; Cross-Sectional Studies; Drug Combinations; Drug S | 2017 |
Long-term viral suppression and immune recovery during first-line antiretroviral therapy: a study of an HIV-infected adult cohort in Hanoi, Vietnam.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studie | 2017 |
A Bayesian Analysis of Prenatal Maternal Factors Predicting Nonadherence to Infant HIV Medication in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Bayes Theorem; Depression; Depression, Postpartum; Disclosure; F | 2018 |
Hypersensitivity to antiretroviral drugs.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Male; Middle | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2016 |
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop | 2018 |
Severe eye complications from toxic epidermal necrolysis following initiation of Nevirapine based HAART regimen in a child with HIV infection: a case from Cameroon.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blindness; Cameroon; Child, Preschool; HIV I | 2018 |
Retention of children under 18 months testing HIV positive in care in Swaziland: a retrospective study.
Topics: Anti-HIV Agents; Child Health Services; Cross-Sectional Studies; Eswatini; Female; HIV Infections; H | 2017 |
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cycl | 2018 |
A multivariate genetic analysis confirms rs5010528 in the human leucocyte antigen-C locus as a significant contributor to Stevens-Johnson syndrome/toxic epidermal necrolysis susceptibility in a Mozambique HIV population treated with nevirapine.
Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Female; Gene Frequency; Genetic Predispositio | 2018 |
Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cros | 2018 |
"High" antiretroviral deintensification, a strategy to avoid drug interactions and unfavourable long-term effects of HAART.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug | 2018 |
Depression and Suicidal Ideation Among HIV-Infected Adults Receiving Efavirenz Versus Nevirapine in Uganda: A Prospective Cohort Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Depression; Female; HIV Infections; Hu | 2018 |
Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions.
Topics: Adult; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Benzoxazines; Biological Transport; | 2018 |
Polymorphisms in TH1-TH2 cytokine and receptor genes associated with risk of vertical HIV transmission, in Mumbai, India.
Topics: Anti-HIV Agents; Cohort Studies; Cytokines; Gene Frequency; Genetic Predisposition to Disease; Genot | 2018 |
Maternal age, infant age, feeding options, single/multiple pregnancy, type of twin sets and mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cameroon; Female; HIV | 2019 |
Low HIV viral suppression rates following the intensive adherence counseling (IAC) program for children and adolescents with viral failure in public health facilities in Uganda.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Counseling; Female; Health Facilities; HIV Inf | 2018 |
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blo | 2018 |
Nevirapine Concentrations During the First Month of Life and Maternal Efavirenz Washout in High-Risk HIV-Exposed Infants Receiving Triple Antiretroviral Prophylaxis.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Chemoprevention; Cyclopropanes; Female; HIV Infections; Huma | 2019 |
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitu | 2018 |
Mother-baby dyads enrolled in PMTCT care in western Kenya: characteristics and implications for ART programmes.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant; Infectious Diseas | 2018 |
Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2018 |
Prevalence of CYP2D6*4 1934G/A polymorphism in Western Indian HIV patients.
Topics: Adult; Alcohol Drinking; Alleles; Anti-HIV Agents; Biotransformation; Case-Control Studies; Cytochro | 2018 |
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistanc | 2020 |
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazin | 2019 |
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2018 |
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Interactions; Drug Substitution; | 2019 |
Programmes for the prevention of mother-to-child HIV infection transmission have made progress in Yunnan Province, China, from 2006 to 2015: a cost effective and cost-benefit evaluation.
Topics: Adult; China; Cost-Benefit Analysis; Delivery of Health Care; Female; Health Expenditures; HIV; HIV | 2019 |
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; | 2019 |
Report: A case report on Nevirapine induced exfoliative dermatitis.
Topics: Adult; Anti-HIV Agents; Dermatitis, Exfoliative; Dermatologic Agents; Drug Eruptions; Drug Substitut | 2019 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy | 2019 |
Antiretroviral switching and bedaquiline treatment of drug-resistant tuberculosis HIV co-infection.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Substitution; Fem | 2019 |
Changes in Lipid Indices in HIV+ Cases on HAART.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Dia | 2019 |
Mucocutaneous manifestations of human immunodeficiency virus (HIV) infection in children in relation to the degree of immunosuppression.
Topics: Adolescent; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Eruption | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes | 2019 |
Incidence, prevalence and associated factors of mother-to-child transmission of HIV, among children exposed to maternal HIV, in Belgaum district, Karnataka, India.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Breast Feeding; Child, Preschool; Female; HIV; HIV | 2019 |
Nevirapine in HIV maintenance therapy - can "old drugs" survive in current HIV management?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV; HIV Infecti | 2019 |
Retention of HIV exposed infants in care at Arua regional referral hospital, Uganda: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Chi-Square Distribution; Female; HIV; HIV Infections; Humans; Infant, Newbor | 2019 |
Viral suppression rate among children tested for HIV viral load at the Amhara Public Health Institute, Bahir Dar, Ethiopia.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional | 2019 |
HIV diagnostic challenges in breast-fed infants of mothers on antiretroviral therapy.
Topics: Anti-HIV Agents; Breast Feeding; Early Diagnosis; Female; HIV Infections; HIV Seronegativity; Humans | 2019 |
Impact of the frequency of plasma viral load monitoring on treatment outcomes among children with perinatally acquired HIV.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Coh | 2019 |
Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; Cohort Studies; Cyclopropanes; Female | 2019 |
Increasing body mass index or weight does not appear to influence the association between efavirenz-based antiretroviral therapy and implant effectiveness among HIV-positive women in western Kenya.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cohort Stud | 2019 |
Rates of HIV-1 virological suppression and patterns of acquired drug resistance among fisherfolk on first-line antiretroviral therapy in Uganda.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; H | 2019 |
A pharmacokinetic and pharmacogenetic evaluation of contraceptive implants and antiretroviral therapy among women in Kenya and Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogest | 2019 |
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
Topics: Anti-Retroviral Agents; Chemoprevention; Drug Therapy, Combination; Drug-Related Side Effects and Ad | 2019 |
Complications of long-term antiretroviral therapy in HIV-infected children.
Topics: Anti-HIV Agents; Body Composition; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Hu | 2013 |
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2013 |
ART and tuberculosis: the final nail in nevirapine's coffin?
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections | 2013 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazi | 2013 |
Detection of drug bioactivation in vivo: mechanism of nevirapine-albumin conjugate formation in patients.
Topics: Adult; Aged; Anti-HIV Agents; Biotransformation; Cysteine; Glutathione S-Transferase pi; Histidine; | 2013 |
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-S | 2011 |
Effect of highly active antiretroviral treatment (HAART) during pregnancy on pregnancy outcomes: experiences from a PMTCT program in western India.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Fem | 2013 |
HIV-1 drug resistance among newly HIV-1 infected individuals attending tertiary referral center in Chennai, India.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Genotype | 2011 |
Scaling up prevention of mother-to-child HIV transmission programs in sub-Saharan African countries: a multilevel assessment of site-, program- and country-level determinants of performance.
Topics: Africa South of the Sahara; Anti-HIV Agents; Female; Follow-Up Studies; HIV Infections; Humans; Infe | 2013 |
Birth diagnosis of HIV infection in infants to reduce infant mortality and monitor for elimination of mother-to-child transmission.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant Mortality; Infant, Newborn; I | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2013 |
Nevirapine-induced Stevens-Johnson syndrome following HIV postexposure prophylaxis.
Topics: Adult; Diagnosis, Differential; HIV Infections; Humans; Male; Nevirapine; Post-Exposure Prophylaxis; | 2013 |
Association between efavirenz-based compared with nevirapine-based antiretroviral regimens and virological failure in HIV-infected children.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Botswana; Child; Child, Preschool; Cohort | 2013 |
Talk of HIV cure goes viral.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administratio | 2013 |
Nevirapine and/or co-trimoxazole induced Stevens Johnson syndrome in HIV infected patient--a case report.
Topics: Anti-HIV Agents; Anti-Infective Agents; Fatal Outcome; HIV Infections; Humans; Male; Middle Aged; Ne | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carba | 2013 |
Antiretroviral drugs in Africa: a public health versus a market approach.
Topics: Africa; Anti-HIV Agents; Drug Packaging; Health Resources; Health Services Accessibility; HIV Infect | 2013 |
A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.
Topics: Adult; Anti-HIV Agents; Antiprotozoal Agents; Cohort Studies; Drug Therapy, Combination; Female; HIV | 2013 |
Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cyclopropanes; Databases, Factual; Drug Resi | 2013 |
Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Hematologic Tests; HIV Infections; Humans; Imm | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studi | 2013 |
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopro | 2015 |
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; C | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug | 2013 |
Stevens-Johnson syndrome and HIV in children in Swaziland.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; C | 2013 |
Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Caregivers; CD4 Lymphocyte Count; Child; Child, Preschool; | 2013 |
HIV-positive nigerian adults harbor significantly higher serum lumefantrine levels than HIV-negative individuals seven days after treatment for Plasmodium falciparum infection.
Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Artemether, Lumefantri | 2013 |
Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Female; Genotype; HI | 2013 |
Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Topics: Acute-Phase Proteins; Adenine; Adult; Anti-HIV Agents; Cross-Sectional Studies; Deoxycytidine; Emtri | 2013 |
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte | 2013 |
Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Eswatini; Female; Foll | 2013 |
Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cross-Sectional Studies; Cyclopropane | 2013 |
Sensitive assessment of the virologic outcomes of stopping and restarting non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopro | 2013 |
The effect of antiretrovirals on Plasmodium falciparum liver stages.
Topics: HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Liver; Lopinavir; Malaria, Fal | 2013 |
Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis.
Topics: Anti-HIV Agents; Chemoprevention; Cluster Analysis; Drug Resistance, Viral; Female; Genotype; HIV In | 2013 |
Rash and hepatitis within days of starting a new antiretroviral regimen: nevirapine hypersensitivity, secondary syphilis or both?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diagnosis, Differential; Exanthema; Hepatitis; HIV Inf | 2014 |
Risk of nevirapine-associated Stevens-Johnson syndrome among HIV-infected pregnant women: the Medunsa National Pharmacovigilance Centre, 2007 - 2012.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; Humans; Logistic Models; Nevir | 2013 |
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistan | 2013 |
Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.
Topics: Adolescent; Adult; Anemia; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child | 2013 |
Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?
Topics: Adult; Aged; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfa | 2013 |
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Stu | 2013 |
Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lym | 2014 |
Child cured of HIV: can this be repeated?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newb | 2013 |
Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Delayed-Action Preparations; Dr | 2014 |
Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; En | 2014 |
Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Drug Substitution; F | 2014 |
[Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; | 2013 |
Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings.
Topics: Anti-HIV Agents; Chromatography, Thin Layer; Hair; HIV Infections; Humans; Medication Adherence; Nev | 2014 |
HIV infection, viral load, low birth weight, and nevirapine are independent influences on growth velocity in HIV-exposed South African infants.
Topics: Adolescent; Adult; Anti-HIV Agents; Black People; Female; Growth Disorders; HIV; HIV Infections; HIV | 2014 |
Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Biotransformation; Black People; Cytochrome P | 2014 |
HIV-1 drug-resistant minority variants: sweating the small stuff.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine | 2014 |
Nevirapine concentrations in saliva measured by thin layer chromatography and self-reported adherence in patients on antiretroviral therapy at Kilimanjaro Christian Medical Centre, Tanzania.
Topics: Adolescent; Adult; Alcohol Drinking; Anti-HIV Agents; Body Mass Index; Chromatography, Thin Layer; C | 2014 |
Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou | 2014 |
The effect of efavirenz versus nevirapine-containing regimens in the HIV-CAUSAL Collaboration: reply to Llibre and Podzamczer and additional results.
Topics: Anti-HIV Agents; Benzoxazines; Hepatitis C; HIV Infections; Humans; Nevirapine; Reverse Transcriptas | 2013 |
Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies.
Topics: Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Contraceptive Agents, Female; Cycl | 2014 |
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Inte | 2014 |
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highl | 2014 |
Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Coun | 2013 |
Population pharmacokinetics of nevirapine in Thai HIV-infected patients.
Topics: Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Datasets as Topic; Drug Monitoring; Female; HI | 2014 |
Lack of association between plasma levels of non-nucleoside reverse transcriptase inhibitors & virological outcomes during rifampicin co-administration in HIV-infected TB patients.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genetic Association St | 2013 |
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal F | 2014 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; C | 2014 |
Accelerated suppression of primary Epstein-Barr virus infection in HIV-infected infants initiating lopinavir/ritonavir-based versus nevirapine-based combination antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Epstein-Barr Virus Infections; HIV Infections; Humans; I | 2014 |
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dried Blood Spot Testing; Female; HIV Infect | 2014 |
Birth prevalence of congenital cytomegalovirus among infants of HIV-infected women on prenatal antiretroviral prophylaxis in South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2014 |
Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique.
Topics: Anti-HIV Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infe | 2014 |
Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Contraceptive Agents, Female; Cyclopropanes; Desogestrel; Do | 2014 |
Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; | 2014 |
Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya.
Topics: Adult; Aged; Anti-Retroviral Agents; Biomarkers; Chromatography, Thin Layer; Feasibility Studies; Fe | 2014 |
Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity.
Topics: Anti-HIV Agents; Carbamazepine; Chemoprevention; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Indu | 2014 |
The incremental cost of switching from Option B to Option B+ for the prevention of mother-to-child transmission of HIV.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cost- | 2014 |
The impact of HBV or HCV infection in a cohort of HIV-infected pregnant women receiving a nevirapine-based antiretroviral regimen in Malawi.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; Hepatitis B; He | 2014 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemo | 2014 |
HIV status, breastfeeding modality at 5 months and postpartum maternal weight changes over 24 months in rural South Africa.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; Humans; Infant; I | 2014 |
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cy | 2014 |
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance, | 2014 |
Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drugs, Generic; Femal | 2014 |
Evaluating the benefits of incorporating traditional birth attendants in HIV prevention of mother to child transmission service delivery in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Feasibility Studies; Female; Focus Groups; HIV Infections; Humans; Infant, N | 2014 |
Evaluation of polycaprolactone matrices for sustained vaginal delivery of nevirapine in the prevention of heterosexual HIV transmission.
Topics: Administration, Intravaginal; Anti-HIV Agents; Chromatography, High Pressure Liquid; Delayed-Action | 2014 |
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV R | 2014 |
Outcome of artemether-lumefantrine treatment for uncomplicated malaria in HIV-infected adult patients on anti-retroviral therapy.
Topics: Adult; Africa South of the Sahara; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Artemether, | 2014 |
Synergistic activity of tenofovir and nevirapine combinations released from polycaprolactone matrices for potential enhanced prevention of HIV infection through the vaginal route.
Topics: Adenine; Anti-HIV Agents; Drug Administration Routes; Drug Synergism; Drug Therapy, Combination; Fem | 2014 |
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Com | 2014 |
HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.
Topics: Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; Drug Hypersensitivity | 2014 |
Switching from efavirenz to nevirapine in children: 1-week dose escalation strategy.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Female; HIV Infections; Hu | 2014 |
Nevirapine concentrations in preterm and low birth weight HIV-exposed infants: implications for dosing recommendations.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; | 2014 |
Improved retention of patients starting antiretroviral treatment in Karonga District, northern Malawi, 2005-2012.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Hu | 2014 |
HIV is detected in child thought to have been cured.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Early Medical Intervention | 2014 |
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infecti | 2014 |
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; | 2014 |
Impact of adherence and anthropometric characteristics on nevirapine pharmacokinetics and exposure among HIV-infected Kenyan children.
Topics: Adolescent; Anthropometry; Anti-HIV Agents; Biological Availability; Body Size; Body Water; Child; C | 2014 |
CYP2B6 c.983T>C polymorphism is associated with nevirapine hypersensitivity in Malawian and Ugandan HIV populations.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Cytochrome P-450 CYP2B6; Drug Hypersen | 2014 |
Therapeutic drug monitoring of nevirapine in saliva in Uganda using high performance liquid chromatography and a low cost thin-layer chromatography technique.
Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Cohort Studies; Cross-Secti | 2014 |
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Relate | 2014 |
Induction with lopinavir-based treatment followed by switch to nevirapine-based regimen versus non-nucleoside reverse transcriptase inhibitors-based treatment for first line antiretroviral therapy in HIV infected children three years and older.
Topics: Child; Child, Preschool; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Femal | 2014 |
Optimization of the oligonucleotide ligation assay for the detection of nevirapine resistance mutations in Zimbabwean Human Immunodeficiency Virus type-1 subtype C.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Hum | 2014 |
Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: exposure and virological failure relationship.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo | 2015 |
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; | 2015 |
Variable and suboptimal nevirapine levels in infants given single-dose nevirapine at birth without maternal prophylaxis.
Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Nevirapine; Plasma | 2014 |
Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; Hepatitis C Antibodies; HIV In | 2014 |
Lipodystrophy syndrome among HIV infected children on highly active antiretroviral therapy in northern India.
Topics: Adolescent; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; | 2014 |
The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Follow-Up Studies; | 2014 |
Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.
Topics: Adult; Aged; Anti-Retroviral Agents; Asia; CD4 Lymphocyte Count; Cohort Studies; Drug Administration | 2014 |
Detecting virological failure in HIV-infected Tanzanian children.
Topics: Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2014 |
Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi.
Topics: Adult; Anti-HIV Agents; Blood Stains; Burundi; Child; Cross-Sectional Studies; Drug Monitoring; Drug | 2015 |
Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Lopinavir; Nevi | 2014 |
HIV testing in pregnancy.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmiss | 2014 |
Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy.
Topics: Adult; Age Factors; Alkynes; Ambulatory Care Facilities; Anti-Retroviral Agents; Benzoxazines; Cross | 2014 |
Assessment of HIV antiretroviral therapy adherence by measuring drug concentrations in hair among children in rural Uganda.
Topics: Anti-HIV Agents; Child; Child, Preschool; Female; Hair; HIV Infections; Humans; Longitudinal Studies | 2015 |
[Hepatotoxicity in healthy infants exposed to nevirapine during pregnancy].
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Female; HIV Infect | 2016 |
Missing HIV prevention opportunities in South African children--a 7-year review.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Health Promotion; HIV Infection | 2014 |
Stealth anti-CD4 conjugated immunoliposomes with dual antiretroviral drugs--modern Trojan horses to combat HIV.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; Drug Carriers; HEK293 Cells; H | 2015 |
Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes | 2015 |
Virological efficacy of a reduced dose of nevirapine in a small cohort of suppressed HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; | 2015 |
Proteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.
Topics: Alanine Transaminase; Anti-HIV Agents; Biomarkers; Blood Proteins; Chemical and Drug Induced Liver I | 2014 |
Comprehensive evaluation of caregiver-reported antiretroviral therapy adherence for HIV-infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Caregiver | 2015 |
[Recurrence of Stevens-Johnson syndrome following erroneous readministration of nevirapine].
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Medication Errors; Nevirapine; Recurrence; S | 2015 |
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R | 2015 |
The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.
Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Cyclopropane | 2015 |
A pharmacogenetics study in Mozambican patients treated with nevirapine: full resequencing of TRAF3IP2 gene shows a novel association with SJS/TEN susceptibility.
Topics: Adaptor Proteins, Signal Transducing; Adult; Alleles; Anti-HIV Agents; Black People; Exons; Genetic | 2015 |
Painless penile papule.
Topics: Adenine; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biops | 2015 |
Nevirapine, sodium concentration and HIV-1 RNA in breast milk and plasma among HIV-infected women receiving short-course antiretroviral prophylaxis.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV-1; Humans | 2015 |
Genetic Analyses of HIV-1 Strains Transmitted from Mother to Child in Northern Vietnam.
Topics: Anti-HIV Agents; Cluster Analysis; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variat | 2015 |
CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.
Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dr | 2015 |
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Clinical Trials as | 2015 |
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; H | 2015 |
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD | 2015 |
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
Topics: Adult; Aged; Alkynes; Anti-Retroviral Agents; Antimalarials; Benzoxazines; Cyclopropanes; Drug Inter | 2015 |
Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcript | 2015 |
Current Efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r) use correlates with elevate markers of atherosclerosis in HIV-infected subjects in Addis Ababa, Ethiopia.
Topics: Adult; Alkynes; Anti-HIV Agents; Atherosclerosis; Benzoxazines; Biomarkers; Blood Pressure; C-Reacti | 2015 |
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Deoxycytidine; Drug Administra | 2015 |
Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Carriers; Drug Delivery System | 2015 |
Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; Cohort Studies; Del | 2015 |
CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; ATP Binding Cassette Transporter, | 2016 |
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Retrosp | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
Nevirapine Concentration in Hair Samples Is a Strong Predictor of Virologic Suppression in a Prospective Cohort of HIV-Infected Patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Drug Monitoring; Female; Hair; HIV Infections; Huma | 2015 |
The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.
Topics: Anti-HIV Agents; Cell Line; China; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase | 2015 |
Performance of HIV Prevention of Mother-To-Child Transmission Programs in Sub-Saharan Africa: Longitudinal Assessment of 64 Nevirapine-Based Programs Implemented in 25 Countries, 2000-2011.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infection | 2015 |
Drug resistance mutations 18 months after discontinuation of nevirapine-based ART for prevention of mother-to-child transmission of HIV in Malawi.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; | 2015 |
Lower Preprandial Insulin and Altered Fuel Use in HIV/Antiretroviral-Exposed Infants in Cameroon.
Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Energy Metabolism; Female; HIV Infect | 2015 |
Missed Opportunities along the Prevention of Mother-to-Child Transmission Services Cascade in South Africa: Uptake, Determinants, and Attributable Risk (the SAPMTCTE).
Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studie | 2015 |
Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.
Topics: Anti-HIV Agents; Cross-Sectional Studies; DNA Mutational Analysis; Drug Resistance, Viral; Female; G | 2015 |
Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis.
Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Drug Resistance, Viral; Female; Genotype; HIV Infe | 2015 |
Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.
Topics: Anti-Retroviral Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Male; Nevirapine; | 2015 |
Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Depression; Fema | 2015 |
Outcome of neuropsychiatric symptoms related to an antiretroviral drug following its substitution by nevirapine: the RELAX study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Central Nervous System Di | 2015 |
CYP2B6 poor metaboliser alleles involved in efavirenz and nevirapine metabolism: CYP2B6*9 and CYP2B6*18 distribution in HIV-exposed subjects from Dschang, Western Cameroon.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Black People; Cameroon; Child; Child, Preschool; Cross-Sec | 2015 |
Stevens Johnson Syndrome and Toxic Epidermal Necrolysis: Maternal and Foetal Outcomes in Twenty-Two Consecutive Pregnant HIV Infected Women.
Topics: Anti-HIV Agents; Female; Fetus; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Outcome; St | 2015 |
Manuscript title: Facilitators and barriers to cotrimoxazole prophylaxis among HIV exposed babies: a qualitative study from Harare, Zimbabwe.
Topics: Adult; Cross-Sectional Studies; Drug Combinations; Female; HIV Infections; Humans; Infant; Nevirapin | 2015 |
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2016 |
HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; DNA, Viral; | 2015 |
Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Cytochrome P-450 CYP1A2; Cyto | 2015 |
Notes on the road to perfection; use of nevirapine in combination antiretroviral therapy for children with perinatal nevirapine exposure.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Male; Nevirapine; Viral Load | 2015 |
Raltegravir/nevirapine dual therapy at reduced doses as 'maintenance' treatment in virally suppressed HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV; HI | 2015 |
Artemether-Lumefantrine Exposure in HIV-Infected Nigerian Subjects on Nevirapine-Containing Antiretroviral Therapy.
Topics: Adult; Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Case-Control Studies; Coinfection; | 2015 |
Improvement in renal function and bone mineral density after a switch from tenofovir/emtricitabine plus ritonavir-boosted protease inhibitor to raltegravir plus nevirapine: a pilot study.
Topics: Adult; Anti-HIV Agents; Bone Density; Cohort Studies; Emtricitabine, Tenofovir Disoproxil Fumarate D | 2016 |
Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy | 2016 |
A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".
Topics: Adult; Cross-Sectional Studies; Disclosure; Fear; Female; HIV Infections; HIV-1; Humans; Mass Screen | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Cameroon; Co | 2015 |
Longitudinal adherence to antiretroviral drugs for preventing mother-to-child transmission of HIV in Zambia.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2015 |
Tracing defaulters in HIV prevention of mother-to-child transmission programmes through community health workers: results from a rural setting in Zimbabwe.
Topics: Adult; Cohort Studies; Community Health Workers; Female; HIV Infections; Humans; Infant, Newborn; In | 2015 |
Presence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort Study.
Topics: Adult; Anti-HIV Agents; Drug Liberation; Feces; Female; HIV Infections; HIV-1; Humans; Male; Middle | 2015 |
Outcome of Prevention of Parent-to-Child Transmission of HIV in an Urban Population in Southern India.
Topics: Adult; Anti-HIV Agents; Antibiotic Prophylaxis; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; | 2015 |
Antiretroviral Therapy for Nevirapine-Exposed Children With HIV Infection.
Topics: Anti-Retroviral Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmissio | 2015 |
Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort S | 2016 |
Antibodies against pneumococcal capsular polysaccharide in Malawian HIV-positive mothers and their HIV-exposed uninfected children.
Topics: Adult; Anti-HIV Agents; Bacterial Capsules; Child, Preschool; Female; HIV Infections; Humans; Immuno | 2016 |
The last and first frontier--emerging challenges for HIV treatment and prevention in the first week of life with emphasis on premature and low birth weight infants.
Topics: Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature | 2015 |
Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe.
Topics: Adolescent; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; C | 2015 |
Supra-treatment threshold neonatal jaundice: Incidence in HIV-exposed compared to non-exposed neonates at Queen Elizabeth Central Hospital in Blantyre, Malawi.
Topics: Anti-HIV Agents; Bilirubin; Breast Feeding; Comorbidity; Female; Gestational Age; HIV Infections; Hu | 2015 |
Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Combinations; Drug Interactions; Drug Monitorin | 2016 |
Nevirapine Plasma Concentrations in Human Immunodeficiency Virus-Exposed Neonates Receiving High-Dose Nevirapine Prophylaxis as Part of 3-Drug Regimen.
Topics: Adult; Anti-Retroviral Agents; Drug Therapy, Combination; False Positive Reactions; Female; HIV; HIV | 2017 |
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Gene Frequency; Gene-Environment Interaction; | 2016 |
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate D | 2016 |
Prevention of perinatal transmission of zidovudine- and nevirapine-resistant HIV.
Topics: Adolescent; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infectio | 2016 |
Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance | 2016 |
HIV-1 Antiretroviral Drug Resistance Mutations in Treatment Naïve and Experienced Panamanian Subjects: Impact on National Use of EFV-Based Schemes.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; | 2016 |
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistan | 2016 |
Providing Safe and Effective Preventative Antiretroviral Prophylaxis to HIV-exposed Newborns via a Novel Drug Delivery System in Tanzania.
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Dried Blood Spot Testing; Drug Delivery Systems; Female; HI | 2016 |
Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Therapy | 2016 |
Antiretroviral Therapy in Children Less Than 24 Months of Age at Pediatric HIV Centers in Tanzania: 12-Month Clinical Outcomes and Survival.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Male; Nevirapine; Retrospective Stud | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Co | 2016 |
Nevirapine prophylaxis to prevent HIV-1 mother-to-child transmission: pharmacokinetic considerations in preterm infants.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infant, Premature; Infectio | 2016 |
First-line antiretroviral therapy durability in a 10-year cohort of naïve adults started on treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combinat | 2016 |
HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infec | 2016 |
Effect of co-administration of Hypoxis hemerocallidea extract and antiretroviral therapy (HAART) on the histomorphology and seminal parameters in Sprague Dawley rats.
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascorbic Acid; Chemotherapy, Adjuva | 2017 |
Morphine Increases Lamivudine- and Nevirapine-Induced Human Immunodeficiency Virus-1 Drug-Resistant Mutations In Vitro.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Morph | 2017 |
Severe antiretroviral-associated skin reactions in South African patients: a case series and case-control analysis.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Drug Therapy, Combination; Female; HIV | 2016 |
Maternal Influences on Access to and Use of Infant ARVs and HIV Health Services in Uganda.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Anti-Retroviral Agents; Cross-Sectional Studies; | 2017 |
Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children.
Topics: Child, Preschool; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavi | 2016 |
Early infant diagnosis of HIV infection using DNA-PCR at a referral center: an 8 years retrospective analysis.
Topics: Anti-HIV Agents; DNA, Viral; Early Diagnosis; Ethiopia; Female; HIV; HIV Infections; Humans; Infant; | 2016 |
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
Topics: Adult; Dideoxynucleosides; Drug Therapy, Combination; Female; France; HIV Infections; Humans; Lamivu | 2016 |
Adverse drug reactions associated with antiretroviral therapy in South Africa.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dizziness; Exanthema; Fema | 2016 |
Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: a prospective study during 2004-2011.
Topics: Adult; Anti-HIV Agents; China; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmissio | 2016 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; | 2017 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studi | 2016 |
Clinical analysis of HIV/AIDS patients with drug eruption in Yunnan, China.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Aged, 80 and over; Antiretroviral Therapy, Highly A | 2016 |
Development of a Qualitative Quantitative Polymerase Chain Reaction Test to Identify Patients Failing First-Line Therapy to Non-Nucleotide Reverse Transcriptase Inhibitor.
Topics: Alkynes; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Drug Monitoring; Drug Resistance, Vir | 2017 |
Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.
Topics: Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Genes, Reporter; Green | 2016 |
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc | 2017 |
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, N | 2016 |
Antiretrovirals causing severe pre-eclampsia.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; F | 2016 |
Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antitubercular Agents; Diarylquinolines | 2017 |
Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.
Topics: Africa; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; Huma | 2017 |
Genome-wide association study of nevirapine hypersensitivity in a sub-Saharan African HIV-infected population.
Topics: Adult; Africa South of the Sahara; Aged; Anti-HIV Agents; Biomarkers; Black People; Case-Control Stu | 2017 |
Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Comorbidity; Female; Heterosexuality; | 2017 |
Exploring CYP2B6 activity by measuring the presence ofnevirapine hydroxy metabolites in plasma.
Topics: Anti-HIV Agents; Cytochrome P-450 CYP2B6; HIV Infections; Humans; Nevirapine; Reverse Transcriptase | 2016 |
Nevirapine Pharmacokinetics and Safety in Neonates Receiving Combination Antiretroviral Therapy for Prevention of Vertical HIV Transmission.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemoprevention; Female; HIV Infectio | 2017 |
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymph | 2017 |
In situ hybrid nano drug delivery system (IHN-DDS) of antiretroviral drug for simultaneous targeting to multiple viral reservoirs: An in vivo proof of concept.
Topics: Animals; Anti-HIV Agents; Drug Delivery Systems; Female; HIV Infections; Nanoparticles; Nevirapine; | 2017 |
Plasma nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Female; HIV Infections; HIV-1; Humans; Kenya; Male; | 2017 |
Effect of
Topics: Adult; Aged; Anti-HIV Agents; Chromatography, Liquid; Cross-Over Studies; Drug Interactions; Female; | 2017 |
Persistence of HIV drug resistance among South African children given nevirapine to prevent mother-to-child-transmission.
Topics: Anti-HIV Agents; Child, Preschool; Drug Resistance, Viral; Female; Genotyping Techniques; HIV Infect | 2017 |
Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; | 2008 |
Study of the genotypic resistant pattern in HIV-infected women and children from rural west Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; Child; Child, Preschool; Cohort Studies; Drug Resistance, Multiple | 2008 |
Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in cameroon.
Topics: Adult; Anti-HIV Agents; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans; | 2008 |
Breast-feeding, antiretroviral prophylaxis, and HIV.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Tra | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin | 2008 |
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; Cycl | 2008 |
Voluntary counselling and testing (VCT) uptake, nevirapine use and infant feeding options at the University of Nigeria Teaching Hospital.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS Serodiagnosis; Ambulatory Care; Breast F | 2008 |
Nevirapine resistance in women and infants after first versus repeated use of single-dose nevirapine for prevention of HIV-1 vertical transmission.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infec | 2008 |
Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Male; | 2008 |
Extra drugs and slower weaning lowers HIV risk for newborns.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Case-Control Studies; Female; HIV Infec | 2008 |
HIV and obstetric complications and fetal outcomes in Vellore, India.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seronegativity; Humans; India; Infan | 2008 |
Effect of haematological alterations on thalassaemia investigation in HIV-1-infected Thai patients receiving antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; Case-Control Studies; Erythrocyte Indices; Female; Hemogl | 2008 |
Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Cou | 2008 |
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1 | 2008 |
Extended nevirapine prophylaxis to prevent HIV transmission.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Mul | 2008 |
SWEN--when authors disagree.
Topics: Anti-HIV Agents; Attitude of Health Personnel; Bias; HIV Infections; Humans; India; Infant; Infant, | 2008 |
Nevirapine to prevent HIV transmission via breastfeeding.
Topics: Anti-HIV Agents; Breast Feeding; HIV Infections; Humans; India; Infant; Infant, Newborn; Nevirapine; | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Extended-dose nevirapine to 6 weeks of age for infants to prevent HIV transmission via breastfeeding in Ethiopia, India, and Uganda: an analysis of three randomised controlled trials.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Ethiopia; Female; HIV Infectio | 2008 |
Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; | 2008 |
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzo | 2008 |
A review of the prevention of mother-to-child transmission programme of the Western Cape provincial government, 2003 - 2004.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infectious Disease Transmissi | 2008 |
Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Infec | 2008 |
Hepatotoxicity in patients prescribed efavirenz or nevirapine.
Topics: Adult; Alkynes; Benzoxazines; CD4-Positive T-Lymphocytes; Chemical and Drug Induced Liver Injury; Cy | 2008 |
Preventing mother-to-child transmission of HIV in resource-limited settings: the Elizabeth Glaser Pediatric AIDS Foundation experience.
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; Foundations; Health Education; HIV Infect | 2009 |
Serious toxicity associated with continuous nevirapine-based HAART in pregnancy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Multivariate | 2008 |
FDA notifications. FDA approves label change for nevirapine.
Topics: Adolescent; Child; Child, Preschool; Drug Approval; Drug Labeling; HIV Infections; Humans; Infant; I | 2008 |
Fatal outcome of nevirapine-associated toxic epidermal necrolysis.
Topics: Adult; Anti-HIV Agents; Fatal Outcome; HIV Infections; HIV-1; Humans; Male; Nevirapine; Stevens-John | 2008 |
Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; | 2008 |
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; | 2008 |
Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Black People; Body Weight; Cyc | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; H | 2008 |
Analysis of nevirapine resistance mutations in cloned HIV type 1 variants from HIV-infected Ugandan infants using a single-step amplification-sequencing method (AmpliSeq).
Topics: Amino Acid Substitution; Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; HIV Infec | 2008 |
Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults.
Topics: Adult; Africa, Southern; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazin | 2008 |
Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine.
Topics: Anti-HIV Agents; Child; HIV Infections; Humans; Male; Nevirapine; Stevens-Johnson Syndrome | 2008 |
Clinical manifestations and antiretroviral management of HIV/AIDS patients with tuberculosis co-infection in Kramat 128 Hospital.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV | 2008 |
Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Fem | 2008 |
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Stu | 2008 |
Therapeutic drug monitoring of nevirapine in resource-limited settings.
Topics: Adolescent; Adult; Africa; Aged; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; D | 2008 |
Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.
Topics: Absorptiometry, Photon; Adipose Tissue; Adolescent; Antiretroviral Therapy, Highly Active; CD4 Lymph | 2008 |
Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.
Topics: Anti-Retroviral Agents; Breast Feeding; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human | 2008 |
Persistence of nevirapine in breast milk and plasma of mothers and their children after single-dose administration.
Topics: Adult; Chromatography, Liquid; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease T | 2009 |
Infant feeding, HIV transmission and mortality at 18 months: the need for appropriate choices by mothers and prioritization within programmes.
Topics: Adolescent; Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Choice | 2008 |
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti | 2008 |
Transient antiretroviral therapy selecting for common HIV-1 mutations substantially accelerates the appearance of rare mutations.
Topics: Antiviral Agents; Female; Genome; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Ve | 2008 |
[Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Long-T | 2008 |
Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Drug Admini | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyc | 2009 |
Prevalence of nevirapine-associated resistance mutations after single dose prophylactic treatment among antenatal clinic attendees in north rift Kenya.
Topics: Anti-HIV Agents; Chemoprevention; DNA, Viral; Drug Resistance, Viral; Female; HIV Infections; HIV Re | 2008 |
HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Topics: Adult; Alleles; Anti-HIV Agents; Case-Control Studies; Exanthema; Female; Genotype; HIV Infections; | 2009 |
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood; Breast Feeding; Cl | 2009 |
Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV; HIV Infections; Humans; I | 2008 |
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2009 |
Determinants of nonadherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Rwanda.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newborn | 2009 |
Single-dose nevirapine to prevent mother-to-child transmission of HIV type 1: balancing the benefits and risks.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis | 2009 |
Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV | 2009 |
[Evaluation of the adverse effects of nevirapine in HIV-infected pregnant women in a South Brazilian University Hospital].
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Female; HIV Infections; Hospitals, University; Humans; N | 2008 |
Prevention of mother-to-child HIV transmission using 3-drug combination antiretroviral treatment: observational cohort in clinical practice setting in India.
Topics: Adolescent; Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV | 2009 |
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; | 2009 |
Estimating the lost benefits of antiretroviral drug use in South Africa.
Topics: Anti-Retroviral Agents; Cost of Illness; Health Care Costs; HIV Infections; Humans; Infectious Disea | 2008 |
[Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Dru | 2008 |
Does gender and nevirapine (NVP) influence abnormal liver functions in HIV disease?
Topics: Adult; Female; Gender Identity; HIV Infections; Humans; Liver; Male; Nevirapine | 2009 |
Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochr | 2009 |
Switch to Viramune safe for some who can't tolerate Sustiva.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tran | 2008 |
Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.
Topics: Adult; Aged; Alleles; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B; ATP Bindi | 2009 |
Which ART regimen is best after receipt of single-dose nevirapine?
Topics: Disease Transmission, Infectious; Female; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy C | 2009 |
Cryptococcal meningoradiculitis: an atypical presentation after initiation of antiretroviral therapy.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Retroviral Agents; Ceftriaxone; | 2007 |
The cost-effectiveness analysis of initiating HIV/AIDS treatment with efavirenz-based regimens compared with nevirapine-based regimens in Thailand.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cost-Benefit Analys | 2008 |
Predicting factors for unsuccessful switching from nevirapine to efavirenz in HIV-infected patients who developed nevirapine-associated skin rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Chi-Square Distribution; Cohort | 2009 |
Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals.
Topics: Adult; Antiviral Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Ne | 2009 |
Higher placental anti-inflammatory IL-10 cytokine expression in HIV-1 infected women receiving longer zidovudine prophylaxis associated with nevirapine.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Interleukin-10; Nevirapine; Placenta; | 2009 |
Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Botswana; CD4 Lymphocyte Count; Comorbidity; Cyclopro | 2009 |
Women exposed to single-dose nevirapine in successive pregnancies: effectiveness and nonnucleoside reverse transcriptase inhibitor resistance.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV | 2009 |
Prevention of mother-to-child transmission of HIV in a refugee camp setting in Tanzania.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; Infecti | 2008 |
Proinflammatory cytokine changes in clinically stable, virologically suppressed, HIV-infected patients switching from protease inhibitors to abacavir.
Topics: Adiponectin; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Adminis | 2009 |
Generic combination approved.
Topics: Anti-HIV Agents; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudin | 2009 |
Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Demography; Drug Therapy, Combination; Drugs, Generic; | 2009 |
Establishment of drug-resistant HIV-1 in latent reservoirs.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Breast Feeding; Developing Countries; Disease R | 2009 |
Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Reservoirs; Drug Resistance, Viral; Female; HIV Infec | 2009 |
The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; | 2009 |
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female; | 2008 |
Arthritis as the presenting feature of HIV infection in a child.
Topics: Ankle Joint; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Infectious; Child, | 2009 |
The obstetric face and challenge of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Inf | 2009 |
Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cohort Studies; Cyclopropanes; Dose | 2009 |
Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Mutation; Nevirapine | 2009 |
Efavirenz and nevirapine interactions with rifampicin: resolving the dilemmas?
Topics: Alkynes; Anti-Bacterial Agents; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV | 2009 |
Reducing vertical HIV transmission in Kinshasa, Democratic Republic of Congo: trends in HIV prevalence and service delivery.
Topics: Anti-HIV Agents; Delivery of Health Care; Democratic Republic of the Congo; Female; HIV Infections; | 2009 |
HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania.
Topics: Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Eruptions; HIV Infections; Huma | 2009 |
Long-term follow-up of nevirapine-treated patients in a single-centre cohort.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; CD4 Lymphocyte Cou | 2009 |
Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach.
Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Darunavir; Drug Therapy, Combination; Female; | 2009 |
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Hypersensi | 2009 |
Mortality and virologic outcomes after access to antiretroviral therapy among a cohort of HIV-infected women who received single-dose nevirapine in Lusaka, Zambia.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Hu | 2009 |
Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Nevirapine; Suicide, Attempted | 2009 |
Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
Topics: Adolescent; Adult; Anti-HIV Agents; Blood; Chemoprevention; Drug Resistance, Viral; HIV Infections; | 2009 |
Prevention of human immunodeficiency virus mother-to-child transmission in Israel.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Emigrants and Immigrants; | 2009 |
Report from the 16th Conference on Retroviruses and Opportunistic Infections. Lopinavir/r is superior to nevirapine in women who previously received single-dose nevirapine.
Topics: Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Pyrimidinones; Rever | 2009 |
In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Administration Schedule; Drug | 2009 |
Evolving care of HIV-infected pregnant women in Jamaica--from nevirapine to HAART.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; H | 2008 |
Adherence to antiretroviral drug therapy in children with HIV/AIDS in Jamaica.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; | 2008 |
Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infecti | 2009 |
No influence of nevirapine on vitamin D deficiency in HIV-infected patients.
Topics: Anti-HIV Agents; HIV; HIV Infections; Humans; Longitudinal Studies; Nevirapine; Vitamin D Deficiency | 2009 |
Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants.
Topics: Age Factors; Drug Resistance, Viral; HIV; HIV Infections; Humans; Infant; Mutation; Nevirapine; Reag | 2009 |
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lym | 2009 |
Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Administration Schedule; Female; Foll | 2010 |
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Female; Follow-Up Studies | 2009 |
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
Topics: Acidosis, Lactic; Adult; Age Factors; Anti-HIV Agents; Drug Therapy, Combination; Drugs, Generic; Ex | 2010 |
Mother-to-child HIV and HHV-8 transmission in neonates at Saint Camille Medical Centre in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Burkina Faso; CD4 Lymphocyte Count; DNA, Viral; Female; Herpesviridae Infect | 2009 |
Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Drug | 2009 |
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2009 |
Single-dose nevirapine exposure affects T cell response and cytokine levels in HIV type 1-infected women.
Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Cytokines; Female; HIV Infections; Humans; Infa | 2009 |
Modeling vertical transmission of HIV: imperfect vaccines can be of benefit.
Topics: AIDS Vaccines; Anti-HIV Agents; Antibodies, Monoclonal; Breast Feeding; Child, Preschool; Female; HI | 2009 |
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
Topics: Administration, Oral; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Femal | 2009 |
Reflections: neurology and the humanities: reflections for October.
Topics: Anti-HIV Agents; Anticonvulsants; Drug Combinations; Drug Interactions; Female; HIV Infections; Huma | 2009 |
Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infect | 2009 |
Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Developing Countries; Female; Gastroenteritis; HIV Infection | 2010 |
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infectio | 2009 |
Substituting nevirapine for efavirenz: risk factors for toxicity in nonnaive patients in a resource-constrained setting.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Risk Fac | 2009 |
Plasma lipid profile in pregnant women with HIV receiving nevirapine.
Topics: Adolescent; Adult; Anti-HIV Agents; Cholesterol; Drug Therapy, Combination; Female; HIV Infections; | 2009 |
Improving the coverage of the PMTCT programme through a participatory quality improvement intervention in South Africa.
Topics: Anti-HIV Agents; Continuity of Patient Care; Female; HIV Infections; Humans; Infant, Newborn; Infect | 2009 |
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Inf | 2010 |
Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Administration Schedule; Drug Hypersensitivity | 2009 |
Long-term effectiveness and safety outcomes in HIV-1-infected patients after a median time of 6 years on nevirapine.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Retrospective | 2009 |
Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu | 2010 |
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birt | 2009 |
Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies | 2009 |
Dammarenolic acid, a secodammarane triterpenoid from Aglaia sp. shows potent anti-retroviral activity in vitro.
Topics: Aglaia; Animals; Anti-Retroviral Agents; Cell Cycle; Cell Proliferation; Cytotoxins; Esters; Haplorh | 2010 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, | 2010 |
Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; Infectious D | 2010 |
Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique.
Topics: Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily | 2010 |
Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Child; Child, Prescho | 2009 |
Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Chromatography, Liquid; Drug Resistanc | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; | 2010 |
Decline in early life mortality in a high HIV prevalence rural area of South Africa: evidence of HIV prevention or treatment impact?
Topics: Adult; Anti-HIV Agents; Child, Preschool; Cohort Studies; Female; HIV Infections; Humans; Infant; In | 2010 |
Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liver Inj | 2010 |
Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Blotting, Western; | 2009 |
Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HI | 2010 |
Determinants of adherence to a single-dose nevirapine regimen for the prevention of mother-to-child HIV transmission in Gert Sibande district in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; Health Knowledge, Attitudes, Practice; HIV Infections; H | 2010 |
Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant; | 2010 |
Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Female; HIV Infect | 2010 |
Suboptimal etravirine activity is common during failure of nevirapine-based combination antiretroviral therapy in a cohort infected with non-B subtype HIV-1.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genot | 2010 |
Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HI | 2010 |
Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Ke | 2010 |
Nevirapine-associated early hepatotoxicity: incidence, risk factors, and associated mortality in a primary care ART programme in South Africa.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical a | 2010 |
Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.
Topics: Adult; Anti-HIV Agents; Chemoprevention; DNA Primers; DNA, Viral; Drug Resistance, Viral; Female; HI | 2010 |
Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Female; HIV Inf | 2010 |
Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coho | 2010 |
17th Conference on Retroviruses and Opportunistic Infections, 16-19 February, San Francisco, CA. Limits of success.
Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infectious Disease Tr | 2010 |
HIV type 1 antiretroviral resistance mutations in subtypes B, C, and F in the City of São Paulo, Brazil.
Topics: Alkynes; Benzoxazines; Brazil; Cohort Studies; Cyclopropanes; Darunavir; Drug Resistance, Multiple, | 2010 |
Epidemic Stevens-Johnson syndrome in HIV patients in Guinea-Bissau: a side effect of the drug-supply policy?
Topics: Adult; Anti-HIV Agents; Epidemics; Female; Guinea-Bissau; HIV Infections; Humans; Male; Nevirapine; | 2010 |
Predicting virologic failure among HIV-1-infected children receiving antiretroviral therapy in Tanzania: a cross-sectional study.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Antigens; CD4 Lympho | 2010 |
A Safe Motherhood project in Kenya: assessment of antenatal attendance, service provision and implications for PMTCT.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Health Knowledge, Attitudes, Practice; HIV Infect | 2010 |
Couples' voluntary counselling and testing and nevirapine use in antenatal clinics in two African capitals: a prospective cohort study.
Topics: Adult; Cohort Studies; Counseling; Family Characteristics; Female; HIV Infections; Humans; Infectiou | 2010 |
Rising mother-to-child HIV transmission in a resource-limited breastfeeding population.
Topics: Adult; Breast Feeding; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Inf | 2010 |
Successful bosentan and nonnucleoside reverse transcriptase inhibitor-based therapy in a patient with acquired immunodeficiency syndrome and pulmonary arterial hypertension.
Topics: Acquired Immunodeficiency Syndrome; Arteries; Bosentan; Drug Interactions; Female; HIV Infections; H | 2010 |
Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.
Topics: Botswana; Drug Resistance, Viral; Female; Gene Frequency; Genetic Variation; HIV Infections; HIV-1; | 2010 |
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therap | 2010 |
Evaluation of a 6-year highly active antiretroviral therapy in Chinese HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; China; Chole | 2010 |
Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; HIV Inf | 2010 |
Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resista | 2010 |
Nevirapine resistance by timing of HIV type 1 infection in infants treated with single-dose nevirapine.
Topics: Chemoprevention; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Inf | 2010 |
Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
Topics: Anti-HIV Agents; Area Under Curve; Child; Confidence Intervals; Dosage Forms; Drug Therapy, Combinat | 2010 |
Better health-related quality of life after switching from a virologically effective regimen to a regimen containing efavirenz or nevirapine.
Topics: Adult; Aged; Alkynes; Anxiety; Benzoxazines; Cyclopropanes; Depression; Female; France; Health Statu | 2010 |
Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte | 2010 |
[Durability and tolerability of long-term nevirapine-based HAART].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatit | 2010 |
Non-adherence to the single dose nevirapine regimen for the prevention of mother-to-child transmission of HIV in Bindura town, Zimbabwe: a cross-sectional analytic study.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Delivery, Obstetric; Educational Status; Female; He | 2010 |
Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Re | 2010 |
Pharmacokinetics of the treatment switch from efavirenz to nevirapine.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV In | 2010 |
Testing and interval estimation for two-sample survival comparisons with small sample sizes and unequal censoring.
Topics: Algorithms; Biostatistics; Breast Neoplasms; Clinical Trials as Topic; Computer Simulation; Confiden | 2010 |
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapin | 2009 |
Constrained patterns of covariation and clustering of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analy | 2010 |
The benefit of supplementary feeding for wasted Malawian adults initiating ART.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Retroviral Agents; Body Mass | 2010 |
Report from the 17th Conference on Retroviruses and Opportunistic Infections. Randomized studies of once-daily darunavir and tenofovir/FTC + nevirapine.
Topics: Adenine; Anti-HIV Agents; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV In | 2010 |
Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Epidemi | 2010 |
Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to etravirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1 | 2010 |
Predictors of treatment failure in Cambodian children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Child; Child, Preschoo | 2010 |
Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
Topics: Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Stud | 2010 |
Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; | 2010 |
Reducing pediatric HIV infection: estimating mother-to-child transmission rates in a program setting in Zambia.
Topics: Antiretroviral Therapy, Highly Active; Breast Feeding; Child; DNA, Viral; Drug Therapy, Combination; | 2010 |
Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Ag | 2010 |
Prevention of mother-to-child transmission of HIV infection: views and perceptions about swallowing nevirapine in rural Lilongwe, Malawi.
Topics: Administration, Oral; Adult; Aged; Anti-HIV Agents; Attitude to Health; Female; Focus Groups; Health | 2010 |
Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2010 |
Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; CD4 Lymphocyte Count; | 2010 |
Switching from efavirenz to nevirapine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Time Fact | 2010 |
Extensive hypertrophic lichen planus in an HIV positive patient.
Topics: Adult; Anti-HIV Agents; Clobetasol; Drug Combinations; Hand Dermatoses; HIV Infections; Humans; Lami | 2010 |
Theoretical studies on the molecular basis of HIV-1RT/NNRTIs interactions.
Topics: Alkynes; Amino Acids; Benzoxazines; Binding Sites; Cyclopropanes; HIV Infections; HIV Reverse Transc | 2011 |
Hemodialysis does not significantly affect the pharmacokinetics of nevirapine in HIV-1-infected persons requiring hemodialysis: results from ACTG A5177.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Combined Modality Therapy; HIV Infections; HIV- | 2010 |
[Fate of children born to HIV positive mothers followed in the context of preventing mother-to-child transmission of HIV in Togo. Study of 1042 infants].
Topics: Anti-HIV Agents; Breast Feeding; Delivery, Obstetric; Female; HIV Infections; HIV Seropositivity; Hu | 2010 |
Vanishing bile duct syndrome in human immunodeficiency virus: nevirapine hepatotoxicity revisited.
Topics: Adult; Anti-HIV Agents; Bile Duct Diseases; Bile Ducts, Intrahepatic; Cholestasis, Intrahepatic; Fem | 2010 |
Suboptimal nevirapine steady-state pharmacokinetics during intrapartum compared with postpartum in HIV-1-seropositive Ugandan women.
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Longitudinal Studies; Nev | 2010 |
CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.
Topics: Adult; Aged; Alkynes; Aryl Hydrocarbon Hydroxylases; Asian People; ATP Binding Cassette Transporter, | 2010 |
Impact of maternal HAART on the prevention of mother-to-child transmission of HIV: results of an 18-month follow-up study in Ouagadougou, Burkina Faso.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burkina Faso; Cohort Stud | 2010 |
Coverage of nevirapine-based services to prevent mother-to-child HIV transmission in 4 African countries.
Topics: Adult; Africa; Anti-HIV Agents; Cross-Sectional Studies; Female; Fetal Blood; HIV Infections; Humans | 2010 |
Nevirapine-induced stevens johnson-syndrome and fulminant hepatic failure requiring liver transplantation.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hemofiltration; HIV Infections; Huma | 2010 |
Evaluation of the safety of nevirapine therapy during pregnancy.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; HI | 2010 |
Nevirapine-associated hepatotoxicity was not predicted by CD4 count ≥250 cells/μL among women in Zambia, Thailand and Kenya.
Topics: Adolescent; Adult; Alanine Transaminase; Aspartate Aminotransferases; CD4 Lymphocyte Count; Chemical | 2010 |
Operational evaluation of a service for prevention of mother-to-child transmission of HIV in rural Uganda: barriers to uptake of single-dose nevirapine and the role of birth reporting.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2010 |
Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.
Topics: Drug Resistance, Viral; Evolution, Molecular; Female; Genome, Viral; HIV Infections; HIV-1; Humans; | 2010 |
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; | 2010 |
Antenatal HIV-1 RNA load and timing of mother to child transmission; a nested case-control study in a resource poor setting.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Cohort Studies; Female; HIV Infections; HIV-1; Humans; | 2010 |
Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; | 2010 |
Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Fem | 2010 |
Recent FDA approvals and changes.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Approval; Drug Combinations; Drugs, Generic; HIV Anti | 2010 |
[Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; HIV Infections; Ho | 2010 |
Protein adducts as prospective biomarkers of nevirapine toxicity.
Topics: Amino Acid Sequence; Anti-HIV Agents; Biomarkers; Chromatography, High Pressure Liquid; Hemoglobins; | 2010 |
A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study.
Topics: Alkynes; Argentina; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Resistance; Drug | 2011 |
Outcomes and challenges of scaling up comprehensive PMTCT services in rural Swaziland, Southern Africa.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Eswatini; Female; HIV Infections; Humans; Infant; Infant | 2010 |
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infecti | 2010 |
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2011 |
Treatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Confide | 2010 |
Extended antenatal antiretroviral use correlates with improved infant outcomes throughout the first year of life.
Topics: Adult; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Female; H | 2010 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV | 2010 |
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cervix Uteri; Disease Transmission, I | 2010 |
Recent FDA approvals and changes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Capsules; Clinical Trials as Topic; Drug Approval; Drug Combina | 2010 |
Acute porphyria precipitated by nevirapine.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Porphyria, Acute Intermittent; P | 2010 |
Preventing mother-to-child transmission of HIV—protecting this generation and the next.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Female; HIV Infections; Humans; Infectious Disease Transmis | 2010 |
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV In | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Anti-Retroviral Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infe | 2010 |
Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Côte d'Ivoire.
Topics: Abortion, Induced; Abortion, Spontaneous; Adult; Africa, Western; Alkynes; Anti-HIV Agents; Benzoxaz | 2011 |
The impact of maternal highly active antiretroviral therapy and short-course combination antiretrovirals for prevention of mother-to-child transmission on early infant infection rates at the Mulago national referral hospital in Kampala, Uganda, January 20
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Confidence Intervals; Female; HIV Inf | 2011 |
Virologic failure and second-line antiretroviral therapy in children in South Africa--the IeDEA Southern Africa collaboration.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschoo | 2011 |
Comparing two service delivery models for the prevention of mother-to-child transmission (PMTCT) of HIV during transition from single-dose nevirapine to multi-drug antiretroviral regimens.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-Retroviral Agents; CD4 Lymphocyte Count; Clinica | 2010 |
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Benzoxazines; Breast Feeding; CD4 Lymphocyte C | 2011 |
A combined sequence-structure approach for predicting resistance to the non-nucleoside HIV-1 reverse transcriptase inhibitor Nevirapine.
Topics: Drug Resistance, Viral; Genetic Testing; Genetic Vectors; HIV Infections; HIV Reverse Transcriptase; | 2011 |
Emergence of drug resistant mutations after single dose nevirapine exposure in HIV-1 infected pregnant women in south India.
Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India | 2010 |
Antiretroviral treatment for HIV-infected infants exposed to nevirapine.
Topics: Anti-Retroviral Agents; Child; Drug Resistance, Viral; Endpoint Determination; HIV Infections; Human | 2010 |
Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2011 |
Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Monitoring; Drug Ther | 2011 |
Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug-Related Side Effects an | 2010 |
Automatic nevirapine concentration interpretation system using support vector regression.
Topics: Anti-HIV Agents; Artificial Intelligence; Drug Resistance, Viral; HIV Infections; Humans; Models, Th | 2011 |
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; DNA Primers; Female; HIV Infections; HIV-1; Human | 2011 |
Induction therapy with protease-inhibitors modifies the effect of nevirapine resistance on virologic response to nevirapine-based HAART in children.
Topics: Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Resistance, Viral; Female; Genotype; H | 2011 |
Clinical manifestations and outcome in HIV-infected young infants presenting with acute illness in Durban, South Africa.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmi | 2011 |
Perinatal tuberculosis: two unusual cases.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Antimalarials; Drug Therapy, Combination; Endometritis; F | 2011 |
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cli | 2011 |
First-line antiretroviral therapy after single-dose nevirapine exposure in South Africa: a cost-effectiveness analysis of the OCTANE trial.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Infant, Newborn; Infe | 2011 |
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec | 2011 |
Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.
Topics: Adult; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptas | 2011 |
Study leads to revision in WHO guidelines for HIV women.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Practice Guid | 2010 |
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Topics: Amino Acid Substitution; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Vir | 2011 |
Effectiveness of a PMTCT programme in rural Western Kenya.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Epidemiologic Methods; Fe | 2011 |
Efavirenz-based combination antiretroviral therapy after peripartum single-dose nevirapine.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; | 2011 |
Factors associated with short-course antiretroviral prophylaxis (dual therapy) adherence for PMTCT in Nkangala district, South Africa.
Topics: Anti-HIV Agents; Chi-Square Distribution; Depression, Postpartum; Directive Counseling; Female; Heal | 2011 |
Cumulative exposure to cell-free HIV in breast milk, rather than feeding pattern per se, identifies postnatally infected infants.
Topics: Adult; Anthropometry; Anti-HIV Agents; Case-Control Studies; Chemoprevention; Feeding Behavior; Fema | 2011 |
Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
Topics: Amino Acid Substitution; Anti-HIV Agents; Brazil; Drug Resistance, Viral; HIV Infections; HIV Revers | 2011 |
Factors influencing plasma nevirapine levels: a study in HIV-infected children on generic antiretroviral treatment in India.
Topics: Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; | 2011 |
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretrov | 2010 |
Do nevirapine and efavirenz affect vitamin D homeostasis similarly?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Vitamin D | 2011 |
Short communication: high prevalence of drug resistance in HIV type 1-infected children born in Honduras and Belize 2001 to 2004.
Topics: Anti-HIV Agents; Base Sequence; Belize; Cohort Studies; Drug Resistance, Multiple, Viral; Female; HI | 2011 |
Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Body Wei | 2011 |
[Immune reconstitution inflammatory syndrome and HIV leprosy co-infection].
Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Dapsone; Diagnostic Errors; Female; HIV Infections; | 2011 |
Trial in youngest group points to HIV treatment overhaul.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; HIV Protease Inhibitors; Humans; | 2011 |
Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; In | 2011 |
Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; Humans; Infant; Infectious Disease Transmis | 2011 |
"They call our children "Nevirapine babies?" ": A qualitative study about exclusive breastfeeding among HIV positive mothers in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Family; Female; Health Knowledge, Attitudes, Pra | 2010 |
Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Follow-Up Studies; Health Status; HIV Infectio | 2011 |
Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent.
Topics: Adolescent; Adult; Asian People; Black People; CD4-Positive T-Lymphocytes; Female; Genetic Variation | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabi | 2011 |
[Mass screening for hypothyroidism in a cohort of HIV infected patients in a Bogotá hospital, Colombia].
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Col | 2011 |
Improving retention in the early infant diagnosis of HIV program in rural Mozambique by better service integration.
Topics: Adult; Anti-HIV Agents; Delivery of Health Care; Drug Therapy, Combination; Female; HIV Infections; | 2011 |
Serum Nevirapine and Efavirenz concentrations and effect of concomitant rifampicin in HIV infected children on antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropa | 2011 |
Targeted maximum likelihood estimation of effect modification parameters in survival analysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Female; HIV | 2011 |
Discontinuation rate of nevirapine-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver | 2012 |
Reduced HIV transmission at subsequent pregnancy in a resource-poor setting.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Infant, Newb | 2011 |
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
Topics: Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Human | 2011 |
WHO 2010 guidelines for prevention of mother-to-child HIV transmission in Zimbabwe: modeling clinical outcomes in infants and mothers.
Topics: Anti-HIV Agents; Breast Feeding; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2011 |
Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine; U | 2011 |
Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Monitoring; Feasibility Studies; Female; HIV I | 2011 |
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Lo | 2011 |
Pregnancy outcome among HIV positive women receiving antenatal HAART versus untreated maternal HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Cesarean Section; Chi-Sq | 2011 |
Rilpivirine: a step forward in tailored HIV treatment.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; | 2011 |
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Administration Schedule; Drug The | 2011 |
Selection of HIV resistance associated with antiretroviral therapy initiated due to pregnancy and suspended postpartum.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV; HIV Inf | 2011 |
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
Topics: Anti-HIV Agents; Chromosomes, Human, Pair 6; Drug Eruptions; Genetic Predisposition to Disease; Geno | 2011 |
Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant; Infectious Disease T | 2011 |
Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HI | 2011 |
Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclop | 2011 |
A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infection | 2011 |
Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry.
Topics: Anti-HIV Agents; Chromatography, Liquid; Cohort Studies; Hair; HIV Infections; Humans; Nevirapine; R | 2011 |
The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA Mutational Analysis; Drug Re | 2012 |
Nevirapine for the prevention of mother-to-child transmission of HIV: a nation-wide coverage survey in Côte d'Ivoire.
Topics: Adult; Cote d'Ivoire; Disease Transmission, Infectious; Female; HIV Infections; Humans; Multivariate | 2011 |
Prevalence of etravirine-associated mutations in clinical samples with genotypic resistance to nevirapine and efavirenz in Brazilian clinics.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cyclopropanes | 2011 |
HIV Therapy Simulator: a graphical user interface for comparing the effectiveness of novel therapy regimens.
Topics: Anti-HIV Agents; Computer Graphics; Computer Simulation; HIV Infections; Humans; Models, Biological; | 2011 |
Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Fat Dist | 2011 |
Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child, Preschool; Fema | 2012 |
Should sponsors and DSMBs share interim results across trials?
Topics: Anti-HIV Agents; Clinical Trials as Topic; Clinical Trials Data Monitoring Committees; Confidentiali | 2011 |
Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: a combined pharmacokinetic, pharmacodynamic, and viral dynamic analysis to predict clinical outcomes.
Topics: Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; HIV-1; Humans; Infant, | 2011 |
Trends in the clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Kenya, Uganda and Tanzania between 2002 and 2009.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional | 2011 |
Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Revers | 2011 |
Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynu | 2011 |
Impact of internal standard addition on dried blood spot analysis in bioanalytical method development.
Topics: Anti-HIV Agents; Dried Blood Spot Testing; HIV Infections; Humans; Isotope Labeling; Nevirapine; Spe | 2011 |
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Live | 2011 |
Resistance data in the ARTEN trial.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Female; HIV Infections; Humans; Male; Nevirapine; Oligopept | 2011 |
F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis.
Topics: Amino Acid Motifs; Anti-HIV Agents; Binding Sites; Cells, Cultured; Drug Resistance, Viral; Drug Syn | 2012 |
HIV and pregnancy: maternal and neonatal evolution.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Female; Follow-Up Studies; | 2011 |
Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.
Topics: Adult; Asian People; CD4 Lymphocyte Count; China; Clinical Trials as Topic; Demography; Female; Hepa | 2011 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cli | 2012 |
Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.
Topics: Adult; Africa South of the Sahara; Alleles; Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydr | 2012 |
Nevirapine-based regimens in routine clinical settings: results from a large Italian cohort of HIV-1 infected adults.
Topics: Adult; Age Factors; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Databa | 2011 |
Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; N | 2012 |
Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bayes Theorem; Benzoxazines; | 2011 |
Pharmacokinetics of nevirapine in HIV and tuberculosis-coinfected children receiving antiretroviral fixed-dose combination tablets while receiving rifampicin-containing tuberculosis treatment and after rifampicin discontinuation.
Topics: Administration, Oral; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Child; Child, Presch | 2012 |
Nevirapine extended-release for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV-1; H | 2012 |
Surveillance of antiretroviral drug resistance mutations in untreated young children living in the Central African Republic.
Topics: Anti-HIV Agents; Central African Republic; Child; Child, Preschool; DNA Fingerprinting; DNA Mutation | 2011 |
Malaria therapy in HIV: drug interactions between nevirapine and quinine.
Topics: Anti-HIV Agents; Antimalarials; Atovaquone; Drug Combinations; Drug Interactions; HIV Infections; Hu | 2011 |
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis | 2012 |
Kinetics of nevirapine and its impact on HIV-1 RNA levels in maternal plasma and breast milk over time after perinatal single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious D | 2012 |
Hcv coinfection, an important risk factor for hepatotoxicity in pregnant women starting antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cohort Studies; Coinfection; Drug Th | 2012 |
Treatment challenges in co-infected HIV and TB children.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Male; Nevirap | 2011 |
Predictors of attrition among children born in a PMTCT programme in Zimbabwe followed up over 5 years.
Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Female; Follow-Up Studies; Forecasting; HIV Infecti | 2012 |
Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combina | 2012 |
Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up.
Topics: Adult; Analysis of Variance; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV I | 2011 |
Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics.
Topics: Adult; Aged; Anti-HIV Agents; Biological Availability; Drug Interactions; Female; Food-Drug Interact | 2012 |
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Blood Chemical Analysis; Cyclopropanes; Desicca | 2012 |
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Topics: Acyclovir; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; HIV Fusion Inhibitors | 2012 |
Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hy | 2012 |
Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.
Topics: Adult; Anti-HIV Agents; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Molecu | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cycloprop | 2012 |
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
Topics: Adult; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genetic Variation; HIV Infec | 2012 |
Low-frequency nevirapine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment.
Topics: Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; D | 2012 |
Projecting the clinical benefits and risks of using efavirenz-containing antiretroviral therapy regimens in women of childbearing age.
Topics: Abnormalities, Drug-Induced; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cot | 2012 |
Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Computer Simulation; Cyclopropa | 2012 |
Hemodiafiltration with online regeneration of ultrafiltrate for severe nevirapine intoxication in a HIV-infected patient.
Topics: Adult; Anti-HIV Agents; Hemodiafiltration; HIV Infections; Humans; Nevirapine; Stevens-Johnson Syndr | 2012 |
Transplacental passage of nevirapine, nelfinavir and lopinavir.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Female; Fetal Blood; HIV Infections; Humans; | 2012 |
Nevirapine-based therapy after suppression: can we switch?
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Nevirapin | 2012 |
Effects of short-course zidovudine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human | 2012 |
Susceptibility to etravirine of HIV type 1 subtype C isolates from nevirapine/efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
Topics: Alkynes; Amino Acid Sequence; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resista | 2012 |
Policy. 3 steps can drastically reduce mother-to-child transmission.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2012 |
Lignosulfonic acid exhibits broadly anti-HIV-1 activity--potential as a microbicide candidate for the prevention of HIV-1 sexual transmission.
Topics: Anti-HIV Agents; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Viral; Antibody Specific | 2012 |
Nevirapine prophylaxis during breastfeeding.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss | 2012 |
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple | 2012 |
Use of service data to inform pediatric HIV-free survival following prevention of mother-to-child transmission programs in rural Malawi.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Disease-Free Survival; Female; Follow-Up Studies; Health Ser | 2012 |
Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B | 2012 |
Standing genetic variation and the evolution of drug resistance in HIV.
Topics: Anti-HIV Agents; Computational Biology; Computer Simulation; Drug Resistance, Viral; Evolution, Mole | 2012 |
N348I in HIV-1 reverse transcriptase counteracts the synergy between zidovudine and nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; | 2012 |
Influence of rifampicin on nevirapine plasma concentration in HIV-TB coinfected patients.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Cross-Sectional Studies; Female; H | 2012 |
Rash, hepatotoxicity and hyperbilirubinemia among Kenyan infants born to HIV-infected women receiving triple-antiretroviral drugs for the prevention of mother-to-child HIV transmission.
Topics: Adult; Aging, Premature; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Fe | 2012 |
HIV-1 mother-to-child transmission, post-test counselling, and antiretroviral prophylaxis in Northern Viet Nam: a prospective observational study.
Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Counseling; Delivery, Obstetric; Drug Resistance, Vi | 2012 |
Nevirapine- and efavirenz-associated hepatotoxicity under programmatic conditions in Kenya and Mozambique.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Chemical and Drug Induced Liver | 2012 |
Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Binding Sites; Cyclopropanes; Deoxycytidine; Drug Resistance | 2012 |
Dosage optimization of treatments using population pharmacokinetic modeling and simulation.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Cohort S | 2012 |
Nevirapine exposure with WHO pediatric weight band dosing: enhanced therapeutic concentrations predicted based on extensive international pharmacokinetic experience.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Female; HIV Infe | 2012 |
[Goal: a long-term successful HIV therapy. Nevirapine as sustained-release tablet offers good prospects].
Topics: Anti-HIV Agents; Cardiovascular Diseases; Delayed-Action Preparations; Dose-Response Relationship, D | 2012 |
Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitro.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; China; Computational Biology; Drug Resistance, Viral | 2012 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 | 2013 |
Editorial commentary: turning the tide on HIV in women and children: preventing breast-milk HIV transmission while increasing maternal life expectancy.
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Female; HIV Infections; HIV-1; Humans; Infectious Disease T | 2013 |
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Nevira | 2012 |
Effect of efavirenz versus nevirapine in antiretroviral-naive individuals in the HIV-CAUSAL Collaboration Cohort.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Dose-Respo | 2012 |
Long term outcomes of nevirapine containing antiretroviral therapy at a center in Thailand.
Topics: Adult; Age Factors; Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Female; HIV Infections; | 2012 |
Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.
Topics: Adult; Anti-HIV Agents; Asian People; Cohort Studies; Female; Genetic Variation; Genotype; HIV Infec | 2012 |
Influence of intragenic CCL3 haplotypes and CCL3L copy number in HIV-1 infection in a sub-Saharan African population.
Topics: Africa South of the Sahara; Anti-HIV Agents; CD4 Antigens; Chemokine CCL3; Female; Gene Dosage; Gene | 2013 |
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; C | 2013 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induce | 2013 |
Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Gene D | 2013 |
Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Ad | 2012 |
Evaluation of nevirapine dosing recommendations in HIV-infected children.
Topics: Adolescent; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; | 2013 |
Long-term clinical and immunologic outcomes of HIV-infected women with and without previous exposure to nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow- | 2013 |
Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HI | 2013 |
Infant feeding and transmission of human immunodeficiency virus in the United States.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Cooperative Behavior; Developin | 2013 |
Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; Drug Hypersensitivity; Female; Gene Freque | 2013 |
The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; CD4 Lymphocyte | 2012 |
Nevirapine bioactivation and covalent binding in the skin.
Topics: Animals; Exanthema; Female; HIV Infections; Humans; Liver; Mice; Mice, Inbred BALB C; Mice, Inbred C | 2013 |
Performance evaluation of PPTCT (Prevention of parent to child transmission of HIV) programme: an experience from West Bengal.
Topics: Adult; Female; Focus Groups; HIV Infections; Humans; India; Infant; Infectious Disease Transmission, | 2012 |
Nevirapine inhibits the anti-HIV activity of CD8+ cells.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Coculture | 2013 |
Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Nevirapine; Occupat | 2002 |
Side effects. Severe nevirapine rash found more likely in women than men.
Topics: Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib | 2001 |
NNRTIs compared in switch group.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Nevirapine; Oxazines; | 2002 |
South Africans win MTCT court case.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
South Africa shifts position on antiretroviral drugs.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2002 |
An interim plan to reduce mother-to-child HIV infection in South Africa.
Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; Health Promotion; HIV Infections; Humans; | 2002 |
Court ruling orders South Africa to provide nevirapine.
Topics: Adult; Child; Female; HIV Infections; Hospitals; Humans; Nevirapine; Reverse Transcriptase Inhibitor | 2002 |
Extent and importance of cross-resistance to efavirenz after nevirapine failure.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infection | 2002 |
Nevirapine (Viramune) strengthens warning on liver, skin toxicities.
Topics: Drug Labeling; HIV Infections; Humans; Liver; Liver Function Tests; Nevirapine; Reverse Transcriptas | 2000 |
Nevirapine, prednisone and rash.
Topics: Diphenhydramine; Exanthema; HIV Infections; Humans; Nevirapine; Prednisone | 2000 |
Nevirapine warning on post-exposure prophylaxis.
Topics: Centers for Disease Control and Prevention, U.S.; Female; HIV Infections; Humans; Infectious Disease | 2001 |
Nevirapine reduces perinatal HIV transmission.
Topics: Disease Transmission, Infectious; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibito | 1999 |
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Mut | 2002 |
Nevirapine-induced neuropsychiatric complications, a class effect of non-nucleoside reverse transcriptase inhibitors?
Topics: Adult; Anti-HIV Agents; Dreams; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Male; Midd | 2002 |
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Bilirubin; Female; Hepati | 2002 |
Antiretroviral treatment in developing countries.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Fe | 2002 |
WHO takes major steps to make HIV treatment accessible.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Developing Countries; Drug Therapy, Combination | 2002 |
WHO and UNAIDS continue to support use of nevirapine for prevention of mother-to-child HIV transmission.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2002 |
Regression of HIV parotid swellings after antiviral therapy: case reports with computed tomographic scan evidence.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD8-Positive T-Lymphocytes; HIV Infec | 2002 |
A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Cholesterol; Cohort Studies; Female; France; HIV Infec | 2002 |
Two drugs reduce transmission.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2002 |
Underpowered clinical trials of antiretroviral treatment.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; HIV Infections; HI | 2002 |
Survival of Ugandan infants with subtype A and D HIV-1 infection (HIVNET 012).
Topics: Cohort Studies; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmis | 2002 |
Nevirapine patient assistance program: model for better administration?
Topics: Drug Industry; Eligibility Determination; HIV Infections; Humans; Medicaid; Medical Assistance; Mode | 2002 |
Hope emerges for controlling perinatal HIV transmission.
Topics: Developing Countries; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Diseas | 1999 |
Mass treatment with nevirapine to prevent mother-to-child transmission of HIV/AIDS in sub-Saharan African countries.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infa | 2002 |
Nevirapine all set to succeed in Gauteng.
Topics: Anti-HIV Agents; Counseling; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra | 2002 |
The right to health and the nevirapine case in South Africa.
Topics: Anti-HIV Agents; Child Advocacy; Female; Health Care Costs; Health Policy; Health Services Accessibi | 2003 |
Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; | 2003 |
Preventing HIV transmission.
Topics: Anti-HIV Agents; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevi | 2003 |
Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients.
Topics: Alanine Transaminase; Anti-HIV Agents; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Che | 2003 |
Nevirapine levels may predict toxicity.
Topics: Hepatitis C; HIV Infections; Humans; Liver Function Tests; Nevirapine; Reverse Transcriptase Inhibit | 2002 |
Comparing liver toxicity between efavirenz and nevirapine.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Humans; Male; Ne | 2002 |
Negligence. Liver transplant patient too late to sue Viramune maker.
Topics: Drug Combinations; Drug Industry; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivud | 2003 |
Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV Infections; Humans; Nevirapine; | 2003 |
Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; | 2003 |
A saga in international HIV policy modeling: preventing mother-to-child HIV transmission.
Topics: Africa; Antiretroviral Therapy, Highly Active; Female; Fetus; Health Policy; HIV Infections; Humans; | 2002 |
Preventing mother-to-infant transmission of HIV in the developing world.
Topics: Anti-HIV Agents; Developing Countries; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infe | 1999 |
More good news on reducing the incidence of maternal-fetal transmission of HIV and simplifying HAART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Developing Countri | 1999 |
Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2003 |
Resistant HIV in breast milk.
Topics: Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Milk, Human; Nevirapine; Pregnancy | 2003 |
'Buffalo-hump' dermatitis: a hat trick of antiretroviral side-effects.
Topics: Anti-HIV Agents; Dermatitis, Irritant; Diagnosis, Differential; Drug Eruptions; HIV Infections; Huma | 2003 |
Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Female; HIV Infectio | 2003 |
PMTCT court order: Manana in contempt?
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Jurispru | 2003 |
[Decrease of HIV-1 virus load by nevirapin/efavirenz].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Ox | 2003 |
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Sch | 2003 |
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
Topics: Adult; Cohort Studies; Female; HIV Infections; HIV-1; Homosexuality; Humans; Male; Nevirapine; Rever | 2003 |
Prevention of mother-to-child transmission of HIV in Africa: successes and challenges in scaling-up a nevirapine-based program in Lusaka, Zambia.
Topics: Antiviral Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Drug Costs; Female; HIV I | 2003 |
Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resis | 2003 |
Mother-to-child HIV transmission in resource poor settings: how to improve coverage?
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Humans; Infant, Newborn; | 2003 |
"All-in-One Assay", a direct phenotypic anti-human immunodeficiency virus type 1 drug resistance assay for three-drug combination therapies that takes into consideration in vivo drug concentrations.
Topics: Anti-HIV Agents; CD4 Antigens; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; He | 2003 |
Nevirapine: an option for preventing as well as treating paediatric HIV infection.
Topics: Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease | 2001 |
Nevirapine-based fixed-dose combination ARVs.
Topics: Dose-Response Relationship, Drug; Drug Eruptions; Drug Therapy, Combination; HIV Infections; Humans; | 2003 |
Nevirapine use in HIV-1-infected children.
Topics: Adolescent; Anti-HIV Agents; Body Height; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Secti | 2003 |
Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.
Topics: Adult; Developing Countries; Drug Resistance, Viral; Female; Gene Frequency; HIV Infections; HIV-1; | 2003 |
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; HIV-1; H | 2003 |
Scaling the frontier--should traditional birth attendants also be used to provide nevirapine for PMTCT in Uganda?
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver | 2003 |
Cost-effectiveness of strategies to reduce mother-to-child HIV transmission in Mexico, a low-prevalence setting.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cost of Illness; Cost-Benefit | 2003 |
Incidence and risk factors for nevirapine-associated rash.
Topics: Adult; Ambulatory Care; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination | 2003 |
South African government threatens to ban nevirapine. Move would take away option for treating vertical HIV transmission.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Disease Outbreaks; Dr | 2003 |
[Antiviral agents for reduction of mother-to-child transmission of HIV infection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Evidence-Based Medicine; Female; HIV Infecti | 2003 |
[Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Eruptions; Exanthema; | 2003 |
Monitoring nevirapine-based programmes for prevention of mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; Antibodies, Viral; Child; Developed Countries; Female; Fetal Blood; HIV Infections; | 2003 |
Long-term findings of HIVNET 012: the next steps.
Topics: Anti-HIV Agents; Clinical Protocols; Disease Outbreaks; Disease-Free Survival; Drug Administration S | 2003 |
Thailand's do-it-yourself therapy.
Topics: Anti-HIV Agents; Drug Combinations; Drug Compounding; Drug Costs; Drug Industry; Drugs, Generic; HIV | 2003 |
Decision analysis to guide choice of interventions to reduce mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Decision Support Techniques; Decision Tree | 2003 |
Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclop | 2003 |
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
Topics: Acute Disease; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Therapy, Combination; Female; He | 2003 |
The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south India.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; | 2003 |
Pharmacokinetic drug interactions with nevirapine.
Topics: Drug Interactions; Herbal Medicine; HIV Infections; HIV Protease Inhibitors; Humans; Methadone; Nevi | 2003 |
A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Trials as Topic; Cohort Studies; HIV Inf | 2003 |
Defining the toxicity profile of nevirapine and other antiretroviral drugs.
Topics: Exanthema; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 2003 |
Efficacy and durability of nevirapine in antiretroviral drug näive patients.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse Tra | 2003 |
Sex differences in nevirapine disposition in HIV-infected patients.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhibitors; | 2003 |
The relationship between prevention of mother to child transmission of HIV and stakeholder decision making in Uganda: implications for health policy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Attitude to Health; Cost-Benefit Analysis; E | 2003 |
CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Stud | 2003 |
Does prior short-course nevirapine reduce the effectiveness of subsequent combination treatment with efavirenz?
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cycloprop | 2003 |
Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
Topics: Adult; Alanine Transaminase; Alcoholism; Alkynes; Anti-HIV Agents; Benzoxazines; Chemical and Drug I | 2003 |
Resolution of HCV infection in a HIV-infected patient under HAART after several hepatitis flare-ups.
Topics: Acute Disease; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; | 2003 |
[A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Drug Thera | 2003 |
Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience.
Topics: Bottle Feeding; Delivery, Obstetric; Developing Countries; Dominican Republic; Female; HIV Infection | 2003 |
Nevirapine reduced mother-to-child transmission better than AZT--at 70 times less the cost.
Topics: Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertic | 2003 |
Substitution for protease inhibitors in HIV therapy.
Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; O | 2003 |
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2003 |
Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients.
Topics: Adult; Animals; Anti-HIV Agents; Cells, Cultured; Female; HIV Infections; Humans; Immunoenzyme Techn | 2004 |
Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; | 2003 |
Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs.
Topics: Acquired Immunodeficiency Syndrome; Adenosine Triphosphate; Allosteric Site; Anti-HIV Agents; Bindin | 2004 |
Detection of nevirapine in plasma using thin-layer chromatography.
Topics: Anti-HIV Agents; Chromatography, Thin Layer; HIV Infections; Humans; Nevirapine; Reproducibility of | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Counseling; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant, Newbo | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; I | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Follow-Up Studies; Genetic Variation; HIV Infection | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; | 2004 |
Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.
Topics: Animals; Anti-HIV Agents; Azepines; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptas | 2004 |
Nurses in Zambia gain access to antiretroviral treatment.
Topics: Anti-HIV Agents; Female; Health Policy; Health Services Accessibility; HIV Infections; Humans; Mater | 2004 |
Preventing mother-to-child transmission: landmark decision by South African court.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2002 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Comorbidity; Female; HIV Infections; HIV Protease In | 2004 |
Access to health care services as a justiciable socio-economic right under the South African constitution.
Topics: Civil Rights; Female; Health Services Accessibility; HIV Infections; Humans; Infant, Newborn; Infect | 2003 |
Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Liver; Liver Diseases | 2004 |
[A "once daily" drug that with proven effectiveness. Efavirenz has successful outcome also in direct comparisons].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Admini | 2003 |
Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Coho | 2004 |
Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV infection.
Topics: Adolescent; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Coun | 2004 |
[Assessment of nevirapine liver toxicity in patients with HIV and HVC coinfection].
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis C, Chronic; HIV In | 2004 |
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studi | 2004 |
Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genetic Variation; HIV | 2004 |
Universal nevirapine upon presentation in labor to prevent mother-to-child HIV transmission in high prevalence settings.
Topics: Adult; Anti-HIV Agents; Developing Countries; Directly Observed Therapy; Female; HIV Infections; Hum | 2004 |
Newly identified human retrovirus receptor; new ways to prevent viral infections.
Topics: Chemoprevention; HIV Infections; HIV-1; Human T-lymphotropic virus 1; Human T-lymphotropic virus 2; | 2004 |
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Disease Prog | 2004 |
Safe substitution for efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Cyclopropanes; HIV Infectio | 2004 |
Antiretroviral therapy for previously untreated HIV-1-infected adults: 2NN, or just one?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI | 2004 |
Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Area Under Curve; CD4 Lymphocyte Count; Drug Interactions; Femal | 2004 |
Mother-to-child transmission. How will AZT and nevirapine use for MTCT affect future treatment? Two studies provide clues.
Topics: CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmissi | 2004 |
WHO hopes 3-by-5 plan will reverse Africa's HIV/AIDS epidemic.
Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Anti-HIV Agents; Child; Developing Countries; Dis | 2004 |
HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
Topics: Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV Protease; HIV Reverse Transcriptase; | 2004 |
Nevirapine precautions published.
Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Liver; Nevirapine; Practice Guidelines as Topic; Rever | 2004 |
New nevirapine label underscores the risk for hepatotoxicity in key populations.
Topics: CD4 Lymphocyte Count; Drug Labeling; Female; HIV Infections; Humans; Liver; Male; Nevirapine; Revers | 2004 |
Retrovirus conferees discuss new strategies.
Topics: Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn; | 2004 |
Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopro | 2004 |
Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Indu | 2004 |
PMTCT from research to reality--results from a routine service.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2004 |
Nevirapine warning.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Nevirapine; | 2004 |
Nevirapine may promote resistance.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infectious Disease Transmis | 2004 |
No relationship between high nevirapine plasma concentration and hepatotoxicity in HIV-1-infected patients naive of antiretroviral treatment or switched from protease inhibitors.
Topics: Anti-HIV Agents; Aspartate Aminotransferases; Bayes Theorem; Female; Half-Life; HIV Infections; HIV- | 2004 |
Immune status and uptake of antiretroviral interventions to prevent mother-to-child transmission of HIV-1 in Africa.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Female; HIV Infections; HIV-1; Humans; | 2004 |
[Antiretroviral therapy of acute HIV-infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; HIV Infect | 2004 |
Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2004 |
Risk of archived resistance after intrapartum nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans; | 2004 |
Nevirapine-induced resistance is a problem.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; Humans; | 2004 |
Acceptability and utilisation of voluntary HIV testing and nevirapine to reduce mother-to-child transmission of HIV-1 integrated into routine clinical care.
Topics: Anti-HIV Agents; Diagnostic Tests, Routine; Female; HIV Infections; HIV-1; Humans; Infant Welfare; I | 2004 |
Implementing a rural programme of prevention of mother-to-child transmission of HIV in Zimbabwe: first 18 months of experience.
Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious D | 2004 |
HIV/AIDS news: comparable anti-HIV antiviral efficacy of Viramune and Efavirenz--the Lancet publishes first large-scale comparison study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HI | 2004 |
Antiretroviral agents--how best to protect infants from HIV and save their mothers from AIDS.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Developing Countries; Drug Resistance | 2004 |
Health minister ignites row over drugs for HIV mothers.
Topics: Congresses as Topic; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; I | 2004 |
Some design issues in trials of microbicides for the prevention of HIV infection.
Topics: Anti-HIV Agents; Anti-Infective Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase I | 2004 |
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries.
Topics: Adult; Anti-HIV Agents; Botswana; Cost-Benefit Analysis; Cote d'Ivoire; Female; HIV Infections; Huma | 2004 |
Nevirapine-containing regimens in HIV-infected naive patients with CD4 cell counts of 200 cells/microl or less.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans | 2004 |
South Africa rejects use of AIDS drug for women.
Topics: Acquired Immunodeficiency Syndrome; Female; Health Policy; HIV Infections; Humans; Infectious Diseas | 2004 |
Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors.
Topics: Adiponectin; Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; | 2004 |
The relationship between nevirapine plasma concentrations and abnormal liver function tests.
Topics: Alanine Transaminase; Anti-HIV Agents; Cross-Sectional Studies; Ethnicity; Female; gamma-Glutamyltra | 2004 |
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; | 2004 |
Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnancy; Pregnancy Complicatio | 2004 |
Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu | 2004 |
Mutations correlated to NVP concentrations.
Topics: Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2004 |
[Favorable new data for nevirapine. Antiretroviral effect confirmed--and also lipid profile].
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol, HDL; Clinical Trials as Topic; HIV Infections; H | 2004 |
[CROI--presentation of new study results. In a comparison of NNRTI nevirapine is equally effective].
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; HIV Infections | 2004 |
Infant HIV infection: acceptability of preventive strategies in central Tanzania.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Community Health Services; Female; Focus Groups; Health Educ | 2004 |
Decreased likelihood [correction of likelyhood] of infants contracting HIV when taking nevirapine.
Topics: Female; HIV Infections; Humans; Infant; Infant, Newborn; Nevirapine; Pregnancy | 2003 |
Severe leukopenia associated with mild hepatotoxicity in an HIV carrier treated with nevirapine.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; HIV Infections; Humans; Leuk | 2004 |
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle | 2004 |
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2004 |
Nevirapine plus zidovudine to prevent mother-to-child transmission of HIV.
Topics: Anti-Retroviral Agents; DNA, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious | 2004 |
The efficacy-effectiveness gap in PMTCT.
Topics: Anti-HIV Agents; Breast Feeding; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2004 |
Meeting report from the XV International AIDS Conference. Perinatal transmission.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2004 |
[Highly active antiretroviral therapy (HAART) in HIV-positive pregnant women in the Netherlands, 1997-2003: safe, effective and with few side effects].
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; F | 2004 |
Antenatal couple counseling increases uptake of interventions to prevent HIV-1 transmission.
Topics: Adult; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Condoms; Contact Tracing; Counseling; Fa | 2004 |
Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1 | 2004 |
Reduction of materno-fetal transmission of HIV by improved delivery techniques combined with nevirapine treatment in women attending two family planning clinics in Yaounde, Cameroon.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Delivery, Obstetric; Family Planning Services; Female; | 2004 |
Tolerance of a short course of nevirapine, associated with 2 nucleoside analogues, in postexposure prophylaxis of HIV.
Topics: Alanine Transaminase; Anti-HIV Agents; Drug Evaluation; Drug Therapy, Combination; History, 21st Cen | 2004 |
Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideox | 2005 |
Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combinatio | 2004 |
HIV transmission. Allegations raise fears of backlash against AIDS prevention strategy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infant, Newborn; | 2004 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Ther | 2005 |
US AIDS chief altered report on nevirapine safety risks.
Topics: Anti-HIV Agents; Government Publications as Topic; HIV Infections; Humans; National Institutes of He | 2005 |
Articles criticising nevirapine trial may endanger babies' lives.
Topics: Anti-HIV Agents; Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newbor | 2005 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; | 2004 |
Drug reaction. Rev. Jackson calls study 'crime against humanity'.
Topics: Black or African American; Ethics; HIV Infections; Humans; Nevirapine; Politics; Reverse Transcripta | 2004 |
Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.
Topics: Adenine; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; D | 2005 |
Inhibitory drug levels found in breast milk.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Lamivudine; Milk, Human; Nevirapine; | 2004 |
An extremely different dysmetabolic profile between the two available nonnucleoside reverse transcriptase inhibitors: efavirenz and nevirapine.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Cross-Sectional Studies | 2005 |
HIV seroprevalence, uptake of interventions to reduce mother-to-child transmission and birth outcomes in greater Kingston, Jamaica.
Topics: Adolescent; Adult; Female; HIV Infections; HIV Seropositivity; HIV Seroprevalence; Humans; Infectiou | 2004 |
Uptake of interventions, outcomes and challenges in caring for HIV-exposed infants in Kingston, Jamaica.
Topics: Antibiotic Prophylaxis; Female; HIV Infections; Humans; Infant; Infant Care; Infant, Newborn; Infect | 2004 |
Nevirapine-associated rash in a Jamaican child with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Exanthema; HIV Infections; Humans; Infant; Jama | 2004 |
Zidovudine monotherapy and the prevention of mother-to-child HIV-1 transmission.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmis | 2005 |
Recent advances in prevention of mother to child (PMTCT) of HIV.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; Humans; Infant, | 2004 |
Effectiveness of nevirapine and zidovudine in a pilot program for the prevention of mother-to-child transmission of HIV-1 in Uganda.
Topics: Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Disease Outbreaks; Female; HIV Infections; | 2004 |
Controversy around nevirapine trials continues.
Topics: Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Nevirapine | 2005 |
Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and D | 2005 |
Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors.
Topics: Adult; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; H | 2005 |
Top stories of 2004. Perinatal transmission interventions: the benefits come with resistance.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2005 |
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Developing Countries; Drug Therapy, Combination; Female; HIV | 2005 |
Reports on nevirapine threaten public health.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Female; Government Publications as Topic; HIV Infe | 2005 |
HIV drug remains unproven without placebo trial.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2005 |
Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; HIV Infections; Hum | 2005 |
FDA advisory on nevirapine.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan | 2005 |
Potential cost-effectiveness of maternal and infant antiretroviral interventions to prevent mother-to-child transmission during breast-feeding.
Topics: Anti-HIV Agents; Breast Feeding; Costs and Cost Analysis; Female; HIV Infections; HIV Seroprevalence | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopro | 2005 |
Should nevirapine be used to prevent mother-to-child transmission of HIV among women of unknown serostatus?
Topics: Anti-HIV Agents; Female; Health Status; HIV Infections; HIV Seropositivity; Humans; Infectious Disea | 2005 |
Routine provision of nevirapine to women of unknown serostatus: at best a temporary solution to prevent MTCT.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infe | 2005 |
Women in couples antenatal HIV counseling and testing are not more likely to report adverse social events.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cohort Studies; Counseling; Disclosure; Divorce; Domestic Vi | 2005 |
[Toxic epidermal necrolysis associated with abacavir].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; HIV I | 2005 |
The non-nukes. Sustiva. Viramune. The two major players.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Hu | 2005 |
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
Topics: Anti-HIV Agents; Drug Monitoring; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic; | 2005 |
Study gives backing to HIV drug for mothers.
Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm | 2005 |
AIDS research. IOM panel clears HIV prevention study.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio | 2005 |
Nevirapine-related death draws attention.
Topics: Clinical Trials as Topic; Fatal Outcome; Female; HIV Infections; Humans; Liver Failure; National Ins | 2005 |
Resistance with short-course nevirapine.
Topics: Clinical Trials as Topic; Drug Resistance, Viral; Female; HIV Infections; Humans; Nevirapine; Pregna | 2005 |
Averting drug resistance while preventing MTCT.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human | 2005 |
Maternal self-medication and provision of nevirapine to newborns by women in Rakai, Uganda.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2005 |
A drug is effective if better than a harmless control.
Topics: Controlled Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Dis | 2005 |
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Com | 2005 |
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients.
Topics: Adult; Alkynes; Alleles; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes | 2005 |
Rare one and two amino acid inserts adjacent to codon 103 of the HIV-1 reverse transcriptase (RT) affect susceptibility to non-nucleoside RT inhibitors.
Topics: Alkynes; Benzoxazines; Cell Line; Codon; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV- | 2005 |
Nelfinavir and nevirapine side effects during pregnancy.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp | 2005 |
Reducing HIV vertical transmission scrutinized.
Topics: Anti-HIV Agents; Developing Countries; Drug Resistance, Viral; Female; HIV Infections; Humans; Infan | 2005 |
Nevirapine misinformation: will it kill?
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Nevirapi | 2004 |
IOM: nevirapine study is reliable.
Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, V | 2005 |
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 | 2005 |
Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretroviral Program.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymph | 2005 |
Single-dose nevirapine and drug resistance: the more you look, the more you find.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Human | 2005 |
Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1 | 2005 |
Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV Infecti | 2005 |
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Female; Genotype; HIV | 2005 |
Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protea | 2005 |
[Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2005 |
HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HI | 2005 |
Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Chemical and Drug Induced | 2005 |
Nevirapine absorbed well despite chronic diarrhea.
Topics: Adult; Anti-HIV Agents; Chronic Disease; Diarrhea; HIV Infections; HIV-1; Humans; Intestinal Absorpt | 2005 |
Appropriate use of nevirapine for long-term therapy.
Topics: CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Liver; Nevirapine; Reverse Transcriptase Inhibi | 2005 |
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N | 2005 |
Treatment of primary HIV infection: a pilot study of stavudine and didanosine plus nevirapine with or without hydroxyurea.
Topics: Acute Disease; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme | 1999 |
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System Diseases; Chemical and Drug In | 2005 |
Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Female; Genotype; HIV Infections; HIV-1; Humans; Infectious D | 2005 |
TDM: therapeutic drug measuring or therapeutic drug monitoring?
Topics: Anti-Retroviral Agents; Carbamazepine; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; H | 2005 |
Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Calibration; Cyclopro | 2005 |
Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Fetal Blood; HIV Infections; Humans; Infant, Newb | 2005 |
Roundtable. Revisiting the role of single-dose nevirapine for preventing perinatal HIV transmission.
Topics: Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tr | 2005 |
Safety and tolerability of nevirapine-based antiretroviral therapy in HIV-infected patients receiving fluconazole for cryptococcal prophylaxis: a retrospective cohort study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Acti | 2005 |
Attitudes to voluntary counselling and testing prior to the offer of Nevirapine to prevent vertical transmission of HIV in northern Tanzania.
Topics: Adolescent; Adult; Anti-HIV Agents; Attitude to Health; Counseling; Female; Focus Groups; HIV Infect | 2005 |
Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV-1; Humans; Molecula | 2005 |
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Mal | 2005 |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-S | 2005 |
Antiretroviral therapy in HIV-1 infected children.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymph | 2005 |
Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Disease Outbreaks; Female; HIV Infections; Humans; Infant | 2006 |
Effectiveness of the first district-wide programme for the prevention of mother-to-child transmission of HIV in South Africa.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cross-Sectional Studies; Female; HIV Infections; Humans; Inf | 2005 |
Nevirapine concentration in cervicovaginal and oropharyngeal secretions after single-dose administration to the mother.
Topics: Anti-HIV Agents; Cervix Uteri; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Di | 2005 |
Preventing mother-to-child transmission of HIV in Western Kenya: operational issues.
Topics: Anti-HIV Agents; Counseling; Developing Countries; Female; HIV Infections; Hospitals, General; Hospi | 2005 |
Third-trimester maternal toxicity with nevirapine use in pregnancy.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Nevirapine; Pregnanc | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2005 |
Meeting notes from the 3rd IAS Conference. Treating TB and HIV concurrently.
Topics: Brazil; Congresses as Topic; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Rifampin | 2005 |
Integrating prevention of mother-to-child HIV transmission into routine antenatal care: the key to program expansion in Cameroon.
Topics: Adolescent; Adult; Age Factors; Anti-HIV Agents; Cameroon; Counseling; Female; HIV Infections; Human | 2005 |
HIV-1 drug resistance in Thailand: before and after National Access to Antiretroviral Program.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Genes, pol; Government Programs; Health Surveys; HIV | 2005 |
Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients.
Topics: Adenine; Administration, Oral; Alkynes; Benzoxazines; Cyclopropanes; Drug Administration Schedule; D | 2006 |
Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; C | 2006 |
[Detection of HIV infection in pregnant women by rapid testing: a successful strategy to reduce its vertical transmission].
Topics: Adolescent; Adult; Anti-HIV Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; HI | 2005 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Presc | 2005 |
Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Female; | 2005 |
[Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Infections; H | 2005 |
[Efavirenz--comprehensive status of studies].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug R | 2005 |
Nevirapine toxicity in a cohort of HIV-1-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholestasis; Cohort Studies; Female; Hepatitis B; Hepa | 2006 |
HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; | 2006 |
Nevirapine-related adverse events in a patient receiving a fixed-drug combination pill.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Exanthema; Female; HIV Infections; Humans; Nevirapine; Re | 2005 |
HIV and pregnancy at the 12 CROI.
Topics: AIDS Serodiagnosis; Diabetes, Gestational; Drug Resistance, Viral; Female; HIV Infections; HIV Prote | 2005 |
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; H | 2006 |
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Topics: Cote d'Ivoire; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hum | 2006 |
Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Female; HIV Infections; Humans; Male; Middle Age | 2005 |
[Cutaneous drug-reactions to nevirapine: study of risk factors in 101 HIV-infected patients].
Topics: Adult; Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Male; | 2005 |
Concerns regarding a randomized trial of two postexposure prophylaxis regimens.
Topics: Anti-HIV Agents; Bottle Feeding; Breast Feeding; HIV Infections; Humans; Infant; Infectious Disease | 2006 |
The value of contraception to prevent perinatal HIV transmission.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Contraception; Cost-Benefit Analysis | 2006 |
Transmission of human immunodeficiency virus type 1 nevirapine resistance mutation K103N from a treatment-naive mother to her child.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Fatal Outcome; Female; HIV Infections; HIV-1; Humans; Infan | 2006 |
The controversies of nevirapine for preventing mother-to-child HIV transmission.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2006 |
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Female; HIV Infectio | 2006 |
Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Lactates; Lamivudine; Male; Mitoch | 2007 |
Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.
Topics: Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Viral; Female; Gene Freq | 2006 |
This is no time to stop use of nevarapine to prevent mother-to-child transmission of HIV.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious | 2006 |
Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chi-Square Distribution; Cholesterol, HDL; Clinical Tr | 2006 |
Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Chemical and Drug | 2006 |
Increasing nevirapine dose can overcome reduced bioavailability due to rifampicin coadministration.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Drug Administration Sched | 2006 |
Cost-effectiveness of HIV rescreening during late pregnancy to prevent mother-to-child HIV transmission in South Africa and other resource-limited settings.
Topics: Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Female; HIV Infection | 2006 |
Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission.
Topics: Adult; Alleles; Anti-HIV Agents; Child; Drug Resistance, Microbial; Female; Genotype; HIV Infections | 2006 |
Prevention of mother-to-child transmission of HIV in Cameroon: experiences from the University Teaching Hospital in Yaounde (Cameroon).
Topics: Administration, Oral; Anti-HIV Agents; Cameroon; Developing Countries; Female; Follow-Up Studies; HI | 2006 |
Severe liver disease associated with prolonged exposure to antiretroviral drugs.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascites; Budd-Chiari Syndrome; Case-C | 2006 |
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Coun | 2006 |
Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost.
Topics: Adult; Anti-HIV Agents; Computer Simulation; Cost-Benefit Analysis; Decision Support Techniques; Fem | 2006 |
HIV denialists ignore large gap in the study they cite.
Topics: Clinical Trials as Topic; Denial, Psychological; Female; History, 20th Century; HIV Infections; HIV | 2006 |
Routine intrapartum HIV counseling and testing for prevention of mother-to-child transmission of HIV in a rural Ugandan hospital.
Topics: Anti-HIV Agents; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropositivity; Humans | 2006 |
Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Revers | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cy | 2006 |
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; | 2006 |
Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Interacti | 2006 |
Urine nevirapine as a predictor of antiretroviral adherence.
Topics: Adult; Anti-HIV Agents; Drug Monitoring; Female; Half-Life; HIV Infections; Humans; Male; Middle Age | 2006 |
Comparison of HIV-1 mother-to-child transmission after single-dose nevirapine prophylaxis among African women with subtypes A, C, and D.
Topics: Black People; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vert | 2006 |
In vivo effects of HIV-1 exposure in the presence and absence of single-dose nevirapine on cellular plasma activation markers of infants born to HIV-1-seropositive mothers.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; Biomarkers; Blood Chemical Analysis; Female; Fetal Blo | 2006 |
Effect of widely used combinations of antiretroviral therapy on liver CYP3A4 activity in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breath Tests; Cohort Studies; Cytochr | 2006 |
HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.
Topics: Adolescent; Adult; Drug Hypersensitivity; Female; Gene Frequency; Haplotypes; Hepatitis C; Histocomp | 2006 |
Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Lipids; | 2006 |
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV I | 2006 |
Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Exanthema; Female; HIV | 2006 |
Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity.
Topics: Adult; Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Case-Control Studies; | 2006 |
Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration.
Topics: Adult; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Case-Control Studies; Chemical and Drug Induc | 2006 |
Outcome of different nevirapine administration strategies in preventing mother-to-child transmission (PMTCT) programs in Tanzania and Uganda.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N | 2006 |
Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery.
Topics: Amniotic Fluid; Antiretroviral Therapy, Highly Active; Drug Combinations; Drug Interactions; Female; | 2006 |
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women.
Topics: Adult; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Cohort Studies; Fe | 2006 |
Rapid HIV testing and counselling in labour in a northern Nigerian setting.
Topics: Adolescent; Adult; Anti-HIV Agents; Counseling; Cross-Sectional Studies; Female; HIV Infections; HIV | 2006 |
Stability of nevirapine suspension in prefilled oral syringes used for reduction of mother-to-child HIV transmission.
Topics: Administration, Oral; Anti-HIV Agents; Drug Packaging; Drug Stability; Drug Storage; Female; HIV Inf | 2006 |
Implementation of single-dose nevirapine for prevention of MTCT of HIV--lessons from Cape Town.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Guideline Adherence; Health Planning; HIV Inf | 2006 |
Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2006 |
A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pregnancy; Pr | 2006 |
Nevirapine versus efavirenz in 742 patients: no link of liver toxicity with female sex, and a baseline CD4 cell count greater than 250 cells/microl.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; | 2006 |
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV; HIV Infections | 2007 |
Liver transplantation for fulminant hepatitis related to nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis; HIV Infections; HIV-1; Humans; Liver Failure, Acute; Live | 2006 |
Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administratio | 2007 |
Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combinati | 2007 |
The ethics of placebo-controlled studies on perinatal HIV transmission and its treatment in the developing world.
Topics: Anti-HIV Agents; Breast Feeding; Control Groups; Controlled Clinical Trials as Topic; Developing Cou | 2006 |
Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Weight; CD4 Ly | 2007 |
HLA-Cw8 primarily associated with hypersensitivity to nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Hypersensitivity; Female; Genetic Predisposition to Disease; HIV Infect | 2007 |
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Topics: Adult; Cohort Studies; Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combina | 2007 |
Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
Topics: Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; H | 2007 |
Estimation of the rate of mother to child transmission of HIV in Nigeria.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Female; HIV Infecti | 2006 |
Reasons for discontinuation of nevirapine-containing HAART: results from an unselected population of a large clinical cohort.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Administration Schedule; Female; | 2007 |
A model of directional selection applied to the evolution of drug resistance in HIV-1.
Topics: Anti-HIV Agents; Codon; Computer Simulation; Drug Resistance, Viral; Evolution, Molecular; Female; G | 2007 |
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, H | 2007 |
Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model.
Topics: Africa South of the Sahara; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infect | 2007 |
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
Topics: Adult; Anti-HIV Agents; Asia; Australia; Drug Therapy, Combination; Female; HIV Infections; Humans; | 2007 |
The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymp | 2006 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; F | 2007 |
Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Ther | 2006 |
Nevirapine-induced fulminant hepatitis.
Topics: Adult; Anti-Retroviral Agents; Fatal Outcome; HIV Infections; Humans; Liver Failure, Acute; Male; Ne | 2006 |
Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cohort Studies; Cytochrome P-450 CYP2B6; Female; Genotype; HIV | 2007 |
Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.
Topics: Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2007 |
Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; La | 2007 |
[Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy].
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Treatment Outcome; V | 2007 |
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; | 2007 |
Early clinical and immune response to NNRTI-based antiretroviral therapy among women with prior exposure to single-dose nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administra | 2007 |
Expanded services for the prevention of mother-to-child HIV transmission: field acceptability of a pilot program in Lusaka, Zambia.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cities; Drug Therapy, Combination; Female; HIV Infections; Hu | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black | 2007 |
Pharmacokinetics of methadone in human-immunodeficiency-virus-infected patients receiving nevirapine once daily.
Topics: Adult; Analgesics, Opioid; Analysis of Variance; Anti-HIV Agents; Area Under Curve; Drug Interaction | 2007 |
Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Dr | 2007 |
Home deliveries: implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Delivery, Obstetric; Female; HIV Infections; Home Childbi | 2007 |
Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women.
Topics: Adolescent; Adult; Africa, Western; Antiretroviral Therapy, Highly Active; Europe; Female; HIV Infec | 2007 |
Delaying maternal NVP-based ART more effective.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2007 |
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyt | 2007 |
Emergence of NNRTI drug resistance mutations after single-dose nevirapine exposure in HIV type 1 subtype C-infected infants in India.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Feasibility Studies; Fema | 2007 |
Antiretroviral therapy in children: Indian experience.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Therapy | 2007 |
Hepatotoxicity during nevirapine-based fixed-dose combination antiretroviral therapy in kampala, Uganda.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans | 2007 |
Safety of HIV-1 Perinatal Transmission Prophylaxis With Zidovudine and Nevirapine in Rural South India.
Topics: Anti-HIV Agents; Cohort Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmiss | 2007 |
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Ther | 2007 |
Surveillance of mother-to-child transmission prevention programmes at immunization clinics: the case for universal screening.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-HIV Agents; Drug Administration Schedule; Female | 2007 |
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; CD4 Lymphocyte Count; Coho | 2007 |
Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Hum | 2007 |
Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2007 |
Safety issues about nevirapine administration in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Bilirubin; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Con | 2007 |
Most common prescribing error in postexposure prophylaxis of HIV/AIDS.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I | 2007 |
Persistence of nevirapine in breast milk after discontinuation of treatment.
Topics: Anti-HIV Agents; Female; Functional Laterality; HIV Infections; Humans; Milk, Human; Nevirapine; Pre | 2007 |
Effect of exposure to clinic-based health education interventions on behavioural intention to prevent mother-to-child transmission of HIV infection.
Topics: Adolescent; Adult; Catchment Area, Health; Condoms; Cross-Sectional Studies; Female; Health Behavior | 2006 |
Uncomplicated outcome after an accidental overdose of nevirapine in a newborn.
Topics: Anti-HIV Agents; Drug Overdose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, New | 2008 |
Immunochromatographic strip test for rapid detection of nevirapine in plasma samples from human immunodeficiency virus-infected patients.
Topics: Adult; Anti-HIV Agents; Chromatography; Chromatography, High Pressure Liquid; Drug Monitoring; Femal | 2007 |
Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Topics: Adult; Amino Acid Sequence; China; Cohort Studies; Consensus Sequence; Databases, Factual; Drug Resi | 2007 |
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dru | 2007 |
HIV variants of low frequency may have a big impact.
Topics: Animals; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Nevirapine; Reverse Transcri | 2007 |
[Efficacy and tolerance of non nucleosidic reverse transcriptase inhibitors containing tritherapy in HIV-1 infection].
Topics: Adolescent; Adult; Aged; Alkynes; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infect | 2005 |
Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lactic Acid; Lamivudine; M | 2007 |
Operational effectiveness of single-dose nevirapine in preventing mother-to-child transmission of HIV.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Inf | 2007 |
Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Topics: Antiretroviral Therapy, Highly Active; Drug Eruptions; Female; HIV Infections; Humans; Infectious Di | 2007 |
Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk.
Topics: Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Infectious Disease Transmissio | 2007 |
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administr | 2007 |
African infants' CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Chemok | 2007 |
Considerations on the effectiveness of nevirapine in protease inhibitor-based regimen simplification.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Hum | 2007 |
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Developing Countr | 2007 |
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Cohort | 2007 |
Diffuse interstitial pulmonary opacities induced by nevirapine.
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lung Diseases, Interstitial; M | 2007 |
Widespread vitiligo after erythroderma caused by nevirapine in a patient with AIDS.
Topics: Adult; Dermatitis, Exfoliative; Facial Dermatoses; HIV Infections; Humans; Male; Nevirapine; Reverse | 2007 |
Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; M | 2007 |
Human immunodeficiency virus infection in a child presenting as herpes zoster ophthalmicus.
Topics: Acyclovir; Child; Eye Diseases; Herpes Zoster Ophthalmicus; HIV Infections; Humans; Lamivudine; Male | 2007 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; CD4 Lymphocyte Coun | 2007 |
Detection of K103N in Ugandan women after repeated exposure to single dose nevirapine.
Topics: Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease | 2007 |
Effect of anticoagulants on plasma nevirapine and efavirenz concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Anticoagulants; Benzoxazines; Cyclopropanes; Drug Monitoring; Edeti | 2007 |
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; | 2007 |
Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cervical Vertebrae; Child; Disease Pr | 2007 |
[Treatment of children born of AIDS mothers in Tsevie hospital regional center, Togo].
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Breast Feeding; Child Health Services; Femal | 2007 |
Nevirapine-associated rash with eosinophilia and systemic symptoms in a child with human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Child; Drug Hypersensitivity; Eosinophilia; Exanthema; Female; HIV Infections; HIV- | 2007 |
Reduction of HIV-1 drug resistance after intrapartum single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; I | 2007 |
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Huma | 2007 |
Incidence and risk factors of nevirapine-associated skin rashes among HIV-infected patients with CD4 cell counts <250 cells/microL.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Exanthema; Female; HIV Infections; Humans; Incidence; M | 2007 |
Once-daily dosing of nevirapine in HAART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; HIV Infections | 2008 |
Analysis of severe hepatic events associated with nevirapine-containing regimens: CD4+ T-cell count and gender in hepatitis C seropositive and seronegative patients.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; CD4 Lymphocyte Count; Che | 2007 |
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Topics: Cell Line; Drug Resistance, Multiple, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HI | 2007 |
Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing.
Topics: Drug Resistance, Multiple, Viral; Genetic Testing; Genotype; HIV Infections; HIV Reverse Transcripta | 2007 |
Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience.
Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Psoriasis; Stavudine | 2008 |
Prevention of parent-to-child transmission of HIV: an experience in rural population.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2007 |
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette | 2007 |
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette | 2007 |
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette | 2007 |
CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette | 2007 |
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
Topics: Adult; Developing Countries; Drug Combinations; Drug Resistance, Multiple, Viral; Drugs, Generic; Fe | 2007 |
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; | 2008 |
Initiating highly active antiretroviral therapy with newer protease inhibitors is associated with better survival compared to first-generation protease inhibitors or nevirapine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Hepatitis C; HIV Infections; HIV Protease Inhi | 2007 |
An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.
Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; | 2007 |
Reverse transcriptase mutations in Cambodian CRF01_AE isolates after antiretroviral prophylaxis against HIV Type 1 perinatal transmission.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; Female; HIV Infections; HIV Revers | 2007 |
Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria.
Topics: Amino Acid Sequence; Anti-HIV Agents; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Huma | 2007 |
Effectiveness of repeat single-dose nevirapine for prevention of mother-to-child transmission of HIV-1 in repeat pregnancies in Uganda.
Topics: Anti-HIV Agents; Cohort Studies; DNA, Viral; Female; Follow-Up Studies; HIV; HIV Infections; Humans; | 2007 |
Association between exposure to nevirapine and reduced liver fibrosis progression in patients with HIV and hepatitis C virus coinfection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Disease Progr | 2008 |
Extensive hypopigmentation after starting antiretroviral treatment in an human immunodeficiency virus (HIV)-seropositive African woman.
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Female; HIV Infections; Humans; Hypopigmentation; Lam | 2008 |
Oral adverse effects due to the use of Nevirapine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Burning Mouth Syndrome; CD4 Lymphocyt | 2008 |
Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral | 2008 |
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infe | 2008 |
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Resistance, Viral; Female; HIV Inf | 2008 |
Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Exanthema; Female; HI | 2008 |
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte | 2008 |
Nevirapine-associated toxicity in Niger.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Epidemiologic Methods; Exanthema; Fe | 2008 |
Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.
Topics: Amino Acid Substitution; Animals; Cell Line; Drug Resistance, Viral; HIV Infections; HIV Reverse Tra | 2008 |
Steady-State Pharmacokinetics of Nevirapine in HIV-1 Infected Adults in India.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; India; Nevirapine | 2007 |
Outputs, cost and efficiency of public sector centres for prevention of mother to child transmission of HIV in Andhra Pradesh, India.
Topics: Abortion, Induced; AIDS Serodiagnosis; Anti-HIV Agents; Costs and Cost Analysis; Counseling; Deliver | 2008 |
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; C | 2007 |
A grave delay for South Africa's mothers and infants.
Topics: Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine | 2008 |
Impact of nevirapine or efavirenz co-administration on ritonavir-boosted amprenavir pharmacokinetics in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Bayes Theorem; Benzoxazines; Carbamates; Cyclopropanes; Drug Therap | 2008 |
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alkynes; Aryl Hydrocarbon Hydroxylases; Benzoxazines; B | 2008 |
A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
Topics: Amino Acid Substitution; Anti-HIV Agents; Cluster Analysis; DNA, Viral; Drug Resistance, Viral; Gene | 2008 |
18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; Humans; | 2008 |
Risk factors for nevirapine-associated rash among HIV-infected patients with low CD4 cell counts in resource-limited settings.
Topics: Adult; Body Weight; Case-Control Studies; CD4 Lymphocyte Count; Developing Countries; Drug Hypersens | 2008 |
Improvement in allele-specific PCR assay with the use of polymorphism-specific primers for the analysis of minor variant drug resistance in HIV-1 subtype C.
Topics: Alleles; Anti-HIV Agents; Binding Sites; Botswana; DNA Primers; Drug Resistance, Viral; Female; HIV | 2008 |
HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infe | 2008 |
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Hepatitis C, Chronic; HIV Infections; Humans; Nevirapine | 2008 |
Response to Birbeck et al.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Anti-Retroviral Agents; Anticonvulsa | 2008 |
From PMTCT to a more comprehensive AIDS response for women: a much-needed shift.
Topics: Abortion, Induced; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Developing Countries; | 2008 |
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Femal | 2008 |
Estimating vertically acquired HIV infections and the impact of the prevention of mother-to-child transmission program in Zimbabwe: insights from decision analysis models.
Topics: Decision Support Techniques; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra | 2008 |
Nevirapine-induced side effects in pregnant women: experience of a Brazilian university hospital.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Drug Eruptions | 2007 |
Incidence of nevirapine-associated hepatitis in an antenatal clinic.
Topics: Adult; Alanine Transaminase; Ambulatory Care Facilities; Chemical and Drug Induced Liver Injury; Fem | 2008 |
Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Case-Co | 2008 |
Feasibility of prevention of perinatal HIV infection by nevirapine in rural areas of the northeast Democratic Republic of Congo, 2002-2004.
Topics: Chemoprevention; Democratic Republic of the Congo; Female; HIV Infections; Humans; Infant, Newborn; | 2008 |
Syncope as a probable side effect to combination antiretroviral therapy initiated during primary HIV-1 infection.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics.
Topics: Adult; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Nevirapine; Postpartum Period; Pregnancy; | 2008 |
Steady-state nevirapine plasma concentrations are influenced by pregnancy.
Topics: Adult; Africa; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; Infectious Disease Trans | 2008 |
Comparison of LigAmp and an ASPCR assay for detection and quantification of K103N-containing HIV variants.
Topics: Anti-HIV Agents; Base Sequence; Drug Resistance, Viral; Female; Genes, pol; Genetic Variation; HIV I | 2008 |
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; | 2008 |
Characteristics of pregnancy with human immuno-deficiency virus (HIV) and perinatal transmission in Nakornping Hospital.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Female; HIV Infections; Humans; Incidence; Infant, Newbor | 2008 |
Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; C | 2008 |
Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Antitubercular Agents; Benzoxazines; CD4 Lymp | 2008 |
Self-reported adherence to single dose nevirapine in the prevention of mother to child transmission of HIV at Kitale District Hospital.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Child Welfare; Cross-Sectional Studies; Female; Health Su | 2007 |
FDA notifications. Tentative approval granted of generic nevirapine.
Topics: Drug Approval; Drugs, Generic; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors; | 2007 |
Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
Topics: Adult; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemica | 2008 |
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'I | 2008 |
Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; H | 2008 |
[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkina Faso; | 2008 |
Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine.
Topics: Child; HIV Infections; Humans; Male; Nevirapine; Stevens-Johnson Syndrome | 2008 |
Update on HIV transmission and pathogenesis.
Topics: Animals; Antiviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Genes, env; HIV; HIV | 1995 |
Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.
Topics: Antiviral Agents; Base Sequence; CD4-Positive T-Lymphocytes; Drug Resistance, Microbial; Drug Therap | 1994 |
High turnover of HIV in blood revealed by new studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; HIV; HIV Infections; HIV Proteas | 1995 |
Alternating nevirapine and zidovudine treatment of human immunodeficiency virus type 1-infected persons does not prolong nevirapine activity.
Topics: Adolescent; Adult; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Core | 1994 |
Pharmacokinetics of nevirapine: initial single-rising-dose study in humans.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Female; Half-Life; HIV Infections; HIV- | 1993 |
Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.
Topics: Base Sequence; Cohort Studies; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Kinetics; | 1996 |
Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.
Topics: Antiviral Agents; Cell Line, Transformed; Cytotoxicity, Immunologic; Drug Resistance, Microbial; Dru | 1996 |
New HIV drugs cast in supporting roles.
Topics: Antiviral Agents; HIV; HIV Infections; Humans; Nevirapine; Pyridines; Reverse Transcriptase Inhibito | 1996 |
Comparison of virus burden in blood and sequential lymph node biopsy specimens from children infected with human immunodeficiency virus.
Topics: Antiviral Agents; Biopsy; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; DNA, Viral; Dru | 1996 |
Use of standardized SCID-hu Thy/Liv mouse model for preclinical efficacy testing of anti-human immunodeficiency virus type 1 compounds.
Topics: Animals; Antiviral Agents; Didanosine; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Fetal Tissue T | 1996 |
FDA approval of nevirapine for HIV.
Topics: Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Nevirapine; Pyridines; United States; United | 1996 |
Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients.
Topics: Clinical Trials as Topic; Double-Blind Method; Drug Resistance, Microbial; HeLa Cells; HIV; HIV Infe | 1996 |
[Nevirapine: a new principle of action against HIV].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Do | 1996 |
Triple therapy reduces HIV virus to undetected levels.
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Pyridines; Reverse | 1996 |
More new drugs for HIV and associated infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Anti-Bacterial Agents; Antiviral Agents; Cido | 1997 |
Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV-1; Humans; Models, Biological; Mut | 1997 |
Viramune, new antiretroviral agent, crosses the blood-brain barrier.
Topics: Anti-HIV Agents; Blood-Brain Barrier; HIV Infections; Humans; Nevirapine; Pyridines | 1997 |
Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase.
Topics: Animals; Anti-HIV Agents; DNA, Viral; HIV Antibodies; HIV Infections; HIV-1; Leukocytes, Mononuclear | 1997 |
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Codon; DNA Mutational Analysis; Drug Resistance, | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Th | 1997 |
Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indinavi | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Inte | 1997 |
Confusion of nelfinavir and nevirapine.
Topics: Anti-HIV Agents; Drug Labeling; Female; HIV Infections; Humans; Medication Errors; Nelfinavir; Nevir | 1998 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV | 1998 |
Nevirapine-associated Stevens-Johnson syndrome.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Nevirapine; Reverse Transcriptase Inhib | 1998 |
Induction-maintenance antiretroviral therapy: proof of concept.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; N | 1998 |
Researchers report sustained suppression of HIV with nevirapine--didanosine--zidovudine.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse | 1998 |
Nevirapine-induced hepatitis treated with corticosteroids?
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; HIV Infecti | 1998 |
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; HIV Infections; Humans; | 1998 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combinat | 1998 |
Rebound of plasma HIV viral load following prolonged suppression with combination therapy.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirap | 1998 |
HIV drug now approved for use with protease inhibitors.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; | 1998 |
High incidence of nevirapine-associated rash in HIV-infected Chinese.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; China; Didanosine; Drug Eruptions; Drug Therapy, Combination; | 1998 |
DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Drug Therapy, Combination; Eosinophil | 1998 |
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
Topics: Analysis of Variance; Anti-HIV Agents; Data Interpretation, Statistical; Didanosine; HIV Infections; | 1998 |
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; | 1998 |
Lest we forget: neuropsychiatry and the new generation anti-HIV drugs.
Topics: Anti-HIV Agents; Antipsychotic Agents; Blood-Brain Barrier; Central Nervous System; Cytochrome P-450 | 1998 |
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomiz | 1999 |
Nevirapine, didanosine, and zidovudine for patients with HIV: the INCAS trial. Italy, Netherlands, Canada, and Australia.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Randomiz | 1999 |
[Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
Topics: Adult; Cardiovascular Diseases; CD4 Lymphocyte Count; Diabetes Mellitus, Type 2; Drug Therapy, Combi | 1998 |
Incidence of rash and discontinuation of nevirapine using two different escalating initial doses.
Topics: Anti-HIV Agents; Exanthema; HIV Infections; HIV-1; Humans; Incidence; Nevirapine; Reverse Transcript | 1999 |
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
Topics: Adult; Aging; Anti-HIV Agents; Didanosine; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunol | 1999 |
Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
Topics: Adult; Amino Acids; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Microbial; Genotype; HIV I | 1999 |
Methadone withdrawal when starting an antiretroviral regimen including nevirapine.
Topics: Adult; Anti-HIV Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; E | 1999 |
Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine.
Topics: Adipose Tissue; Adult; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Female; HIV | 1999 |
Lipodystrophy associated with nevirapine-containing antiretroviral therapies.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lipodystrophy; Ma | 1999 |
HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers.
Topics: Aged; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Patient-to-Pr | 1999 |
Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone.
Topics: Adult; Anti-HIV Agents; Drug Interactions; Female; HIV Infections; Humans; Male; Methadone; Middle A | 1999 |
Nevirapine-induced withdrawal symptoms in HIV patients on methadone maintenance programme: an alert.
Topics: Adult; Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Methadone; Narcotics; Nevirapine; | 1999 |
Changing cost of English HIV service provision 1996-1997. NPMS Steering Group. National Prospective Monitoring System.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Costs; Drug Therapy, Combination; HIV Infections; HIV Prote | 1999 |
Kaposi's sarcoma regression following treatment with a triple antiretroviral regimen containing nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Male; Nevirapine; Reverse | 1999 |
Drug could slash rate of perinatal HIV.
Topics: Anti-HIV Agents; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Inf | 1999 |
Low-cost drug cuts perinatal HIV-transmission rate.
Topics: Anti-HIV Agents; Drug Costs; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Tra | 1999 |
Substituting nevirapine for protease inhibitors because of intolerance.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ma | 1999 |
Nevirapine-induced cutaneous hypersensitivity reactions and successful tolerance induction.
Topics: Adult; Drug Tolerance; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Transcriptase Inhib | 1999 |
Severe hepatic failure related to nevirapine treatment.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Liver Failure; Male; Middle Aged; Nevirapine; Revers | 1999 |
Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma.
Topics: Anti-HIV Agents; Codon; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1 | 1999 |
Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anti-HIV Agents; Cost-Benefit Analysis; Drug Administration Schedule; Fe | 1999 |
Call to buy nevirapine for developing countries.
Topics: Africa; Congresses as Topic; Developing Countries; Female; HIV Infections; Humans; India; Infectious | 1999 |
Perinatal HIV prevention.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 1999 |
AIDS drug trials in Thailand and Uganda.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio | 1999 |
Prolonged therapy with the fusion inhibitor T-20 in combination with oral antiretroviral agents in an HIV-infected individual.
Topics: Administration, Oral; Anti-HIV Agents; Drug Therapy, Combination; HIV Envelope Protein gp41; HIV Inf | 1999 |
Prednisolone does not prevent the occurrence of nevirapine-induced rashes.
Topics: Anti-HIV Agents; Anti-Inflammatory Agents; Drug Eruptions; HIV Infections; Humans; Nevirapine; Predn | 1999 |
HIVNET nevirapine trials.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newbor | 1999 |
HIVNET nevirapine trials.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Counseling; Developing Countries; Female; HIV Infections; HI | 1999 |
HIVNET nevirapine trials.
Topics: Anti-HIV Agents; Counseling; Ethics, Medical; Female; HIV Infections; HIV-1; Humans; Infectious Dise | 1999 |
AZT--the saga continues.
Topics: Adolescent; Adult; Child; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, | 1999 |
[Pharma-clinics. The drug of the month. Nevirapine. Viramune].
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Nevirapine; Viral Load | 1999 |
Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
Topics: Adult; Alkynes; Benzoxazines; Cohort Studies; Cyclopropanes; Delavirdine; Drug Resistance, Microbial | 2000 |
Are nelfinavir-containing regimens effective as second-line triple therapy?
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Human | 2000 |
[Nevirapine induces abstinence symptoms in patients on a methadone maintenance program with HIV infection].
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Chronic Disease; Drug Interactions; Drug Therapy, Comb | 2000 |
Stopping vertical transmission of HIV: global strategies.
Topics: Anti-HIV Agents; Breast Feeding; Drug Costs; Global Health; Health Priorities; HIV Infections; Human | 1999 |
South Africa to tighten control on drug trials after five death.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Death, Sudden; Deoxycytidine; Drug Combinations; Emtricit | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease | 2000 |
Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Nelfinavir; | 2000 |
Late onset hepatitis and prolonged deterioration in hepatic function associated with nevirapine therapy.
Topics: Anti-HIV Agents; Biopsy; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Liver; Male | 2000 |
Antiretroviral drug removal by haemodialysis.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Kidney Failure, Chronic; Nevirap | 2000 |
Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine.
Topics: Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Pr | 2000 |
Can early failure with nevirapine be rescued with efavirenz?
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; | 2000 |
[Effectiveness also in general practice conditions. Just as good in routine practice as in studies].
Topics: Ambulatory Care; Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infection | 2000 |
The mother of all HIV challenges.
Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Breast Feeding; Clinical Trials as | 2000 |
Pharmacological implications of lengthened in-utero exposure to nevirapine.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Fetal Blood; Half-Life; HIV Infections; HIV-1 | 2000 |
Nevirapine: new preparation. In second-line triple-drug anti-HIV regimens.
Topics: Clinical Trials as Topic; Drug Combinations; Drug Interactions; HIV Infections; Humans; Nevirapine; | 1998 |
Methadone withdrawal symptoms with nevirapine and efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV Infections; Hum | 2000 |
Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with previous nucleoside analogue and protease inhibitor use.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV Prote | 2000 |
South African government continues policy of inactivity.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Female; HIV Infections; Humans; Maternal-Fetal | 2000 |
Lactic acidosis associated with nucleoside analog therapy in an HIV-positive patient.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Diagnosis, Differen | 2000 |
Europe warned of side effects.
Topics: Chemical and Drug Induced Liver Injury; Drug Eruptions; Europe; HIV Infections; Humans; Liver Failur | 2000 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Mic | 2000 |
Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse Transcriptase; HIV- | 2000 |
Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Human | 2000 |
Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Eruptions; Exanthema; HIV Infections; Hu | 2000 |
AZT blues.
Topics: Anti-HIV Agents; Counseling; Female; Foster Home Care; HIV Infections; HIV-1; Humans; Infant, Newbor | 2000 |
Determination of nevirapine, an HIV-1 non-nucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography.
Topics: Adult; Chromatography, High Pressure Liquid; Drug Stability; Female; HIV Infections; HIV Reverse Tra | 2000 |
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lamivu | 2000 |
Prevention of mother-child HIV transmission: progress and problems.
Topics: Africa; Antiviral Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Cohort Studies | 2000 |
Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Arteriosclerosis; Benzoxazines; Cholesterol; Cyclopropanes; Drug Th | 2000 |
Cost-effective use of nevirapine to prevent vertical HIV transmission in sub-Saharan Africa.
Topics: Africa South of the Sahara; AIDS Serodiagnosis; Anti-HIV Agents; Cost-Benefit Analysis; Decision Sup | 2000 |
The tolerability of efavirenz after nevirapine-related adverse events.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Anxiety Disorders; Benzoxazines; Cyclopropanes; Female; HIV; | 2000 |
Nevirapine plus didanosine: once or twice daily combination?
Topics: Administration, Oral; Adult; Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy | 2000 |
Genotypic and phenotypic nevirapine resistance correlates with virological failure during salvage therapy including abacavir and nevirapine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; DNA, Viral; Drug Resistance, Microbial; D | 2000 |
No turning back now.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis | 2000 |
Nevirapine for HIV prevention after rape.
Topics: Africa; Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Rape | 2000 |
[Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy].
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; End | 2000 |
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; I | 2000 |
Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; H | 2000 |
Human immunodeficiency virus type-1: mother-to-child transmission. Meeting of World Federation of Scientists in Erice, Italy, August 2000. Joint report of AIDS/Infectious Diseases PMP and Mother and Child PMP.
Topics: Acquired Immunodeficiency Syndrome; Africa South of the Sahara; Age Factors; Anti-HIV Agents; Breast | 2000 |
Sex differences in nevirapine rash.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Eruptions; Exanthema; Female; HIV Infections; Humans; M | 2001 |
A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.
Topics: Antiviral Agents; Base Sequence; Cross-Sectional Studies; DNA Probes; Drug Resistance, Microbial; Ev | 2001 |
Authorities fiddle while HIV burns in South Africa.
Topics: Anti-HIV Agents; Communicable Disease Control; HIV Infections; Humans; Nevirapine; South Africa | 2000 |
Future directions.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Bottle Feeding; Breast Feeding; Counseling; Fem | 2000 |
Antiretroviral pharmacology in pregnant women and their newborns.
Topics: Administration, Oral; Anti-HIV Agents; Delivery, Obstetric; Female; HIV Infections; Humans; Infant; | 2000 |
Incomplete genotypic resistance to nonnucleoside reverse transcriptase inhibitors in patients treated with nevirapine: a potential interest in clinical practice.
Topics: Adult; Cross-Sectional Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genot | 2000 |
Experience with nevirapine in previously treated HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV | 2000 |
Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Prognosis; Ris | 2001 |
Nevirapine and postexposure prophylaxis for human immunodeficiency virus.
Topics: Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Nevirapine; Occupational Exposure | 2001 |
Switch study of nevirapine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Drug Resistance, Microbial; HIV | 2000 |
[Exanthema in a patient infected with the human immunodeficiency virus after starting antiretroviral treatment].
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; HIV Infections; Humans; Male; Nevirapine; Revers | 2000 |
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; HIV Infectio | 2001 |
Pharmacokinetic of nevirapine in haemodialysis.
Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Kidney Failure, Chronic; Male; Middle Aged; Nevirapi | 2001 |
Need for increased dose of warfarin in HIV patients taking nevirapine.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Dose-Response Relationship, Drug; HIV Infections; Humans; Ma | 2001 |
Leukocytopenia due to zidovudine- and nevirapine-containing regimens in elderly patients with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Drug Therapy, Combination; | 2000 |
Further views by the Erice working group on mother-to-child transmission of HIV type 1.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease T | 2001 |
Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Nevirapine; | 2001 |
Galactorrhoea, hyperprolactinaemia, and protease inhibitors.
Topics: Adult; Drug Therapy, Combination; Female; Galactorrhea; HIV Infections; HIV Protease Inhibitors; HIV | 2001 |
Drug interaction between St John's wort and nevirapine.
Topics: Adult; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; Humans; Hyperi | 2001 |
Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
Topics: Codon; Cysteine; Drug Resistance, Microbial; Follow-Up Studies; HIV Infections; HIV-1; Humans; Mutat | 1996 |
[Cutaneous adverse events related to simultaneous nevirapine treatment and pneumococcal vaccination in HIV-infected patients].
Topics: Adult; Drug Eruptions; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Pneumococcal Vaccines; | 2001 |
Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
Topics: Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Cells, Cultured; Clinical Trials, P | 2001 |
Triple therapy in previously untreated patients reduces viral load below limit of detection.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; P | 1996 |
Viramune Expanded Access Program begins.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drugs, Investigational; Female; HIV Infections; | 1996 |
Two studies suggest nevirapine benefit for children.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; Female; HIV Infect | 1997 |
Viramune triple therapy shows suppression of HIV after 1 year, 7 months.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Zidovudi | 1997 |
Data on nevirapine combinations released.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinav | 1998 |
Recruitment underway for oral contraceptive trial.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Contraceptives, Oral, Combined; Drug Combinations; Drug I | 1998 |
Protease inhibitor-sparing regimen suppresses HIV.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse | 1998 |
New information on HIV rapid turnover--what does it mean?
Topics: Antiviral Agents; CD4 Lymphocyte Count; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indina | 1995 |
Nevirapine triple combo results released.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combinat | 1995 |
New combo trial/same old style.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Protocols; Drug Therapy, Combination; HIV Infection | 1995 |
Nevirapine: ethical dilemmas and care for HIV-infected mothers.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Counseling; Ethics, Medical; F | 1995 |
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; | 1996 |
Nevirapine recommended for approval.
Topics: Antiviral Agents; Drug Approval; HIV Infections; Humans; Nevirapine; Pyridines; United States; Unite | 1996 |
FDA approves first new class of HIV drugs. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibi | 1996 |
Nevirapine and delavirdine plus protease inhibitors.
Topics: Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indoles; Ne | 1996 |
Nevirapine: new drug, new class, new questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Approval; Drug Therapy, Combi | 1996 |
New York ADAP to cover new AIDS drugs plus viral load testing.
Topics: Acquired Immunodeficiency Syndrome; Antibiotics, Antineoplastic; Antiviral Agents; Cytomegalovirus I | 1996 |
Nevirapine--first of a new class of drugs.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV; HIV | 1996 |
Nevirapine approved by FDA. Food and Drug Administration.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Approval; Drug Th | 1996 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as To | 1997 |
Scientific basis for PEP rests in animal trials.
Topics: Adenine; Animals; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Health Personne | 1997 |
Update on nevirapine: quest for a niche.
Topics: Adult; Anti-HIV Agents; Child; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Dru | 1997 |
Pregnant women eligible for single-dose nevirapine study.
Topics: Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transm | 1997 |
Perinatal HIV down as treatment increases.
Topics: Adult; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, | 1997 |
Preventing HIV infection in infants in developing countries: NIAID's role. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Developing Countries; Ethiopia; | 1997 |
Pediatric HIV clinical trials in the United States.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Drug Therapy, Combin | 1997 |
HIV in the brain: an interview with Dr. Michael Wool, UCLA researcher.
Topics: AIDS Dementia Complex; Anti-HIV Agents; Blood-Brain Barrier; Brain; Drug Therapy, Combination; Drugs | 1998 |
Oral contraceptive/nevirapine interaction trial, New York and San Francisco.
Topics: Clinical Trials as Topic; Contraceptives, Oral; Drug Interactions; Female; HIV Infections; Nevirapin | 1998 |
Thai study success affects ongoing placebo trials.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectio | 1998 |
Late breaking news: two additional DHHS guidelines changes. Department of Health and Human Services.
Topics: Adolescent; Adult; Anti-HIV Agents; Delavirdine; HIV Infections; Humans; Nevirapine; Reverse Transcr | 1998 |
NNRTIs: a neglected class.
Topics: Alkynes; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Delavirdine; Drug Resistance, Microb | 1998 |
Salvage therapy studies.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance | 1998 |
Nevirapine receives green light from Health Protection Branch.
Topics: Canada; Drug Approval; HIV Infections; Humans; Nevirapine; Reverse Transcriptase Inhibitors | 1998 |
Viral load--how low is best?
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Nevirapine; Reverse | 1998 |
Unequal care sustains vertical transmission rate.
Topics: Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; | 1999 |
FDA news. Food and Drug Administration.
Topics: Antineoplastic Agents; Child; Dermatologic Agents; Drug Approval; HIV Infections; Humans; Nevirapine | 1999 |
Methadone and anti-HIV drugs.
Topics: Alkynes; Analgesics, Opioid; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; HIV In | 1999 |
Switching drugs for lipodystophy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Administration Schedule; HI | 1999 |
Strategy update: protease-sparing regimens.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Drug Therapy, Combination; HIV Infections; HIV Pr | 1998 |
Nevirapine in children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; Humans; Infant; | 1998 |
Antivirals update.
Topics: Anti-HIV Agents; Carbamates; Delavirdine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Thera | 1998 |
Single-dose Nevirapine during pregnancy.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmis | 1999 |
Prevention of perinatal HIV infection: cause for optimism.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Cesarean Section; Clinical Trials as Topic; Drug Therapy, Combi | 1999 |
Gender difference in Nevirapine-associated rash.
Topics: Anti-HIV Agents; Drug Hypersensitivity; Female; HIV Infections; Humans; Male; Nevirapine; Reverse Tr | 1999 |
Transfer therapy--Nevirapine for protease problems?
Topics: Adipose Tissue; Anthropometry; Blood Glucose; CD4 Lymphocyte Count; Cholesterol; Drug Therapy, Combi | 1999 |
Perinatal transmission.
Topics: Anti-HIV Agents; Developing Countries; Female; Foundations; HIV Infections; Humans; Infant, Newborn; | 1999 |
Hope for Africa's next generation.
Topics: Administration, Oral; Clinical Trials as Topic; Drug Administration Schedule; Female; HIV Infections | 1999 |
Study offers hope for Africa's next generation.
Topics: Administration, Oral; Anti-HIV Agents; Breast Feeding; Clinical Trials as Topic; Drug Administration | 1999 |
Can a $4 drug stop vertical HIV transmission?
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; Health Services Accessibility; HIV Infections | 1999 |
Perinatal transmission.
Topics: Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infe | 1999 |
Desensitization to Nevirapine.
Topics: Anti-HIV Agents; Desensitization, Immunologic; Drug Hypersensitivity; HIV Infections; Humans; Nevira | 1999 |
HIV transmission.
Topics: Condylomata Acuminata; Gonorrhea; HIV Infections; Homosexuality, Male; Humans; Male; Nevirapine; New | 1999 |
Global strategies for the prevention of HIV transmission from mothers to infants: the second conference.
Topics: Anti-HIV Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Congresses as Topic; De | 1999 |
Simpler regimens for preventing mother-to-child HIV transmission.
Topics: Delivery, Obstetric; Developing Countries; Drug Administration Schedule; Female; HIV Infections; Hum | 1999 |
[Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; HIV; HIV Infections | 2001 |
[Highly active antiretroviral therapy with nevirapine. Therapy compliance determines success].
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Nevirapine; Patient Compliance; Treat | 2001 |
Jaundice and hepatocellular damage associated with nevirapine therapy.
Topics: Adult; Chemical and Drug Induced Liver Injury; HIV Infections; Humans; Jaundice; Male; Middle Aged; | 2001 |
An in vivo model for HIV resistance development.
Topics: Animals; Chimera; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance; HIV Inf | 2001 |
Preventing mother-to-child transmission of HIV in developing countries: recent developments and ethical implications.
Topics: Anti-HIV Agents; Developing Countries; Ethics, Medical; Female; HIV Infections; Humans; Infant, Newb | 2000 |
Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV | 2001 |
Rwanda to receive cheaper anti-HIV drugs for chronic treatment and free viramune to prevent viral transmission from mother to child.
Topics: Anti-HIV Agents; Chronic Disease; Developing Countries; Drug Costs; Drug Industry; Female; HIV Infec | 2001 |
Hypersensitivity syndrome (DRESS) and meningoencephalitis associated with nevirapine therapy.
Topics: Adult; Anti-HIV Agents; Drug Eruptions; Drug Hypersensitivity; Eosinophilia; Exanthema; HIV Infectio | 2001 |
Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; | 2001 |
New drug regimen helps prevent HIV infection in infants.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 1999 |
In vitro anti-HIV-1 synergy between non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Microbial; Drug Synergism; D | 2001 |
Female sex and the use of anti-allergic agents increase the risk of developing cutaneous rash associated with nevirapine therapy.
Topics: Adult; Anti-Allergic Agents; Anti-HIV Agents; Drug Therapy, Combination; Exanthema; Female; HIV Infe | 2001 |
Adverse effects of nevirapine.
Topics: Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient- | 2001 |
Adverse effects of nevirapine.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; Health Personnel; HIV Infections; Humans; Infect | 2001 |
Taking HIV to court.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2001 |
Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu | 2001 |
Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users.
Topics: Adult; Analgesics, Opioid; Anti-HIV Agents; Drug Antagonism; Female; HIV Infections; HIV-1; Humans; | 2001 |
St. John's wort found to lower nevirapine levels.
Topics: Anti-HIV Agents; Drug Interactions; HIV Infections; Humans; Hypericum; Nevirapine; Phytotherapy; Pla | 2001 |
Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; Drug Eruptions; Female; HIV Infections; Humans; Male; | 2001 |
To test or not to test--ethical dilemmas and practical realities in the use of co-trimoxazole and nevirapine in HIV-infected adults.
Topics: Adult; AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Developing Countr | 2001 |
Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resist | 2001 |
Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD4 Lymphocyte Count; Furans; HI | 2001 |
South Africa's stance on nevirapine on trial.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant; Infant, Newborn; Infectious | 2001 |
Nevirapine (Viramune).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Nevirapine; Practice Guidelines as Topic; R | 2000 |
Zambian women's attitudes toward mass nevirapine therapy to prevent perinatal transmission of HIV.
Topics: Anti-HIV Agents; Attitude to Health; Female; HIV Infections; Humans; Infectious Disease Transmission | 2001 |
Drugs for HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dose-Response Relationship, Drug; HIV | 2001 |
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy, | 2000 |
Experience of nevirapine use in a London cohort of HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; HIV-1; Humans; | 2001 |
Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Chromatography, High Pressure Liquid; Drug Interaction | 2001 |
Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Female; Health Personnel; Hearing Disorders; HIV Infections | 2002 |
I want to see them grow up.
Topics: Anecdotes as Topic; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission | 2001 |
The faces of AIDS in Uganda: Mulago Hospital.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Male; Nevirapine; Pregnan | 2001 |
South Africa: activists, physicians sue government to prevent maternal transmission, ask international support.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Internat | 2001 |
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspart | 2002 |
Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injur | 2001 |
Development of resistance mutations to nevirapine as part of triple-drug therapy in children.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Resistance, Viral; | 2002 |
Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse-transcriptase inhibitors.
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Nevirapine; Retrospective Stud | 2002 |
Liver toxicity caused by nevirapine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Hepatitis C, Chronic; HIV Infections; Humans | 2002 |
Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures--Worldwide, '97-'00.
Topics: HIV Infections; Humans; Nevirapine; Occupational Exposure; Practice Guidelines as Topic; Reverse Tra | 2001 |
Primary HIV-1 drug resistance in Abidjan (Côte d'Ivoire): a genotypic and phenotypic study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cote d'Ivoire; Drug Resistance, Viral; Female; Genotype; HIV | 2002 |
S Africa state offers HIV drug to pregnant women.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, V | 2002 |
South African government procrastinates over policy on HIV drug.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infant, Newborn; Infectious Disease | 2002 |
Rapid determination of nevirapine in human plasma by gas chromatography.
Topics: Chromatography, Gas; HIV Infections; Humans; Nevirapine; Reproducibility of Results; Reverse Transcr | 2002 |
South African President hints at expansion of HIV-drug pilot programmes.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapi | 2002 |
Effect of nevirapine toxicity on choice of perinatal HIV prevention strategies.
Topics: Anti-HIV Agents; Cohort Studies; Decision Support Techniques; Female; Fetal Death; HIV Infections; H | 2002 |
Nevirapine + efavirenz based salvage therapy in heavily pretreated HIV infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Ne | 2002 |
Confusion over Mandela's "support" of ANC HIV policy.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; Humans; Infectious Disease Transmission, Ver | 2002 |
A South African perspective on 2001.
Topics: Anti-HIV Agents; Drug Industry; Female; HIV Infections; Humans; Infant; Infectious Disease Transmiss | 2002 |
Stage of the epidemic and viral phenotype should influence recommendations regarding mother-to-child transmission of HIV-1.
Topics: Anti-HIV Agents; Breast Feeding; Disease Outbreaks; Female; HIV Infections; HIV-1; Humans; Infant; I | 2002 |
South African judge reaffirms judgement to expand access to AIDS drug.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Seropositivity; Humans; Infectious Disease Transmission | 2002 |
Feasibility of antenatal and late HIV testing in pregnant women in Phnom Penh Cambodia: the PERIKAM/ANRS1205 study.
Topics: AIDS Serodiagnosis; Cambodia; Counseling; Feasibility Studies; Female; HIV Infections; HIV Seropreva | 2002 |
HIV drug under review as firm withdraws FDA application.
Topics: Anti-HIV Agents; Drug Approval; HIV Infections; Humans; Infectious Disease Transmission, Vertical; N | 2002 |
Vertical HIV transmission in South Africa: translating research into policy and practice.
Topics: Anti-HIV Agents; Breast Feeding; Developing Countries; Female; HIV Infections; Humans; Infant; Infan | 2002 |
Enough time wasted in South Africa.
Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Legislation, Drug; Nevirapine; | 2002 |
South African court again tells government to increase access to AIDS drug.
Topics: Anti-HIV Agents; Female; Health Policy; HIV Infections; HIV Seropositivity; Humans; Infant, Newborn; | 2002 |
South African nevirapine policy faces growing pressure.
Topics: Anti-HIV Agents; Female; Government Programs; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnan | 2002 |
Genotype resistance profiles in patients failing an NNRTI-containing regimen, and modifications after stopping NNRTI therapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Multip | 2002 |
Mothers, orphans, and prevention of paediatric AIDS.
Topics: Anti-HIV Agents; Female; Foster Home Care; HIV Infections; Humans; Infant, Newborn; Infectious Disea | 2002 |
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies | 2002 |
South African leader relents in storm over HIV drugs for women.
Topics: Anti-HIV Agents; Female; Government; HIV Infections; Humans; Infectious Disease Transmission, Vertic | 2002 |
Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infe | 2002 |
Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Hepatitis C, Chronic; HIV Infections; Hu | 2002 |
FDA application withdrawn to market Viramune for new use.
Topics: Drug Approval; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine | 2002 |
Let nevirapine do what it does best.
Topics: Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Nevirapine; Pregnancy; Pr | 2002 |
Thailand markets low-cost, 3-in-1 antiretroviral medication.
Topics: Drug Combinations; Drug Costs; HIV Infections; Humans; Lamivudine; Nevirapine; Reverse Transcriptase | 2002 |
High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma.
Topics: Alkynes; Benzoxazines; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Drug Monitor | 2002 |
Paying to waste lives: the affordability of reducing mother-to-child transmission of HIV in South Africa.
Topics: Adult; Anti-HIV Agents; Child Welfare; Child, Preschool; Cost of Illness; Cost-Benefit Analysis; Fem | 2002 |
Judasa, HPCSA and CMSA take up cudgels.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Nevirapine; Patient Advocacy; Pregnancy; Pregnancy | 2002 |
[Hepatotoxicity with antiretroviral therapy. The liver is affected as well].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical | 2002 |
[Delayed virus suppression has its price. Heart and liver are no longer secondary theaters].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical | 2002 |
Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.
Topics: Alkynes; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Delavirdine; HIV Infecti | 2002 |
PMTCT--who decides on the right to life?
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Male; Nevirapine; Practice | 2002 |
Policy watch. Good news, bad news.
Topics: Anti-HIV Agents; Bioterrorism; Budgets; Female; Health Policy; HIV Infections; Humans; Infant, Newbo | 2002 |
Nevirapine-associated toxicity.
Topics: Anti-HIV Agents; Exanthema; HIV Infections; Humans; Liver Diseases; Nevirapine | 2002 |
Court orders South Africa to treat pregnant HIV-positive women with nevirapine.
Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp | 2002 |
HIV does cause AIDS but it's hard to prescribe the drugs, says South Africa's ANC.
Topics: Female; Health Services Accessibility; HIV Infections; Humans; Nevirapine; Pregnancy; Pregnancy Comp | 2002 |
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Dr | 2002 |